<SEC-DOCUMENT>0000906709-20-000017.txt : 20201106
<SEC-HEADER>0000906709-20-000017.hdr.sgml : 20201106
<ACCEPTANCE-DATETIME>20201105204307
ACCESSION NUMBER:		0000906709-20-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201106
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		201292142

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:cd8fadd9-b103-4bc6-8d6e-f7c780e13194,g:a9acc073-30b2-4f27-83c9-2e78baac043d,d:76c17a3bff6245868336286074c47608--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:nktr="http://www.nektar.com/20200930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF8yLTEtMS0xLTA_a2ed7d8f-0651-4c0c-b148-e58e173717c6">false</ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF80LTEtMS0xLTA_a9f04263-6efc-493f-9184-d9f04d0e62cf">2020</ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF81LTEtMS0xLTA_7b3073df-6280-42da-8db3-4bf1bdb0a3dc">Q3</ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF84LTEtMS0xLTA_3533ea13-28e3-4b93-90d5-de3540f0cdff">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF85LTEtMS0xLTA_55dc0fd8-5a16-4d59-a530-5b4f492ebeba">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i343224da827f4bbeac5b7f4ae124d5ec_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a">us-gaap:AccountingStandardsUpdate201911Member</ix:nonNumeric><ix:nonNumeric contextRef="i2ec4527be1534df98cec180cba27efc6_D20200101-20200930" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_6487ad2f-0a2c-49f7-a09d-7a3056d0d81a">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i47d77652e9b74bc68a1e5f8c43837e06_D20190101-20191231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_fdc76534-bf62-4bbf-b64b-4b7ddc523e0b">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic767cc0152094283b2c82057c082b070_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6de4d4cf296147b9b48d391257b6a758_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5f71a0b03c924b7ebf4cd6dbf957f7c8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75044dd0147640e5b1fac0562a87587c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6969bdf41a51409b8a3d5bf7778889bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2800d81e37fd467db7a4aca36a05d4bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia126490b6ef14bb4a093175bf42e2418_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i303a516554ef450b8448d3c781d28e80_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10840689944434c895b2dfca85a5616_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2f1f1d59f94c80a40b88d73a9a2be8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb124e879ded4a61bfe1de6ec906bff3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb8ea2d87eb4ce4ab0dd27a38c19513_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f858bd314a45b9ae191c88d38cd186_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95068a05c9ad44ddb61821a3b2c8a545_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2590b46764604c54a3d32865b6ec27bc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53db0c02ed7c4e17a3693e7d65bc6cae_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313a392f3bd047bdb605af3500053b1f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78caf101002144188da0d0d44a27eaf1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157373b14ace4588bdde4627501185ae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaaf5f4ff58e4da6bca583978f3daf4a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ff659e615b460f9c093c4a103a776e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858dd57c9a6f47d1bd0a261f843802fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a84d3c13ef34b45b2f416e11bddf2ca_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia970b1a5f74e4c1fba7646c288d7230c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87caf582c5b348409d849ad28e65fb60_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d1a58961d641009b5e86d347a0058d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddea23a1ec4b41868773cb20d92277fc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4417f3eae14daa9f325143c6d2f354_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7284e4ebcf84dd3adb2a1222f43f4a2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f2ffe64a6e4e6e97acf57b6dc4a3b8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0b165e31da484a832227b4de929b21_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45990bd690b44a3a8403017280dfa90a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad0245d6766404ea4787ad9559bfd8e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic244ee9628594318be13017bcb360127_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a7699705cf4129838e5f75907bd07c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32375c3beebb4e78b2f7c912d4700f16_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8a195c14f447e9a410d1fb69eca97b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cdb5931a79a4157adfde1e280185bb4_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee27510abcb4480a16999d9a511ef67_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c206fe665047a39807c0608f01de69_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb0cdd57490423f8151ff5d9f8d3808_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b87bba6556485180623116c2eec80e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e77eaab1bd5407c90009309bd132727_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie64a09a837b3492bab38342b31ec23d3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be993ee27de4d5482714a9a8d0bbdba_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie847c6b6f4ac493aa3ce259242b96632_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d60f5bc3164799b0998de07ea9cd3c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09986fe227e4792bf9ce78a90cd56a1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f4942ff30d942a493ecdc359f515bc5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d5c14945d649cdbf34148f277c6321_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0027733ae46c426cb1305e97f7951913_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb4997e742034bfcb18329b32d6494b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia250ad305dd745fb96c8da18a5a40df4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2da35b042264ec58ed356a8af423513_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a69e560a4145479538f76aa786d0de_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42af22d15904460ca50e4626fa04aa1f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d3221693d14493a695856c97fd42d6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4113b9c3da104478b5f0000b7c68a664_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556ea3ab98f84204a42ed81a9ee36489_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc06d2c657945d9a36b5af38466ad66_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6cf1302dfa64b698b6c252166b100f4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1445fc508f7c4c48b2ed3508a75cb01b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777f5bdef8e24ef0b10ba35773ffbeb7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c030ee76e84c0692871baedf495fd8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i762ce4970a5f44b595a60613ff383dd0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i401f9b86bf1042419786acedec068f35_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8582351bb534ee8ad9404fecfdcdf22_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85af4c6dbd84c249ab3d00291d566bd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00153f8c513746068c52bffc86e33bdc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9e807e7b494401938118258ef486c7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe10e55d58b42c3a4ccd2c01211cfb3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib024f3e4564e41a4a8e24660abc87c66_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb35818bd5746499ac50bdf2cf1d6cc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39788d0d7cfb42eda37e02c0b7b04e7b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d271708d2b4cad96036ef906972a1a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fc796f6db24fe1a7fdadd7ca120a84_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5d1fecab1a49a6b1af85520f20a093_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1d2d4811144e91aa10ee049f266ae8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88bf65501e44247a07c0e4d791274ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f70ef47de44a5c9d729e3baf53387e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:A775PercentSeniorSecuredNotesDueOctober2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343224da827f4bbeac5b7f4ae124d5ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:segment</xbrli:measure></xbrli:unit><xbrli:context id="idd7c1bf4db6948b1bb6785b82b5b0daa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f9ecd4583d46a880165db35da02267_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc1a07c27b84916915a50371664cedf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d011c835d542eb8b915f244d635460_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:A775PercentSeniorSecuredNotesDueOctober2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4092cae66ba8439e93d82fcef25ef788_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec4527be1534df98cec180cba27efc6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d77652e9b74bc68a1e5f8c43837e06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d27ec3cd0a45d79c70cd319b7561fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieddedc2d43614f2087b4f389cf2e70c7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1705ff08143644c9aeb769a8d112dba7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e7e0b20231423f97aeee88223671b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4109b2d9da47bf8b79061158ea7bed_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ad5f6efc6b4bf5a108654c05274301_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e408faa719445eb3434a16e7c18e9f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55c58c72e60443e98000bbf5d2344984_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88c859d81c749cea39bca6e05b73950_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i681a6443e0ce4fa6947d2139b2f64812_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc9da2b38604cb796fa39f895a0a59d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ce117291d34d628c9bc23c2c80ca8d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d1299e9f894636b79988ee324b7611_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic439350a60194b1db29410760ac99acc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c4343e72de4e6dbb67b27ed682ae85_D20120223-20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-23</xbrli:startDate><xbrli:endDate>2012-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb87b6b488548d1888654100aa59ffb_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04a6efe880524704ab1efed03af7179b_D20120223-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-23</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f32928a5bb24c13afe5414f859db8ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8dbe95429a94b1c9fd1c219421ebb89_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64de59193e145bbaa8bdb17a62c36da_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6d1e8753ba4393b9f44eb4e488b692_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3db9156ad10469f95b14481d96f4a7f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68cb20163e74653bd4f64db0c6311c7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4343dbd440dc46b69ff260a863af163c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7162a81a95b64baeb3fac89305ceb96e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id53b17ca10224ac0ac514957ad57da99_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c27af66b7349d5aea18d07614a95df_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad28b26555d4a329b5591d767c77570_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18551d4bf36b467d8fdc3c19c639a8b6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ea63c983d8410db8d44a3393069d40_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ed2104c72e46488602d090a349d252_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c1a1a466fb4bc0bc106d1025995c65_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie76e0a45148544e2a7c2e165f1d8e4ab_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee96693c04e4f7db443a9718ecae73f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5211c0643104c9bae3e1bc6a61751c3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e0829dcbda4d3cb7e7f5488eaa3b04_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac03f04314684a77ac56ecd63ce7fd06_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea06231b1c44280b52f314d797baf6f_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ebd9a821b2a46cfb77bd1fed0e162c0_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5e9092d71c49cc890b7c52af5e1209_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839037e7f6a34cd693275417607356c0_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99091a9d1fe04ff8974bd1aaf88b38b4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab76208d9ee4ff2988ff083957e0c4b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70be8a1e2a64792b0121d05ff80c80d_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1580321c09614031b9d42400c15746cf_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d453fedad74b76a89c1def968cf6c9_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62bb08ae1ed42499bf0502605a0aabd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a47c82fe5384724ac972e8f0118a042_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55e78d80f65f41df99be245f4785d48d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca0ee0445d2406481c1a68226274962_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345310330b5c404386610c6ffb7eb919_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f01add1280492bb87f2040bd86e237_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399485e14223466ab18e166f27bb67af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9a8b5809804afe80662a5640dc611a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0ac9a686224749809a811eb1aee975_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972a45764b0e465282335687170894e5_I20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i845230a255e24070ad64f4430f5f672e_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa275d5aaa564026bf559d0b72b3f69f_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6b27f69ae44774a99f76b9be930ea9_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c5b100e5d54cb1b29df1fb69b79fcf_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd4979f3b7b4006aa4dc73336bb0e51_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i825ba9383adc4f57b11ab95a166bb2c3_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac727c6b64f4df7857a4b3e2d0ea358_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4bc86daabe478d9199134b3ced767a_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4450164353469089e6a5715b63820c_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5825f573d218444c8a02aa2a76c1e143_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a3e8af9af343f3af75c19ca2ff410e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf21631db7ee40ac9b0a17f839fb1811_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45d9817ecdf46ae9c87ba4e76263729_D20101001-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2981e0957f0f4a1695bcd34c346c09c3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c367beebd6f4d79ba026bb215d28964_D20090901-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-09-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfa614f55b340eca7394aa4a2d91432_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26da6534944946e088095dadd2086834_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007147b59fd8496894c45965e29e7c2e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11cfe9f36c27416a8410b5c100442563_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d135950a41412bbe0141268927497b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f2917a58fe349269bb836b1b174986d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia646a70ced924165adc2d5633324fb08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c2ed5b2588478a815cd96dd3fa4d70_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ed0979123649adb4dc059466490ec4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4f7a1f2a934d41827c699b4ead106e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421586bc96a448849e0605a587727f4c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ee132789b94f38b825c9ceecbd65a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb8af90d2ea34d3e9c87ef4323285570_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac31e6a7286d4bbfa722ce15fd4b5f5d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69fe287ef8140e69c41a0fc1cf62e80_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f16026628714f2a9d7e1c922ae55c2f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30945d826eaa4db1aee3efa6d35c52bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1bab0b44b74b74ab8679821ad533a9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e080a50510b45d7985955e0bc237be8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6b1642d5d74c94b8fc02f648ad3e3a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ebfaa0c2694404bb2fe78ec756a33b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd21aca8ffb4b5b93b574af7f8c16bc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39cc4e2705b448d299937048e267e868_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if19b4a9eac04440dae63a1c159632e2a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03e08fc98c644e6be4bef8a349474ac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d349f8e26343058e7e9dd3492bdb7e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c6d347086b42f780f70922a18208d4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2129dcc350a4c9fb39c6f59f2f20fe8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8432c50c56094a11aa02e5f29d960026_D20200617-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:Restated2017PerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf8410935d84e55bd4f0436c35fcb2c_D20200617-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i76c17a3bff6245868336286074c47608_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY2_a6e30f12-548e-4e18-b137-7dd92d803843">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6NjEzMjUyYzEzMGVmNDkwMThlYjM5ODZkMTdjYzk4MzgvdGFibGVyYW5nZTo2MTMyNTJjMTMwZWY0OTAxOGViMzk4NmQxN2NjOTgzOF8wLTAtMS0xLTA_e8d017e7-4e40-47fb-8ee8-d232f362de11">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yNjg_64552413-21a1-42ba-86c1-af68524c9ce3">September&#160;30, 2020</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTVhNjJiZjA1NDMwNDg4NGE5YWU1ZmFiOTExY2I2MmQvdGFibGVyYW5nZTplNWE2MmJmMDU0MzA0ODg0YTlhZTVmYWI5MTFjYjYyZF8wLTAtMS0xLTA_34afd9c1-6db6-48e1-99b8-522a71743093">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY3_f533f20f-463a-4fd4-bcf1-8a446b3368af">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcw_7d15d19b-3334-49e6-9442-a22e260ab60c">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6MjhjMDAxZGIzMjRjNDI2NTlhODQwZTljZWE5MDNiZWUvdGFibGVyYW5nZToyOGMwMDFkYjMyNGM0MjY1OWE4NDBlOWNlYTkwM2JlZV8wLTAtMS0xLTA_947e0c3e-4aed-44be-a013-e5ac2f15a529">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6MjhjMDAxZGIzMjRjNDI2NTlhODQwZTljZWE5MDNiZWUvdGFibGVyYW5nZToyOGMwMDFkYjMyNGM0MjY1OWE4NDBlOWNlYTkwM2JlZV8wLTItMS0xLTA_8ebc2414-c201-413c-a9e2-4daad125fe44">94-3134940</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcx_6a38625e-921c-485c-8889-8fef68b3dabe">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY4_121ad538-e5bc-4e24-b0be-fffa0fc6e82d">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcy_2c3c53cc-1175-4e1e-b327-2aa1406fd20a">California</ix:nonNumeric> <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcz_ab595b50-3e07-4e5d-9039-bf90c89e3437">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY5_6c0ff24a-09c8-4c45-9ce9-f11fd49005f9">415</ix:nonNumeric>-<ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjYy_e5be27fd-96b6-409f-a2a6-b059aea638eb">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTlmOTE1YzMxOGIzNDRhZmE3OWY5ODJkZTlkMmRhYWIvdGFibGVyYW5nZTplOWY5MTVjMzE4YjM0NGFmYTc5Zjk4MmRlOWQyZGFhYl8yLTAtMS0xLTA_09d5a2bd-8e52-4382-9f80-4a30f68ff600">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTlmOTE1YzMxOGIzNDRhZmE3OWY5ODJkZTlkMmRhYWIvdGFibGVyYW5nZTplOWY5MTVjMzE4YjM0NGFmYTc5Zjk4MmRlOWQyZGFhYl8yLTEtMS0xLTA_09d1b7c3-8914-46e6-aa63-72bdb1c96ec5">NKTR</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTlmOTE1YzMxOGIzNDRhZmE3OWY5ODJkZTlkMmRhYWIvdGFibGVyYW5nZTplOWY5MTVjMzE4YjM0NGFmYTc5Zjk4MmRlOWQyZGFhYl8yLTItMS0xLTA_cb47f7b2-d6d5-48f1-9238-22e1f9c8a6b8">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjYz_0bd5878f-e21e-4ff0-96e6-18e801d907d0">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY0_70df4be4-b9cf-4380-b018-19a53e764da5">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZjEyMjVmODZjNjk5NDliMWI5ZTViM2Y5NmQ1ODhkNGMvdGFibGVyYW5nZTpmMTIyNWY4NmM2OTk0OWIxYjllNWIzZjk2ZDU4OGQ0Y18wLTAtMS0xLTA_6272aefc-60aa-4e61-8614-6d16cefe5f9c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZjEyMjVmODZjNjk5NDliMWI5ZTViM2Y5NmQ1ODhkNGMvdGFibGVyYW5nZTpmMTIyNWY4NmM2OTk0OWIxYjllNWIzZjk2ZDU4OGQ0Y18yLTYtMS0xLTA_4c99a3e0-c93a-4ea5-8326-9a8c160e7b4e">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZjEyMjVmODZjNjk5NDliMWI5ZTViM2Y5NmQ1ODhkNGMvdGFibGVyYW5nZTpmMTIyNWY4NmM2OTk0OWIxYjllNWIzZjk2ZDU4OGQ0Y180LTItMS0xLTA_788a5f5e-b984-420c-9a67-89d9c10bd5c1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY1_94576380-f1aa-4fbe-bd49-395d257fc5de">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic767cc0152094283b2c82057c082b070_I20201030" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjU0_0481dfdb-6941-4d2a-87b2-7fca22db16cc">179,398,666</ix:nonFraction> o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n October&#160;30, 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i76c17a3bff6245868336286074c47608_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_13">PART I: FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_16">Condensed Consolidated Financial Statements &#8212; Unaudited:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_19">Condensed Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_19">Sept</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_19">ember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_19"> 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_22">Condensed Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_22"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_25">Condensed Consolidated Statements of Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_25"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_28">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_28"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_31">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_31">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_31"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_31"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_34">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_73">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_73">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_88">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_91">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_91">54</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_94">PART II: OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_97">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_97">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_82">Item 1A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_82">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_82">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_100">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_100">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_103">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_106">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_109">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_109">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_112">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_112">56</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_115">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i76c17a3bff6245868336286074c47608_115">57</a></span></div></td></tr></table></div><div style="text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this quarterly report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation, any statements concerning estimates and predictions of the COVID-19 pandemic's impact on our business and clinical trials and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this quarterly report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this quarterly report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="i76c17a3bff6245868336286074c47608_16"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div><div id="i76c17a3bff6245868336286074c47608_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:70.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMy0xLTEtMS0w_98c4442c-5e78-43d1-9f70-192d5e55ea96">55,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMy0zLTEtMS0w_a5805052-b512-440e-bb11-9fd3cd7c410e">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNC0xLTEtMS0w_14ddbf41-27a4-43f4-bcfe-6b4cfdcb6180">900,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNC0zLTEtMS0w_f283befe-7cbd-4488-aad5-1c74c48f741b">1,228,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNS0xLTEtMS0w_3702c036-19bf-45a3-8c84-483237258926">42,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNS0zLTEtMS0w_da69ef57-0773-4417-80d5-f9fac1bbbfc3">36,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNi0xLTEtMS0w_b82b6f4b-9cf7-4fd8-bd72-a51b2512d725">12,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNi0zLTEtMS0w_6c1a5389-fff7-467a-ad33-cf172c330647">12,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments to contract manufacturers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:AdvancePaymentsToContractManufacturers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNy0xLTEtMS0w_8323aef0-7613-4aea-ae5a-acc25808192e">10,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AdvancePaymentsToContractManufacturers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNy0zLTEtMS0w_754c8d24-3362-470b-bb16-12b0d238b6c5">31,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOC0xLTEtMS0w_bd269cf5-b1a5-43c0-a6d5-c02023ebdffd">21,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOC0zLTEtMS0w_1935c4ad-2c9a-4c6d-b6a3-db41f1251c8f">15,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOS0xLTEtMS0w_65d9fe9e-b145-45f5-8b78-59293134c6e2">1,043,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOS0zLTEtMS0w_4750be0d-af92-4643-bfde-17b27ecbebff">1,421,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTAtMS0xLTEtMA_cf3c4944-77ed-4fd7-acc7-0838fd9fb39b">197,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTAtMy0xLTEtMA_512deccb-7c82-4e68-9ead-4c2fe4c9c56d">279,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTEtMS0xLTEtMA_6e69c711-3002-471b-80be-88b391d12da4">60,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTEtMy0xLTEtMA_9c0f8480-21f8-42e6-bcc6-4ebac9961fba">65,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTItMS0xLTEtMA_3e4a282e-96b7-46db-b93c-d77ba98690e5">128,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTItMy0xLTEtMA_9e2629b3-a7fa-4fc1-bd22-ac5fbd67db16">134,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTMtMS0xLTEtMA_946298f3-8307-4709-b43e-6d2eb7c1c921">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTMtMy0xLTEtMA_9e463bca-8e5a-44e5-853d-4d91f350bc2d">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTQtMS0xLTEtMA_7af48295-cb40-48cc-b57e-19218d3ff872">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTQtMy0xLTEtMA_aff38a12-8b68-4897-a26f-4543872fb216">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTUtMS0xLTEtMA_cbf9904e-ab89-4f50-99c8-6f9b5ae2e5f5">1,508,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTUtMy0xLTEtMA_75e4d996-35e3-4103-bd3d-e38fb48f1f9d">1,977,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured notes, net and interest payable (see Note 1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:SeniorNotesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTgtMS0xLTEtMA_ba72e06b-9135-4d7e-8e01-888345f665d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeniorNotesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTgtMy0xLTEtMA_5a80e086-fe6f-422b-a594-7c7072287d80">252,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTktMS0xLTEtMA_3d5a1c56-81fd-4f61-9fe3-9818a3ca440e">15,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTktMy0xLTEtMA_eb295b34-c4ed-4571-9f07-ae5b33bcbc9b">19,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjAtMS0xLTEtMA_efeceac6-5185-4895-8f40-a451a7bdca95">29,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjAtMy0xLTEtMA_18d34be3-aff3-4bf2-a284-dd52470b96ce">11,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjEtMS0xLTEtMA_256dfd74-cd25-49fb-8632-b12745b304a0">48,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjEtMy0xLTEtMA_2058ae8e-0b27-4b3f-b235-aa1f7beef294">32,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjItMS0xLTEtMA_594870b6-db8a-47ef-8a8a-669356333d9c">7,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjItMy0xLTEtMA_90c697fd-b254-4d49-9720-0b0d0a216a75">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjMtMS0xLTEtMA_a956b065-c8b8-4244-878d-0a658c95d3e9">9,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjMtMy0xLTEtMA_80540f86-fd17-4f4b-8c90-7c6637e3b039">12,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjQtMS0xLTEtMA_25c0b929-31b9-40de-ae1b-2f64d8426a5e">15,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjQtMy0xLTEtMA_b60c0a6a-587f-4793-8f5f-6d3dfb6e75e1">12,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjUtMS0xLTEtMA_6701c8c0-b886-40eb-90a1-1889d38f4a3d">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjUtMy0xLTEtMA_b6430e25-7960-4cb8-a7e5-577eddabccb5">5,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjYtMS0xLTEtMA_fc748132-6bf6-4eed-bd6a-ccb7079aa904">126,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjYtMy0xLTEtMA_f5820b06-34db-43ab-9263-6fcdc18c1213">353,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjctMS0xLTEtMA_19dead38-a481-44e2-b2ff-4e588faf0bb7">139,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjctMy0xLTEtMA_c6d2f914-44b6-4308-9e55-2d5654e79400">142,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability related to the sale of future royalties, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjgtMS0xLTEtMA_3ab538d6-3fd0-43eb-9dc5-86cc1582c423">66,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjgtMy0xLTEtMA_dfe96a04-19c5-4158-adcc-180aabbb707a">72,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, less current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjktMS0xLTEtMA_9159bf9d-26b4-46c0-a351-4130949c5909">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjktMy0xLTEtMA_e5394489-1fad-45cc-9900-243e09223e06">2,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzAtMS0xLTEtMA_ab33d887-e1c0-411f-87f4-adecf86aa856">3,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzAtMy0xLTEtMA_307ac47a-58df-4b21-9feb-d8ae9f392df8">768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzEtMS0xLTEtMA_14810238-744f-495d-9d36-e61d63eedb17">337,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzEtMy0xLTEtMA_1e97aac0-95c3-4078-ae65-810421fa6810">571,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzItMS0xLTEtMA_dab13ea7-17cf-4cff-8bde-bd88b85f31a8"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzItMy0xLTEtMA_86ad250e-f63a-415d-bd3e-9935debb16cc"></ix:nonFraction>Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzIx_54734187-3aa3-447d-bb5e-056ad2f9df36"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzIx_cf1b9864-ec3d-464f-afa7-54abd8b98f37">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzM1_282bec2f-7bc3-472d-9dc4-bb2c9887d967"><ix:nonFraction unitRef="shares" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzM1_312fe389-a1d7-4aca-a106-eb06a835650a">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_4b8fe738-78b8-4ae5-86f1-8e431e7eee0d"><ix:nonFraction unitRef="shares" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_69b9af42-9a5e-42d2-9a8f-298024ae7fa2"><ix:nonFraction unitRef="shares" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_cb62c63e-41f5-4515-a047-5a8e69a0650f"><ix:nonFraction unitRef="shares" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_d91b7e05-b8df-4737-8c2a-83ea2847666e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated or outstanding at September 30, 2020 or December 31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMS0xLTEtMA_e928c38f-82d9-42d3-8397-343f47119579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMy0xLTEtMA_67aeddc3-e0d6-4367-8ce1-d208b21c7a21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzE4_7a47cb85-661d-442b-bc0f-7c1ca013960b"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzE4_9254e6f2-762e-4ed8-b9a3-cac61a1b3421">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzMy_05c9c975-b2f6-422d-8a1c-e5a0ff29ced9"><ix:nonFraction unitRef="shares" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzMy_7fe8c8e5-d16d-49cb-848e-241d36e81088">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzU0_c843524d-4fc2-449b-8bbf-6c577dbf6018">179,394</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzY4_7a64c088-a5ad-47b3-b179-2f3a52371373">176,505</ix:nonFraction> shares outstanding at September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMS0xLTEtMA_9433fdf6-dcf4-4180-ae61-80cb09279697">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMy0xLTEtMA_4d9f7848-163e-4e9a-8327-fe45104cada8">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital in excess of par value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzYtMS0xLTEtMA_30894dad-d982-46b8-b8d9-2bd1cbef915c">3,363,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzYtMy0xLTEtMA_da1baddc-9ec3-447a-9ac0-e192cd6d33d4">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzctMS0xLTEtMA_112eae8c-e074-4705-a9a7-7838ed08f2b7">1,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzctMy0xLTEtMA_f3fdaa93-b805-4ed3-b4e0-923d31fc4de7">1,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzgtMS0xLTEtMA_688ceec4-0a01-4cfa-8f5f-9fddfb828da7">2,191,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzgtMy0xLTEtMA_d48dc79d-d649-4248-89c3-a84884b11474">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzktMS0xLTEtMA_81b90f67-88ef-4b02-b728-902251b8f7dd">1,170,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzktMy0xLTEtMA_b38461bf-65ed-46e4-845a-d577a8b3376d">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNDAtMS0xLTEtMA_0bf21ca9-a2e4-47c4-aa0f-6efc5d832c94">1,508,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNDAtMy0xLTEtMA_06c4565b-38ff-4d04-b033-e5ec54390b11">1,977,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f71a0b03c924b7ebf4cd6dbf957f7c8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy0xLTEtMS0w_ae405de1-8036-4639-b4b4-d0e659f8bf47">5,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75044dd0147640e5b1fac0562a87587c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy0zLTEtMS0w_cb649b9d-2429-409d-a106-2887fcda0033">5,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6969bdf41a51409b8a3d5bf7778889bb_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy01LTEtMS0w_9f87cc00-44d8-47fb-9028-6c7a961bbed8">14,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2800d81e37fd467db7a4aca36a05d4bb_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy03LTEtMS0w_2272a060-3448-4ca7-bcd3-6450ae779104">14,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia126490b6ef14bb4a093175bf42e2418_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC0xLTEtMS0w_979b0a41-ec01-4f12-9d23-8e4a415e9c03">12,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i303a516554ef450b8448d3c781d28e80_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC0zLTEtMS0w_4f6ab030-a41a-4143-a875-2d6575f1f93d">10,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10840689944434c895b2dfca85a5616_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC01LTEtMS0w_ba9b13a7-ce42-490c-9821-a243e40af695">31,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2f1f1d59f94c80a40b88d73a9a2be8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC03LTEtMS0w_16cc8b98-cee1-45b0-88e1-a95edbfeee9b">29,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb124e879ded4a61bfe1de6ec906bff3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS0xLTEtMS0w_84c82ff0-5c6b-4872-9a8e-63e5f3f3482e">10,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb8ea2d87eb4ce4ab0dd27a38c19513_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS0zLTEtMS0w_cb134ae7-8ea5-4ef0-bf75-20219795e53f">10,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f858bd314a45b9ae191c88d38cd186_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS01LTEtMS0w_19269715-bec5-4b60-ae24-d22b0d1d3069">28,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95068a05c9ad44ddb61821a3b2c8a545_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS03LTEtMS0w_cd0d33f3-059f-42e1-bacb-abb724f366ee">27,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2590b46764604c54a3d32865b6ec27bc_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi0xLTEtMS0w_242792c6-f93e-465c-bc76-661e34184fcd">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53db0c02ed7c4e17a3693e7d65bc6cae_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi0zLTEtMS0w_6f264b7c-d5eb-43e6-9f44-b49575620a98">3,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313a392f3bd047bdb605af3500053b1f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi01LTEtMS0w_b762701a-7625-4571-97de-184fa60270d4">55,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78caf101002144188da0d0d44a27eaf1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi03LTEtMS0w_a57f3a82-fcde-430c-8ef6-47d254400b61">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy0xLTEtMS0w_aba71af2-2078-49a5-a6de-7eddbf8f5154">30,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy0zLTEtMS0w_3ee5b5aa-8fc0-4f8c-8412-fd4b8705d6bf">29,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy01LTEtMS0w_04d2662f-e136-4588-a602-abd53c74c96a">129,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy03LTEtMS0w_63689299-a580-4acc-96c8-c23ebdc39a6c">80,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS0xLTEtMS0w_b230b063-bf54-4434-8fcd-0e4ac4b0fe5c">5,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS0zLTEtMS0w_cced3e21-0f05-4079-98e9-8ece8e5aaef0">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS01LTEtMS0w_e7f440fc-d0cf-4bcc-b92e-f1830b6f758a">15,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS03LTEtMS0w_cbdab8d1-d4f3-42dd-9a94-600e43dc7732">15,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtMS0xLTEtMA_9bb4cac6-e6f4-4e4e-bc3a-350ac4201d8f">100,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtMy0xLTEtMA_015f10c1-6bea-433e-9c56-0cbb8ba7ad03">99,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtNS0xLTEtMA_976597ba-1929-4aa4-a688-54d6c3b93242">305,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtNy0xLTEtMA_09b5c83f-3f3b-4c35-ac83-c1f01873ea13">324,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtMS0xLTEtMA_8e84dec0-fc72-4989-ae6a-d3e6ea035403">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtMy0xLTEtMA_51b2ef6d-ff1b-4fe2-98cc-e5e8bcb455d3">23,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtNS0xLTEtMA_df74a5e9-f0c9-44c4-94b5-1209e7c6a869">77,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtNy0xLTEtMA_2e9d3f17-0408-4f36-b7a3-b93e8db165fd">71,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItMS0xLTEtMA_f8756397-019a-41fb-976d-7eaffce41541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItMy0xLTEtMA_852b56fe-07f8-4ba4-a574-74ba82f0005d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItNS0xLTEtMA_dc8438cf-e272-471e-9fd0-8ff0db6674c8">45,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItNy0xLTEtMA_22726e16-f0b9-449c-88cc-2624babe9a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtMS0xLTEtMA_0d87e205-0b4a-4329-9d5f-88d7fd56b73b">133,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtMy0xLTEtMA_b0c897d0-5309-4ac2-a9d4-f6f098eaabb5">127,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtNS0xLTEtMA_78ea1a78-bf9f-4c42-8407-786ef3a054ea">443,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtNy0xLTEtMA_f653809d-369a-4ad8-8dfd-868c993683de">411,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtMS0xLTEtMA_971c9945-21f9-45f8-948e-9843804f4e97">103,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtMy0xLTEtMA_ec481c72-1de6-4682-8160-c72df789781c">98,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtNS0xLTEtMA_1d136f67-8126-4a88-836e-074ccfe8646d">314,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtNy0xLTEtMA_ffbcadb0-0fdf-4859-9048-a7eaf3f9fb1e">330,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtMS0xLTEtMA_968d57f4-9fe9-49b0-aa8c-97cb17bd6c68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtMy0xLTEtMA_cf04ad68-a981-4787-8aa6-8bb41288d0e8">5,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtNS0xLTEtMA_e75b6bca-f7da-4d99-80d8-1e235859be28">6,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtNy0xLTEtMA_fbc1108b-5220-405e-b7a3-e6676b393ba4">15,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctMS0xLTEtMA_5bc2d863-4d85-406d-ba98-dff3b3f9dad7">8,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctMy0xLTEtMA_a1c275e1-5376-4445-a81a-aec831c1d737">5,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctNS0xLTEtMA_0a73f47b-78ec-4e9b-8080-f7d40d972f32">22,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctNy0xLTEtMA_464bee43-daa0-4128-838f-d91d6279ea86">17,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtMS0xLTEtMA_fcb92f0b-3e24-47ff-b652-d4ae9aa54864">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtMy0xLTEtMA_1224a64b-7b18-4627-8838-f319bc6616d6">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtNS0xLTEtMA_9d2366d8-e8d0-4d24-bea4-7524f5ffa5d8">16,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtNy0xLTEtMA_1f82b11b-a191-4002-a0a3-2a3101410811">35,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktMS0xLTEtMA_d79116a1-ffaa-4f73-b38c-8587a23c8a98">5,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktMy0xLTEtMA_324e14f9-28a5-4074-9dab-5050a021e48f">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktNS0xLTEtMA_ef439b62-e698-4239-a82a-9b40a37b9dca">12,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktNy0xLTEtMA_8fd8a77c-f29e-4b08-9d6a-0e4f0f8c3a52">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtMS0xLTEtMA_1b08d3c8-355d-4b5a-84b7-0caab5b61c74">108,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtMy0xLTEtMA_cd997429-22c6-40f9-bcf7-4323db7dc807">98,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtNS0xLTEtMA_d0585313-e839-4a32-9021-654f7631ccec">326,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtNy0xLTEtMA_6ceeddc0-a2ab-4a05-adde-bedbe3d94ab6">328,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtMS0xLTEtMA_83c8bf13-7623-4021-a817-afa184d91528">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtMy0xLTEtMA_f6e533ca-c6c5-495e-ab11-9e2faff63989">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtNS0xLTEtMA_119f5ea5-fc1e-426d-8479-425b0bb2712d"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtNS0xLTEtMA_77fe5b5b-d9f7-4c72-835a-c0aec7d3c4f8">365</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtNy0xLTEtMA_c0b314c7-c74d-4b53-b5f5-a6f6780f8255">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItMS0xLTEtMA_c2545cfd-e6ea-4281-95b8-169231d665df">108,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItMy0xLTEtMA_a6e98004-fccc-4614-a3d3-503664b37524">98,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItNS0xLTEtMA_7bd574c7-5376-4dd0-8310-9a4b00c480b1">327,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItNy0xLTEtMA_34d836f0-3a66-4522-ad4b-6183bb4c7a9f">328,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtMS0xLTEtMA_aaa555e7-a148-4306-9c1b-5f2a08c42d5c">0.61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtMy0xLTEtMA_896180d0-2281-42f8-b2da-7ca8e37dfdc7">0.56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtNS0xLTEtMA_207658fd-e83e-4526-8b1a-cfb8b67c2b81">1.84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtNy0xLTEtMA_d8c2f586-68be-4576-9162-22260557804e">1.88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtMS0xLTEtMA_591fa54a-1e0d-4fd9-9ad0-7f300193a64b">179,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtMy0xLTEtMA_37e5196c-691a-45ce-b172-625bb79fb8c7">175,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtNS0xLTEtMA_16273641-1a7a-4208-9f3c-b11e469dd845">178,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtNy0xLTEtMA_14ce3cae-94ce-4ca7-9175-17417fce8936">174,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi0xLTEtMS0w_2a6e2b39-52ac-435e-b9d2-2cee0d4b8716">108,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi0zLTEtMS0w_78a7a77b-938e-477d-82a9-1899c1040d63">98,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi01LTEtMS0w_66af4f95-1bb0-4fb4-90a4-09b635eafa39">327,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi03LTEtMS0w_e63cd70e-4b98-4df1-8787-b3b87b0443f2">328,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC0xLTEtMS0w_fca12fff-2e76-41b0-afd6-89edde3c5725">2,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC0zLTEtMS0w_3ee5f51c-9c85-4c2b-a228-00ee23ea621d">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC01LTEtMS0w_b6ff2516-8d5f-4085-803e-701a8e7011c2">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC03LTEtMS0w_8e6dff85-e664-4d83-8f51-27189bb40b4b">6,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS0xLTEtMS0w_e58361ce-b40a-4940-a524-ef4271ba398a">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS0zLTEtMS0w_7f16ea2c-9879-4ec9-9833-696ff40f4a49">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS01LTEtMS0w_1ee7252e-f2b3-4757-ac8d-db6de1372f0a">498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS03LTEtMS0w_400c4a89-0964-46bc-a47b-a0706da1a094">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi0xLTEtMS0w_517890c4-056a-40ac-b573-3af668bc364f">1,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi0zLTEtMS0w_aa7cbaf8-af90-4c8c-b5d5-9661b9bc5704">621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi01LTEtMS0w_2796bd6e-943d-40f9-8390-55d4c1357841">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi03LTEtMS0w_e35ac300-21b8-49cd-808e-9a9abbf0894e">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy0xLTEtMS0w_2e68f70b-e8b3-4c5d-a4a6-10b6116d1709">110,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy0zLTEtMS0w_cc1b2556-2cfa-4db8-b157-5831d079b87a">99,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy01LTEtMS0w_1d22485b-fa20-4049-a0c2-021a5f22cde9">327,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy03LTEtMS0w_17df0dfc-46a8-4918-a24d-f1cda1ee7663">322,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS0xLTEtMS0w_910c720c-12ba-4c3f-b929-a87ccde72649">173,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS0zLTEtMS0w_5a392380-5190-487c-acdf-f2717f99d5da">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaaf5f4ff58e4da6bca583978f3daf4a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS01LTEtMS0w_2eb3c160-4ba9-4190-87af-3170adb857df">3,147,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ff659e615b460f9c093c4a103a776e_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS03LTEtMS0w_80826eaf-d381-4982-9c7c-ecb95e44cf6d">6,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i858dd57c9a6f47d1bd0a261f843802fe_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS05LTEtMS0w_23fe19c8-231f-445d-87db-9836196847ad">1,424,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a84d3c13ef34b45b2f416e11bddf2ca_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS0xMS0xLTEtMA_044bd8d0-9fcf-41e0-9ec2-ee84aee4fefd">1,717,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia970b1a5f74e4c1fba7646c288d7230c_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMi0xLTEtMS0w_27daf50e-94b8-480d-a7e4-eb7bede61219">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87caf582c5b348409d849ad28e65fb60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMi01LTEtMS0w_b0d09c2b-40fe-48fa-96b2-cfb142e46d5c">5,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMi0xMS0xLTEtMA_d4b0673b-9e4d-4417-ba9d-ed61d7acbe08">5,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87caf582c5b348409d849ad28e65fb60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMy01LTEtMS0w_9485e113-a465-4683-9e3d-083b4fa0b623">25,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMy0xMS0xLTEtMA_7456a566-afc5-407b-87f9-dd6a955ed3b5">25,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6d1a58961d641009b5e86d347a0058d_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNC03LTEtMS0w_64953914-8ba6-4150-a764-bc1053fcdf4c">4,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddea23a1ec4b41868773cb20d92277fc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNC05LTEtMS0w_29821733-93d9-484e-8f08-bc8ef0f70119">119,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNC0xMS0xLTEtMA_fd387ed3-2f21-401a-af9a-54bbdb981a8d">114,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d4417f3eae14daa9f325143c6d2f354_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS0xLTEtMS0w_76287e37-2268-490c-be16-2f8ce28d6449">174,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4417f3eae14daa9f325143c6d2f354_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS0zLTEtMS0w_9fc46d1b-28f1-42b0-97c4-8e640bbcf5eb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7284e4ebcf84dd3adb2a1222f43f4a2_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS01LTEtMS0w_98b74297-2dda-447f-8f11-1a38556dbb27">3,178,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f2ffe64a6e4e6e97acf57b6dc4a3b8_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS03LTEtMS0w_f276cb6b-15a3-49cb-a125-e7e8c7390275">1,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0b165e31da484a832227b4de929b21_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS05LTEtMS0w_c26df1f7-e440-4111-9bdb-742ca2ef8a6d">1,543,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45990bd690b44a3a8403017280dfa90a_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS0xMS0xLTEtMA_ac56db3b-08fd-49b7-bffe-deca09db3af4">1,633,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ad0245d6766404ea4787ad9559bfd8e_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNi0xLTEtMS0w_a906bcd7-c70c-41d4-bafa-19334ad858b5">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic244ee9628594318be13017bcb360127_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNi01LTEtMS0w_81018759-0ad3-462f-bc7c-710904ffc5bc">7,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNi0xMS0xLTEtMA_02ac8876-2c61-4cc6-810b-873ceb8edc94">7,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic244ee9628594318be13017bcb360127_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNy01LTEtMS0w_8c4fe7ed-2c9c-47d3-8771-6b5b66cc8c27">24,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNy0xMS0xLTEtMA_e8dfa859-edc7-4a73-9c52-f0a850b4ca76">24,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a7699705cf4129838e5f75907bd07c_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOC03LTEtMS0w_aa482c29-786b-4e52-9357-0fa25dcffdce">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32375c3beebb4e78b2f7c912d4700f16_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOC05LTEtMS0w_f781b7a3-b72c-46c4-a668-77b47400d8d9">110,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOC0xMS0xLTEtMA_a1858091-c73b-463a-9add-93e1f7d93d4d">107,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf8a195c14f447e9a410d1fb69eca97b_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS0xLTEtMS0w_c9eb2447-f7d0-4fb7-aef0-0832f235f390">174,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8a195c14f447e9a410d1fb69eca97b_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS0zLTEtMS0w_12b657f1-4a53-4fe1-a725-5956bc34dd36">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdb5931a79a4157adfde1e280185bb4_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS01LTEtMS0w_83473aae-3591-408d-9742-a4372e697be1">3,210,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee27510abcb4480a16999d9a511ef67_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS03LTEtMS0w_5370b9ba-52d4-4831-a2e0-cd4ad26a576f">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c206fe665047a39807c0608f01de69_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS05LTEtMS0w_928610db-f7bf-4593-b82a-667513883415">1,653,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb0cdd57490423f8151ff5d9f8d3808_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS0xMS0xLTEtMA_fdb26d54-817c-481f-a6bb-8c6530460d48">1,557,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0b87bba6556485180623116c2eec80e_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTAtMS0xLTEtMjI_12a05acd-61cf-46b7-8a89-61a7b5e6091d">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e77eaab1bd5407c90009309bd132727_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTAtNS0xLTEtMjI_076b9357-0746-4725-ae3d-640f564b073b">5,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTAtMTEtMS0xLTIy_1cb0fd22-0711-4b19-b08c-f0f084106d0e">5,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e77eaab1bd5407c90009309bd132727_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTEtNS0xLTEtMjI_b5aa6650-cfd5-44b3-b0f7-9cb8bef67658">24,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTEtMTEtMS0xLTIy_3a19a50b-c9be-45e4-a216-306956245322">24,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie64a09a837b3492bab38342b31ec23d3_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItNy0xLTEtMjI_bca08951-f371-4b22-80c9-533556f890b6">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6be993ee27de4d5482714a9a8d0bbdba_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItOS0xLTEtMjI_dfffa52d-d702-46fd-ba88-f247be2377da">98,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMTEtMS0xLTIy_365bcfb9-0802-45b9-9308-c5a95142b979">99,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie847c6b6f4ac493aa3ce259242b96632_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMS0xLTEtMjI_d0ec3607-fc1c-4033-bc79-f1fd22d33ba1">175,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie847c6b6f4ac493aa3ce259242b96632_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMy0xLTEtMjI_830d47a7-3470-4897-97ce-a1cf979f82be">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d60f5bc3164799b0998de07ea9cd3c_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtNS0xLTEtMjI_e97cf6e3-02d0-4e57-8219-638fd8112db9">3,241,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09986fe227e4792bf9ce78a90cd56a1_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtNy0xLTEtMjI_b4724369-7547-4373-a0e7-3aafc206bbf9">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f4942ff30d942a493ecdc359f515bc5_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtOS0xLTEtMjI_07692460-f6cf-4da3-ba05-2e4e0f94cfda">1,752,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d5c14945d649cdbf34148f277c6321_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMTEtMS0xLTIy_7a1d0d0d-1827-4e0f-b66a-d5944201ee2e">1,488,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0027733ae46c426cb1305e97f7951913_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMS0xLTEtMA_169f902e-8785-4982-b28d-20f10ab3d818">176,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0027733ae46c426cb1305e97f7951913_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMy0xLTEtMA_d67e2e97-4b65-4627-86e0-d11c1ed7dcc1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4997e742034bfcb18329b32d6494b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItNS0xLTEtMA_384c0b0b-ad9a-4626-b0ae-c7fa128fcd45">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia250ad305dd745fb96c8da18a5a40df4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItNy0xLTEtMA_54d96b46-c9c3-4038-b82a-372715913b3d">1,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2da35b042264ec58ed356a8af423513_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItOS0xLTEtMA_7725916c-3bfb-44da-8d02-00ae7676b110">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMTEtMS0xLTA_6c3b4868-51fe-4f57-97b7-6b5b29fd1577">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6a69e560a4145479538f76aa786d0de_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMS0xLTEtMA_459f48c2-e19c-48f8-9841-664e92ed5774">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42af22d15904460ca50e4626fa04aa1f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtNS0xLTEtMA_b02b1e7c-7606-47d8-afc4-550322d14072">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMTEtMS0xLTA_704b99cb-fc48-4515-b933-20163babed96">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42af22d15904460ca50e4626fa04aa1f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTQtNS0xLTEtMA_ea14a99a-7111-49df-a4be-a87e60db203f">24,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTQtMTEtMS0xLTA_258b3c25-beae-4808-aaeb-24d4ce6f3c81">24,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8d3221693d14493a695856c97fd42d6_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTUtNy0xLTEtMA_664b13a4-1a42-4e12-ab15-6b0c2c655245">5,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4113b9c3da104478b5f0000b7c68a664_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTUtOS0xLTEtMA_772384e3-6e6c-4fbc-b24d-a7ee70de6cf7">138,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTUtMTEtMS0xLTA_ad4fd8ec-2eae-4505-8dcc-fbd4009bb664">144,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i556ea3ab98f84204a42ed81a9ee36489_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtMS0xLTEtMA_3cebd1c5-f14f-46a6-aa14-22f09871b9da">177,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556ea3ab98f84204a42ed81a9ee36489_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtMy0xLTEtMA_365b801b-5cda-4494-8e5a-008ba2343b20">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdc06d2c657945d9a36b5af38466ad66_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtNS0xLTEtMA_48fcd045-e9c5-431f-a7c0-d4faa3033ea5">3,306,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6cf1302dfa64b698b6c252166b100f4_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtNy0xLTEtMA_1a136a48-992f-44b2-906a-f6019a78e4de">6,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1445fc508f7c4c48b2ed3508a75cb01b_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtOS0xLTEtMA_79208f3f-97a6-4893-aaaf-9a5851198550">2,003,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777f5bdef8e24ef0b10ba35773ffbeb7_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtMTEtMS0xLTA_4f5c29a3-16fc-4032-a4fb-6ea017951110">1,296,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1c030ee76e84c0692871baedf495fd8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctMS0xLTEtMA_39e9e7bb-3854-4ab7-aa6e-fc5a531538cc">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c030ee76e84c0692871baedf495fd8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctMy0xLTEtMA_bbeb13ff-bfa0-45fe-b63c-c5265ee76d31">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762ce4970a5f44b595a60613ff383dd0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctNS0xLTEtMA_54763042-5e6d-41bd-af60-c58b2363d67d">7,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctMTEtMS0xLTA_ea2d93f3-fd55-4f7c-b0af-5361520541e5">7,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762ce4970a5f44b595a60613ff383dd0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTgtNS0xLTEtMA_2a38ff5d-76af-4814-bdba-0fe9655d01fc">24,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTgtMTEtMS0xLTA_597c3b34-4720-4c06-b53a-a276ea7b15dc">24,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401f9b86bf1042419786acedec068f35_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTktNy0xLTEtMA_608c5447-855c-4c68-af6e-53507825db8b">7,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8582351bb534ee8ad9404fecfdcdf22_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTktOS0xLTEtMA_8cc4b32a-b906-47f1-90b2-ef89113b7bea">80,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTktMTEtMS0xLTA_11b6dc07-b8ed-4f6e-87cc-9cd9dc0fbbb0">72,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id85af4c6dbd84c249ab3d00291d566bd_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtMS0xLTEtMA_af4bf50a-275f-47a5-a216-83a08d86c21f">178,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85af4c6dbd84c249ab3d00291d566bd_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtMy0xLTEtMA_3bb88ee9-6027-4df0-b93d-be6a5baf487b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00153f8c513746068c52bffc86e33bdc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtNS0xLTEtMA_b3096514-0a2d-40eb-a8d3-e135d0a69f9c">3,338,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e807e7b494401938118258ef486c7_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtNy0xLTEtMA_4595dc55-73e9-46ae-bbe4-f6a9c8ebed1a">715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabe10e55d58b42c3a4ccd2c01211cfb3_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtOS0xLTEtMA_a8f75c95-ea75-4bf3-9ff6-488836e86962">2,083,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib024f3e4564e41a4a8e24660abc87c66_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtMTEtMS0xLTA_c069a568-8916-437c-bdfe-385c66ac2131">1,256,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fb35818bd5746499ac50bdf2cf1d6cc_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjUtMS0xLTEtNDY_a6d81d21-73ae-44a5-b712-097e5e2e603d">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39788d0d7cfb42eda37e02c0b7b04e7b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjUtNS0xLTEtNDY_d6657ec3-dc21-4f5d-88a4-0e3240ebedf5">1,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjUtMTEtMS0xLTQ2_e51589f7-98a3-4c0f-9d8d-22f82fc45a21">1,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39788d0d7cfb42eda37e02c0b7b04e7b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjYtNS0xLTEtNDY_face02a0-4d4e-41c3-847e-e82e0b7d312c">23,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjYtMTEtMS0xLTQ2_5decf3b1-4e5b-4d25-9e01-d459f4b28ef0">23,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d271708d2b4cad96036ef906972a1a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjctNy0xLTEtNDY_6abde88f-e0df-4046-9785-fa9c3127d8d3">1,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66fc796f6db24fe1a7fdadd7ca120a84_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjctOS0xLTEtNDY_6a21f8bc-c121-499a-9ee4-e1c8df6437ea">108,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjctMTEtMS0xLTQ2_0a046b67-7702-453e-8585-7e40e24e9b0b">110,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c5d1fecab1a49a6b1af85520f20a093_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtMS0xLTEtNDY_072b7c53-ddbd-4cb9-8792-69bf4847b0e5">179,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5d1fecab1a49a6b1af85520f20a093_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtMy0xLTEtNDY_911e197f-ae80-4916-9127-0536b3b8d40d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida1d2d4811144e91aa10ee049f266ae8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtNS0xLTEtNDY_772738b5-3269-4366-97e6-a6ece081b2f2">3,363,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic88bf65501e44247a07c0e4d791274ca_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtNy0xLTEtNDY_80ae1d6e-ada1-43a0-8419-2eaa5dfc3bf2">1,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70f70ef47de44a5c9d729e3baf53387e_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtOS0xLTEtNDY_ccbbb623-7534-462a-b753-5876aa994f24">2,191,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtMTEtMS0xLTQ2_55b9c317-4986-4f97-b1d7-f51fcc8e4460">1,170,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMy0xLTEtMS0w_ee781f22-a57a-4af6-9f13-36b509ed9735">327,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMy0zLTEtMS0w_261788de-568f-4f70-85ef-2db49b23d463">328,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNS0xLTEtMS0w_d3964a41-77c2-4530-bc93-ea8949b047b0">28,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNS0zLTEtMS0w_fbf4678c-565d-43aa-a408-abd8ff5adf4d">27,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNi0xLTEtMS0w_30b062c5-f88f-44b5-a473-ce89e74b7aad">22,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNi0zLTEtMS0w_7d606c43-c116-4eaf-a2ef-d5e07de79536">17,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNy0xLTEtMS0w_f91166c9-204a-485d-a181-b6c738e6ea6b">72,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNy0zLTEtMS0w_56b76578-da1e-4607-9fe7-cbfc14cf6d8e">74,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOC0xLTEtMS0w_9b96a17b-748a-40ed-bb21-2c5b2c40a904">10,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOC0zLTEtMS0w_a279e180-5658-4e6e-bb3c-6891b69a049d">9,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of advance payments to contract manufacturers and equipment for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOS0xLTEtMS0w_c70785ce-a382-406f-9a0e-df1926f6c570">20,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOS0zLTEtMS0w_7bcd4212-f43f-4d3a-985e-5680e7ff2fa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTAtMS0xLTEtMA_4795ebe6-1c40-4829-8687-d4b1bfd60e12">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTAtMy0xLTEtMA_6320bb94-f5fc-4e4b-82e5-e11b7abfbd2c">9,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTItMS0xLTEtMA_01e5f7c3-05f3-4318-ac94-ff84536f5e3a">6,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTItMy0xLTEtMA_000c0cfd-7cb9-4bd6-8edb-e49c968a3cb7">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTMtMS0xLTEtMA_73f8d7f5-1379-47d2-859c-3c174f69c1a2">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTMtMy0xLTEtMA_5944b1fe-3794-4a91-aa84-ecfed9bbbda6">2,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTQtMS0xLTEtMA_75d9a771-6a9d-40af-90e6-494fcc0e1570">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTQtMy0xLTEtMA_e5101397-7d7d-4985-aa9e-19f721e115c7">11,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTUtMS0xLTEtMA_c0a17a20-5f3a-4017-8532-3d58733bbab3">5,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTUtMy0xLTEtMA_fe70fc46-b05b-4e9c-a929-97146c748d23">18,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTYtMS0xLTEtMA_9ae9d33d-589f-458b-850f-d6d4d5d78ae0">3,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTYtMy0xLTEtMA_0d054560-bb66-456c-8ae6-2bbdceffecf5">16,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTctMS0xLTEtMA_f7ceef5a-7679-4f39-bb06-f7cc50894d76">20,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTctMy0xLTEtMA_a4fb1961-33bf-4988-9998-1b8538f57d2c">13,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTgtMS0xLTEtMA_ec86b90b-2e49-4dc0-a07b-82ede8b44faa">9,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTgtMy0xLTEtMA_774f7b40-10b2-41ec-88ff-def19feeab45">10,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTktMS0xLTEtMA_0b0ff5c5-16b9-42f7-b49a-04b8e224f1b7">5,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTktMy0xLTEtMA_dfee6daf-7a23-4d08-8ce7-9c3d541c8dbf">9,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjAtMS0xLTEtMA_35b30601-1e26-48f4-a638-66ebbaaf7a45">214,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjAtMy0xLTEtMA_387381c5-7acb-4f18-b844-74e22ef487df">203,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjItMS0xLTEtMA_0068f15d-5af0-4f84-b6d5-fa6b35c79f49">791,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjItMy0xLTEtMA_143d8f3d-e97f-44ef-a3f5-4286f1038053">1,028,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjMtMS0xLTEtMA_34ef3ad8-4ce0-4ced-81fb-4ea9f33e8cd8">1,158,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjMtMy0xLTEtMA_d4acdc9e-3f76-485f-a751-758ba51b4a50">1,122,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjUtMS0xLTEtMA_22ef80c0-111e-4b6e-a823-fc398c018b2e">41,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjUtMy0xLTEtMA_0e16a046-4dd7-4071-b89c-f8cc5a0bae7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjYtMS0xLTEtMA_d1df9ae7-95e0-4935-8858-1437977c9df6">5,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjYtMy0xLTEtMA_e6168e05-ef99-45b9-8023-57c1a84d5524">22,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjgtMS0xLTEtMA_60a29960-f6b2-4748-8e11-83e34b95e426">403,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjgtMy0xLTEtMA_b947f967-64b9-4e75-ad8c-1805ddf7b5c6">71,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzEtMS0xLTEtMA_6ce5a5a3-f23e-4a50-a5db-0053711d7c23">20,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzEtMy0xLTEtMA_f0db6702-3f68-4db7-a732-531ffc56728f">18,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzItMS0xLTEtMA_924b08c2-bd36-4ef3-98fa-0019a3dca9d7">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzItMy0xLTEtMA_12281fb8-5891-446d-8ba1-35167e2d9fa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzMtMS0xLTEtMA_a892f93d-3198-4f00-8489-03d3a7f99355">229,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzMtMy0xLTEtMA_ea836089-47df-4d93-93a3-875ec9d5f209">18,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzQtMS0xLTEtMA_1f565fb2-f5b9-4d6e-a3bb-6e1cadbafe0c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzQtMy0xLTEtMA_4e871667-6c94-4b8d-81a4-b457e6c422c5">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzUtMS0xLTEtMA_5cf32839-bdbe-45e9-9f17-0910ce3f7203">40,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzUtMy0xLTEtMA_fd27b6bf-1122-4202-a72f-2c351584c2ee">113,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzYtMS0xLTEtMA_bfb10b91-69c3-4a77-8e76-585eacba9cdd">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a84d3c13ef34b45b2f416e11bddf2ca_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzYtMy0xLTEtMA_e7b9da87-6ed9-487e-b571-eb39f3522ae6">194,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzctMS0xLTEtMA_cd85154e-f00d-4117-bf99-e82187481d55">55,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d5c14945d649cdbf34148f277c6321_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzctMy0xLTEtMA_9a591969-6892-4668-b137-af4dfe013700">81,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzktMS0xLTEtMA_a36b75d4-7e06-49fb-a4a8-80a8542b30bb">9,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzktMy0xLTEtMA_9871eb6c-5692-4ae0-8b10-9bd59543467c">14,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset recognized in exchange for lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNDAtMS0xLTEtMA_baae3893-c94e-414f-90da-5f45d39f40cc">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNDAtMy0xLTEtMA_a7a74c22-8cf0-4402-a13b-f51d407fbe6e">56,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September&#160;30, 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i76c17a3bff6245868336286074c47608_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTM_93490f1f-2310-4fe4-9782-82eba7a1c990" continuedAt="ie1fbbe901162466f9ec90da677d71c9d" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ie1fbbe901162466f9ec90da677d71c9d" continuedAt="i2e1871ef33fe4d0fac27c0ed68b30ea4"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDk_25851213-abcc-413c-b11d-9f31860af7d1" continuedAt="i73b9327b6bfe450fba1ae57665fb8b10" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73b9327b6bfe450fba1ae57665fb8b10">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At September&#160;30, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-8" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTAyOA_e52a015d-1386-40bb-a3a7-2458b904b3c1">1.2</ix:nonFraction> billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $<ix:nonFraction unitRef="usd" contextRef="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413" decimals="-5" format="ixt:numdotdecimal" name="nktr:RepaymentsOfLongTermDebtIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTE3NA_0b6ac86d-7289-48a2-aa33-2a59b9372cd3">254.8</ix:nonFraction>&#160;million, as described further below.</span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTU_2fe49aac-8c79-4ece-bc02-99bf26cb7c68" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTc_68c56063-6b6a-4bbb-8589-329805d4a5f0" continuedAt="id38d62bfbe6c424ab072e804acbb4ca6" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i2e1871ef33fe4d0fac27c0ed68b30ea4" continuedAt="i8fe27d807300404aa0ebf691245fd04d"><ix:continuation id="id38d62bfbe6c424ab072e804acbb4ca6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div></ix:continuation><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MTE_661659d8-56d3-48ff-afe8-666a25a86a22" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a">ASU 2019-12</span> - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss). The tax effect in continuing operations was a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNjYwNg_dd3d500f-9ff2-4a8c-ba69-698988daba0c">1.3</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2019, and was a tax expense of $<ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfOTg5NTYwNDY3NzUwOA_7fc262e5-66ce-4493-99c4-40ea98207215">0.2</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2019.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MTI_cf17f4ec-d367-4528-80dd-47d780efa4e9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNjk5Mw_147b6def-a077-41b5-b356-0e8622cad47e">one</ix:nonFraction> business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as <ix:nonFraction unitRef="segment" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNzMzNQ_c66b9801-6fc4-44a9-ac58-8683bdd4a5d3">one</ix:nonFraction> business segment by our Chief Executive Officer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDU_d4b5de26-710c-4bf8-9fdb-2a14754b16dc" continuedAt="i57f85aa9bd764dcf87388174c4ae017e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of September&#160;30, 2020, our accounts receivable includes $<ix:nonFraction unitRef="usd" contextRef="idd7c1bf4db6948b1bb6785b82b5b0daa_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNzkzMg_bc806379-1e59-4b5f-a787-49d9ad1369c4">13.0</ix:nonFraction>&#160;million under customer contracts from our collaboration partners and $<ix:nonFraction unitRef="usd" contextRef="ie5f9ecd4583d46a880165db35da02267_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNzk5Ng_b7c8c80e-4979-43f2-b2fe-34013b497044">29.9</ix:nonFraction> million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i0fc1a07c27b84916915a50371664cedf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfODQ1OA_e1747581-16dd-42f7-b6f8-e8860a7e1a54">12.8</ix:nonFraction>&#160;million from customer contracts and $<ix:nonFraction unitRef="usd" contextRef="i86d011c835d542eb8b915f244d635460_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfODQ4OQ_e300c589-e777-4994-9276-590f4fc70e4e">24.0</ix:nonFraction> million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2020 and 2019. We have not recorded a reserve for credit losses at September&#160;30, 2020 or December 31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i8fe27d807300404aa0ebf691245fd04d" continuedAt="i63a7838e88f34b9ebff4514b86bcf309"><ix:continuation id="i57f85aa9bd764dcf87388174c4ae017e"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2015, we completed the sale and issuance of $<ix:nonFraction unitRef="usd" contextRef="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTA1MDI_076ec937-e06f-4dab-869a-cc67d13d8a73">250.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTA1Mzg_d8acafd5-a994-4ac2-a952-b1e0d857f077">7.75</ix:nonFraction>% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTA3MzE_e4d434d1-46b8-443b-a321-fcd01a9cc446">7.75</ix:nonFraction>% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would have been due and payable.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $<ix:nonFraction unitRef="usd" contextRef="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTExMjA_34c33653-67dd-47e9-bfcc-192c75377a2b">250.0</ix:nonFraction>&#160;million and accrued interest of $<ix:nonFraction unitRef="usd" contextRef="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestPaidCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTExNDc_120fefa9-fbc6-4ea6-954d-a84a4d30f6d1">4.8</ix:nonFraction>&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.</span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDY_51cbbce0-1ac1-4abd-b62a-39fa7aeebedb" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MTQ_95a40d64-6371-4ae8-bc5e-7f0797270d2f" continuedAt="i1828fa82b0104cd8a7f73769bc0c7e3f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i63a7838e88f34b9ebff4514b86bcf309" continuedAt="i8ea963a8de6b44bc892c019f6d7c50c6"><ix:continuation id="i1828fa82b0104cd8a7f73769bc0c7e3f"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and other Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDQ_ab42048a-c988-47e4-9bde-0ddeabcc3dc9" continuedAt="i93e913543ed540f8a8179bc25ca3f769" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i8ea963a8de6b44bc892c019f6d7c50c6" continuedAt="ic2966823bac04a9b8f21a0d6962610ac"><ix:continuation id="i93e913543ed540f8a8179bc25ca3f769"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $<ix:nonFraction unitRef="usd" contextRef="i4092cae66ba8439e93d82fcef25ef788_I20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:WriteOffOfPrepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjM1OTg_7f9c4147-0b70-4a30-8fe0-4ed46efc607b">19.7</ix:nonFraction>&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $<ix:nonFraction unitRef="usd" contextRef="i4092cae66ba8439e93d82fcef25ef788_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjM3MDA_c45d373f-6f03-4295-b957-48cc64ef8077">25.5</ix:nonFraction>&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program in the three months ended September&#160;30, 2020. As of September 30, 2020, we have substantially completed our wind-down and do not expect additional costs.</span></div></ix:continuation><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTk_04d75785-43cd-476c-8e57-b3670f5fba5c" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security (CARES) Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. We do not expect that the CARES Act will have a material effect on our results of operations or financial position.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDc_462abec8-2a01-4dd4-8eec-1203a410b733" continuedAt="i140c37ddb0ec4dd1bdb6d4aa39f1fa9e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="ic2966823bac04a9b8f21a0d6962610ac"><ix:continuation id="i140c37ddb0ec4dd1bdb6d4aa39f1fa9e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="i76c17a3bff6245868336286074c47608_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjIwMQ_9372ce71-87d4-4087-83a8-cf59064b18e8" continuedAt="iac6a3e1970904df4989de248c3b2ff41" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="iac6a3e1970904df4989de248c3b2ff41" continuedAt="i79342d2b99514f86be0f631544fefdd8"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjIwNQ_cd7d5f3e-a6da-4d18-8ad1-8fdf87ea6265" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMi0xLTEtMS0w_bd57c4ba-ae61-4060-b3fa-c7b5c7b1784f">55,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMi0zLTEtMS0w_3d4dccc0-0182-4e5a-93e0-c3edcb314550">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMy0xLTEtMS0w_87dbcce3-fe13-443f-b5fb-036de6e3c39a">900,163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMy0zLTEtMS0w_68a892b3-0f2d-45f0-9b74-6968ddb7211c">1,228,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNC0xLTEtMS0w_3f5dc393-536a-4224-a0bf-7846162f7db5">197,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNC0zLTEtMS0w_6e0cf04c-6db2-448c-a6e8-4793cf5208c3">279,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNS0xLTEtMS0w_52ebb527-9710-4798-b2e5-0b21fca4fd01">1,153,721</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNS0zLTEtMS0w_ce5549ae-43ac-4da5-a779-6cd8c2861fde">1,603,981</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:durwordsen" name="nktr:DebtInvestmentMaximumMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNDAw_3b7b5d34-db5b-4b0b-b023-dc7040974dfb">two years</ix:nonNumeric> or less and maintain a weighted average maturity of <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" format="ixt-sec:durwordsen" name="nktr:DebtInvestmentMaturityTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNDU1_0f9e4f58-034e-42e9-a619-bd3a64a01ebe">one year</ix:nonNumeric> or less. As of September&#160;30, 2020 and December&#160;31, 2019, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_6487ad2f-0a2c-49f7-a09d-7a3056d0d81a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_fdc76534-bf62-4bbf-b64b-4b7ddc523e0b">one</span></span> and <ix:nonNumeric contextRef="i88d27ec3cd0a45d79c70cd319b7561fe_D20190101-20191231" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQ3_1940f999-ec57-4b95-be73-a5ac198ebe70"><ix:nonNumeric contextRef="ieddedc2d43614f2087b4f389cf2e70c7_D20200101-20200930" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQ3_84f15026-7032-4641-87dc-f153680d4d58">two years</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, we sold <ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjc0ODc3OTA3MTc1MQ_dbd00752-2f4a-4d43-9411-37455fe94245">no</ix:nonFraction> available-for-sale securities. During the nine months ended September&#160;30, 2020, we sold available-for-sale securities totaling $<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNjQw_41e26e15-fb8e-442c-aa4d-26d6685de5ea">41.7</ix:nonFraction>&#160;million. Gross realized gains and losses on those sales were not significant. During the three and nine months ended September 30, 2019, we did <ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNzcz_84eae040-23bd-4f78-b9e0-bb227d752ecd"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNzcz_fa8bf450-6523-4697-b476-8811dc3c882b">no</ix:nonFraction></ix:nonFraction>t sell any of our available-for-sale securities. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $<ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfOTU3_6f22432c-982d-46e1-982c-d230cefa90d3">5.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfOTY0_12ba013b-e718-4926-a527-e59495879494">6.5</ix:nonFraction>&#160;million at September&#160;30, 2020 and December 31, 2019, respectively, in other current assets on our Condensed Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjIwNw_d2799a72-ae29-48fa-8910-9548cba7612a" escape="true"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi0zLTEtMS0w_2f239360-3a26-483c-a49c-74eb87cf221f">831,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi01LTEtMS0w_c95a8264-23c0-4c93-8d26-0ca6d617ab10">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi03LTEtMS0w_a2e832e9-66a3-46f5-a678-4c5f7aa6627c">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi05LTEtMS0w_06a31b7d-3293-4ecd-9e7b-dfd345096832">833,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e7e0b20231423f97aeee88223671b2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi0xMS0xLTEtMA_5fe5ace8-d812-4157-8a02-cbbfef811b21">1,132,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy0zLTEtMS0w_1f029280-1dc6-4c91-8482-6b1af908bcb3">245,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy01LTEtMS0w_87ecc527-7ffc-4a42-85f7-1116f42b9973">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy03LTEtMS0w_166d6dc2-fafe-4ae4-9abc-ef50786ed5a3">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy05LTEtMS0w_e2b4e6b5-02a4-48b5-94d3-a5457e0bad06">245,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad5f6efc6b4bf5a108654c05274301_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy0xMS0xLTEtMA_eed648af-e81e-4b58-bb22-5eb568145e3a">375,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC0zLTEtMS0w_1b536970-21b9-4d38-92d2-45addf7efb96">9,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC01LTEtMS0w_fd29e5f6-7240-452c-9b7e-449249e15189">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC03LTEtMS0w_18bce600-7c86-4f74-aacc-f0c3c13ef816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC05LTEtMS0w_326af3ba-ecfc-4952-9932-ef869ebd0ec5">9,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c58c72e60443e98000bbf5d2344984_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC0xMS0xLTEtMA_3d685abc-e9e2-4498-a99a-131b7e609b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS0zLTEtMS0w_35bc103e-d818-4b75-9b3e-070dbac448b0">1,087,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS01LTEtMS0w_35717a70-512e-452c-bb67-e7240c2cbc11">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS03LTEtMS0w_28011306-de08-4be0-ad74-56d47e78a63f">215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS05LTEtMS0w_416b6ada-0af6-40a7-8bbc-c5daa7f3eea7">1,089,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681a6443e0ce4fa6947d2139b2f64812_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS0xMS0xLTEtMA_8f223e43-58c3-4813-a9c4-2791474a1748">1,507,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdc9da2b38604cb796fa39f895a0a59d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNi05LTEtMS0w_b3dbc435-f9db-4c59-b4c3-c33ebe6ea9e3">48,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ce117291d34d628c9bc23c2c80ca8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNi0xMS0xLTEtMA_0af1bc99-f984-40f0-9e83-07fa6b051cc0">83,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d1299e9f894636b79988ee324b7611_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNy05LTEtMS0w_f89424a2-4357-4861-9d8e-02ff1082fae5">8,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic439350a60194b1db29410760ac99acc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNy0xMS0xLTEtMA_ead809f3-8f5f-4374-a533-0f9a471fa986">6,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOC05LTEtMS0w_7b70fb21-a6a5-4ebe-a15f-ea2d48a7767c">6,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOC0xMS0xLTEtMA_3b2b81a1-aff4-415f-ac6a-b1cdce5071df">5,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOS05LTEtMS0w_c2e8fee6-1d98-4c2b-84f7-705d9080cb5d">1,153,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOS0xMS0xLTEtMA_915ff078-abf7-447d-a202-f196be38fa6f">1,603,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i79342d2b99514f86be0f631544fefdd8"><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2019, our gross unrealized gains and losses totaled $<ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjE3OA_65d2d368-0e08-4d22-a229-35c9d0c9c064">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjE4NQ_59976113-5189-430d-bd75-3f9d59f7336a">0.3</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="i76c17a3bff6245868336286074c47608_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RleHRyZWdpb246ZWZlYWYxNWY2YmQ1NDMxYmI0YmViNTgyN2ZjYzkwZGZfODQ4_8f96cbc4-c4d3-4ae1-a0f2-d89c1d0bd276" continuedAt="i6fb70af8938e4b0ab0c24b437aa8488a" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i6fb70af8938e4b0ab0c24b437aa8488a" continuedAt="i7ba0a7893dfd40b4812e7e215ca9cf04"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RleHRyZWdpb246ZWZlYWYxNWY2YmQ1NDMxYmI0YmViNTgyN2ZjYzkwZGZfODUw_687eb20a-4de2-4c0f-8221-3e748ca8f35a" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMS0xLTEtMS0w_a6cc89e8-956a-4ce4-892b-274102bc15f9">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMS0zLTEtMS0w_585c706a-a003-4263-9950-6e9b9eadbc19">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMi0xLTEtMS0w_8c52c7e6-5237-4cd0-a2fe-1f50822a16f7">11,188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMi0zLTEtMS0w_1602ec9c-d5f5-48d9-960a-fe409f2a4ac6">8,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMy0xLTEtMS0w_4d234618-a0c3-444d-8296-331ec1b06625">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMy0zLTEtMS0w_80d697a8-0dbc-46e5-8d0b-9f5920893729">2,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfNC0xLTEtMS0w_e0abbee6-d20a-4b00-80d0-0631e1b03c3c">12,892</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfNC0zLTEtMS0w_807dcda2-c9bd-4b4f-b7c4-0af026475c66">12,665</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7ba0a7893dfd40b4812e7e215ca9cf04">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RleHRyZWdpb246ZWZlYWYxNWY2YmQ1NDMxYmI0YmViNTgyN2ZjYzkwZGZfODQ0_f327b88d-0654-4f34-97aa-60a4645befb7" escape="true">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric></ix:continuation> </span></div><div id="i76c17a3bff6245868336286074c47608_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMzg2NA_5be8147d-e472-4fbc-b0fb-6b3ebe7e96f4" continuedAt="i262294f8408c4a57be57259cb2471e35" escape="true">Liability Related to Sale of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="i262294f8408c4a57be57259cb2471e35" continuedAt="i36fa233386ee424e83b5e6abc0b0c2da"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="id0c4343e72de4e6dbb67b27ed682ae85_D20120223-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfNjk4_9779ebbf-b387-4df4-b0ef-75dd4fde3576">124.0</ix:nonFraction> million for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="iafb87b6b488548d1888654100aa59ffb_I20120224" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfNzc4_7f728b05-1744-416f-a72e-3b286c489196">4.4</ix:nonFraction> million in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $<ix:nonFraction unitRef="usd" contextRef="id0c4343e72de4e6dbb67b27ed682ae85_D20120223-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTE4MA_cc6888cf-5dac-45c9-851e-c6758bae2f62">124.0</ix:nonFraction> million in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the effective interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. During the nine months ended September&#160;30, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTQ5MA_14da0501-5904-4bd5-a566-e368386a5e2e">28.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTQ5Nw_2bfbc8de-cf65-4b0d-9a07-cd90f03d5d33">27.6</ix:nonFraction> million, respectively, in non-cash royalty revenue from net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we recorded $<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTU5OQ_e2d390cc-67dc-49e5-b90a-57f5e916ec8e">22.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTYwNg_971bc270-197f-4b4d-91c1-c66109d07aa2">17.9</ix:nonFraction> million, respectively, of related non-cash interest expense.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMzg2Mg_fa528f52-c5ad-4568-aa26-7ea9d3776728" escape="true">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.</ix:nonNumeric> From inception through 2017, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately <ix:nonFraction unitRef="number" contextRef="i04a6efe880524704ab1efed03af7179b_D20120223-20171231" decimals="2" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMjE0MQ_7050a022-54b7-40f7-a10c-7378163cdf9b">17</ix:nonFraction>%. We have periodically adjusted our imputed interest rate over the years since inception as actual and forecasted sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have increased and such increases have been sustained. During the three months ended September&#160;30, 2020, primarily as a result of increases in the forecasted sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our estimate of the effective annual interest rate over the life of the agreement increased to <ix:nonFraction unitRef="number" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMjc0ODc3OTA3MzY3Mg_1f1d251a-b2d3-4985-8be1-20b7af0d923a">20.2</ix:nonFraction>%, which results in a prospective interest rate of <ix:nonFraction unitRef="number" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="2" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMjc0ODc3OTA3MzY3OQ_8a040d33-4aee-4460-ad70-3ae5ccfd961d">48</ix:nonFraction>%. Since the proceeds from this agreement are fixed, any future changes in royalty revenue results in an equal corresponding change in imputed interest expense, which would result in changes in the prospective interest rate we use to amortize the liability.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations (often with time limitations) that are customary for a transaction of this nature. For example, we provided representations and warranties concerning intellectual property matters in the Purchase and Sale Agreement; however, the time limitation we have to indemnify </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i36fa233386ee424e83b5e6abc0b0c2da">RPI with respect to any breach of these intellectual property-based representations and warranties has passed. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.</ix:continuation></span></div><div id="i76c17a3bff6245868336286074c47608_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81NS9mcmFnOjVhNTg3MTM3MzMzNjQwOGJhOWFhNzhkMTM3Zjg4ZWJmL3RleHRyZWdpb246NWE1ODcxMzczMzM2NDA4YmE5YWE3OGQxMzdmODhlYmZfNTM2OA_32992d95-8342-49dc-beb3-e1c64b9f2948" continuedAt="i8d031b41d3a24a6cb1d54a1ffacec680" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i8d031b41d3a24a6cb1d54a1ffacec680" continuedAt="i22ac643479b943ee9f1c2877f050cb56"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019. Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On July 13, 2020, the U.S. District Court in California Court granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, stating (among other things) that the amended complaint failed &#8220;to adequately allege that any of the statements &#8230; identified by Plaintiffs were false or misleading.&#8221;  Following the motion to dismiss, on August 10, 2020, the class action plaintiffs filed a second consolidated class action complaint, and the matter remains pending.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either September 30, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 4. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i22ac643479b943ee9f1c2877f050cb56">we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="i5f32928a5bb24c13afe5414f859db8ad_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81NS9mcmFnOjVhNTg3MTM3MzMzNjQwOGJhOWFhNzhkMTM3Zjg4ZWJmL3RleHRyZWdpb246NWE1ODcxMzczMzM2NDA4YmE5YWE3OGQxMzdmODhlYmZfNTI2Nw_3be15b95-2e75-4819-9afe-bcdaed76e823"><ix:nonFraction unitRef="usd" contextRef="ic8dbe95429a94b1c9fd1c219421ebb89_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81NS9mcmFnOjVhNTg3MTM3MzMzNjQwOGJhOWFhNzhkMTM3Zjg4ZWJmL3RleHRyZWdpb246NWE1ODcxMzczMzM2NDA4YmE5YWE3OGQxMzdmODhlYmZfNTI2Nw_da9c5787-c9c7-4087-b7c8-f65f539b4f93">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations in our Condensed Consolidated Balance Sheets at either September&#160;30, 2020 or December&#160;31, 2019.</ix:continuation></span></div><div id="i76c17a3bff6245868336286074c47608_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk3OTg_b37356ab-84c2-4124-9824-a0f550cb9e40" continuedAt="id04767e7bfe042f1a70eaa032374c857" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="id04767e7bfe042f1a70eaa032374c857" continuedAt="i8bcfbebc22754365a54177efea04e136"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk4MDA_5608f3dd-3f70-4d76-8592-4e3fbc59edc2" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:31.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug or Drug Candidate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64de59193e145bbaa8bdb17a62c36da_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi00LTEtMS0w_f8a9f18e-d782-4abd-8557-d36f5c49995e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6d1e8753ba4393b9f44eb4e488b692_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi02LTEtMS0w_eea64df0-8103-4b7c-8428-104af12fa62a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3db9156ad10469f95b14481d96f4a7f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi04LTEtMS0w_aa1b82f4-65d2-4012-9b25-d5b6516f8a73">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68cb20163e74653bd4f64db0c6311c7_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi0xMC0xLTEtMA_f0ae12b0-d1a3-4c2d-9bf6-1ad62935aa09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4343dbd440dc46b69ff260a863af163c_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy00LTEtMS0w_56f56f29-1898-4db5-9684-a63ac98f5e01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7162a81a95b64baeb3fac89305ceb96e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy02LTEtMS0w_9359e51d-38b6-4755-9091-af3cbcd5fda8">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53b17ca10224ac0ac514957ad57da99_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy04LTEtMS0w_4ae0984d-24bb-4b54-8ce7-1106a166f04d">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c27af66b7349d5aea18d07614a95df_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy0xMC0xLTEtMA_b3e5abc6-ca75-4958-9d78-30a2d7cd90ea">5,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen, Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad28b26555d4a329b5591d767c77570_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC00LTEtMS0w_b668cc60-2696-4d50-a313-8c44305fbe48">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18551d4bf36b467d8fdc3c19c639a8b6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC02LTEtMS0w_8d718821-aaa5-4051-8fff-0d4886d66639">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ea63c983d8410db8d44a3393069d40_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC04LTEtMS0w_200c1cd9-49f3-4b20-a6f2-7e41d676d3b4">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ed2104c72e46488602d090a349d252_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC0xMC0xLTEtMA_48fd90d7-ba5e-4e15-ac49-b9e0962567b6">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c1a1a466fb4bc0bc106d1025995c65_D20200701-20200930" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS00LTEtMS0w_d74878d2-7fb6-4cad-bad1-8a8b90d7d3d0">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76e0a45148544e2a7c2e165f1d8e4ab_D20190701-20190930" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS02LTEtMS0w_5ef20af9-8fce-42a3-bec3-c7a68f34873d">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee96693c04e4f7db443a9718ecae73f_D20200101-20200930" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS04LTEtMS0w_154d3d2f-fbe0-472c-a078-070430e1b1f7">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5211c0643104c9bae3e1bc6a61751c3_D20190101-20190930" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS0xMC0xLTEtMA_4ec58440-8d6e-4a04-8a54-2616916f9fd9">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi00LTEtMS0w_55e330c9-aec7-477c-b28f-7afd978abbe1">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi02LTEtMS0w_dc3a9fb7-658f-4021-9919-dfe0c952f0e7">3,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi04LTEtMS0w_2967b3a9-a4a7-4347-aef6-80451a4aeaf4">55,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi0xMC0xLTEtMA_588c4fcd-a182-4cba-ac44-bfeea7f641bb">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTE2Mg_b58daba4-6aaf-474d-9331-2f6c0ec128e1">22.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTE2OQ_aeb3604b-8a0f-4423-a5c8-f0688ab5c2e3">109.4</ix:nonFraction>&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as $<ix:nonFraction unitRef="usd" contextRef="i01e0829dcbda4d3cb7e7f5488eaa3b04_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="nktr:SalesMilestoneRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTM2Mg_48ca4222-5734-47e1-a72e-9fff4189677d">50.0</ix:nonFraction>&#160;million in BMS Collaboration milestones received in the nine months ended September 30, 2020, as further described below.</span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk3OTY_df88aeee-4907-4778-9b8b-77a9005b9ec6" escape="true"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:84.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOmExYmE0NGY3ZmI4ZDRmMDNhYzI4ODNkOWRkNjgzOGMxL3RhYmxlcmFuZ2U6YTFiYTQ0ZjdmYjhkNGYwM2FjMjg4M2Q5ZGQ2ODM4YzFfMS0xLTEtMS0w_25f2cae1-97e4-4714-b0a2-111fdc785842">8,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of previously unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOmExYmE0NGY3ZmI4ZDRmMDNhYzI4ODNkOWRkNjgzOGMxL3RhYmxlcmFuZ2U6YTFiYTQ0ZjdmYjhkNGYwM2FjMjg4M2Q5ZGQ2ODM4YzFfMi0xLTEtMS0w_6ed26947-4ff8-4b4d-8862-6be26800f89f">5,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOmExYmE0NGY3ZmI4ZDRmMDNhYzI4ODNkOWRkNjgzOGMxL3RhYmxlcmFuZ2U6YTFiYTQ0ZjdmYjhkNGYwM2FjMjg4M2Q5ZGQ2ODM4YzFfMy0xLTEtMS0w_d997fa55-3069-414a-bfcb-418ef1f77595">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTkxNw_79d346cb-b26f-4cad-9c81-5bea4ca41cbc">1.7</ix:nonFraction> billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three and nine months ended September&#160;30, 2020, except as described below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing <ix:nonFraction unitRef="number" contextRef="iac03f04314684a77ac56ecd63ce7fd06_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzIxOQ_ed712079-f7d4-4087-b3b2-1dcd34daf558">65</ix:nonFraction>% and BMS sharing <ix:nonFraction unitRef="number" contextRef="idea06231b1c44280b52f314d797baf6f_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzIzOA_07e6b456-8d9e-4722-8c1c-16365dee9b96">35</ix:nonFraction>% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i8bcfbebc22754365a54177efea04e136" continuedAt="ib4a04b571e754f2a98ac68422a040a4d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="i3ebd9a821b2a46cfb77bd1fed0e162c0_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzU5NA_39083b35-e7e8-4772-bf94-c17150d963af">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="i6c5e9092d71c49cc890b7c52af5e1209_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzYxNw_e8364641-03dd-4e46-9c5d-ea72a35a51c4">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="idea06231b1c44280b52f314d797baf6f_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzgxMg_a22d9cdc-5a49-4dda-a5ed-d1f41e7c5543">35</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="iac03f04314684a77ac56ecd63ce7fd06_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzgzNQ_ae7cd0fc-b807-4c8b-899a-15fa0b7f21b0">65</ix:nonFraction>% to Nektar.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i839037e7f6a34cd693275417607356c0_D20180401-20180430" decimals="-8" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzk3Ng_83a1059f-2ebf-40cd-9a96-9240bb80e88c">1.0</ix:nonFraction> billion. We are eligible to receive additional cash payments up to a total of approximately $<ix:nonFraction unitRef="usd" contextRef="i99091a9d1fe04ff8974bd1aaf88b38b4_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDA2Mw_f5b45bbf-39c8-49c0-a1c8-c2b7089a262d">1.455</ix:nonFraction> billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones, and up to a total of $<ix:nonFraction unitRef="usd" contextRef="i6ab76208d9ee4ff2988ff083957e0c4b_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDM3OQ_80036199-b66d-4f1e-9bde-990509b4f7b8">350.0</ix:nonFraction> million upon the achievement of certain sales milestones. In April 2018, BMS also purchased <ix:nonFraction unitRef="shares" contextRef="ia70be8a1e2a64792b0121d05ff80c80d_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDQ2Ng_2330bbd2-9bcd-4cc6-8a63-bec2b2643534">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i1580321c09614031b9d42400c15746cf_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="nktr:SaleOfStockConsiderationReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDU4MA_1e4f9b1a-6637-4b0b-9d56-4cf4e1fde2f6">850.0</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i62d453fedad74b76a89c1def968cf6c9_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMjc0ODc3OTA5NDA4MQ_4a552cf8-b63a-4f87-a8e8-1a54d7bcfd82">25.0</ix:nonFraction>&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i62d453fedad74b76a89c1def968cf6c9_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNTAxNg_703dae9b-6307-4aaa-9997-586acc9bcf29">25.0</ix:nonFraction>&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we aggregated the total consideration of $<ix:nonFraction unitRef="usd" contextRef="ib62bb08ae1ed42499bf0502605a0aabd_D20180101-20181231" decimals="-7" format="ixt:numdotdecimal" name="nktr:AggregateConsiderationReceivedFromAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjM0NA_4b59a3e3-6b83-46d1-8323-af5cc4781f80">1.85</ix:nonFraction> billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $<ix:nonFraction unitRef="usd" contextRef="i3a47c82fe5384724ac972e8f0118a042_I20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:EstimatedFairValueOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjY5NQ_eabc6629-58a7-4015-ba08-f03b5794497d">790.2</ix:nonFraction> million in stockholders&#8217; equity. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="ib62bb08ae1ed42499bf0502605a0aabd_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjc1MA_18aa37f9-d2ea-42ed-b3b3-87134170c403">1,059.8</ix:nonFraction> million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i3a47c82fe5384724ac972e8f0118a042_I20181231" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentRegulatoryAndSalesMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjk0MA_110d1d82-ff9d-4ada-8c7b-22121f3e664d">1.8</ix:nonFraction> billion to be variable consideration. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, we updated the transaction price by $<ix:nonFraction unitRef="usd" contextRef="i55e78d80f65f41df99be245f4785d48d_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNzA1Ng_5b513ded-9312-4970-8625-efbe5a763b0d">25.0</ix:nonFraction>&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial. During the three months ended June 30, 2020, we updated the transaction price by $<ix:nonFraction unitRef="usd" contextRef="i4ca0ee0445d2406481c1a68226274962_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNzI1NA_05edc301-14e0-4b60-8ab7-60561786350c">25.0</ix:nonFraction>&#160;million for the milestone for the first patient, first visit in the registrational adjuvant melanoma trial because we concluded that a reversal of the milestone was not probable. Since we had already completed our sole performance obligation of delivery of the licenses, we recognized $<ix:nonFraction unitRef="usd" contextRef="i345310330b5c404386610c6ffb7eb919_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNzY0OA_1e1f7946-a336-435b-8bdd-6564652922fa">50.0</ix:nonFraction>&#160;million in license, collaboration and other revenue during the nine months ended September&#160;30, 2020. We continue to exclude the other milestones from the transaction price as of September&#160;30, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the three and nine months ended September&#160;30, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i91f01add1280492bb87f2040bd86e237_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfODkzNw_36c5dbf1-b22a-4966-a9b7-e75c6902ba15">29.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i399485e14223466ab18e166f27bb67af_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfODk0NA_f6473b10-91bc-4af4-9428-5bca27169468">93.8</ix:nonFraction>&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. During the three and nine months ended September&#160;30, 2019, we recorded $<ix:nonFraction unitRef="usd" contextRef="i3e9a8b5809804afe80662a5640dc611a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTEzNA_f62236f5-9e21-4e6b-be86-336272ab9657">28.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ide0ac9a686224749809a811eb1aee975_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTE0MQ_dc333bd7-91f0-473e-a98e-ba5a694276e3">81.4</ix:nonFraction>&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.&#160;As of September&#160;30, 2020, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="ie5f9ecd4583d46a880165db35da02267_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTMzMA_b7c8c80e-4979-43f2-b2fe-34013b497044">29.9</ix:nonFraction> million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTc0NQ_d20ea313-b9e9-481f-92be-345f828a454a">150.0</ix:nonFraction> million in September 2017 and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i972a45764b0e465282335687170894e5_I20170823" decimals="INF" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTc5Mw_162c70c2-f9b5-4611-852e-5f06d62ac03c">250.0</ix:nonFraction> million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and are responsible for certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with <ix:nonFraction unitRef="number" contextRef="i845230a255e24070ad64f4430f5f672e_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAwODk_bd681273-b43b-4cd7-a21e-771cf2076bd3">75</ix:nonFraction>% of those costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="ifa275d5aaa564026bf559d0b72b3f69f_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAxMjY_593cb609-e174-419c-a1f2-e1b659d0d3c0">25</ix:nonFraction>% of the costs borne by us, (iv) will have the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="ib4a04b571e754f2a98ac68422a040a4d" continuedAt="i914712e87da5467fa24415eca052dee6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from <ix:nonFraction unitRef="number" contextRef="i1a6b27f69ae44774a99f76b9be930ea9_D20170822-20170823" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAyNzY_317629e3-2582-46cb-860b-5a4889d45b42">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i82c5b100e5d54cb1b29df1fb69b79fcf_D20170822-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAyODI_310aa385-17a9-4f36-93e5-9f91c2adaf31">25</ix:nonFraction>% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="i1fd4979f3b7b4006aa4dc73336bb0e51_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTA3MTA_a2cb92b2-33d5-4e7c-b900-5a11a4312b00">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="i1fd4979f3b7b4006aa4dc73336bb0e51_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTA5NDU_dfbd8351-4a63-4d32-a3b2-24555d4b7e4d">75</ix:nonFraction>% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through September&#160;30, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI2NTQ_b978815e-203a-4771-b51f-5981fa00ef87">150.0</ix:nonFraction> million received in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $<ix:nonFraction unitRef="usd" contextRef="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI3ODE_919a8925-93d3-44c2-95c1-5b9203ed9cb8">150.0</ix:nonFraction> million upfront payment as $<ix:nonFraction unitRef="usd" contextRef="i825ba9383adc4f57b11ab95a166bb2c3_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI4MDM_1320c68b-b99a-448f-8dec-bb136ffa8b89">125.9</ix:nonFraction> million to the license, $<ix:nonFraction unitRef="usd" contextRef="i8ac727c6b64f4df7857a4b3e2d0ea358_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI4MjI_cd7b59d0-5768-4d86-b1ea-6ccaaf8329ef">17.6</ix:nonFraction> million to our portion of the Phase 1 clinical development and $<ix:nonFraction unitRef="usd" contextRef="i1f4bc86daabe478d9199134b3ced767a_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI4ODA_8a95c27b-23ee-443d-b6ac-ddd67a21a660">6.5</ix:nonFraction> million to the drug product development.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the $<ix:nonFraction unitRef="usd" contextRef="icd4450164353469089e6a5715b63820c_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI5MzQ_ff930a6f-6490-4c4d-ac67-5b871b0f4e6f">125.9</ix:nonFraction> million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of September&#160;30, 2020, we have completed our performance obligations and we have no deferred revenue related to this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Inc. / Takeda Pharmaceutical Company Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Hemophilia</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Hemophilia A program includes ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $<ix:nonFraction unitRef="usd" contextRef="i5825f573d218444c8a02aa2a76c1e143_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTQ4NDE_13391f79-efb7-4267-954c-3de640f1ca44">10.0</ix:nonFraction> million development milestone, which we received in March 2018. During 2018, we earned an additional $<ix:nonFraction unitRef="usd" contextRef="i01a3e8af9af343f3af75c19ca2ff410e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTQ5Mzc_a9c90f11-28ad-4bf8-a417-76ff7c8e9930">10.0</ix:nonFraction> million milestone for annual sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $<ix:nonFraction unitRef="usd" contextRef="icf21631db7ee40ac9b0a17f839fb1811_D20171101-20171130" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentsReceivedUnderRightsToSublicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTU1NDY_8a25c572-0fa5-460a-8e2d-c1c1beb5b9cb">12.0</ix:nonFraction> million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><ix:continuation id="i914712e87da5467fa24415eca052dee6"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of September&#160;30, 2020, our deferred revenue from this arrangement is not significant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.: Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a $<ix:nonFraction unitRef="usd" contextRef="ic45d9817ecdf46ae9c87ba4e76263729_D20101001-20101231" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTYzNjc_62c23179-e31f-4b8f-8ddc-5f4f9afb2cc9">50.0</ix:nonFraction> million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. As of September&#160;30, 2020, we have deferred revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i2981e0957f0f4a1695bcd34c346c09c3_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTcwMjY_e2bff106-b375-420f-a4cc-ee94873d56f5">0.4</ix:nonFraction> million related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2014 and December 2014, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> /MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the US and EU, respectively. As of September&#160;30, 2020, we have received a total of $<ix:nonFraction unitRef="usd" contextRef="i0c367beebd6f4d79ba026bb215d28964_D20090901-20151231" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTc3NjQ_03d568e4-f29a-4351-b38d-d2dc98324c68">385.0</ix:nonFraction> million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving <ix:nonFraction unitRef="number" contextRef="i5cfa614f55b340eca7394aa4a2d91432_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTg1MzU_c7d3ad09-8013-4274-baec-049da7f2fda0">60</ix:nonFraction>% and Nektar receiving <ix:nonFraction unitRef="number" contextRef="i26da6534944946e088095dadd2086834_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTg1NTk_bcc6fa66-9232-4104-94b4-76b5631e0b92">40</ix:nonFraction>%. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we do <ix:nonFraction unitRef="usd" contextRef="i007147b59fd8496894c45965e29e7c2e_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTg1ODA_a7cfe093-30ec-437d-8e80-5702665577bd">no</ix:nonFraction>t have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of September&#160;30, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma and Pfizer, Inc., under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="i11cfe9f36c27416a8410b5c100442563_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTkxNjE_73173e96-7ba0-460a-b101-05699b79b3a7">40.0</ix:nonFraction> million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of September&#160;30, 2020, we have deferred revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i11cfe9f36c27416a8410b5c100442563_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk3NDU_e941c5f8-1934-49ab-b9dd-2aaff4021304">2.0</ix:nonFraction> million related to these other collaboration agreements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAxNQ_5f04e5f7-6099-44b9-8655-d3ee77490d5a" continuedAt="i2297514fe4884c14bdfddc0f97f93b3b" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i2297514fe4884c14bdfddc0f97f93b3b"><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAxMg_b69c84dd-d50e-4448-8272-118266eb4f47" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:47.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d135950a41412bbe0141268927497b_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi0xLTEtMS0w_107472e7-2a65-49fc-a620-f763f99ac897">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2917a58fe349269bb836b1b174986d_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi0zLTEtMS0w_2e619715-a958-4f76-92c8-77037b5dda73">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia646a70ced924165adc2d5633324fb08_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi01LTEtMS0w_e16627bf-71ac-406c-aed2-f8fe4b542a4b">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c2ed5b2588478a815cd96dd3fa4d70_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi03LTEtMS0w_4f4a24fd-f608-4cbf-a8cc-8a75f389517b">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ed0979123649adb4dc059466490ec4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy0xLTEtMS0w_73576421-4dc1-45d5-b986-a4466f37c7e1">14,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4f7a1f2a934d41827c699b4ead106e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy0zLTEtMS0w_95f8b4f4-57f2-456f-9784-70e3fbebbf90">15,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421586bc96a448849e0605a587727f4c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy01LTEtMS0w_1046901b-9c5a-4068-ba9b-d1c6c0cc04af">43,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ee132789b94f38b825c9ceecbd65a6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy03LTEtMS0w_497fbf81-3e37-4d12-9734-77f1969cd5aa">47,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8af90d2ea34d3e9c87ef4323285570_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC0xLTEtMS0w_1569e770-a2d4-413e-abb4-57a029db6512">8,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac31e6a7286d4bbfa722ce15fd4b5f5d_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC0zLTEtMS0w_6f704ce8-9149-4166-8c0a-32ba36dad55c">8,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69fe287ef8140e69c41a0fc1cf62e80_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC01LTEtMS0w_cf54cb8c-ece0-41f8-8b84-273f3ccb46be">25,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f16026628714f2a9d7e1c922ae55c2f_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC03LTEtMS0w_aa3f69b6-be36-4c7f-80aa-b2bcd9d085ab">24,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30945d826eaa4db1aee3efa6d35c52bf_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS0xLTEtMS0w_5812d6b8-01b8-452f-b6de-da7556fd1b9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1bab0b44b74b74ab8679821ad533a9_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS0zLTEtMS0w_fade4827-5186-47df-b49c-68c2ffc0b2a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e080a50510b45d7985955e0bc237be8_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS01LTEtMS0w_e1034031-832e-48f3-888b-f8ae182d9a05">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6b1642d5d74c94b8fc02f648ad3e3a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS03LTEtMS0w_1547d22e-d9d4-404d-b33c-75e159517e58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi0xLTEtMS0w_a2c7a980-cbfa-4287-aaf1-a263672a571b">23,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi0zLTEtMS0w_b1c95a65-2e1a-4268-8aa1-f529d494652c">24,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi01LTEtMS0w_eb3ed979-5a75-4689-8bff-21684aec65ed">72,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi03LTEtMS0w_7fabea2b-41a7-46cf-b4cd-a3813c509f7b">74,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we accounted for as a liability award. Upon issuance of the award in the three months ended June 30, 2020, we reclassified the award into equity.</span></div><ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAxNA_8ed515b5-5afb-48ac-ad88-0b47370588fc" escape="true"><div style="margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:47.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8ebfaa0c2694404bb2fe78ec756a33b_D20200701-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi0xLTEtMS0w_8a9b1037-62b8-448e-bf8c-d7a67a2fc7a7">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd21aca8ffb4b5b93b574af7f8c16bc_D20190701-20190930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi0zLTEtMS0w_c354a88f-98c2-4a35-844c-7d8278a0b2ec">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39cc4e2705b448d299937048e267e868_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi01LTEtMS0w_50e60ddf-7ccf-419a-855f-7f055b6fd024">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if19b4a9eac04440dae63a1c159632e2a_D20190101-20190930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi03LTEtMS0w_5f79e228-7d4a-48df-934b-0a49d5a455d1">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie8ebfaa0c2694404bb2fe78ec756a33b_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy0xLTEtMS0w_55d1fd81-4587-4283-b5c7-9a7dc37566bf">11.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bd21aca8ffb4b5b93b574af7f8c16bc_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy0zLTEtMS0w_b8d901e6-7d65-4751-9f05-19b881d09760">13.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i39cc4e2705b448d299937048e267e868_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy01LTEtMS0w_b0a0be77-2932-47a0-a77d-ecb58a4660af">11.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if19b4a9eac04440dae63a1c159632e2a_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy03LTEtMS0w_642b6f36-5d9f-49f2-8df5-fe5e29e6aa40">15.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib03e08fc98c644e6be4bef8a349474ac_D20200701-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC0xLTEtMS0w_fdc985a1-3d46-47fc-975f-0321f6aa59f7">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1d349f8e26343058e7e9dd3492bdb7e_D20190701-20190930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC0zLTEtMS0w_010eb307-8628-476c-9286-3c31986a375a">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6c6d347086b42f780f70922a18208d4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC01LTEtMS0w_d8c62307-f7da-404a-a67b-d75ef923e3f6">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2129dcc350a4c9fb39c6f59f2f20fe8_D20190101-20190930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC03LTEtMS0w_84575bcd-a870-4062-ab50-232110cbf974">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib03e08fc98c644e6be4bef8a349474ac_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS0xLTEtMS0w_5bdff9b5-ae21-410c-aa30-38fc171d0914">21.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1d349f8e26343058e7e9dd3492bdb7e_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS0zLTEtMS0w_56e75a82-45ed-4e02-ac46-d680c38c7609">28.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6c6d347086b42f780f70922a18208d4_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS01LTEtMS0w_6eeb7d23-3ad5-4216-a727-b5c23ef7f068">21.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2129dcc350a4c9fb39c6f59f2f20fe8_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS03LTEtMS0w_9ae2f07f-d987-4364-b48c-8cda5e0adcc4">31.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi0xLTEtMS0w_6f22e8fe-7e87-4439-bb78-24a7316114c0">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi0zLTEtMS0w_597dcec1-dff9-4f9c-b2cc-c39370442ca3">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi01LTEtMS0w_c05076ed-6453-46e2-b0b1-813457352d67">2,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi03LTEtMS0w_ed78eb10-b160-47d2-b207-d869f9c072ce">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2020, the Stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="i8432c50c56094a11aa02e5f29d960026_D20200617-20200617" decimals="INF" format="ixt:numdotdecimal" name="nktr:CommonStockAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfODAx_b16c54bd-3f7a-455f-9248-ed0a5d036641">10,000,000</ix:nonFraction> shares, and an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by <ix:nonFraction unitRef="shares" contextRef="i3bf8410935d84e55bd4f0436c35fcb2c_D20200617-20200617" decimals="INF" format="ixt:numdotdecimal" name="nktr:CommonStockAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAwMw_5ba392c8-cba0-4398-a8f2-b1ae9b12aec2">1,000,000</ix:nonFraction> shares.</span></div></ix:continuation><div id="i76c17a3bff6245868336286074c47608_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8212; <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RleHRyZWdpb246NDAxNjg2ZWEzYmJmNDQyMWExMDNmMGRhMDY3ZmY4OTNfOTQ0_8c650b10-5be7-4516-a039-0f9a1c55e53a" continuedAt="i669d9f0e3b1045a0ba98154f725af070" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i669d9f0e3b1045a0ba98154f725af070"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. <ix:nonNumeric contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RleHRyZWdpb246NDAxNjg2ZWEzYmJmNDQyMWExMDNmMGRhMDY3ZmY4OTNfOTQ3_79cc949f-4587-48c4-a8ea-6e150941750f" continuedAt="i2ae4f3d644a84bf79e0ea5690b155991" escape="true">During the three and nine months ended September&#160;30, 2020 and 2019, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i2ae4f3d644a84bf79e0ea5690b155991"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:47.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi0xLTEtMS0w_24c72de7-1dc6-4fd8-97d0-cebf8a11ed2e">16,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi0zLTEtMS0w_d0304230-901f-4550-a12b-6bcb0b080ff0">17,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi01LTEtMS0w_564ece33-dbfb-42ee-9de0-cfe479c46f35">17,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi03LTEtMS0w_a670ff1b-94f7-4eec-b9b6-6f12984f1922">18,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div id="i76c17a3bff6245868336286074c47608_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and viral infections. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immuno-oncology (I-O), we are executing a clinical development program for bempegaldesleukin (previously referred to as NKTR-214), in collaboration with Bristol-Myers Squibb Company (BMS) as well as other independent development work evaluating bempegaldesleukin in combination with other agents with potential complementary mechanisms of action. We announced in August of 2019 that the FDA granted a Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with untreated unresectable or metastatic melanoma. We expect our research and development expense to continue to grow over the next few years as we expand and execute our broad clinical development program for bempegaldesleukin. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into an Amendment No.&#160;1 (the Amendment) to the Collaboration Agreement. dated February 13, 2018 (the BMS Collaboration Agreement). Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. Specifically, pursuant to the updated Collaboration Development Plan, bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently being evaluated in ongoing registrational trials in first-line metastatic melanoma, first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), muscle-invasive bladder cancer, and adjuvant melanoma, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with either axitinib or cabozantinib in first line RCC in order to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently underway. Also, as specifically allowed under the BMS Collaboration Agreement, Nektar is independently studying bempegaldesleukin in combination with pembrolizumab in a non-small cell lung cancer (NSCLC) Phase 1/2 trial.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amendment did not alter the cost-sharing methodology under the BMS Collaboration Agreement. The parties share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share clinical development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BMS 67.5% and Nektar 32.5%. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. BMS supplies Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> free of charge. We also share commercialization related costs, 35% BMS and 65% Nektar, which we present in general and administrative expense. Our share of development costs is limited to an annual cap of $125.0 million. To the extent this annual cap is exceeded, we will recognize our full share of the research and development expense and BMS will reimburse us for the amount over the annual cap which will be recorded as a contingent liability. This contingent liability will generally be paid to BMS only if bempegaldesleukin is approved and solely by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Collaboration Agreement entitles Nektar to receive up to $1.455 billion of clinical, regulatory and commercial launch milestones. Of these milestones, we received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. Of the remaining milestones, $625.0 million are associated with the approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (which reflects the reduction for the $25.0 million nonrefundable, creditable milestone for the first patient, first visit in the muscle-invasive bladder cancer trial). As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the collaboration development plan with BMS, we are conducting and pursuing additional I-O research and development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to enhance the standard of care in multiple oncology settings. With our non-BMS clinical collaborations for bempegaldesleukin, we generally share clinical development costs on a substantially pro-rata basis commensurate with our ownership interest in the underlying compounds. We expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging scientific findings in cancer biology and preclinical development work.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2020, we received FDA clearance for an Investigational New Drug application for bempegaldesleukin to be evaluated in a Phase 1b clinical study in adult patients who have been diagnosed with mild COVID-19 infection. The study design allows us to evaluate whether bempegaldesleukin&#8217;s adaptive immune-stimulating mechanism to promote priming and proliferation of T cells and NK cells could be useful in the emerging treatment options for COVID-19. Enrollment in the Phase 1b randomized, double-blind, placebo-controlled study is planned to start in early November. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing other molecules, including NKTR-262 and NKTR-255, in our I-O portfolio. NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic bempegaldesleukin in order to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. The Phase 1/2 dose-escalation and expansion trial of NKTR-262 in patients with solid tumors is currently ongoing. NKTR-255 is a biologic that targets the interleukin-15 (IL-15) pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8 memory T cells. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody dependent cellular cytoxicity molecules as well as enhance CAR-T therapies. We have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. We also have initiated a Phase 1 study for NKTR-255 in solid tumor settings.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, we are developing NKTR-358, which is designed to correct the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358. We received an initial payment of $150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones. We were responsible for completing Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the Phase 3 development costs and receive a royalty rate on global NKTR-358 sales up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. Results from this study demonstrated a multiple-fold increase in regulatory T cells with no change in CD8 positive or natural killer cell levels and no dose-limiting toxicities were observed. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis, has initiated a Phase 2 study in SLE in October 2020, and is planning to initiate a Phase 2 study in ulcerative colitis. Under the terms of the agreement, Lilly is to initiate two additional Phase 2 studies in other auto-immune diseases.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were developing NKTR-181 for the treatment of chronic low back pain in adult patients and had submitted an NDA for NKTR-181. At the FDA advisory committee meeting held on January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of NKTR-181, and, as a result, we withdrew the NDA and decided to make no further investment commitments to this program.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level of our future research and development investment will depend on a number of trends and uncertainties including clinical outcomes, future studies required to advance programs to regulatory approval, and the economics related to potential future collaborations that may include up-front payments, development funding, milestones, and royalties. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements including the BMS Collaboration Agreement, pursuant to which we have recognized $1.11 billion in revenue and recorded $790.2 million in additional paid in capital for shares of our common stock issued in the transaction. While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, including the potential remaining $1.405 billion in development and regulatory milestones under the BMS collaboration, in the medium- to long-term, our plan is to generate significant commercial revenue from proprietary products including bempegaldesleukin. Since we do not have experience commercializing products or an established commercialization organization, there will be substantial risks and uncertainties in future years as we build commercial, organizational, and operational capabilities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalties and milestones from two approved drugs. We have a collaboration with AstraZeneca for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with non-cancer pain which was approved by the FDA and subsequently launched in March 2015 and MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives, which was approved by health authorities in the European Union and many other countries beginning in 2014. We also have a collaboration with Baxalta Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd.) for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that was approved by the FDA in late 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by health authorities in Europe in January 2018, and has also been approved in many other countries.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A. Risk Factors.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the approved drugs and clinical development programs described above are key elements of our future success, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research that we are preparing to advance into the clinic in future years. We are also advancing several other drug candidates in preclinical development in the areas of I-O, immunology, and other therapeutic indications. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market value.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of the COVID-19 Pandemic</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, COVID-19, the disease resulting from a novel strain of coronavirus infection, was declared a global pandemic. Many countries, including the United States and India, initially took steps such as restricting travel, closing schools, and issuing shelter-in-place orders to slow or moderate the spread of the virus.  More recently, states and countries have adopted individualized approaches to respond to the COVID-19 pandemic. In particular, local resurgences in number and rates of infections, and the further spread of the virus may result in the return of prior restrictions or the institution of restrictions in the affected areas. Although vaccines intended to reduce the incidence of infection are in development, it remains unclear how long the negative impacts caused by the coronavirus will continue into the future.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, with respect to the operation of our facilities, we are closely adhering to applicable guidelines and orders.  Essential operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with the permissions granted under government ordinances. Across all our locations, we have instituted a temporary work from home policy for all office personnel who do not need to work on site to maintain productivity. At this time, we have not identified a material change to our productivity as a result of these measures, but this could change, particularly if restricted travel, closed schools, and shelter-in-place orders are not removed or significantly eased in the areas in which we operate.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety and well-being of our employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We believe that the safety measures we are taking and instructing our contractors to take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials.   </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are currently engaged in the clinical testing of our proprietary drug candidates and the COVID-19 pandemic introduces significant challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have thus far had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic. The rapid development and fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on our clinical trials, our operations and our business. As a result, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our specific clinical programs as discussed below, is difficult to predict and subject to change.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, for the ongoing registrational clinical trials studying the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cancer indications being led by Nektar (such as adjuvant melanoma, RCC and first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer), although we have not seen evidence to date that the COVID-19 pandemic has had a significant impact on enrollment for these trials, the future impact of the COVID-19 pandemic on these trials is very difficult to predict and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Nektar&#8217;s Phase 1/2 trial studying bempegaldesleukin and pembrolizumab in NSCLC, although the COVID-19 pandemic delayed the initiation of certain investigator sites in Europe earlier in the trial, we currently expect to have initial safety as well as preliminary overall response rate data for an initial set of patients in the dose-escalation and NSCLC cohorts of this study by the first part of 2021. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Nektar&#8217;s ongoing clinical study of NKTR-262 (the Phase 1/2 REVEAL study), this study has largely remained on track although we have experienced some challenges with new investigator site initiations. Nektar's Phase 1 clinical study of NKTR-255 in patients with relapsed/refractory hematologic malignancies has enrolled slower than anticipated due to challenges caused by the COVID-19 pandemic, and the dose-escalation monotherapy portion of the study is expected to be completed in the first quarter of 2021. For both of these Nektar-run clinical programs, the ongoing COVID-19 pandemic could still impact investigator site initiations and trial enrollment despite our mitigation efforts.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For clinical studies of our proprietary drug candidates being run by our partners, BMS is enrolling patients in each of the BMS-led registration studies and has re-started initiation of new investigator sites following a pause in the initiation of new investigator sites it instituted for all of its studies as a result of the COVID-19 pandemic. Earlier in the summer, BMS extended their timeline estimates by approximately six months for the first data read-outs for the first-line melanoma trial. We will continue to monitor the progress of the BMS-led studies. Our partner Lilly, which is running clinical trials of NKTR-358, has indicated it will likely have delays of at least three to six months following its temporary suspension of recruitment for the ongoing Phase 1b studies in atopic dermatitis and psoriasis as a result of the COVID-19 pandemic. Lilly recently started a Phase 2 study in moderate to severe lupus patients in October and is planning to start an additional Phase 2 study in ulcerative colitis before the end of the year. The rapid development and fluidity of the COVID-19 pandemic preclude any firm estimates as to the ultimate effect this disease will have on our collaborator&#8217;s clinical trials. As a result, there remains substantial uncertainty as to potential impacts on our collaboration partner studies.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to our IND-enabling research, although the COVID-19 pandemic has caused us to reduce the number of employees working at our sites, a subset of our research-based employees continues to conduct laboratory work in our research facilities (which is permitted under the applicable government ordinances). As a result, we continue to make progress in the identification of new drug candidates.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients. Particularly, in the context of our clinical trials directed to investigational cancer treatments, for example, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for patient visit delays caused by limited access to healthcare facilities, to leverage alternative methods for maintaining clinical trial integrity, and to properly record patient event data that may be influenced by the COVID-19 pandemic.  In addition, to the extent that the integrity of individual patient data is negatively affected by the COVID-19 pandemic, we will consider measures to maintain the integrity of the clinical study overall (such as over-enrolling patients into the study and removing all patients originating from an affected study site when performing statistical analyses of study endpoints). Although these measures may have the benefit of preserving the overall integrity of a clinical study, implementing these measures could result in a delay in completing the study.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this respect, we are also incorporating recent direction and flexibility provided by regulatory authorities, including the United States Food and Drug Administration in its March 18, 2020 Guidance (most recently updated September 21, 2020) entitled &#8220;FDA Guidance on Conduct of Clinical Trials of Medicinal Products during COVID-19 Public Health Emergency.&#8221; This Guidance is continually being updated by FDA and updates can be found on the FDA&#8217;s website at www.fda.gov. In addition, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may refer to guidance documents from other regulatory agencies, such as, for example, the European Medicines Agency&#8217;s &#8220;Implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials&#8221; found on www.ema.europa.eu, which are also continually being updated.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans through at least the next twelve months. As of September&#160;30, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million. See Note 1 to our Condensed Consolidated Financial Statements for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three and Nine Months Ended September 30, 2020 and 2019</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:49.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,453&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales were consistent for the nine months ended September&#160;30, 2020 as compared to the nine months ended September&#160;30, 2019. We expect product sales for the full year of 2020 to be lower than 2019. At this time, we do not anticipate that effects of the COVID-19 pandemic will impact our product sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue from certain of our collaboration partners based on their net sales of commercial products. Royalty revenue for the nine months ended September&#160;30, 2020 increased as compared to the nine months ended September&#160;30, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 due to increases in the net sales of the underlying commercial products of our collaboration partners. At this time, we cannot estimate the effects of the COVID-19 pandemic on the net sales of the commercial products of our collaboration partners and our resulting royalty revenues.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Royalty Revenue Related to Sale of Future Royalties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of our research and development services, and entering into new collaboration agreements, if any.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, we recognized $25.0&#160;million in license, collaboration and other revenue for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial under the BMS Collaboration Agreement. During the three months ended June 30, 2020, we recognized $25.0 million in license, collaboration and other revenue for the milestone for the first patient, first visit in the registrational adjuvant melanoma trial, also under the BMS Collaboration Agreement. Although we did not achieve the first patient, first visit until July 27, 2020, in the adjuvant melanoma trial, we concluded that a reversal of the milestone was not probable as of June 30, 2020. As a result, license, collaboration and other revenue increased during the nine months ended September&#160;30, 2020 as compared to the nine months ended September&#160;30, 2019 due to the recognition of these milestones. We expect that our license, collaboration and other revenue will increase significantly in the full year of 2020 compared to 2019 as a result of the recognition of the two milestones under the BMS Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Product Gross Margin (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Percentage change represents improvement, since the negative gross margin has decreased.</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin was negative for the nine months ended September&#160;30, 2020 and September&#160;30, 2019. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. In addition to product sales from reagent materials supplied to the partner where our sales are less than our fully burdened manufacturing cost, we also receive royalty revenue from this collaboration. In the three and nine months ended September&#160;30, 2020 and 2019, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We currently expect product gross margin to be negative in 2020 as a result of the manufacturing arrangement described above.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.126%"><tr><td style="width:1.0%"></td><td style="width:47.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for the three months ended September&#160;30, 2020 were consistent with the three months ended September&#160;30, 2019. Total research and development costs for the nine months ended September&#160;30, 2020 decreased compared to the nine months ended September&#160;30, 2019. The clinical trial costs for our bempegaldesleukin, NKTR-255 and NKR-262 programs increased for the nine months ended September&#160;30, 2020 compared to the nine months ended September&#160;30, 2019. These costs were offset by decreases in pre-commercial manufacturing costs for NKTR-181 which we incurred during 2019, manufacturing costs for clinical trials materials, and costs for our clinical development program for NKTR-358. As noted above, as a result of our decision to withdraw the NKTR-181 NDA in January 2020, we present all costs related to the wind-down of the NKTR-181 program, including pre-commercial manufacturing activities, in the Impairment of assets and other costs related to terminated program line in our Condensed Consolidated Statements of Operations for the nine months ended September&#160;30, 2020. The decrease in NKTR-358 development costs reflects our completion of our Phase 1 clinical development and drug product development deliverables, for which we were responsible for 100% of costs, to the Phase 1B and Phase 2 development, for which we are responsible for 25% of costs and Lilly is responsible for 75% of costs. Additionally, during the three and nine months ended September&#160;30, 2020, we recorded net reductions to research and development expense for BMS&#8217;s reimbursements of our costs of $29.2&#160;million and $93.8&#160;million, respectively. During the three and nine months ended September&#160;30, 2019, we recorded net reductions to research and development expense for BMS&#8217;s reimbursements of our costs of&#160;$28.3&#160;million and $81.4&#160;million, respectively.&#160;Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin. Please see Note 6 to our Condensed Consolidated Financial Statements for additional information regarding our BMS Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expense to be generally consistent for 2020 compared to 2019. However, excluding the pre-commercial manufacturing costs for NKTR-181 that we incurred in 2019 as discussed above, we expect research and development expense to increase marginally for 2020 compared to 2019 primarily due to advancing our development of bempegaldesleukin under the BMS Collaboration Agreement, as well as studies outside of this agreement, including our Phase 1/2 trial studying bempegaldesleukin and pembrolizumab in NSCLC. In addition, we are collaborating with Lilly to develop NKTR-358, and Lilly is planning additional studies, for which we are responsible for 25% of costs. We are also continuing our Phase 1 dose-escalation studies for NKTR-255 in multiple myeloma and non-Hodgkin lymphoma, and we have initiated a Phase 1 study for NKTR-255 in solid tumors. We are continuing to enroll patients in the expansion phase of the Phase 1/2 study for NKTR-262 in combination with bempegaldesleukin. The timing and amount of our future clinical investments will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of potential collaboration partnerships (if any) for these programs.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug candidates that we are evaluating in clinical development during 2020, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates by applying our polymer conjugate technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for bempegaldesleukin, NKTR-358 and MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the evolving situation around the COVID-19 pandemic has had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the pandemic. We have experienced delays of approximately three months for earlier stage Nektar-run clinical studies (such as the Phase 1/2 trial studying bempegaldesleukin and pembrolizumab in NSCLC and the Phase 1 trial studying NKTR-255 in patients with relapsed/refractory hematologic malignancies) and given the evolving situation around the COVID-19 pandemic it is possible there could be additional delays in the future. In addition, for certain clinical studies involving our proprietary drug candidates that are run by our partners, study timelines have been delayed at least three to six months and given the evolving situation around the COVID-19 pandemic it is possible there could be additional delays in the future. As a result of these delays and potential delays, we may incur additional costs associated with these clinical trials. At this time, we cannot estimate if such increases would have a material effect on our results of operations or financial position. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks and uncertainties associated with our research and development projects are discussed more fully in Item&#160;1A. Risk Factors. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:49.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,983&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:49.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,546&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,570&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense includes the cost of administrative staffing, finance, legal and initial commercial readiness activities. General and administrative expense increased during the three and nine months ended September&#160;30, 2020 compared with the three and nine months ended September&#160;30, 2019. We expect general and administrative expenses in the full year of 2020 to increase compared to 2019, primarily due to increased personnel costs as we begin a stage appropriate build of our commercial capability to co-commercialize bempegaldesleukin with BMS. At this time, we do not anticipate that the effects of the COVID-19 pandemic will materially affect our general and administrative expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7 million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5 million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:48.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,425)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:48.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,851&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,882&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,031)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September&#160;30, 2020 decreased as compared to the three and nine months ended September&#160;30, 2019. In October 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes due October 2020. Interest on the 7.75% senior secured notes was calculated based on actual days outstanding over </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a 360 day year. On April 13, 2020, we redeemed the senior secured notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million. After the repayment, we incurred no interest expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue and Non-Cash Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,422&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,264&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,001&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,585&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,084&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the sale of future royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see Note 4 to our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, we continue to recognize non-cash royalty revenue for net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was consistent for the nine months ended September&#160;30, 2020 and September&#160;30, 2019. Non-cash interest expense increased for the three and nine months ended September&#160;30, 2020 compared with the three and nine months ended September&#160;30, 2019 due to an increase in the estimated implicit interest rate over the life of the transaction. When forecasted future revenues rise, this results in an increase to the estimated implicit interest rate over the life of the transaction, which, in turn, increases the prospective effective interest rate in the current and future periods.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized non-cash interest expense at an effective rate of 29% for the three and nine months ended September&#160;30, 2019, reflecting the estimated implicit interest rate over the life of the transaction of approximately 18.7%. During the fourth quarter of 2019, due to sustained increases in the forecasted sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we increased our estimated implicit interest rate over the life of the agreement from 18.7% to approximately 19.5%, which resulted in a prospective interest rate of 38%. During the three months ended September&#160;30, 2020, primarily as a result of continued increases in the forecasted sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our estimate of the effective annual interest rate over the life of the agreement increased to 20.2%, which results in a prospective interest rate of 48%.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the non-cash interest expense. To date, we have amortized $46.4 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $67.6 million of the net proceeds. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. At this time, we cannot estimate the effects of the COVID-19 pandemic on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the resulting effects on our non-cash royalty revenue and potential effects on our estimated implicit rate for non-cash interest expense.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.126%"><tr><td style="width:1.0%"></td><td style="width:47.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.126%"><tr><td style="width:1.0%"></td><td style="width:47.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense) decreased significantly for the three and nine months ended September&#160;30, 2020 compared to the three and nine months ended September&#160;30, 2019 due to decreases in market interest rates and lower investment balances which have been utilized to fund our operations and the repayment of our senior notes on April 13, 2020. The effective interest rate earned on investments which we purchased after the COVID-19 pandemic began has been significantly lower than historical interest rates, and we expect this trend to continue. We expect that our interest income and other income (expense), net will decrease significantly for 2020 compared to 2019 for these same reasons.</span></div><div id="i76c17a3bff6245868336286074c47608_79"></div><div style="margin-top:18pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through revenue from product sales, royalties and strategic collaboration agreements, as well as public offering and private placements of debt and equity securities. At September&#160;30, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. As noted above, on April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for the next twelve months. We expect the clinical development of our proprietary drug candidates including bempegaldesleukin, NKTR-358, NKTR-262 and NKTR-255 will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions. In April 2018, we received a total of $1.85 billion from BMS including a $1.0 billion upfront payment and an $850.0 million premium investment in our common stock. In July 2017, we entered into a collaboration agreement for NKTR-358 with Lilly, under which we received a $150.0 million upfront payment. In the future, we expect to receive substantial payments from our collaboration agreements with BMS and Lilly and other existing and future collaboration transactions if drug candidates in our pipeline achieve positive clinical or regulatory outcomes. In particular, under the BMS Collaboration Agreement, we are entitled to $1.455 billion of clinical, regulatory and commercial launch milestones (of which, we have received $50.0 million). Of the remaining milestones, $625.0 million are associated with approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (which reflects the reduction for the $25.0 million nonrefundable, creditable milestone for the first patient, first visit in the muscle-invasive bladder cancer trial that BMS paid to us in March 2020).&#160;As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future liquidity and capital resources. We have no credit facility or any other sources of committed capital.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by shelter-in place or similar orders. However, if delays caused by the COVID-19 pandemic in commencing and enrolling patients in our clinical trials or those run by our partners result in a delay in completing these trials, our ability to file for regulatory approval and commercialize these products (if approved) or enter into collaboration agreements may also be delayed.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for bempegaldesleukin, the sales levels of our products, if and when they are approved, the sales levels for those products for which we are entitled to royalties, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the nine months ended September&#160;30, 2020 totaled $214.7&#160;million, which includes $255.0 million of net operating cash uses as well as $9.7 million for interest payments on our senior secured notes, partially offset by the receipt of the $25.0 million milestone payment from BMS for the achievement of the first patient, first visit in the registrational muscle invasive bladder cancer trial and the $25.0 million milestone payment from BMS for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the nine months ended September&#160;30, 2019 totaled $203.5 million, which includes $199.2 million of net operating cash uses as well as $14.3 million for interest payments on our senior secured notes, partially offset by the receipt of a $10.0 million sales milestone payment from our collaboration agreement with Baxalta. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, will increase in the full year of 2020 compared to 2019 primarily as a result of increased research and development expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $5.5 million and $22.6&#160;million for the purchase or construction of property, plant and equipment in the nine months ended September&#160;30, 2020 and 2019, respectively. The decrease for the nine months ended September&#160;30, 2020 compared with the nine months ended September 30, 2019 resulted from the construction of leasehold improvements at our facilities lease in San Francisco during 2019. We expect our capital expenditures in the full year of 2020 to decrease compared with 2019, primarily due to the completion of the construction of these leasehold improvements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, our maturities and sales of investments, net of purchases, totaled $409.0 million, which we used to redeem our senior notes and accrued interest of $254.8 million and to fund our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $20.7 million and $18.4&#160;million in the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, on April 13, 2020, we repaid the principal of our senior notes totaling $250.0 million. See Note 1 to our Condensed Consolidated Financial Statements for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the repayment of our senior notes, there were no material changes outside the ordinary course of business during the nine months ended September&#160;30, 2020 to the summary of contractual obligations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 on file with the SEC.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2019. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, results of operations, financial condition, cash flows and future prospects and the trading price of our common stock could be harmed as a result of any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December&#160;31, 2019, including our consolidated financial statements and related notes, and our other filings made from time to time with the SEC.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of bempegaldesleukin, our lead I-O candidate.&#160;We are executing a clinical development program for bempegaldesleukin and clinical and regulatory outcomes for bempegaldesleukin, if not successful, will significantly harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize bempegaldesleukin. In general, most investigational drugs, including I-O drug candidates such as bempegaldesleukin, do not become approved drugs. Accordingly, there is a very meaningful risk that bempegaldesleukin will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;To date, reported clinical outcomes from bempegaldesleukin have had a significant impact on our market valuation, and business prospects and we expect this to continue in future periods.&#160;If one or more clinical studies of bempegaldesleukin are delayed (as a result of, for example, our collaboration partner causing a delay of the initiation of one or more clinical trials for reasons outside of our control) or not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under the BMS Collaboration Agreement, we are entitled to up to $1.455 billion in development milestone payments (of which we have received $50.0 million) that are based upon clinical and regulatory successes from the bempegaldesleukin development program. One or more failures in bempegaldesleukin studies could jeopardize such milestone payments, and any product sales or royalty revenue or commercial milestone payments that we would otherwise be entitled to receive could be reduced, delayed or eliminated.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in clinical trials of drug candidates. We have ongoing trials evaluating bempegaldesleukin, including trials evaluating bempegaldesleukin as a potential combination treatment with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as other ongoing and planned combination trials. Our partner Lilly has initiated clinical Phase 1b studies of NKTR-358 for psoriasis and atopic dermatitis, has recently started a Phase 2 study in moderate to severe lupus patients in October and is planning to initiate a Phase 2 study in patients with ulcerative colitis this year. We also continue to enroll patients in a Phase 1/2 study evaluating bempegaldesleukin in combination with NKTR-262 in patients with solid tumors.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our product candidates could be delayed for a variety of reasons, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for product candidates (such as bempegaldesleukin and NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial to the detriment of enrollment rates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, the regulatory approval process would be delayed and the ability to commercialize and commence sales of these drug candidates could be materially harmed, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting billions of dollars of investment each year.&#160; Our clinical trial plans for bempegaldesleukin, NKTR-262, and NKTR-255 face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="margin-top:18pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and these health epidemics, including the COVID-19 pandemic, could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. In March 2020, the COVID-19 outbreak was declared a pandemic. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. Similarly, the State of California declared a state of emergency related to the spread of COVID-19, and the San Francisco Department of Public Health announced aggressive recommendations to reduce the spread of the disease. In addition, we have implemented work from home policies for most employees. The effects of the shelter-in-place order and our work from home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.  Although we have taken precautions to avoid the spread of the coronavirus among our employees, it is possible one or more members of our workforce will be diagnosed with COVID-19 as a result of a work-place exposure, which could adversely impact our operations and result in litigation against us. These and similar disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Quarantines, shelter-in-place and similar government orders designed to slow or moderate the spread of the coronavirus or other infectious diseases, and even the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, could impact the availability and productivity of personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, any of which could disrupt our supply chain. For example, any manufacturing or supply chain interruptions of our proprietary drugs, or the comparator drugs used in our clinical trials, could adversely affect our ability to conduct ongoing and future clinical trials of our drug product candidates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Investigator recruitment, clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. Some patients who are successfully enrolled in clinical trials involving our drug candidates may not be able to comply with clinical trial protocols due to, for example, shelter-in-place orders impeding movement, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and validity of our clinical trial data. If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency. Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both. As a consequence, a clinical study of our proprietary drug </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, over-enrolling patients into the study or repeating the study), thereby causing substantial harm to our business.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our drug candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As a result of the increase of telehealth, work from home, and virtual meetings being necessitated by the COVID-19 pandemic, the risk or disruptions caused by cyber attacks is increased. Safeguards such as firewalls and other security measures that work well when employees are located within our facilities may not work as effectively when those employees are working remotely, and there is no guarantee that these and other cybersecurity safeguards will successfully prevent all cyber attacks.  If we, our partners, our suppliers, or our contractors experience a cyberattack, experience data accessibility issues, or encounter communication disruptions, our business may suffer as a result of the loss or theft of our important data, and we may be liable for compromising the protection of personal data.     </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a significant negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us.  Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change.  We do not yet know the full extent of potential impacts on our business, our clinical trials, healthcare systems or the global economy as a whole.  However, these effects could have a material negative impact on our operations and our business.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Drug development is a long and inherently uncertain process with a high risk of failure at every stage of development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of proprietary drug candidates and partnered drug candidates in research and development ranging from the early discovery research phase through preclinical testing and clinical trials. Preclinical testing and clinical studies are long, expensive, difficult to design and implement and highly uncertain as to outcome. It will take us, or our collaborative partners, many years to conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes, or our and our partners&#8217; financial constraints.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a highly uncertain scientific and medical endeavor, and failure can unexpectedly occur at any stage of preclinical and clinical development. Typically, there is a high rate of attrition for drug candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care (including commercialization of a competing therapy in the same or similar indication for which our drug candidate is being studied) and other variables (such as commercial supply challenges). The risk of failure increases for our drug candidates that are based on new technologies, such as the application of our advanced polymer conjugate technology to bempegaldesleukin, NKTR-358, NKTR-262, NKTR-255, and other drug candidates currently in discovery research or preclinical development. The failure of one or more of our drug candidates could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to product candidates granted breakthrough therapy by the FDA.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies that could enable us to take advantage of expedited development pathways for certain of our drug candidates, although we cannot be certain that our drug candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant qualifying designations. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough therapy designation is intended to expedite the development and review of drug candidates that are designed to treat serious or life-threatening diseases when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug candidate as a breakthrough therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the drug candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received breakthrough therapy designation for the treatment of patients with previously untreated unresectable or metastatic melanoma, we may elect not to pursue breakthrough therapy designation for our other drug candidates, and the FDA has broad discretion whether or not to grant these designations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accordingly, even if we believe a particular drug candidate is eligible for breakthrough therapy, we cannot be assured that the FDA would decide to grant it. Breakthrough therapy designation does not change the standards for drug approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the breakthrough therapy designation. Thus, even though we have received breakthrough therapy designation, we may not experience a faster development process or review, and, upon any filing seeking regulatory approval, we may not obtain an approval from the FDA.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturers are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on contract manufacturing organizations to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of drugs involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded in the presence of the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing drugs for use in clinical trials may be negatively impacted such that there is an insufficient supply of study treatment drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party contract manufacturers required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our contract manufacturers to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our contract manufacturers are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, the Drug Enforcement Administration or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our contract manufacturers for compliance with applicable regulatory requirements. Any failure to follow and document our or our contract manufacturers&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our contract manufacturers, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. For example, although the FDA granted a Breakthrough Therapy designation to bempegaldesleukin in combination with Opdivo&#174; for the treatment of patients with previously untreated unresectable or metastatic melanoma, there is no guarantee regulatory approval will follow, if at all, for this or any indication of bempegaldesleukin on a timely basis. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a drug candidate. In addition, undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies (other than Nektar-run trials under the BMS Collaboration Agreement), our collaboration partner is generally solely responsible for:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">designing and conducting large scale clinical studies;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of product candidates or to litigation or arbitration proceedings;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">partners may be unable to pay us as expected;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">partners may respond to natural disasters, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our proprietary drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash and investments in marketable securities valued at approximately $1.2 billion. On April 13, 2020, we redeemed our senior notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates &#8212;important examples include bempegaldesleukin and NKTR-358;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our general and administrative expenses, capital expenditures and other uses of cash; </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the sales levels of products marketed by our collaboration partners for which we are entitled to royalties and sales milestone payments &#8212; importantly, the levels of success in marketing and selling MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by RedHill Biopharma pursuant to its sublicense from AstraZeneca in the U.S. and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Baxalta (a wholly owned subsidiary of Takeda) globally, as well as MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the naloxegol brand name in the EU) by Kirin in the EU; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue our later stage research and development programs, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of product candidates due to important factors such as safety and efficacy compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our product candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of product candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a drug candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our product candidates even if there is adequate coverage and reimbursement from third-party payers. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. For example, Congress passed the Affordable Care Act in 2010 which enacted a number of reforms to expand access to health insurance while also reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for healthcare industries, and imposing new taxes on fees on healthcare industry participants, among other policy reforms. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, contract research payments, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including our ability to find and maintain suitable collaboration partners, the timing of the negotiation and conclusion of collaboration agreements with such partners, whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any product candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate development programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:19pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, it could subject us to substantial liabilities and harm our financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control&#8212;important examples of this risk include MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnered with AstraZeneca and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (previously referred to as BAX 855) partnered with Baxalta (a wholly-owned subsidiary of Takeda). In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales or distribution capabilities. To commercialize any of our drugs that receive regulatory approval for commercialization, we must develop robust internal sales, marketing and distribution capabilities, and manage inventory, supply, labeling, storage, record keeping, and advertising and promotion capabilities, which would be expensive and time consuming, or enter into arrangements with third parties to perform these services. If we decide to market our products directly, we must commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or through partnerships include:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability of sales personnel to obtain access to or successfully educate adequate numbers of physicians about the potential benefits associated with the use of, and to subsequently prescribe, our products;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our proprietary product candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary product candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our products to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2020, we reported a net loss of $327.2 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary product candidates and the regulatory approval and market success of our product candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for bempegaldesleukin, NKTR-358, NKTR-262, and NKTR-255;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product candidates could make our technologies, products or product candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and product candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our proprietary product candidates currently in development. For bempegaldesleukin, there are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead Sciences, Inc. (through its acquisition of Kite Pharma, Inc.)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapeutics LLC, Anaveon AG, Adaptimmune LLC, and Novartis AG; potential competitors in the cytokine-based therapies space include Alkermes plc, Altor Bioscience, NantWorks, Neoleukin Therapeutics, Inc., Philogen S.p.A., Roche, Sanofi SA (through its acquisition of Synthorx, Inc.), and Eli Lilly &amp; Co. (through its acquisition of Armo BioSciences); and potential competitors in the checkpoint inhibitor space include GlaxoSmithKline plc (through its acquisition of Tesaro, Inc.), Macrogenics, Inc., Merck, Bristol-Myers Squibb Company, and Roche. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, ILTOO Pharma, Pandion Therapeutics, and Roche). For MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there are currently several alternative therapies used to address opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OBD), including RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methylnaltrexone bromide), oral therapy AMITIZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lubiprostone), and oral and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rectal over-the-counter laxatives and stool softeners such as docusate sodium, senna and milk of magnesia. For ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there is substantial competition from Sanofi&#8217;s Fc fusion protein ELOCTATE&#8482; for Hemophilia A treatment, JIVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (antihemophilic factor (recombinant) PEGylated-aucl), an extended half-life Factor VIII for Hemophilia A treatment, approved in the U.S. in August 2018, and marketed by Bayer Healthcare, and, more recently, an extended half-life product from Novo Nordisk. In addition, technologies other than those based on Fc fusion and polymer conjugation approaches (such as gene therapy approaches being developed by BioMarin Pharmaceutical Inc. and others) are being pursued to treat patients with Hemophilia A. There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability to manage and operate our business as we execute our development and growth strategy will require effective planning. Significant rapid growth could strain our management and internal resources, and other problems may arise that could adversely affect our financial performance. We expect that our efforts to grow will place a significant strain on personnel, management systems, infrastructure and other resources. Our ability to effectively manage future growth will also require us to successfully attract, train, motivate, retain and manage new employees and continue to update and improve our operational, financial and management controls and procedures. If we do not manage our growth effectively, our operations and financial performance could be adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered drug candidates. Our strategy also calls for us to undertake increased research and development activities and to manage an increasing number of relationships with partners and other third parties, while simultaneously managing the capital necessary to support this strategy. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other financing arrangements on unfavorable terms.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of clinical testing, manufacturing, research, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action and shareholder derivative litigation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the nine months ended September&#160;30, 2020, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $14.47 to $27.96 per share. In response to volatility in the price of our common stock in the past, Plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into potential securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, Plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by Plaintiffs&#8217; securities litigation firms following share price fluctuations. </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements by collaboration partners as to their plans or expectations related to drug candidates and approved drugs in which we have a substantial economic interest;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fluctuations in our results of operations;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our financing needs and activities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general market conditions.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the drug, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 290 U.S. and 1000 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the drug. Moreover, even if a patent encompassing a drug has not expired prior to the drugs commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In addition, our patents may be subject to post grant proceedings, such as or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our drug candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. In response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities while local, national and international conditions warrant. Since March 2020, foreign and domestic inspections by FDA have largely been on hold with FDA announcing plans in July 2020 to resume prioritized domestic inspections. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals; however, FDA may not be able to continue its current pace and review timelines could be extended. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or drug candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. For example, we are currently involved in German litigation proceedings whereby we and Bayer Healthcare LLC are seeking at least co-ownership rights in certain of each other&#8217;s patent filings related to PEGylated Factor VIII products. We believe that Bayer&#8217;s claims to an ownership interest in these is without merit and we are vigorously defending our exclusive ownership rights to this intellectual property. These German litigation proceedings are currently stayed pending the outcome of ongoing mediation efforts. In the U.S., Bayer filed a complaint against Baxalta and Nektar alleging the ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product infringes a Bayer patent. Although the U.S. court dismissed all of Bayer&#8217;s claims against Nektar and Nektar was removed as a defendant, a jury found the Bayer patent was valid and infringed, and awarded Bayer damages, the responsibility of which are borne fully by Baxalta. This damages award does not impact our royalties from sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with Baxalta and Baxalta is currently appealing the decision. In other U.S. proceedings, Nektar and Baxalta filed complaints against Bayer Healthcare alleging Bayer&#8217;s JIVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product infringes several Nektar patents. A jury trial in this proceeding is scheduled to begin in September 2020. In addition, in response to notices AstraZeneca and we received from the generic companies, Apotex (Apotex Inc. and Apotex Corp.), MSN Laboratories Pvt. Ltd., and Aurobindo Pharma USA INC. alerting us that they had filed abbreviated new drug applications (ANDAs) with the FDA to market a generic version of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Paragraph IV Certifications), AstraZeneca and we together filed patent infringement suits against each of these generic companies. In these Paragraph IV Certifications, all three generic companies only alleged one patent, U.S. Patent No. 9,012,469, is invalid, unenforceable and/or not infringed by the manufacture, use or sale of their respective generic products. At this time, none of the other five Orange Book listed patents associated with MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are being challenged by these generics companies. In addition, on March 18, 2020, Aether Therapeutics Inc. filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. Also, on June 5, 2020, UCB Pharma S.A. and Celltech R&amp;D Limited (collectively UCB) served notice of a Declaratory Judgment of Patent Invalidity proceeding filed in the United States District Court for the District of Delaware seeking a declaration of invalidity of specified U.S. patents owned by Nektar and licensed to UCB. UCB is also pursuing similar actions in other jurisdictions. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our drugs and platform technologies. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings other than those related to intellectual property. For example, on October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019.&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On July 13, 2020, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, stating (among other things) that the amended complaint failed &#8220;to adequately allege that any of the statements &#8230; identified by Plaintiffs were false or misleading.&#8221;  Following the motion to dismiss, on August 10, 2020, the class action plaintiffs filed a second consolidated class action complaint, and the matter remains pending.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California  naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the putative securities class action lawsuits and shareholder derivative lawsuits) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either September&#160;30, 2020 or December&#160;31, 2019.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business to subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our product candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union (EU) may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, the United Kingdom (UK) withdrew from the EU (Brexit), thereby triggering a transition period that is set to end on December 31, 2020, during which the UK and the EU will negotiate their future relationship. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the terms of the withdrawal have yet to be fully negotiated. The implementation period began February 1, 2020 and will continue until December 31, 2020. During this 11-month period, the UK will continue to follow all of the EU&#8217;s rules and its trading relationship will remain the same. However, regulations (including financial laws and regulations, tax and free trade agreements, intellectual property rights, data protection laws, supply chain logistics, environmental, health and safety laws and regulations, medicine licensing and regulations, immigration laws and employment laws) have yet to be addressed. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations may negatively impact foreign direct investment in the UK, increase costs, depress economic activity, and restrict access to capital. The uncertainty concerning the UK&#8217;s legal, political, and economic relationship with the EU after Brexit may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise) beyond the date of Brexit.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These developments, or the perception that any of them could occur, may have a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the UK financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates, and credit ratings may also be subject to increased market volatility. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the UK and the EU are unable to negotiate acceptable agreements or if other EU Member States pursue withdrawal, barrier-free access between the UK and other EU Member States or among the European Economic Area overall could be diminished or eliminated. The long-term effects of Brexit will depend on any agreements (or lack thereof) between the UK and the EU and, in particular, any arrangements for the UK to retain access to EU markets either during a transitional period or more permanently.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is currently considerable uncertainty on regulatory processes in Europe and the European Economic Area. The lack of clarity about which EU rules and regulations the UK would replace or replicate, such as rules and regulations relating to trade (including the importation and exportation of pharmaceuticals), clinical research, and intellectual property, increases the risk that our clinical trials being carried out in UK are delayed or disrupted.&#160;Further, depending on which rules and regulations the UK ultimately adopts, our business could be negatively affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions, our business may be adversely affected following new or increased tariffs that result in the increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="i76c17a3bff6245868336286074c47608_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. Other than as the result of the adoption of the new credit impairment accounting guidance as described in Note 1 to our Condensed Consolidated Financial Statements, there have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div><div id="i76c17a3bff6245868336286074c47608_88"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.                Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks at September&#160;30, 2020 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2019 on file with the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended September&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related shelter-in-place requirements, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="i76c17a3bff6245868336286074c47608_97"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 5 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div id="i76c17a3bff6245868336286074c47608_100"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended September&#160;30, 2020.</span></div><div id="i76c17a3bff6245868336286074c47608_103"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i76c17a3bff6245868336286074c47608_106"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i76c17a3bff6245868336286074c47608_109"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Exhibit Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Description of Documents</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.1(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.2(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.3(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.4(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.5(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000119312519315711/d851417dex31.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.1(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2020-09x30xexx311.htm">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.2(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2020-09x30xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2020-09x30xexx321.htm">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.SCH(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.CAL(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.LAB(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.PRE(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.DEF(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">_____________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       1. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 1998.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       2. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 2000.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       3.     Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               January 23, 2003.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       4. &#160;&#160;&#160;&#160; Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               December 31, 2009.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       5. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               December 17, 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       6.     Filed herewith.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i76c17a3bff6245868336286074c47608_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i76c17a3bff6245868336286074c47608_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ GIL M. LABRUCHERIE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie<br/>Senior&#160;Vice&#160;President, Chief Operating Officer, and&#160;Chief&#160;Financial&#160;Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 5, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JILLIAN B. THOMSEN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen<br/>Senior&#160;Vice&#160;President,&#160;Finance&#160;and&#160;Chief&#160;Accounting&#160;Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 5, 2020</span></td></tr></table></div><div style="margin-top:6pt;text-align:right"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nktr2020-09x30xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i82f794eaebea4cacbb5744447acbd0ee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2020 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 5, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; HOWARD W. ROBIN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin<br>Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nktr2020-09x30xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6d48ac760e3741d39c4353bef78a5829_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gil M. Labrucherie, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2020 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 5, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie<br>Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nktr2020-09x30xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i049e033091dc4bb388293afc4810a20b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended September&#160;30, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 5, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HOWARD W. ROBIN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer, President and Director</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gil M. Labrucherie</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nktr-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cd8fadd9-b103-4bc6-8d6e-f7c780e13194,g:a9acc073-30b2-4f27-83c9-2e78baac043d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.nektar.com/role/InventoryDetails">
        <link:definition>2411405 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties">
        <link:definition>2112104 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesDetail" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail">
        <link:definition>2413406 - Disclosure - Liability Related to Sale of Future Royalties (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2114105 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail">
        <link:definition>2415407 - Disclosure - Commitments and Contingencies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2116106 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>2317303 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
        <link:definition>2418408 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2419409 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail">
        <link:definition>2420410 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2121107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2322304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail">
        <link:definition>2424412 - Disclosure - Stock-Based Compensation - Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.nektar.com/role/NetLossPerShare">
        <link:definition>2125108 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.nektar.com/role/EarningsPerShareTables">
        <link:definition>2326305 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetail" roleURI="http://www.nektar.com/role/NetLossPerShareDetail">
        <link:definition>2427413 - Disclosure - Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_WriteOffOfPrepayment" abstract="false" name="WriteOffOfPrepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_ProspectiveInterestRatePercentage" abstract="false" name="ProspectiveInterestRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_SalesMilestoneRevenue" abstract="false" name="SalesMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" abstract="false" name="PotentialDevelopmentRegulatoryAndSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NKTR181Member" abstract="true" name="NKTR181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AccruedContractManufacturingExpenseCurrent" abstract="false" name="AccruedContractManufacturingExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RepaymentsOfLongTermDebtIncludingInterest" abstract="false" name="RepaymentsOfLongTermDebtIncludingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" abstract="true" name="A775PercentSeniorSecuredNotesDueOctober2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_HemophiliaMember" abstract="true" name="HemophiliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" abstract="false" name="AmountOfTransactionPriceAllocatedToPerformanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentAndOtherMember" abstract="true" name="ImpairmentAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreementMember" abstract="true" name="PurchaseAndSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" abstract="false" name="EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" abstract="false" name="EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_CollaborationPartnerMember" abstract="true" name="CollaborationPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationOtherRevenue" abstract="false" name="LicenseCollaborationOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_Nektar358LicenseMember" abstract="true" name="Nektar358LicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" abstract="false" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentFromTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentFromTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BaxaltaIncorporatedOrTakedaPLCMember" abstract="true" name="BaxaltaIncorporatedOrTakedaPLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PhaseOneClinicalDevelopmentMember" abstract="true" name="PhaseOneClinicalDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AmgenIncMember" abstract="true" name="AmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MOVANTIKAndMOVENTIGMember" abstract="true" name="MOVANTIKAndMOVENTIGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AdvancePaymentsToContractManufacturers" abstract="false" name="AdvancePaymentsToContractManufacturers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DebtInvestmentMaximumMaturityPeriod" abstract="false" name="DebtInvestmentMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" abstract="false" name="PaymentsReceivedUnderRightsToSublicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DebtInvestmentMaturityTerm" abstract="false" name="DebtInvestmentMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Restated2017PerformanceIncentivePlanMember" abstract="true" name="Restated2017PerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ProfitsAndLossesSharingPercentage" abstract="false" name="ProfitsAndLossesSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_DrugProductDevelopmentMember" abstract="true" name="DrugProductDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AnnualSalesLevelMilestoneMember" abstract="true" name="AnnualSalesLevelMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NeulastaMember" abstract="true" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_NektarMember" abstract="true" name="NektarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AstraZenecaAbMember" abstract="true" name="AstraZenecaAbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_RemainingAmountAllocatedToTransactionPrice" abstract="false" name="RemainingAmountAllocatedToTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EstimatedFairValueOfShares" abstract="false" name="EstimatedFairValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AggregateConsiderationReceivedFromAgreements" abstract="false" name="AggregateConsiderationReceivedFromAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CommonStockAdditionalSharesAuthorized" abstract="false" name="CommonStockAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AstraZenecaAgreementWithKirinMember" abstract="true" name="AstraZenecaAgreementWithKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nktr-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cd8fadd9-b103-4bc6-8d6e-f7c780e13194,g:a9acc073-30b2-4f27-83c9-2e78baac043d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent_e412d04e-406f-4745-8902-cb7f0836f39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_us-gaap_SeniorNotesCurrent_e412d04e-406f-4745-8902-cb7f0836f39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a0743660-875d-4982-9a10-2b7f004802fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_us-gaap_AccountsPayableCurrent_a0743660-875d-4982-9a10-2b7f004802fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_996874c5-3abc-4634-98f8-374576ea776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_996874c5-3abc-4634-98f8-374576ea776d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_95e2b05b-7736-47bf-8c46-1ca82a885b42" xlink:href="nktr-20200930.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_95e2b05b-7736-47bf-8c46-1ca82a885b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_b0e7e7d3-9d12-43ab-bdfd-a56e6da3fdc5" xlink:href="nktr-20200930.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_b0e7e7d3-9d12-43ab-bdfd-a56e6da3fdc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da62eb96-1775-43a7-b012-4bf75e7fe65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da62eb96-1775-43a7-b012-4bf75e7fe65d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_059a427d-c7a1-433b-8a71-ac61e16b3481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_059a427d-c7a1-433b-8a71-ac61e16b3481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ef1e4006-80ca-4a94-8e61-6ced06e41dde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b97de060-dc7d-4a56-8a64-718e6406c5b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ef1e4006-80ca-4a94-8e61-6ced06e41dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf5c8f10-42eb-48e7-8312-20cf9b2bec27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0105a1af-a06e-4a95-82ea-1343d4dcd853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf5c8f10-42eb-48e7-8312-20cf9b2bec27" xlink:to="loc_us-gaap_Liabilities_0105a1af-a06e-4a95-82ea-1343d4dcd853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6436419b-74da-49b6-b331-1306fd59a84e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf5c8f10-42eb-48e7-8312-20cf9b2bec27" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6436419b-74da-49b6-b331-1306fd59a84e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53e0d1eb-9039-46a8-8727-738c5ecea8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf5c8f10-42eb-48e7-8312-20cf9b2bec27" xlink:to="loc_us-gaap_StockholdersEquity_53e0d1eb-9039-46a8-8727-738c5ecea8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f8990ade-8aaa-4d02-8057-e0298437b4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1b7e40cd-7961-4f0e-aaa5-7b505ee2929f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f8990ade-8aaa-4d02-8057-e0298437b4a3" xlink:to="loc_us-gaap_LiabilitiesCurrent_1b7e40cd-7961-4f0e-aaa5-7b505ee2929f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19d5403e-520c-4b82-863c-aea71550c7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f8990ade-8aaa-4d02-8057-e0298437b4a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19d5403e-520c-4b82-863c-aea71550c7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_c1d31155-93e8-420c-b869-efe5d7f723ef" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f8990ade-8aaa-4d02-8057-e0298437b4a3" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_c1d31155-93e8-420c-b869-efe5d7f723ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92d8bb47-935f-44cc-a757-ac49f3455eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f8990ade-8aaa-4d02-8057-e0298437b4a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92d8bb47-935f-44cc-a757-ac49f3455eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d0d78857-b8cb-416f-9cc7-1e44721522aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f8990ade-8aaa-4d02-8057-e0298437b4a3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d0d78857-b8cb-416f-9cc7-1e44721522aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cf6929d1-3220-48e3-965b-370fc366796e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:to="loc_us-gaap_AssetsCurrent_cf6929d1-3220-48e3-965b-370fc366796e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_18f1e177-d29c-42aa-bf75-d10ea025454f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_18f1e177-d29c-42aa-bf75-d10ea025454f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4dded1b9-bfb7-4eec-85d4-cd028e2494b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4dded1b9-bfb7-4eec-85d4-cd028e2494b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3e63ee6c-9225-4c4d-96d5-950465d9495e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3e63ee6c-9225-4c4d-96d5-950465d9495e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eda2db3d-7945-4e4b-9edd-f5cb3f113c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eda2db3d-7945-4e4b-9edd-f5cb3f113c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_847d0e8f-8895-4450-ae4a-7f47bf9c328e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f95388b-d9f5-4539-92bf-a7023d00a6c7" xlink:to="loc_us-gaap_Goodwill_847d0e8f-8895-4450-ae4a-7f47bf9c328e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bc863c2-cc07-46ef-91ce-53c0b039cf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_185e7c9b-5712-4012-9c66-932b8416f2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bc863c2-cc07-46ef-91ce-53c0b039cf82" xlink:to="loc_us-gaap_PreferredStockValue_185e7c9b-5712-4012-9c66-932b8416f2b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_17f31151-2ea6-474f-87d5-23270530fa35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bc863c2-cc07-46ef-91ce-53c0b039cf82" xlink:to="loc_us-gaap_CommonStockValue_17f31151-2ea6-474f-87d5-23270530fa35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54bfe06e-7c8b-456b-b5eb-a77f65766aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bc863c2-cc07-46ef-91ce-53c0b039cf82" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54bfe06e-7c8b-456b-b5eb-a77f65766aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4da48f32-1187-4dd7-ac0b-5fe48769f6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bc863c2-cc07-46ef-91ce-53c0b039cf82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4da48f32-1187-4dd7-ac0b-5fe48769f6f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e31206c-fdac-4564-9680-74c98ab81de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bc863c2-cc07-46ef-91ce-53c0b039cf82" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e31206c-fdac-4564-9680-74c98ab81de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a1e1a7d-aa3a-4136-bd68-36b28f3879a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a1e1a7d-aa3a-4136-bd68-36b28f3879a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f1b67051-8bfe-4715-b127-99f0ee46d9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f1b67051-8bfe-4715-b127-99f0ee46d9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45709d2e-6f88-4116-844c-dfcaee97a8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45709d2e-6f88-4116-844c-dfcaee97a8ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_89841f00-7bd4-4173-81f6-f96688a15c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:to="loc_us-gaap_InventoryNet_89841f00-7bd4-4173-81f6-f96688a15c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_a6dffd98-ded4-4d38-91df-e6a1b58c1406" xlink:href="nktr-20200930.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_a6dffd98-ded4-4d38-91df-e6a1b58c1406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d17fcb45-c8fc-47ec-8c78-e85877fda202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_514308f2-a2aa-4794-a6d1-605266a41b3b" xlink:to="loc_us-gaap_OtherAssetsCurrent_d17fcb45-c8fc-47ec-8c78-e85877fda202" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7dfd4d8e-2fe1-472b-b26b-0b8a51ad8b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a283e720-c35f-4221-b3a7-7c4a7b124867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7dfd4d8e-2fe1-472b-b26b-0b8a51ad8b37" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a283e720-c35f-4221-b3a7-7c4a7b124867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_74a5b69a-62eb-4b66-b2b3-e810a2e329a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7dfd4d8e-2fe1-472b-b26b-0b8a51ad8b37" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_74a5b69a-62eb-4b66-b2b3-e810a2e329a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f764c0ac-8918-4fd6-9175-9d2128fbbd18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41881b52-2d52-4c00-857e-2144b87b2f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f764c0ac-8918-4fd6-9175-9d2128fbbd18" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41881b52-2d52-4c00-857e-2144b87b2f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_798f53a0-9e3a-454b-9464-902eba6aeef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f764c0ac-8918-4fd6-9175-9d2128fbbd18" xlink:to="loc_us-gaap_CostsAndExpenses_798f53a0-9e3a-454b-9464-902eba6aeef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ee753794-1423-44b5-9eb0-677d44c1527e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fc8f5ac9-c366-4a51-96ce-5d5e53886a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee753794-1423-44b5-9eb0-677d44c1527e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fc8f5ac9-c366-4a51-96ce-5d5e53886a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a1653572-99a3-437f-8124-16896cf1d525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee753794-1423-44b5-9eb0-677d44c1527e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a1653572-99a3-437f-8124-16896cf1d525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0d3f54ae-2cd6-4316-9c91-46cb24ab87e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee753794-1423-44b5-9eb0-677d44c1527e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0d3f54ae-2cd6-4316-9c91-46cb24ab87e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_c5c3cd1e-c40e-4082-a9f9-c1762e70d096" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee753794-1423-44b5-9eb0-677d44c1527e" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_c5c3cd1e-c40e-4082-a9f9-c1762e70d096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b420048b-6742-4bf7-907e-d0c5c1bf54ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d985f39e-ffc2-4cd2-9cab-5e7183d382b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b420048b-6742-4bf7-907e-d0c5c1bf54ae" xlink:to="loc_us-gaap_InterestExpense_d985f39e-ffc2-4cd2-9cab-5e7183d382b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_61d32dad-fa8d-4ff4-a4d3-13a6e6ac1b8f" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b420048b-6742-4bf7-907e-d0c5c1bf54ae" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_61d32dad-fa8d-4ff4-a4d3-13a6e6ac1b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4c037e0f-82e9-41a7-a282-d501c80db0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b420048b-6742-4bf7-907e-d0c5c1bf54ae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4c037e0f-82e9-41a7-a282-d501c80db0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d40af575-9709-4d30-98ee-39e17dbd3325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bb6f9b2f-8ad8-4818-9881-f32ea642197e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d40af575-9709-4d30-98ee-39e17dbd3325" xlink:to="loc_us-gaap_OperatingIncomeLoss_bb6f9b2f-8ad8-4818-9881-f32ea642197e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7941b98b-dcf9-45f3-9466-4db0612374f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d40af575-9709-4d30-98ee-39e17dbd3325" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7941b98b-dcf9-45f3-9466-4db0612374f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d82b706-ac55-4ae0-acf2-f09ba747191a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_09da08dd-3332-4805-83b2-de2d5124e5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d82b706-ac55-4ae0-acf2-f09ba747191a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_09da08dd-3332-4805-83b2-de2d5124e5a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_da3c4d26-f370-4e6f-803d-a8ca22d2ede0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d82b706-ac55-4ae0-acf2-f09ba747191a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_da3c4d26-f370-4e6f-803d-a8ca22d2ede0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a48c29dc-1154-4923-bdf5-a9f67bb613e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_62fd4a59-f68d-4cb4-b575-bfd8dbd11af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a48c29dc-1154-4923-bdf5-a9f67bb613e1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_62fd4a59-f68d-4cb4-b575-bfd8dbd11af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a05fb25-9ba2-428d-8bb7-fefd16a64342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a48c29dc-1154-4923-bdf5-a9f67bb613e1" xlink:to="loc_us-gaap_NetIncomeLoss_7a05fb25-9ba2-428d-8bb7-fefd16a64342" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33546ae0-e325-4be6-9da0-baf4007ef9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1244d42e-0eb3-4527-b3b7-2da4f3ab7803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33546ae0-e325-4be6-9da0-baf4007ef9f7" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1244d42e-0eb3-4527-b3b7-2da4f3ab7803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9997e0ea-92cf-4e62-b8a5-426badff2080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33546ae0-e325-4be6-9da0-baf4007ef9f7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9997e0ea-92cf-4e62-b8a5-426badff2080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7970698e-a088-4476-9d94-d416375782f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_67b1ffba-f209-4552-829d-03a9ddb40f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7970698e-a088-4476-9d94-d416375782f5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_67b1ffba-f209-4552-829d-03a9ddb40f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_70063c95-e864-43b5-97cf-407d2e1ad1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7970698e-a088-4476-9d94-d416375782f5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_70063c95-e864-43b5-97cf-407d2e1ad1c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d243a113-61e6-4509-98f0-a92e61e84306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7970698e-a088-4476-9d94-d416375782f5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d243a113-61e6-4509-98f0-a92e61e84306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_12006d64-3ea0-4219-9ed2-6994a1ed5426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7970698e-a088-4476-9d94-d416375782f5" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_12006d64-3ea0-4219-9ed2-6994a1ed5426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b42094c3-8c5d-4759-ab63-d79cbbd34863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_ProfitLoss_b42094c3-8c5d-4759-ab63-d79cbbd34863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_2ef77f96-34b2-46b4-a640-3d09fe72f061" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_2ef77f96-34b2-46b4-a640-3d09fe72f061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_ca224e2e-fdb9-45ef-926e-17d9202e3c35" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_ca224e2e-fdb9-45ef-926e-17d9202e3c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_29f9e72e-ffb0-48a1-b4b1-070ed950b675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_29f9e72e-ffb0-48a1-b4b1-070ed950b675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b4ec79b3-1e5f-40b9-9cf2-b34b5bace3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_DepreciationAndAmortization_b4ec79b3-1e5f-40b9-9cf2-b34b5bace3f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_6c39e8a3-11ae-41cf-b375-d6c737050be2" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_6c39e8a3-11ae-41cf-b375-d6c737050be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dcec5559-7785-4346-9200-49836a9206c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dcec5559-7785-4346-9200-49836a9206c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ecfa59a2-89ea-4e79-b5f0-3e7b89cd587f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ecfa59a2-89ea-4e79-b5f0-3e7b89cd587f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c2d721d5-c150-4c33-8baf-7b198df35830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c2d721d5-c150-4c33-8baf-7b198df35830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_ce11723c-93d8-4f43-acab-db5d3a249009" xlink:href="nktr-20200930.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_ce11723c-93d8-4f43-acab-db5d3a249009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cbef1c7f-4270-4365-b4b8-e6c2dd0a26f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cbef1c7f-4270-4365-b4b8-e6c2dd0a26f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_373e362d-cd1f-4978-bc28-cc0ed41bfbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_373e362d-cd1f-4978-bc28-cc0ed41bfbe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_aa8ecc9a-db78-4e2b-b916-c1d4dd3354b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_aa8ecc9a-db78-4e2b-b916-c1d4dd3354b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1b838ad7-97cf-409f-b5d1-3d2e8f22255a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1b838ad7-97cf-409f-b5d1-3d2e8f22255a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_55201c68-1f9f-4bc6-9902-a6fd73466ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fb6681b-3b67-4805-9b1e-ac6cda9672a5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_55201c68-1f9f-4bc6-9902-a6fd73466ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef7e8a2-7b59-4077-81ef-9a2cd651b4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_431d8599-1df9-44f4-b120-6d9b85711506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef7e8a2-7b59-4077-81ef-9a2cd651b4e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_431d8599-1df9-44f4-b120-6d9b85711506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e577e4b-21f0-4835-99a6-a34393678cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef7e8a2-7b59-4077-81ef-9a2cd651b4e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e577e4b-21f0-4835-99a6-a34393678cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f1b7e18-4f13-4b36-9a96-b6cfa18f4201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef7e8a2-7b59-4077-81ef-9a2cd651b4e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f1b7e18-4f13-4b36-9a96-b6cfa18f4201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0697e172-4541-474b-8ef3-4815f00c7f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef7e8a2-7b59-4077-81ef-9a2cd651b4e9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0697e172-4541-474b-8ef3-4815f00c7f79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_b58c3484-87bd-44df-a061-1d3ef6017bd8" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47016e76-c565-4547-9caa-0e7ad3914fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_b58c3484-87bd-44df-a061-1d3ef6017bd8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47016e76-c565-4547-9caa-0e7ad3914fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_75c7ddb0-de91-49f0-9dbe-30d3cb7c1aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_b58c3484-87bd-44df-a061-1d3ef6017bd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_75c7ddb0-de91-49f0-9dbe-30d3cb7c1aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_45e71711-574e-4cb4-844b-873014891d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_b58c3484-87bd-44df-a061-1d3ef6017bd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_45e71711-574e-4cb4-844b-873014891d9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_62a78968-9bae-4c77-8386-7e94d0cc1491" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6258879-2b02-4aaa-8aba-38da6cb748ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_62a78968-9bae-4c77-8386-7e94d0cc1491" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6258879-2b02-4aaa-8aba-38da6cb748ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5722750c-13a0-4ee7-a214-8459cab61ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_62a78968-9bae-4c77-8386-7e94d0cc1491" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5722750c-13a0-4ee7-a214-8459cab61ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_d90af2ed-5dea-433f-b987-293f815b3d12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_62a78968-9bae-4c77-8386-7e94d0cc1491" xlink:to="loc_us-gaap_Cash_d90af2ed-5dea-433f-b987-293f815b3d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe79d9b6-bf4a-4248-ac49-872256348be9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8acfc704-bc91-47e3-9f8f-0374999f1792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe79d9b6-bf4a-4248-ac49-872256348be9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8acfc704-bc91-47e3-9f8f-0374999f1792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38a53a0e-770a-4d49-ac12-f3efaa7f713b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe79d9b6-bf4a-4248-ac49-872256348be9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38a53a0e-770a-4d49-ac12-f3efaa7f713b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_374b0e18-ba04-43f2-b64b-a42b3066c775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe79d9b6-bf4a-4248-ac49-872256348be9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_374b0e18-ba04-43f2-b64b-a42b3066c775" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20200930.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20200930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_61ae08c4-ef05-4e82-9104-c0bec2dec9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b93f433a-47c4-491f-9f3b-1aa83743b835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_61ae08c4-ef05-4e82-9104-c0bec2dec9f1" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b93f433a-47c4-491f-9f3b-1aa83743b835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cc813f26-45da-48fc-ae62-9338a00d4852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_61ae08c4-ef05-4e82-9104-c0bec2dec9f1" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cc813f26-45da-48fc-ae62-9338a00d4852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_08922bcd-f8c2-46df-a5d8-f5054f51aaa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_61ae08c4-ef05-4e82-9104-c0bec2dec9f1" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_08922bcd-f8c2-46df-a5d8-f5054f51aaa8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20200930.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CommitmentsandContingenciesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationActivityDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20200930.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#NetLossPerShareDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nktr-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cd8fadd9-b103-4bc6-8d6e-f7c780e13194,g:a9acc073-30b2-4f27-83c9-2e78baac043d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended" id="id67e4706c4df462fb6b8e806ab70bf30_CoverPage"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i6b73ea5d0cd8468e8a71c45410c7ce8b_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="iade92cca93054138b494a493a0405190_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="ib040e66f30434137a0c31bcf3b014c0b_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5393adab-442a-47b6-911b-e0cb26ad12e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_RevenuesAbstract_5393adab-442a-47b6-911b-e0cb26ad12e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe4395f4-260f-4473-a672-3eedd7753594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_5393adab-442a-47b6-911b-e0cb26ad12e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe4395f4-260f-4473-a672-3eedd7753594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_aae30515-3b07-4db3-9c5e-3691d6bbf564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_aae30515-3b07-4db3-9c5e-3691d6bbf564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_efa5e7f6-1031-48e7-bb13-d1999fb9cde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_efa5e7f6-1031-48e7-bb13-d1999fb9cde8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8b74cad4-c96f-4aff-b4d4-108f0ecfe4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8b74cad4-c96f-4aff-b4d4-108f0ecfe4a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_d1ea82bb-a2b9-43d0-ba30-9422c0f81185" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_d1ea82bb-a2b9-43d0-ba30-9422c0f81185" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_700dd7a0-3afe-486b-8783-d99083ee14bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_CostsAndExpenses_700dd7a0-3afe-486b-8783-d99083ee14bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_19dc6091-cfd5-40c8-bbb3-789d3fe1a0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_OperatingIncomeLoss_19dc6091-cfd5-40c8-bbb3-789d3fe1a0e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_64f0bf97-c55b-42dc-b67d-ffc4b0f989e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_us-gaap_InterestExpense_64f0bf97-c55b-42dc-b67d-ffc4b0f989e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f1218247-9ac2-4d39-a428-089b404e7549" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f1218247-9ac2-4d39-a428-089b404e7549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f6ec5f8d-07a7-455c-8e8e-e078aa790a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f6ec5f8d-07a7-455c-8e8e-e078aa790a44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_70857031-04a4-44b6-aa5f-75db94307b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_70857031-04a4-44b6-aa5f-75db94307b9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_caee1c50-ab43-4b06-94dc-ebaf5de510f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_caee1c50-ab43-4b06-94dc-ebaf5de510f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b0cb273-085f-475c-bcd5-e567cbb78a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b0cb273-085f-475c-bcd5-e567cbb78a0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_857c0096-8887-4b72-a7c6-f56f8dbc7bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_NetIncomeLoss_857c0096-8887-4b72-a7c6-f56f8dbc7bb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_c5b84edb-a0b5-44d8-b5b3-b5c81cf24a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_c5b84edb-a0b5-44d8-b5b3-b5c81cf24a19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0aa1841c-2d5d-4f75-b324-e9eeb51cfe24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0aa1841c-2d5d-4f75-b324-e9eeb51cfe24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:to="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73a3d128-0156-4516-a98b-447cd5f9cec3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:to="loc_srt_ProductsAndServicesDomain_73a3d128-0156-4516-a98b-447cd5f9cec3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:to="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_56efe2d1-4093-45f8-a9bb-ff423dd50f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_us-gaap_ProductMember_56efe2d1-4093-45f8-a9bb-ff423dd50f66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_827b957f-90bc-4946-9b3b-1bf438e6da8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_us-gaap_RoyaltyMember_827b957f-90bc-4946-9b3b-1bf438e6da8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_904d833e-01de-4af8-ab8f-0c8a1c205dc8" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_904d833e-01de-4af8-ab8f-0c8a1c205dc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_46fba007-ffca-4e31-956e-346ec767824e" xlink:href="nktr-20200930.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_46fba007-ffca-4e31-956e-346ec767824e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i92076ba61e0c46e599bb3a506105bb71_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i510c13226ecb4fa088a71f76eaeb3af4_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9e7de3ca-eb19-4108-874b-c611c842959c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e7de3ca-eb19-4108-874b-c611c842959c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_fdd6503c-85ba-469b-8d7b-e4645f8672be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_SharesOutstanding_fdd6503c-85ba-469b-8d7b-e4645f8672be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ad8eff4-20e6-480b-a83a-beef1449ae4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockholdersEquity_9ad8eff4-20e6-480b-a83a-beef1449ae4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_808f0045-dcca-44c3-a44c-c8ee96d27296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_808f0045-dcca-44c3-a44c-c8ee96d27296" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_901d75f4-6b8a-491c-a35f-d875784e99c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_901d75f4-6b8a-491c-a35f-d875784e99c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237eeda8-fea6-4638-89c9-f7b5c6c5d6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237eeda8-fea6-4638-89c9-f7b5c6c5d6d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_68bc7648-e7af-4f28-9a31-997fa2218295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_68bc7648-e7af-4f28-9a31-997fa2218295" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c1e80e57-971f-42fd-a3e9-b3881fdc68db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e955b3a4-5c92-4949-a8b6-ad9296fe56e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9e7de3ca-eb19-4108-874b-c611c842959c" xlink:to="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4ff2adb-dac7-4a98-ac4d-8e03647653bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:to="loc_us-gaap_EquityComponentDomain_f4ff2adb-dac7-4a98-ac4d-8e03647653bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:to="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a7ce15e-d698-4b25-b554-3066d8daaf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_CommonStockMember_9a7ce15e-d698-4b25-b554-3066d8daaf7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6cc35fac-dc09-4c35-ab24-bcd8cafffe11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6cc35fac-dc09-4c35-ab24-bcd8cafffe11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_977213f5-32a0-4e05-b5df-c1c9257d46ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_977213f5-32a0-4e05-b5df-c1c9257d46ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c1248dcb-93af-4d23-aa1f-b24315195528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_RetainedEarningsMember_c1248dcb-93af-4d23-aa1f-b24315195528" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="ia8b4f40a4e124faf9103c53102314522_CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i2521af02900a46c98566142855731651_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="id602e4b1f81d4a579e6c8a8b6721bd79_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended" id="i879be18d2b01471ab571ab28e0a73bf7_OrganizationandSummaryofSignificantAccountingPoliciesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:href="nktr-20200930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_162878b7-08b0-4f54-96d4-ef436e86bb2d" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_162878b7-08b0-4f54-96d4-ef436e86bb2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0e9c84ce-10f2-4656-92c0-4711a005bdb9" xlink:href="nktr-20200930.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0e9c84ce-10f2-4656-92c0-4711a005bdb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4381e763-3ded-44dd-ac7d-b02eccbe3f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4381e763-3ded-44dd-ac7d-b02eccbe3f14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_5e513356-37d9-4ba7-a69b-60d7fb4cc72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_5e513356-37d9-4ba7-a69b-60d7fb4cc72b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_932da772-1bc8-4dd3-b8c1-cc9e60e97473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_NumberOfOperatingSegments_932da772-1bc8-4dd3-b8c1-cc9e60e97473" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_41d39940-883d-4839-b88c-0a596d7cd282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_41d39940-883d-4839-b88c-0a596d7cd282" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_db30beae-27bb-456f-a58f-a1ee9d0e53c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_db30beae-27bb-456f-a58f-a1ee9d0e53c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed65b145-ecd8-414d-80a3-46178df0e71c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed65b145-ecd8-414d-80a3-46178df0e71c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_4a6772b5-69a9-4bc5-b82d-53c33be28094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_4a6772b5-69a9-4bc5-b82d-53c33be28094" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidCapitalized_387c38ef-dd32-45fc-a843-dafb5b957a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_InterestPaidCapitalized_387c38ef-dd32-45fc-a843-dafb5b957a85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_24275f37-77bd-4cd2-a738-62258dd5f180" xlink:href="nktr-20200930.xsd#nktr_WriteOffOfPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_WriteOffOfPrepayment_24275f37-77bd-4cd2-a738-62258dd5f180" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7c321e81-9d5f-4f9e-975c-b403c122c22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7c321e81-9d5f-4f9e-975c-b403c122c22d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:href="nktr-20200930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember_458dacfb-4355-4b65-bc68-5d6f4da78925" xlink:href="nktr-20200930.xsd#nktr_CollaborationPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:to="loc_nktr_CollaborationPartnerMember_458dacfb-4355-4b65-bc68-5d6f4da78925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_11114828-361e-428b-a674-a7656f076afa" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_11114828-361e-428b-a674-a7656f076afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2801fadd-7862-4418-9a5c-9f0713a9c805_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:to="loc_srt_ProductsAndServicesDomain_2801fadd-7862-4418-9a5c-9f0713a9c805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bade456b-13de-4954-8cbd-ac3da1812a55" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:to="loc_srt_ProductsAndServicesDomain_bade456b-13de-4954-8cbd-ac3da1812a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_350dd45f-27f2-43c0-aae9-eb80e0509a76" xlink:href="nktr-20200930.xsd#nktr_NKTR181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bade456b-13de-4954-8cbd-ac3da1812a55" xlink:to="loc_nktr_NKTR181Member_350dd45f-27f2-43c0-aae9-eb80e0509a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cc02a53b-2a82-4667-b9fd-36f379917515_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cc02a53b-2a82-4667-b9fd-36f379917515_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b03436b-d726-4ddc-8039-5d3a49277e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b03436b-d726-4ddc-8039-5d3a49277e67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_74ea4b42-3829-44e9-8fa3-373fdfc2ad98" xlink:href="nktr-20200930.xsd#nktr_A775PercentSeniorSecuredNotesDueOctober2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b03436b-d726-4ddc-8039-5d3a49277e67" xlink:to="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_74ea4b42-3829-44e9-8fa3-373fdfc2ad98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce88c85e-cf42-4647-9010-76305592498e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce88c85e-cf42-4647-9010-76305592498e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_34f719ac-f20b-4d42-a3e1-f6b97338baa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_34f719ac-f20b-4d42-a3e1-f6b97338baa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_59ab0187-7581-46c0-9dca-8705aa9ecb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_34f719ac-f20b-4d42-a3e1-f6b97338baa8" xlink:to="loc_us-gaap_SeniorNotesMember_59ab0187-7581-46c0-9dca-8705aa9ecb7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended" id="if76ef5f41ccd4e039d527ccde89b45b4_CashandInvestmentsinMarketableSecurities"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended" id="i5b73d4bf0e744570beb42a23d34b4593_CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended" id="i23b0124ae5a8401286ccb912e7caf342_CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="idd3f2482b60846b087e24f820eeb6bf0_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:href="nktr-20200930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_48e46721-4a09-4048-9fa3-812d9144a68a" xlink:href="nktr-20200930.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_48e46721-4a09-4048-9fa3-812d9144a68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_a637a87f-86e2-44b5-a180-bd7078d5f1e5" xlink:href="nktr-20200930.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_a637a87f-86e2-44b5-a180-bd7078d5f1e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_91145e4c-68cd-45e5-a6ff-1c3089852532" xlink:href="nktr-20200930.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_91145e4c-68cd-45e5-a6ff-1c3089852532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_23b85131-0f8f-4f78-9f1f-720902b6912e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_23b85131-0f8f-4f78-9f1f-720902b6912e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_f0925f24-ff65-4cb0-9a2c-cf2fd98b6517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_us-gaap_InterestReceivableCurrent_f0925f24-ff65-4cb0-9a2c-cf2fd98b6517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:href="nktr-20200930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:to="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ce41c90-8068-47a2-876b-b685917c2cd2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:to="loc_srt_RangeMember_1ce41c90-8068-47a2-876b-b685917c2cd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:to="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c00072e-7d23-44ef-8459-93f7666238a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:to="loc_srt_MinimumMember_1c00072e-7d23-44ef-8459-93f7666238a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a3808d8-d4a1-40ac-97ed-e17dd92f70e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:to="loc_srt_MaximumMember_2a3808d8-d4a1-40ac-97ed-e17dd92f70e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="icb514d2cb47d457a9f5425bdfd7c715c_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c4426d38-7111-4829-a431-3284990ae7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c4426d38-7111-4829-a431-3284990ae7dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69628023-4795-46af-9bc8-8c8b4236f334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69628023-4795-46af-9bc8-8c8b4236f334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb694bec-55e7-4b44-8d82-30dc611fd14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb694bec-55e7-4b44-8d82-30dc611fd14a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_128ec0c7-29f8-4af6-b98b-1300170a2d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_128ec0c7-29f8-4af6-b98b-1300170a2d3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_283b32cb-e53d-4980-95c0-04cfe91ec02c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_283b32cb-e53d-4980-95c0-04cfe91ec02c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_3f01db4e-cb9c-47c2-8edf-c38ab2e8b25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_Cash_3f01db4e-cb9c-47c2-8edf-c38ab2e8b25a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c294d29d-8d55-4c79-8ecc-74037b49aae4" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c294d29d-8d55-4c79-8ecc-74037b49aae4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:to="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4354c68-1b9d-424c-953d-cbd9f941fa68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4354c68-1b9d-424c-953d-cbd9f941fa68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1032a545-ba9d-4e8b-bc9f-51f4e3dfa805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1032a545-ba9d-4e8b-bc9f-51f4e3dfa805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_dd143272-e0c7-40b0-8dd1-27007139a4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_CommercialPaperMember_dd143272-e0c7-40b0-8dd1-27007139a4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6faba11a-0618-4ae9-85d6-d91f50f018f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6faba11a-0618-4ae9-85d6-d91f50f018f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a0377067-8ea2-4b0a-9810-de6bc253127c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a0377067-8ea2-4b0a-9810-de6bc253127c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7bebb58e-93fb-4c73-ba92-25751f29d92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7bebb58e-93fb-4c73-ba92-25751f29d92e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46bf5632-cd90-45d8-82c2-c0271335f08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46bf5632-cd90-45d8-82c2-c0271335f08e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1df6fe2f-601e-484d-a44b-c38ef011d07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1df6fe2f-601e-484d-a44b-c38ef011d07e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20200930.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended" id="i022e7694c65e463a8b8c1f12369e1c24_Inventory"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended" id="i9d628760bd8f4a5193571317672c312e_InventoryTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20200930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended" id="i88bc6ec14bdd41f7993bb9d454b84db1_InventoryDetails"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20200930.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended" id="i00771f37d1d147e9a3f56f41d3c8e0e9_LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail" xlink:type="extended" id="i9d555cfe6408473ba9cf2977dbad107e_LiabilityRelatedtoSaleofFutureRoyaltiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_bf1d4d1f-211a-4d73-8537-a24f2912595d" xlink:href="nktr-20200930.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_bf1d4d1f-211a-4d73-8537-a24f2912595d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_da4af112-4754-45c5-adfe-0eb67d375289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_da4af112-4754-45c5-adfe-0eb67d375289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0e77e0ae-8921-4e73-8e1d-47b96f487a2e" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0e77e0ae-8921-4e73-8e1d-47b96f487a2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_24b91229-499c-4dde-a80c-33411ac8dbd5" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_24b91229-499c-4dde-a80c-33411ac8dbd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a05ff71d-a910-4333-ad55-c351932df690" xlink:href="nktr-20200930.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a05ff71d-a910-4333-ad55-c351932df690" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_f8aea713-e522-433b-bbf9-ba9db32b5d4f" xlink:href="nktr-20200930.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_f8aea713-e522-433b-bbf9-ba9db32b5d4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eac5ad5a-6037-4b66-9ca9-a378420c82c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eac5ad5a-6037-4b66-9ca9-a378420c82c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b684d560-cc45-418f-a3b0-a3dab8bc71a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b684d560-cc45-418f-a3b0-a3dab8bc71a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_62d810c4-a0ce-49e5-b0d2-5fff2b18de7c" xlink:href="nktr-20200930.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b684d560-cc45-418f-a3b0-a3dab8bc71a1" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_62d810c4-a0ce-49e5-b0d2-5fff2b18de7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended" id="i8f93f9e712774a3bb5d17d185104aa2d_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CommitmentsandContingenciesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended" id="i8442ef72ab4944d390604c46e4259073_CommitmentsandContingenciesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9937dedd-aefa-44d5-a9af-18d6d44a9e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ab575dd-27db-4601-81e9-ad903af8b606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9937dedd-aefa-44d5-a9af-18d6d44a9e2d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ab575dd-27db-4601-81e9-ad903af8b606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9937dedd-aefa-44d5-a9af-18d6d44a9e2d" xlink:to="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_30db2396-5749-4bbe-b2b3-dc925c020262_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:to="loc_us-gaap_LossContingencyNatureDomain_30db2396-5749-4bbe-b2b3-dc925c020262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_43333078-bd33-4a73-aaa2-e82279790c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:to="loc_us-gaap_LossContingencyNatureDomain_43333078-bd33-4a73-aaa2-e82279790c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_b744b363-9145-40dc-bf33-2b9991dfe537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_43333078-bd33-4a73-aaa2-e82279790c59" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_b744b363-9145-40dc-bf33-2b9991dfe537" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="i2fdb6da645594335abb1b0dde6cabc68_LicenseandCollaborationAgreements"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended" id="i7092f7ba79044bf4aedc48227bb812a8_LicenseandCollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended" id="ia0819449851c4715875039027f3be40b_LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_1c985ad5-8ab2-4ff1-8092-d57adb732fb5" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_67e44127-815c-44ce-8eb6-18cbe83fa3be" xlink:href="nktr-20200930.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_1c985ad5-8ab2-4ff1-8092-d57adb732fb5" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_67e44127-815c-44ce-8eb6-18cbe83fa3be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_1c985ad5-8ab2-4ff1-8092-d57adb732fb5" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:to="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_16f49c5c-cccd-4d34-b70f-5f54757815c2_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:to="loc_dei_EntityDomain_16f49c5c-cccd-4d34-b70f-5f54757815c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:to="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_d781cc32-d071-4068-8c64-c9153795eb1d" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_d781cc32-d071-4068-8c64-c9153795eb1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_9ce6d24e-8355-4747-b482-d83157cfc9ca" xlink:href="nktr-20200930.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_EliLillyAndCompanyMember_9ce6d24e-8355-4747-b482-d83157cfc9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_ef06ba43-69fd-44ea-a2e4-d0a7a01a59a9" xlink:href="nktr-20200930.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_AmgenIncMember_ef06ba43-69fd-44ea-a2e4-d0a7a01a59a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_0d729e21-d76e-4896-9ac7-c499f2e96edf" xlink:href="nktr-20200930.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_OtherPartnerMember_0d729e21-d76e-4896-9ac7-c499f2e96edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbe5009a-b45f-4773-9f59-ef3648536b14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbe5009a-b45f-4773-9f59-ef3648536b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_f96eff60-e92e-4e3a-8db1-cdef379775f6" xlink:href="nktr-20200930.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:to="loc_nktr_Nektar214Member_f96eff60-e92e-4e3a-8db1-cdef379775f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_cd1eee45-e68f-4f11-81bd-9cbbb6c32f98" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:to="loc_nktr_Nektar358Member_cd1eee45-e68f-4f11-81bd-9cbbb6c32f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_5c26d24b-ec33-40db-9229-5eb306492536" xlink:href="nktr-20200930.xsd#nktr_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:to="loc_nktr_NeulastaMember_5c26d24b-ec33-40db-9229-5eb306492536" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="id8413783f4cd43d8a961c00c670d88e0_LicenseandCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a18832-48af-4589-aa25-22fab8448f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a18832-48af-4589-aa25-22fab8448f07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_20bab456-a12c-4924-be98-841a9eabf650" xlink:href="nktr-20200930.xsd#nktr_SalesMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_SalesMilestoneRevenue_20bab456-a12c-4924-be98-841a9eabf650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_c7249560-9a30-4304-9d3b-4da138cb54f6" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_c7249560-9a30-4304-9d3b-4da138cb54f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_b1a7cada-3186-4e03-9812-65c30b01e879" xlink:href="nktr-20200930.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_b1a7cada-3186-4e03-9812-65c30b01e879" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_bd70a028-8d77-4b0c-8c71-337e483af0e3" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_bd70a028-8d77-4b0c-8c71-337e483af0e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_5047594a-ed8c-43c1-9da0-3988aca2a716" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_5047594a-ed8c-43c1-9da0-3988aca2a716" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_de0b48c0-89e8-496e-b2ac-a9061e3ca655" xlink:href="nktr-20200930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_de0b48c0-89e8-496e-b2ac-a9061e3ca655" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_2f24e60f-8455-4eaf-ade4-c429bcb7dd5b" xlink:href="nktr-20200930.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_2f24e60f-8455-4eaf-ade4-c429bcb7dd5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_2ab19643-402b-4a83-8d17-46e9f88d1b6a" xlink:href="nktr-20200930.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_2ab19643-402b-4a83-8d17-46e9f88d1b6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_241855fd-482e-4b3c-a9da-1cf314716f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_SharesIssued_241855fd-482e-4b3c-a9da-1cf314716f4e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_c1f97cad-1c89-4929-8de9-9d755d33c4f2" xlink:href="nktr-20200930.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_c1f97cad-1c89-4929-8de9-9d755d33c4f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_ab6a8a28-6e87-49e9-8776-f57125985ef3" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PotentialDevelopmentMilestones_ab6a8a28-6e87-49e9-8776-f57125985ef3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_a81ac6f5-450c-46be-9ba2-3681bfa48d49" xlink:href="nktr-20200930.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_a81ac6f5-450c-46be-9ba2-3681bfa48d49" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_b576604f-8fe3-42ea-84ab-4f31f5003610" xlink:href="nktr-20200930.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_EstimatedFairValueOfShares_b576604f-8fe3-42ea-84ab-4f31f5003610" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_e488f36c-74d9-40b1-a5b2-829de02799ff" xlink:href="nktr-20200930.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_e488f36c-74d9-40b1-a5b2-829de02799ff" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_2fb8e821-814d-4b38-ae63-9bec5ba41cc1" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_2fb8e821-814d-4b38-ae63-9bec5ba41cc1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_808d9d28-8596-43b3-a9dc-b13da8b09461" xlink:href="nktr-20200930.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_ReimbursementOfExpenses_808d9d28-8596-43b3-a9dc-b13da8b09461" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_80b3445a-a720-448c-a70c-ef9d501841f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_80b3445a-a720-448c-a70c-ef9d501841f9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_a9786d97-db64-4bb0-87b5-d547b7d3665d" xlink:href="nktr-20200930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_a9786d97-db64-4bb0-87b5-d547b7d3665d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_d60562a8-42e5-4b6b-bcf9-a1017c8dfb49" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_d60562a8-42e5-4b6b-bcf9-a1017c8dfb49" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_6c2c7afa-00f7-4288-9e40-f17af50ce78f" xlink:href="nktr-20200930.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_6c2c7afa-00f7-4288-9e40-f17af50ce78f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_5880b26a-3f5d-454f-975a-ea02db33a080" xlink:href="nktr-20200930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_5880b26a-3f5d-454f-975a-ea02db33a080" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_517a5d11-1086-40dd-99c5-5e8997117c1c" xlink:href="nktr-20200930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_517a5d11-1086-40dd-99c5-5e8997117c1c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_577dc3c4-9b38-4947-83b8-e6db29b5575c" xlink:href="nktr-20200930.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_577dc3c4-9b38-4947-83b8-e6db29b5575c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248b78c9-1a72-45bc-b3f2-e29549c58670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248b78c9-1a72-45bc-b3f2-e29549c58670" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_5cd11141-0c76-45c5-9a29-358afefe3e43" xlink:href="nktr-20200930.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_5cd11141-0c76-45c5-9a29-358afefe3e43" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9a3d507f-7816-4e76-9d08-e68a9b453d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9a3d507f-7816-4e76-9d08-e68a9b453d9c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_abcde825-b6a3-4ccc-9047-a96497655929" xlink:href="nktr-20200930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_abcde825-b6a3-4ccc-9047-a96497655929" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_517dff16-b37f-4f9b-a960-58d53d21b61c" xlink:href="nktr-20200930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_517dff16-b37f-4f9b-a960-58d53d21b61c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8d02799b-9419-4577-846e-01f06b5732b7_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:to="loc_dei_EntityDomain_8d02799b-9419-4577-846e-01f06b5732b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:to="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9cdb12cb-3bf3-457f-93c9-476a869fb233" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9cdb12cb-3bf3-457f-93c9-476a869fb233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_63ae07a7-b0ef-4bf0-8fee-fe87099e0beb" xlink:href="nktr-20200930.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_EliLillyAndCompanyMember_63ae07a7-b0ef-4bf0-8fee-fe87099e0beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_d6971edf-f069-4c49-b7b0-943e4d921085" xlink:href="nktr-20200930.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_EliLillyMember_d6971edf-f069-4c49-b7b0-943e4d921085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_10671831-cfdd-4fe1-ac94-fbb7969ad11d" xlink:href="nktr-20200930.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_10671831-cfdd-4fe1-ac94-fbb7969ad11d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_b8c41ce1-dac4-4a67-a6e1-0740c2b54147" xlink:href="nktr-20200930.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_AmgenIncMember_b8c41ce1-dac4-4a67-a6e1-0740c2b54147" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_011f4f6c-3751-42e1-9f5e-6d7961590994" xlink:href="nktr-20200930.xsd#nktr_AstraZenecaAbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_AstraZenecaAbMember_011f4f6c-3751-42e1-9f5e-6d7961590994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_d40ee096-51eb-47a2-8a6e-5e40d745dbe2" xlink:href="nktr-20200930.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_OtherPartnerMember_d40ee096-51eb-47a2-8a6e-5e40d745dbe2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0094b7e7-e16d-4d98-b9cb-68342f3d7f63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0094b7e7-e16d-4d98-b9cb-68342f3d7f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_032a00f4-aa28-4c75-b761-697bf2855177" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_032a00f4-aa28-4c75-b761-697bf2855177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_6010dde2-9ff4-43e5-896d-3009201fcf11" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_Nektar358Member_6010dde2-9ff4-43e5-896d-3009201fcf11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_656a4607-0a21-45f5-b78c-549a97fd19e0" xlink:href="nktr-20200930.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_656a4607-0a21-45f5-b78c-549a97fd19e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_eb35c7f7-0f33-4502-ab94-7b7f7a9bafac" xlink:href="nktr-20200930.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_DrugProductDevelopmentMember_eb35c7f7-0f33-4502-ab94-7b7f7a9bafac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember_0c90360f-4ef7-40a8-8753-7c06561d3037" xlink:href="nktr-20200930.xsd#nktr_HemophiliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_HemophiliaMember_0c90360f-4ef7-40a8-8753-7c06561d3037" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_b95f4a19-4d9d-4127-873b-5444326c73ca" xlink:href="nktr-20200930.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_b95f4a19-4d9d-4127-873b-5444326c73ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_660acb46-4c9a-42b4-ad61-0b65d4f3f531" xlink:href="nktr-20200930.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_660acb46-4c9a-42b4-ad61-0b65d4f3f531" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_3fa803fd-a1fb-4d6f-965c-a10ee889576b" xlink:href="nktr-20200930.xsd#nktr_NektarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_NektarMember_3fa803fd-a1fb-4d6f-965c-a10ee889576b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c18b0a8e-53bf-4416-ac28-e174b3bdfd88_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:to="loc_srt_SegmentGeographicalDomain_c18b0a8e-53bf-4416-ac28-e174b3bdfd88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_11873add-0592-4c54-a9f0-652c2073bd4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:to="loc_srt_SegmentGeographicalDomain_11873add-0592-4c54-a9f0-652c2073bd4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_559fabb4-d544-47b5-94f1-3c987ffabaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_11873add-0592-4c54-a9f0-652c2073bd4c" xlink:to="loc_us-gaap_EuropeanUnionMember_559fabb4-d544-47b5-94f1-3c987ffabaaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33a82f69-ca49-473e-a4ff-14e8a231ea3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:to="loc_srt_ProductsAndServicesDomain_33a82f69-ca49-473e-a4ff-14e8a231ea3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:to="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_926d73c8-6196-4c95-8067-6ef13dc7ecb4" xlink:href="nktr-20200930.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:to="loc_nktr_Nektar214Member_926d73c8-6196-4c95-8067-6ef13dc7ecb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_f60a57d0-d633-4d90-8a62-d51c711fca5d" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:to="loc_nktr_Nektar358Member_f60a57d0-d633-4d90-8a62-d51c711fca5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358LicenseMember_d063d8ff-1d83-4951-a634-10e31a0ad483" xlink:href="nktr-20200930.xsd#nktr_Nektar358LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:to="loc_nktr_Nektar358LicenseMember_d063d8ff-1d83-4951-a634-10e31a0ad483" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c40a5e00-1db7-441b-9aae-bcd8d0d85520_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c40a5e00-1db7-441b-9aae-bcd8d0d85520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_13223e61-fb00-4f37-ae9c-2773825b6e68" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:to="loc_srt_ConsolidatedEntitiesDomain_13223e61-fb00-4f37-ae9c-2773825b6e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_978580b2-b05b-49e4-b6b5-91368d2611fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_13223e61-fb00-4f37-ae9c-2773825b6e68" xlink:to="loc_srt_ParentCompanyMember_978580b2-b05b-49e4-b6b5-91368d2611fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_407397f5-165f-4128-b65c-ccb6fada4654_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_407397f5-165f-4128-b65c-ccb6fada4654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35eb21e0-f8bd-4b94-8277-949d832cee02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35eb21e0-f8bd-4b94-8277-949d832cee02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_d3c48f92-9d26-4e51-aba0-34a046dbdc16" xlink:href="nktr-20200930.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35eb21e0-f8bd-4b94-8277-949d832cee02" xlink:to="loc_nktr_OpdivoMember_d3c48f92-9d26-4e51-aba0-34a046dbdc16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:to="loc_srt_RangeMember_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:to="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d8ad691d-cffd-42c4-a1fe-3940628e1593" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:to="loc_srt_MaximumMember_d8ad691d-cffd-42c4-a1fe-3940628e1593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ada66bd4-a98e-4e70-a5b0-93afbd8d0cfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:to="loc_srt_MinimumMember_ada66bd4-a98e-4e70-a5b0-93afbd8d0cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d75f90c-d8a1-437b-986a-9e761d5da417_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d75f90c-d8a1-437b-986a-9e761d5da417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63390e1d-e0e5-49ea-ac05-71d9ac487bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63390e1d-e0e5-49ea-ac05-71d9ac487bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_a88a12f2-605f-4cc6-be6f-6a9c74d3f392" xlink:href="nktr-20200930.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63390e1d-e0e5-49ea-ac05-71d9ac487bfb" xlink:to="loc_nktr_SharePurchaseAgreementMember_a88a12f2-605f-4cc6-be6f-6a9c74d3f392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b014275-669f-40b7-a159-9fd8f13dd45b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b014275-669f-40b7-a159-9fd8f13dd45b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_047cd6db-aef0-4856-8249-044c1e372450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_047cd6db-aef0-4856-8249-044c1e372450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_700c735a-d5d4-4adc-bd2b-d93eae2ae92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_047cd6db-aef0-4856-8249-044c1e372450" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_700c735a-d5d4-4adc-bd2b-d93eae2ae92e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b533e9e8-f410-4b14-8629-3e43bd69d9ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_b533e9e8-f410-4b14-8629-3e43bd69d9ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a0c9f3cc-b76b-4c86-b2c9-5b3d57d32be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a0c9f3cc-b76b-4c86-b2c9-5b3d57d32be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_15760eb0-8378-4ebc-8fb6-023058d3a4ee" xlink:href="nktr-20200930.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a0c9f3cc-b76b-4c86-b2c9-5b3d57d32be5" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_15760eb0-8378-4ebc-8fb6-023058d3a4ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:href="nktr-20200930.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_43ae04fb-3267-494d-ab28-5a2a54b1fd46_default" xlink:href="nktr-20200930.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:to="loc_nktr_MilestoneDomain_43ae04fb-3267-494d-ab28-5a2a54b1fd46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_67bec678-d021-402f-9698-676e991ee91a" xlink:href="nktr-20200930.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:to="loc_nktr_MilestoneDomain_67bec678-d021-402f-9698-676e991ee91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_81c512a4-1a80-420e-aadd-56e7cfe251d0" xlink:href="nktr-20200930.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_67bec678-d021-402f-9698-676e991ee91a" xlink:to="loc_nktr_MilestoneOneMember_81c512a4-1a80-420e-aadd-56e7cfe251d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended" id="if03773b28a1e4873bbb2ad43dad173cb_LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended" id="ia3802694d59142688c52654c50f6b95a_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended" id="ida51b81994ad4adcb41944f2d6a66f5d_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i28efad2cd0d546fd979898409b9d9ee7_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c07a1e7-33ee-4fd7-bf9c-77032fba2037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5723d67b-bd1b-49b0-9c5e-42d9ac59eeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c07a1e7-33ee-4fd7-bf9c-77032fba2037" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5723d67b-bd1b-49b0-9c5e-42d9ac59eeb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c07a1e7-33ee-4fd7-bf9c-77032fba2037" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_768d66c5-e6ce-4bc5-9671-993b5927f88f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_768d66c5-e6ce-4bc5-9671-993b5927f88f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_585489bc-220a-4271-930e-7def6047acda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_us-gaap_CostOfSalesMember_585489bc-220a-4271-930e-7def6047acda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51422ee1-5af5-4fa0-9e2a-92911deeb69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51422ee1-5af5-4fa0-9e2a-92911deeb69a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72eb03f8-404d-44fe-ad8a-db6e0b7b9292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72eb03f8-404d-44fe-ad8a-db6e0b7b9292" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember_3b76e02f-da36-442f-8340-457aece8f352" xlink:href="nktr-20200930.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_nktr_ImpairmentAndOtherMember_3b76e02f-da36-442f-8340-457aece8f352" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationActivityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended" id="i502250c9034f4f39b5276d485e065af9_StockBasedCompensationActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d45f84fa-9333-4e45-9e1c-03f17636836f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d45f84fa-9333-4e45-9e1c-03f17636836f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44897d38-961c-4939-806f-eb8bd3c78c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44897d38-961c-4939-806f-eb8bd3c78c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1125878e-80bf-40ca-b31b-8d8a4a7d4427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1125878e-80bf-40ca-b31b-8d8a4a7d4427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37cebe2f-fe6c-4a3e-826b-446b0b164c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37cebe2f-fe6c-4a3e-826b-446b0b164c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1bb90943-3f16-40d3-924f-5b59eecab5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1bb90943-3f16-40d3-924f-5b59eecab5b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommonStockAdditionalSharesAuthorized_6616c3e2-4460-4b81-b92d-91fede7d7c19" xlink:href="nktr-20200930.xsd#nktr_CommonStockAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_nktr_CommonStockAdditionalSharesAuthorized_6616c3e2-4460-4b81-b92d-91fede7d7c19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:to="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce1f5bfc-d5e2-4618-b485-3437418e73bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce1f5bfc-d5e2-4618-b485-3437418e73bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0b8724fc-c6a9-4536-949a-4df9b85c9bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0b8724fc-c6a9-4536-949a-4df9b85c9bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_baeb662c-5367-4639-abae-5458dcdcc55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_baeb662c-5367-4639-abae-5458dcdcc55c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3cc69760-cc88-4686-b17a-0da109ab97bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:to="loc_us-gaap_EmployeeStockMember_3cc69760-cc88-4686-b17a-0da109ab97bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:to="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8e87d9f8-8799-4f77-8484-fb35d1136e96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:to="loc_us-gaap_PlanNameDomain_8e87d9f8-8799-4f77-8484-fb35d1136e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea09d224-38eb-430c-af72-7dc85d8c83de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:to="loc_us-gaap_PlanNameDomain_ea09d224-38eb-430c-af72-7dc85d8c83de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Restated2017PerformanceIncentivePlanMember_954161ab-7756-4317-aa82-0406469b2b27" xlink:href="nktr-20200930.xsd#nktr_Restated2017PerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ea09d224-38eb-430c-af72-7dc85d8c83de" xlink:to="loc_nktr_Restated2017PerformanceIncentivePlanMember_954161ab-7756-4317-aa82-0406469b2b27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20200930.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended" id="iab31eec3e5994c889e05deb76c7b562b_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.nektar.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/EarningsPerShareTables" xlink:type="extended" id="i399cce62a6c84973be1113b20c212f41_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#NetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended" id="i15edd931841e49168c6947d49c631ade_NetLossPerShareDetail"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nktr-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cd8fadd9-b103-4bc6-8d6e-f7c780e13194,g:a9acc073-30b2-4f27-83c9-2e78baac043d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_0636f4db-24c0-4ce3-aba4-bdebe606f1a7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0340b2a-900e-4000-9336-03789b22da9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2ca0e3d3-a3de-4bc9-abe8-6f7049315aea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c6c59231-b848-47de-bc53-2241f51824d4_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5db35b6a-0e7d-450b-be7c-e508de4adda8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_02dc71b4-f3fe-4fc5-ab88-12870994c3f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_afe35d3f-d6bd-4d19-974a-7d22931055b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_005eb5e3-bafe-437e-a0a7-7a1704caee30_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_cb4b17ab-f807-404e-9758-bc077c758d4d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_782bd1e7-d896-429e-ba81-c360b9426bac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b0e62fca-15e0-4f85-a04a-d350eb60f820_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_ed3b518d-0ada-4000-9aeb-e7f8735c0eed_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_03e697e4-8cb5-4480-b77c-aaa20116b12b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_368f9e59-c85a-44c9-8c7f-133cb3969dd7_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum maturity term for debt securities investment</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maximum Maturity Period</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maximum maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:href="nktr-20200930.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:to="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_258f4d38-57a9-4402-8348-3b72cbb81398_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_026c4ced-f2a3-4669-957f-ce40c654efe3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_343f4ec0-fe56-40db-9a77-64c672f1ac1c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c1706b3c-3bfb-461b-917b-6db44e0ab6fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e24ed9d7-0d73-467e-88ed-cb7e2669959a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarMember_740956d6-6437-4d51-b4e7-07fc0ac74627_terseLabel_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar</link:label>
    <link:label id="lab_nktr_NektarMember_label_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:label id="lab_nktr_NektarMember_documentation_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember" xlink:href="nktr-20200930.xsd#nktr_NektarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarMember" xlink:to="lab_nktr_NektarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_6192997a-c260-41f0-83da-9c7b09c0839d_terseLabel_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_label_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing Expense Current</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:href="nktr-20200930.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:to="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_91bc2452-af90-433d-abba-caa174144295_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fb91524d-616f-49b9-a488-f0076b7b9b7d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_c73b05fc-8825-4d72-acea-311982ac8dc6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_cfc110ea-7b7d-4535-a6b3-b813dbdd4640_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_71841932-cf11-4e7e-87ef-65c5dd1a5fe0_terseLabel_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercialization profits and losses sharing percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_label_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits And Losses Sharing Percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_documentation_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits and losses sharing percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:href="nktr-20200930.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:to="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_c2e01fd7-e4bf-4e9d-a4da-4e3615e6e487_terseLabel_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration received under agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_label_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Consideration Received From Agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_documentation_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration received from agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:href="nktr-20200930.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:to="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0e3a9bfc-8372-47f0-b137-3a9a3717191f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4d77479-74e9-47af-b970-893020926e35_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9713e8b5-c3e1-4be6-a81e-86315f79da21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_d3b2a521-a190-4dee-841e-296a785e78d1_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20200930.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_818dfc47-efe3-48ea-a9ca-86c6c602de5a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_0d951527-82bb-4f9e-8a09-a22cce517a0a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4330314f-4827-4512-8b3f-86bb8bc4e614_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Restated2017PerformanceIncentivePlanMember_834b060f-3fdd-4f1d-82d0-48b950ea8bd4_terseLabel_en-US" xlink:label="lab_nktr_Restated2017PerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Incentive Plan</link:label>
    <link:label id="lab_nktr_Restated2017PerformanceIncentivePlanMember_label_en-US" xlink:label="lab_nktr_Restated2017PerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated 2017 Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_nktr_Restated2017PerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_nktr_Restated2017PerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated 2017 Performance Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Restated2017PerformanceIncentivePlanMember" xlink:href="nktr-20200930.xsd#nktr_Restated2017PerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Restated2017PerformanceIncentivePlanMember" xlink:to="lab_nktr_Restated2017PerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_bf232a07-923d-41fe-bae9-3b0cdde49a38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ac4c10b-5d21-4474-a7e4-76c66e8abeb2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_8289f7c7-ef41-487e-9d2c-b685f365fb75_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20200930.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b395d1a5-f856-43c3-8fac-8e5a54fda22b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmgenIncMember_43346c82-b84e-4742-b9f9-56aa8715f658_terseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_label_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc [Member]</link:label>
    <link:label id="lab_nktr_AmgenIncMember_documentation_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember" xlink:href="nktr-20200930.xsd#nktr_AmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmgenIncMember" xlink:to="lab_nktr_AmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d4273673-c82a-42e7-82f6-5bdbe5fd9900_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5a9070bb-be6a-4fa0-a325-8e947b0d4d19_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_85644419-44fe-47a8-8bf8-bd457a5ded89_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_44c3a158-a4dc-4174-96ff-0b9bc29a04ed_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_19d8f1cf-8836-4461-926a-56b68dbb2435_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Deferred Revenue Balance from Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c634e8ad-72c0-4706-9219-b688f67b6695_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_f3564a6d-456e-45cd-8af6-809a5693240e_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20200930.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5acb0013-f6fa-4a16-8ca5-f0d8b61809fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3aef0ae6-3493-4865-a739-7b2f05b5b0e2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_50744fd4-d327-4c19-847b-eb2da75ed0f1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_55adaba2-c1e8-496d-ab20-f7a1581f4139_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_0d17ea70-396f-456a-8edf-9647c5050b95_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_69227d26-2d86-47ee-99e8-bc9acd113f80_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment And Other Costs For Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment And Other Costs For Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6056b21b-f233-42d4-a7f4-533f951edd17_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_581f2f13-1dfe-4596-9487-90098d9c2bc6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a902971b-d376-48df-9162-ab6eacf9daba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_251f7050-5f0e-496c-bf81-f6615be7469b_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20200930.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_34611f33-10b8-44cd-b24d-6c28939144c0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fbd46af6-f835-4b4f-871a-7bee2e9c5ae9_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_119651d9-f7c9-462e-a9bd-0156812f97f6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_509e61b7-bf95-445b-96fd-ada1b4c47933_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aae81eac-2c65-4238-b48d-3ec44556079f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6cd89ecc-11da-4d16-be20-c6f96e43d402_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_1209329d-6823-4bcc-83c3-b19a49196853_terseLabel_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_label_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_documentation_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:href="nktr-20200930.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:to="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_c7254539-1020-4b61-a7d1-1071b116a09a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_becfbe90-8c8d-4130-88a8-0b4c4174a824_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20200930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_7d10ca4c-0eed-45d6-ab15-68ca946dfa72_terseLabel_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Sales Level Milestone</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_label_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Sales Level Milestone [Member]</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_documentation_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual sales level milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember" xlink:href="nktr-20200930.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AnnualSalesLevelMilestoneMember" xlink:to="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_49b30654-5d13-4fc3-8767-2bbc0697244e_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e16549ba-3278-4e18-868a-7ee756fc8282_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_94691d1b-ba36-4b6e-a20c-1145225d4523_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1fdffe3c-7ace-4839-ae52-8f0c14a85d95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2d498c50-dc6a-44a1-b3a0-b7dda0da617c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_27ca2663-59eb-406d-8005-7809ab40375a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_c3d57754-82a7-4d2d-a476-5838ea84f309_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9b1d8503-1a80-4ad4-b900-69cd3ca8feab_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2020 or December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_22c3808e-ecd8-4bfb-8f11-c0f327959d83_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9b4f8edb-a439-4835-9a8e-9e7e4464e05c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4b501136-bc6c-4d47-a671-112b5310386f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_65a56ab5-90b4-43dc-a231-c54314b2d7d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6b5b3765-fd8d-4680-aa45-100bebb2fe66_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_25ad08c6-638b-42bc-9e05-ae1c89a9bb46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_654a5c37-e54f-443e-b6d4-ca26dc3c7db2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5f57ec49-9ee1-42b1-811e-5f443728515b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c61e914-3e0a-4645-8cb8-2eca6af61a75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_9ad4fca7-5db5-42fa-a72c-efb07ae4772c_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d86f68ff-2d0f-4173-86fe-55aa2358e681_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_0a99b5d5-c844-4398-a006-694fb0d8bdbc_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20200930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_43f4e639-93ff-442c-9993-53cd4d046fbb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_d1f60319-1bf7-45fa-9fa7-8ca9972473a0_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20200930.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_641502cb-478d-48a3-ab5d-590e6f22ee1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9ca2be7c-b99e-45d2-bb60-f059f0c571a0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_56c8a505-1c56-4673-9634-c2c3edf15df4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3a68f94-e838-4d18-b776-3346b29a290d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_081df612-3ff7-495d-982b-619be294353f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0d6fb0d4-692a-4157-a17d-fd719bd11bcb_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_8fea55c2-1d8a-4bbe-9c75-ff96cb63449d_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_87024cf5-ebef-48e3-adc8-f7646f6ef4ce_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b6255afd-1833-45f9-9cf8-5ebdc27b10b2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_0115c2be-5163-438a-9223-1bee9804c3a2_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8710043-e442-4f3c-a2b7-4a5d8e52a0cc_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e0449ea-7071-4e50-b2cb-60f5ca6f2879_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9c810fdb-630a-43dc-a02e-d6b226c4d3ec_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0ed42f75-9804-469b-9394-62a9318a5c54_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_28fe855f-d286-4fed-bbfe-545a5fa20f5e_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20200930.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3429a924-a1b6-4901-b150-c6e35f062b49_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_3d1943de-a591-4682-89a7-3156cc874ec0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c113ba44-5e59-4734-be20-4556371cea96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_580f6f68-6b22-4b98-a038-fcdcfe0111d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_cddd66ba-8466-441a-bb2e-c780e362dd12_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20200930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1d153bd9-adc6-45b1-ad6d-f3f45019a125_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_430676f3-d991-4c42-aa0e-20d19b7cd051_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f932f403-3cae-4717-a955-47f7bb3e2274_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f2db9bcd-f672-4f07-834e-5a52fb012a28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_db8b58ec-ff4c-44a0-b5ef-30f0b5bd395c_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20200930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_682d0886-ab0f-48ec-a5be-cdcc2b2f18c8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_4a0bb591-e293-4e77-b2f3-ac27642ba062_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_8421312a-5bda-414a-aafd-86a2cb12e3be_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_abb0ebae-bf15-42c9-be28-3ddc5094abb1_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a5fb9fb1-c66d-451d-9ce6-4adf7f3b8023_negatedTerseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_9c6c7b60-6767-4e20-93da-0f6ba5f0e912_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_511f6c49-4fd8-4835-a892-70f94a8409e4_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18b3eaec-c265-4e36-ae47-b372a54f0bbf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc3431de-0971-4d12-9c48-6c858d20c460_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f34cd4a9-2e13-4411-9008-013ea707c05c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2cd63bd3-39b3-4bc9-8aab-fef6bf48f93a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_40c84dcd-9afd-4342-960d-f456925e4f7c_terseLabel_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Development</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_label_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase One Clinical Development [Member]</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:href="nktr-20200930.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:to="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a43ac8f6-b981-4d88-8e15-32cf67f1f840_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b47cfd2d-0d4d-49e7-9c5d-caf8c8110889_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_6169dd98-beb4-469e-91b5-7f01757180de_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_74fb2f4a-e285-44a3-94e7-fcd08dea94a2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_49fd5108-215d-43c8-bcca-dede41fe4870_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 179,394 shares and 176,505 shares outstanding at September 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_5adae8e0-b0b1-429c-bf7b-6845086df177_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20200930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_caf8c8cd-c0f1-489b-a717-b8b3e6029ccd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_a5a3f74b-2854-49bc-b6b6-140110cd372f_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CommonStockAdditionalSharesAuthorized_85ccd0b7-8047-4ce5-b2f9-4899609077a8_terseLabel_en-US" xlink:label="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, additional shares authorized (in shares)</link:label>
    <link:label id="lab_nktr_CommonStockAdditionalSharesAuthorized_label_en-US" xlink:label="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Shares Authorized</link:label>
    <link:label id="lab_nktr_CommonStockAdditionalSharesAuthorized_documentation_en-US" xlink:label="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommonStockAdditionalSharesAuthorized" xlink:href="nktr-20200930.xsd#nktr_CommonStockAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CommonStockAdditionalSharesAuthorized" xlink:to="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f7a1a739-984b-4755-a926-9a838af6b98c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0710f2e8-e721-474f-877f-4dbec384551d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_97421bc9-3f6d-4cc7-8cdd-505f39f79a32_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future development, regulatory and sales milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Regulatory And Sales Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development regulatory and sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:to="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_e4c75fca-a34f-49ae-b4c2-aa374623cea7_terseLabel_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MOVANTIK and MOVENTIG</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_label_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M O V A N T I K And M O V E N T I G [Member]</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_documentation_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MOVANTIK and MOVENTIG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember" xlink:href="nktr-20200930.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MOVANTIKAndMOVENTIGMember" xlink:to="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_18816e62-5be3-4f2d-ab96-06b42b7cf152_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_b7ecbc39-e8f1-4f64-88ba-8e519a24deb3_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborationPartnerMember_e22dc3b3-35c5-43b1-bcb8-21559f41233c_terseLabel_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_label_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner [Member]</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_documentation_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember" xlink:href="nktr-20200930.xsd#nktr_CollaborationPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborationPartnerMember" xlink:to="lab_nktr_CollaborationPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ceed3f80-9171-4029-9b25-1f5a7aea1234_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8e7cddc5-9d8b-4935-bd2d-4769d652d07c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_1e4b0d35-4867-4e37-ab25-4404e27b7606_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20200930.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_a912551a-fce8-419c-a118-181852e7641a_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NeulastaMember_7c2bcbd1-4f80-4639-ba23-8fbc6eccbebe_terseLabel_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta</link:label>
    <link:label id="lab_nktr_NeulastaMember_label_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_nktr_NeulastaMember_documentation_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember" xlink:href="nktr-20200930.xsd#nktr_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NeulastaMember" xlink:to="lab_nktr_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b3414d3a-e835-4225-b704-a4464ea9d941_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66f2172e-8b2e-4b83-9414-cfb232e87f7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_b56960f0-e63e-431e-a1fc-b08e5eb4fc2f_terseLabel_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received under right to sublicense agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_label_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Received Under Rights To Sublicense Agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_documentation_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received under rights to sublicense agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:href="nktr-20200930.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:to="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_7901a9ec-593a-493d-b1f2-68378379b90c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ae85ea57-834e-499c-aa51-1982439c5b42_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b69f5f02-7204-44c4-b134-048c03de9ea2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c4e29c72-90b3-4e87-98ff-95f98afbb82a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_4d8d7e5d-fa5b-47bd-bc23-d8bb01dbe7ea_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20200930.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_ceaa3a93-ff89-49f3-9181-8b78151a084e_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_WriteOffOfPrepayment_3ca6d905-6ebc-4c64-afec-c7a01d769550_terseLabel_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_label_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_documentation_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment" xlink:href="nktr-20200930.xsd#nktr_WriteOffOfPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_WriteOffOfPrepayment" xlink:to="lab_nktr_WriteOffOfPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_8c712edc-5e1f-4ed1-b403-1f6b197eb3a6_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Policy [Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20200930.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7c650dd-9edc-491d-b97a-6c196a4efc9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, RSUs (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_844abf67-246a-435c-aea0-7d8136fe428f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_c95351ca-03e2-416a-8a08-3516199528b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_914098a1-e413-4b39-95a3-4ce34cce767f_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement with RPI</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase And Sale Agreement [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and sale agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember" xlink:href="nktr-20200930.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreementMember" xlink:to="lab_nktr_PurchaseAndSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7874f306-33fb-49ee-a82e-f7ea894c43e4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d0005077-650a-47d8-a444-973bc8f732ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_433a4f43-eaa2-4fd8-9fab-4b299c4aeefb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3f7960d0-abf2-4855-aa4e-9f59e059d916_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b9cda782-8041-4e53-9bf3-e2701cde2f8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_86f4acd1-e55d-48c2-a6e6-4f78f9aca52e_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, remaining minimum amount committed</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAbMember_f98e7e65-b837-4e7f-be54-d3311556ed17_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember" xlink:href="nktr-20200930.xsd#nktr_AstraZenecaAbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAbMember" xlink:to="lab_nktr_AstraZenecaAbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_322dddc1-87f1-4824-9f03-12eb411fa05b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_66d8c488-cb87-4b99-8fb6-1ef76318269a_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_32367aef-4fcd-4b2b-bb3c-607b23e433cd_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20200930.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0ad9215e-5328-4ca3-8937-0d1599fe34b4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_08c1d156-6389-4c6f-a7b7-017a63ffb0b8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_95cb3269-73d9-46f5-9808-618bf53a8050_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_89182ffe-5090-424b-bd8c-e746360390ea_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6fee636a-1bbd-4869-b153-8cc235ac0d46_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_43082af0-a496-4d83-9e7b-3f16b15d2bb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_52fbf0f5-f690-465d-bb68-0ab190841f92_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20200930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ad29f075-da2b-4651-a4fd-4cb82f6bb790_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_870c50fe-5cee-4f53-9e91-9917f847b22f_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3a44d9d0-1f74-46cb-9675-60d0cd79f865_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_c6eabb94-c7dc-4e97-8f1c-b07d4ae90723_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20200930.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_370da050-cd84-4cb7-9066-18f1dc615ba7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_028430ee-9da2-4ddc-9d80-84fbc215ca9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_7c1455f6-c2a4-408f-a2ce-bb23fee20d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_c3bec785-1988-4533-a96f-7863a25a9c0d_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20200930.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e4f5e9be-c9bb-4f1e-b865-c7b1ba2393ee_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1aad8bb5-2a33-49ba-be24-4d19e5c8b93e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_85658ff6-849f-473a-b477-ac16e51d594b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4d0d1876-7198-45c8-ada6-9924f1bc64ab_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c3737bab-6b06-4de1-9b47-59540876db91_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a65762cc-2497-461d-beb0-566abaafd35d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3493ab0d-2678-44b4-8c24-b492716f3d38_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_e7c1d929-ba40-4ea2-bcea-b1701295bee4_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca-Kirin</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Agreement With Kirin [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca agreement with Kirin.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember" xlink:href="nktr-20200930.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAgreementWithKirinMember" xlink:to="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_2af20859-c706-49b0-a6e8-d368cb4ad073_terseLabel_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_label_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Allocated To Transaction Price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_documentation_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:href="nktr-20200930.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:to="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_554da2f6-9086-496b-b06a-afc9b4d0ee61_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_bcc39678-569f-47ec-ae27-fa22cc62dce0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_9c18676b-7eb4-448d-a506-7e9507f30d8b_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity term for debt securities investment (or less)</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maturity Term</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maturity date description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm" xlink:href="nktr-20200930.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaturityTerm" xlink:to="lab_nktr_DebtInvestmentMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_219eee63-7463-4224-a441-327f9fd1e47f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_721151a3-40fd-484a-9ec6-911ce1af63fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0e1b6ab0-e81f-41a6-8eea-c5600f74cec4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7264f389-d9ba-4612-bee3-c6cef41491f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6c60003f-fadc-45c3-abfe-0b24a8ab6860_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ContractWithCustomerLiabilityRollForward_7effee45-b41f-4e1f-b1d3-4582d0efa431_terseLabel_en-US" xlink:label="lab_nktr_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_nktr_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_nktr_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_nktr_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_nktr_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerLiabilityRollForward" xlink:href="nktr-20200930.xsd#nktr_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ContractWithCustomerLiabilityRollForward" xlink:to="lab_nktr_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_eb169871-d095-4ea7-ac6f-0097da7d5342_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7240f97d-9f3b-439f-a0c0-f62468d09ec5_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_640a9501-d274-447b-adda-af49a306de49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NKTR181Member_607bd809-ee04-461f-8353-c925bbdce8af_terseLabel_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181</link:label>
    <link:label id="lab_nktr_NKTR181Member_label_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:label id="lab_nktr_NKTR181Member_documentation_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member" xlink:href="nktr-20200930.xsd#nktr_NKTR181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NKTR181Member" xlink:to="lab_nktr_NKTR181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2d6cc7e1-9ffb-4042-897c-dcd0bfa3e20c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1c1a8adb-2bc2-44f3-8355-4d87824023b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_48fc436d-ddbd-494a-93a5-2eb2eba6aaaf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_84f52978-ab85-4709-9c60-3527c1b03911_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_23c97635-7292-4cb4-9f38-1a2f88bc9006_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b952cc69-a08c-4f62-a496-d0d28c7d5699_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_91e64800-7422-4788-9e8f-0d8b3be9e29c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_949b67e6-eeeb-4455-a09c-114c661d4748_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20200930.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b1526ecf-d870-4752-8ace-e507761cf113_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_44f9ee4b-62bf-4aac-b760-7b7588143342_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7b0335e9-37d8-4bba-a42c-17868cc6abcf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_c2a01541-e53e-48ca-8841-0632d87d3b50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99f0d16f-dd65-4c95-b07e-962879f9104b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_0d73a990-ccf9-47c8-9e52-ba2428b10659_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_87e5ace6-62fb-4bfa-a84a-b70cbfd9ebca_terseLabel_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_label_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development [Member]</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember" xlink:href="nktr-20200930.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DrugProductDevelopmentMember" xlink:to="lab_nktr_DrugProductDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_004319bf-c79e-4a36-8f7c-1a4fe9ce71ce_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358LicenseMember_89380085-f851-4418-aa44-72c1955836da_terseLabel_en-US" xlink:label="lab_nktr_Nektar358LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358 License</link:label>
    <link:label id="lab_nktr_Nektar358LicenseMember_label_en-US" xlink:label="lab_nktr_Nektar358LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 358 License [Member]</link:label>
    <link:label id="lab_nktr_Nektar358LicenseMember_documentation_en-US" xlink:label="lab_nktr_Nektar358LicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 358 license.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358LicenseMember" xlink:href="nktr-20200930.xsd#nktr_Nektar358LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358LicenseMember" xlink:to="lab_nktr_Nektar358LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_723f5969-d869-4e64-968d-3cb749af653f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_104632a2-771a-4871-8b06-02123603c111_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_694da1e8-4d55-4b49-959f-2fd305d0201c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_202efe53-e29b-4956-b8f9-b715213e5278_negatedLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20200930.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2e2ac3f4-757d-4eba-bb70-923cb2523e61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_10125594-2371-44f0-8a65-50b0b78e9c1c_terseLabel_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_label_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Annual Interest Rate Over Life Of Royalty Liability</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_documentation_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual interest rate over life of royalty liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:href="nktr-20200930.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:to="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_68dbe580-3402-4c64-9f86-6a1edd20f0ee_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_1b37fab4-67e8-48c7-9827-970b5e65d512_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20200930.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_364dc79c-2c68-4c01-970e-9c8f21a2ee77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_HemophiliaMember_a0fcdfbc-1d4d-4f36-a00e-5543636c6b97_terseLabel_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia</link:label>
    <link:label id="lab_nktr_HemophiliaMember_label_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia [Member]</link:label>
    <link:label id="lab_nktr_HemophiliaMember_documentation_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember" xlink:href="nktr-20200930.xsd#nktr_HemophiliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_HemophiliaMember" xlink:to="lab_nktr_HemophiliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cc8f6f11-5a83-4694-b100-b79e2a2e6b17_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_dcaf9f9d-42cd-40fb-abc7-3a4ceddb56fe_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bdd66e47-965d-4006-803a-01e938ed92d3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_eb851c90-6a9d-4c53-9387-05bfa2d737c6_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:href="nktr-20200930.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_41b647f5-f7b6-4391-98b1-f9abc7f3de52_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_aea54d59-4916-44e8-bcd2-bac111b8c1ff_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_2fbc72a1-bf25-4b96-954a-a2fec6a23efe_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestones, royalties and sales milestones</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:href="nktr-20200930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_a47d829e-f3b5-4dfe-9855-1e61816bba94_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_e9b18dd4-5385-4255-b123-bc793d6f293b_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of advance payments to contract manufacturers and equipment for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_71813f72-911e-4507-9151-066c8ed756fc_terseLabel_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_label_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Transaction Price Allocated To Performance Obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_documentation_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:href="nktr-20200930.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:to="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_431d48bc-6f71-4f6f-8571-b4f6ac6fd4f6_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1ce3c813-9cda-4dad-a55f-a7990161182a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fcc1741f-59e2-490c-b77a-eaec347dfe54_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1c4ed59-bce7-46fa-8fca-4ecabf992eef_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_783f7b4e-0bff-4416-b9e8-c3f2ff363924_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6f070aa2-71ac-4355-b43c-6bf2d789d1e3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_565c937e-827b-4939-86ce-5f1b8dbdfe55_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_adf4fae5-3d15-4184-96a8-cf2194f5eb5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2dbe8d20-34ba-4f4f-946b-b1698c3dddd4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e5c92359-da99-4d5c-9f1d-ed5b76556dee_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_95cb9301-1bdb-4c8d-8baf-7539302e1403_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, net and interest payable (see Note 1)</link:label>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_label_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesCurrent" xlink:to="lab_us-gaap_SeniorNotesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e0ff91cb-c739-4317-8e65-a85e99ba5707_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c3a2af0d-7c60-4eef-9add-e201f7274c76_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of previously unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_79af224e-a41a-4d41-b52a-e4d92a055d26_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_e12f38e4-d080-4f8e-ad5d-7e33ab5d890b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ad50b309-d0b2-4e40-97e4-555f5f99d84d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8a09131f-be24-40e9-9bb3-14cbe7219b1a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EuropeanUnionMember_0c6626ad-35a3-4685-810e-2f1658fe371c_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember" xlink:to="lab_us-gaap_EuropeanUnionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7a3e8a5-82de-4508-b44c-bc84d349e5e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_18f9ee9a-515d-4d52-a572-603f0a0f9227_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_d4b0a093-0e2c-4c16-8419-daebef68d1ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_704e1c55-03f9-4a65-aa55-5808332f3c04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit elimination in continuing operations and tax provision in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_2e6a012c-f1d3-4ee4-ac47-9275c7876952_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_8a10ca20-7fac-4de0-ba41-386360ceae86_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_13bf511f-026b-4b1f-b5a8-6ced3c6f9844_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d8253aef-6866-497f-a0ef-1d4b2a252b24_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_039142e4-dba6-49e4-982a-eeecab2a4ffb_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:href="nktr-20200930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_af1d42c4-d135-41bf-b315-9549763d41e8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b38eed4a-0c8b-49a6-819a-e6b70eb40fc8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_dc4e70db-715f-4ed3-8070-8e9ac59c9937_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_2c8deaa9-1f24-4844-a3fd-af9a1eda6f43_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ab59b06-e38b-44ce-9419-0d68d9c11294_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_4c0a3286-c728-4390-91b6-748fde865a4a_terseLabel_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_label_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_documentation_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares" xlink:href="nktr-20200930.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedFairValueOfShares" xlink:to="lab_nktr_EstimatedFairValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_d2fbeac7-3307-4c39-8c37-dea14b277df0_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f24445cb-5717-4a31-8da6-5747de9df8e1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in period related to performance in prior periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_7c099f6f-e8bf-4335-aa29-b6f4f7ccc0a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eadc1bc1-87d6-4e86-a5e5-70e8d4df235c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_690abba2-4a1a-41a3-9383-1ccbcbfd9971_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_67ee5eb1-ebc0-4d34-8501-9552ea60fd1b_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20200930.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8ec697f8-d119-4b38-ac34-38ef18dbfcb0_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20200930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25ffc7b6-96c5-44d2-ae3e-259f36f78cec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_550dbb74-b32f-4d0d-a731-66ce186299b5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ce12be87-0b10-44e3-a594-d338b95d3e56_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_21bf4a20-1958-4c73-8fe8-2c9f070995cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57d9be90-286f-4a3e-8fd0-d8572bfe9b9a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_b5268f81-d326-4ab1-b823-fbc2a77ec102_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8a5593f4-50ff-4dbd-9ef9-428ea850ef71_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2880a11b-1c0c-4250-b3e1-2f515a89bd05_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_13c7f3ac-2fc9-4b92-8694-07e4bae1c90b_terseLabel_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long term debt, including interest</link:label>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_label_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Including Interest</link:label>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_documentation_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:href="nktr-20200930.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:to="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_06317d83-3c97-4b7a-962b-a008b37f9f50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_cb1d86e1-962f-488c-8380-5fba3861c2fd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9d522d26-ee1b-4ba4-b2fb-253e25ee40cd_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_b7f862e1-145f-4075-8988-b532f293c1d7_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_65de00d4-333f-43e7-890c-4558362cf10c_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20200930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e19ce01f-7663-4d48-8eb0-bc344d3bb945_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c7d54c07-260f-4658-b15b-7c3e8c1de789_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_dba03328-8c1c-4d1b-9d22-8b5ecef58b0d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_87723f00-e2bb-46ba-85f8-509468aa00c9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_fda2ec3e-24b1-457d-8f3a-17823bbe6ffa_terseLabel_en-US" xlink:label="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75% Senior Secured Notes Due October 2020</link:label>
    <link:label id="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_label_en-US" xlink:label="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75 Percent Senior Secured Notes Due October 2020 [Member]</link:label>
    <link:label id="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_documentation_en-US" xlink:label="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75 percent senior secured notes due October 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:href="nktr-20200930.xsd#nktr_A775PercentSeniorSecuredNotesDueOctober2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:to="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_e831fa77-9865-4893-a035-cf4a4e6f295d_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20200930.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5eb3b1b3-a718-4019-8e71-2a428ac70689_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4c4dfd5-f4de-4acd-9f74-e51977843e64_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ee926712-5431-4305-bc52-eae6832300ee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2df392a5-1e85-4626-96a5-e6bfbe85bdf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7a928d0b-1674-400c-ad1a-a4950da3d28f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c158a494-4ac5-4cfe-9878-9ebfcea6cf8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bfc7a8b6-c6bd-42e0-a0f4-8a3038163052_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db303b27-9dca-4713-a0c6-7c846ba93069_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8bc82db9-276e-450b-9e29-382128cc3b3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_14f96a90-aa4a-480a-9587-b4b8b63768d5_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_f2fcf646-340b-4be6-8f2e-3201c9e2c35d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_cb6586d8-8a6a-49a0-a032-bb088b36e155_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_2d22796d-0333-4fdb-94d2-7f5ad8dcb9fa_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_label_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment And Other [Member]</link:label>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember" xlink:href="nktr-20200930.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentAndOtherMember" xlink:to="lab_nktr_ImpairmentAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_17491609-9ae9-4651-a24f-8ff38c2f2bf0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7f0fe042-eea4-4d93-944c-0e05b9a36454_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_039775f5-68fe-4839-adb6-d8c05a2c1733_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3f47aa9f-b6ec-4f30-a827-36f090f3bfb1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_9d87392a-9e57-43a1-8dee-2717abe08e42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_d7ce9c51-c9d9-4d3b-9ce3-cfe426777f32_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20200930.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_bb2c66cf-0be2-4e8e-9ece-35c60cc832ab_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c1bbeb93-3459-404f-9de1-d131259a9576_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9b5459b7-7216-4ab5-ab7b-9bd25634277e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidCapitalized_86a0b655-42b9-4330-b64d-3454b149a4b2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestPaidCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Capitalized, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidCapitalized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidCapitalized" xlink:to="lab_us-gaap_InterestPaidCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_881e3b3a-6415-4944-bb1f-225e0b1ce693_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SalesMilestoneRevenue_21379b39-be4c-4743-bbb8-6e4e345aefc8_terseLabel_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone, revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_label_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_documentation_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue" xlink:href="nktr-20200930.xsd#nktr_SalesMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SalesMilestoneRevenue" xlink:to="lab_nktr_SalesMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_73222969-43a8-45d3-84be-20540cf3b78f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_b8c53023-e935-4a17-aa1e-55853e370677_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_f486e921-5fe5-4db1-9ffc-7feeab3dc415_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_61d6d070-01c7-4ad6-b752-063369824598_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4a765c95-b6f2-4923-b08a-469af5d12059_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_66f27527-90d3-4471-84de-0e9409d3cc6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9452ca8c-3273-48db-a6a9-208d0a8c5658_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_12e0e300-de60-479c-8d4b-6c43aafb9aca_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d97605e3-bad1-4b30-9d45-6e57472384c1_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_69039f16-ad54-42f0-847b-fa4485a44a57_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3e43485f-d47b-47f1-859b-03c64368c68d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_a636a4e0-627f-4ec3-bf44-b09e29038134_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue" xlink:href="nktr-20200930.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3a89dd2d-da4d-4825-bc0f-d8c4d0b78262_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c3880656-bb49-415e-ad9c-ba14c9e74b7d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_47c49ea7-d328-4a6f-bbfe-75629ba336b8_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_60f8aae1-0441-4823-9fd7-ed17998977b0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d0ac3d99-4bc9-4fb9-bf9a-e0ff4a6ed388_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_95cd2c43-9fcd-4d99-b70f-c96167aa2ac0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_242b167f-e255-4a7b-aaac-67638ae0c7e9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_22321fd9-4107-4ff4-8434-0e21471dc0cf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e5dca422-a8e4-452e-a1ab-ab2516b89ea3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_82d5586e-b86a-4460-ac6d-080cbe1cd462_terseLabel_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective interest rate</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_label_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective Interest Rate Percentage</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_documentation_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective interest rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage" xlink:href="nktr-20200930.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProspectiveInterestRatePercentage" xlink:to="lab_nktr_ProspectiveInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_75cbcd95-0dc5-4409-bd3c-b1b9e513bf67_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_26f56886-b42b-47fd-b47e-fe62234b4aac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_bc9c665b-45e3-4ec6-b57d-1f810b98dc96_terseLabel_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance payments to contract manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_label_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payments To Contract Manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_documentation_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of advance payments to contract manufacturers, net of amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers" xlink:href="nktr-20200930.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AdvancePaymentsToContractManufacturers" xlink:to="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_6693536a-334e-4927-b8f1-d0b4ed6369be_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_059730f0-a2e2-4d04-9ad9-3bd425d9ea15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41d9202d-9b3e-4660-aa41-6f8d717a5d47_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b48f8b2a-44f5-4daa-b5dd-db38225c9096_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_d8197e34-c8ea-4d40-8d1a-d3967511f8c0_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20200930.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_16c6e066-0258-4d5c-88e0-b187037deaa5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d545c0af-ad82-4299-b728-94a78c89d3a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_4a768464-bffd-4563-9df2-1740ce937387_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ea3a94b6-0b54-4591-a4e0-21823b04d759_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_c5ddf95d-bdd5-4828-a71f-4de305ffe9db_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties Policy [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4b654d22-2b4e-4d19-8d19-7b27bdebdacb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_62fc20ad-432b-48a4-b42c-4bd3dfc94874_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bc2a1854-b12a-49af-8c57-073c155dfe28_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_a98eaff8-911d-4866-b3a2-b47f0aa0f5f7_terseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated/Takeda</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_label_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C [Member]</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_documentation_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated or takeda PLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:href="nktr-20200930.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:to="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_6246ebc4-9fbe-47b6-85fa-23cd94453d52_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7748068b-59e3-4a17-9786-814b17c638f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_d393c5d4-31f9-4fe9-a49e-5d3507c1e268_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_83e66cf2-12a9-4778-913a-ad5f09727593_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b54395d-365e-40ca-b7de-78a93790945c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9ead8f19-5376-4904-aa07-e5c996b37cee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c6e01376-4d06-477a-8d61-85feb69bd14a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_d98a39d4-bd5f-406a-9bc6-ea2fe1132f63_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e37ff657-2794-4bf1-aafc-7f87705b8bf4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_04158bd7-8fe9-49bf-84a2-7f66297d6a14_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nktr-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cd8fadd9-b103-4bc6-8d6e-f7c780e13194,g:a9acc073-30b2-4f27-83c9-2e78baac043d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c909a326-8827-4b0b-b9b3-2f63e15da7e2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_DocumentType_c909a326-8827-4b0b-b9b3-2f63e15da7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9425fb75-966f-44f4-9bc7-bd115d25a19c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_DocumentQuarterlyReport_9425fb75-966f-44f4-9bc7-bd115d25a19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_69b14dbd-5c3f-431f-9252-14315163389b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_DocumentPeriodEndDate_69b14dbd-5c3f-431f-9252-14315163389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7bf8da89-1594-44a9-a64d-79257382ea6e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_DocumentTransitionReport_7bf8da89-1594-44a9-a64d-79257382ea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_86fc4351-cfb5-44cf-a40d-4e6dc4555e5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityFileNumber_86fc4351-cfb5-44cf-a40d-4e6dc4555e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8eb28230-3027-4faa-9660-35471d286bb1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityRegistrantName_8eb28230-3027-4faa-9660-35471d286bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0275949a-0b5e-4e83-a076-e41a61025f80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0275949a-0b5e-4e83-a076-e41a61025f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0378cc6e-2055-4511-8ef9-70d702bf609b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityTaxIdentificationNumber_0378cc6e-2055-4511-8ef9-70d702bf609b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_72377802-daa7-4838-9133-1ea58977514d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityAddressAddressLine1_72377802-daa7-4838-9133-1ea58977514d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_af8027db-6d1d-45c2-bd60-24756d9b3180" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityAddressCityOrTown_af8027db-6d1d-45c2-bd60-24756d9b3180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_789c224b-a26c-46f1-9f8e-c15cc9021078" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityAddressStateOrProvince_789c224b-a26c-46f1-9f8e-c15cc9021078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_047f732f-d6cd-4f7f-9f18-447882413c0a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityAddressPostalZipCode_047f732f-d6cd-4f7f-9f18-447882413c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9fa49a8a-6da5-41fb-9398-44b6651bc707" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_CityAreaCode_9fa49a8a-6da5-41fb-9398-44b6651bc707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c0831664-3a83-4cfa-a587-f3ec02f066b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_LocalPhoneNumber_c0831664-3a83-4cfa-a587-f3ec02f066b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9d599fbe-3f2d-4f38-9d34-d60b046ffa6c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_Security12bTitle_9d599fbe-3f2d-4f38-9d34-d60b046ffa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4b9e4005-7be8-4d43-82a4-d985b83a5b0d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_TradingSymbol_4b9e4005-7be8-4d43-82a4-d985b83a5b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_36481b84-a071-4e9b-b575-ce195deb9ec4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_SecurityExchangeName_36481b84-a071-4e9b-b575-ce195deb9ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ded621d9-257f-498b-889d-546426da0b9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityCurrentReportingStatus_ded621d9-257f-498b-889d-546426da0b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_292b4fbc-ce32-4ba3-8bd7-bbd8a31436bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityInteractiveDataCurrent_292b4fbc-ce32-4ba3-8bd7-bbd8a31436bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1c1cca71-fe63-4bd4-9646-ce9ae76a5d5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityFilerCategory_1c1cca71-fe63-4bd4-9646-ce9ae76a5d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_48140697-3627-4659-8cea-c4c4324e74bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntitySmallBusiness_48140697-3627-4659-8cea-c4c4324e74bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0752db33-56c2-45e8-a5eb-b6cca9875730" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityEmergingGrowthCompany_0752db33-56c2-45e8-a5eb-b6cca9875730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c6589ca7-e348-434e-8848-da1a7a6eccde" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityShellCompany_c6589ca7-e348-434e-8848-da1a7a6eccde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f7cc267d-0c05-43b6-91de-08757bfbf9b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f7cc267d-0c05-43b6-91de-08757bfbf9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6ade9c86-ff27-4757-8627-08df8db23bb5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_AmendmentFlag_6ade9c86-ff27-4757-8627-08df8db23bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f45a853f-1c4f-45b8-9efa-fe50607b589a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_DocumentFiscalYearFocus_f45a853f-1c4f-45b8-9efa-fe50607b589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e24232f6-9f28-4752-ba40-2c06b2e6275c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e24232f6-9f28-4752-ba40-2c06b2e6275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7d1deeb9-8f3f-42ba-a118-7f6cee043f22" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_EntityCentralIndexKey_7d1deeb9-8f3f-42ba-a118-7f6cee043f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b320bab8-a876-46f0-b27e-40c22a395f3a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32b2ae28-5107-4cfa-ae4e-115b1fce3dd8" xlink:to="loc_dei_CurrentFiscalYearEndDate_b320bab8-a876-46f0-b27e-40c22a395f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_287e21a5-7624-4314-9607-ebf332f6f527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287e21a5-7624-4314-9607-ebf332f6f527" xlink:to="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04ca363c-c609-4ee0-9223-0a7617c51f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04ca363c-c609-4ee0-9223-0a7617c51f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e464f124-ecc8-4830-82ff-c2fab1f333a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e464f124-ecc8-4830-82ff-c2fab1f333a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da4841e5-aeaa-485a-8d79-249c81b25433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da4841e5-aeaa-485a-8d79-249c81b25433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_43f8309b-249e-4511-9b42-0fa4b12b5174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_us-gaap_InventoryNet_43f8309b-249e-4511-9b42-0fa4b12b5174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_b9635d39-caa5-4495-bf2d-f6d177d85d69" xlink:href="nktr-20200930.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_b9635d39-caa5-4495-bf2d-f6d177d85d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1628a756-080f-40a7-a86b-3b173a481c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_us-gaap_OtherAssetsCurrent_1628a756-080f-40a7-a86b-3b173a481c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_beb9694f-ca6a-42da-911d-1c20de05e933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da53f6cb-0b12-4a04-be17-d6d5fb94e96c" xlink:to="loc_us-gaap_AssetsCurrent_beb9694f-ca6a-42da-911d-1c20de05e933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1bf604d0-ef36-4e10-b8e8-d4aa5aa59115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1bf604d0-ef36-4e10-b8e8-d4aa5aa59115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d678b436-7926-4382-8a7a-8a0198ff6ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d678b436-7926-4382-8a7a-8a0198ff6ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a91a4afd-b54f-476e-ad30-01cbaea67d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a91a4afd-b54f-476e-ad30-01cbaea67d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_26f49adc-2c90-4417-a1c9-297fd3d60e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_Goodwill_26f49adc-2c90-4417-a1c9-297fd3d60e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_92dbab60-e3ae-4a2d-b4e6-5b3c192ea348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_92dbab60-e3ae-4a2d-b4e6-5b3c192ea348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_43ea925d-440b-41a0-b61e-abfe5ccec6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c3b7357d-27e2-4085-a6af-18a96f6a8059" xlink:to="loc_us-gaap_Assets_43ea925d-440b-41a0-b61e-abfe5ccec6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287e21a5-7624-4314-9607-ebf332f6f527" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent_914c913c-23d5-4c7a-a417-867002dc0294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_SeniorNotesCurrent_914c913c-23d5-4c7a-a417-867002dc0294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0e089280-13f1-4698-aa2f-e57cc3a89d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_AccountsPayableCurrent_0e089280-13f1-4698-aa2f-e57cc3a89d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d7137708-1b09-4305-b97c-878e4c532d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d7137708-1b09-4305-b97c-878e4c532d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_d7b77553-79ac-4d04-bdbe-827511d5198f" xlink:href="nktr-20200930.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_d7b77553-79ac-4d04-bdbe-827511d5198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_907a81fe-d78a-42e1-b541-395386fa4664" xlink:href="nktr-20200930.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_907a81fe-d78a-42e1-b541-395386fa4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_65f7235e-079e-4e3a-b7fd-adc6c3c0cd76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_65f7235e-079e-4e3a-b7fd-adc6c3c0cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c69648f0-8839-4a70-88f7-2e4a116dfe93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c69648f0-8839-4a70-88f7-2e4a116dfe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e34c530d-3eba-4329-81cc-01b838376d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e34c530d-3eba-4329-81cc-01b838376d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d0cba7c-1945-4475-9088-1d295416fb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5cd6aa98-76f8-4f92-9f96-7b3ca83d491c" xlink:to="loc_us-gaap_LiabilitiesCurrent_7d0cba7c-1945-4475-9088-1d295416fb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e174938-761b-48d4-95d3-479d4190a447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e174938-761b-48d4-95d3-479d4190a447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_d67219f9-2872-4abd-8094-950b68141a4f" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_d67219f9-2872-4abd-8094-950b68141a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6dd378e4-ea4d-4cc3-80e5-6b2569711d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6dd378e4-ea4d-4cc3-80e5-6b2569711d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b8452d1f-7079-4cd5-8689-c1440ba58333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b8452d1f-7079-4cd5-8689-c1440ba58333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_76dab49d-cd9a-4e5d-9b38-4e55c7a90e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_Liabilities_76dab49d-cd9a-4e5d-9b38-4e55c7a90e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28818e4f-38df-4607-b6ad-b03d978202b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28818e4f-38df-4607-b6ad-b03d978202b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8ac4ced9-056b-4f7e-8850-ccdb5b994097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:to="loc_us-gaap_PreferredStockValue_8ac4ced9-056b-4f7e-8850-ccdb5b994097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3413ee5c-2b65-4863-a8b3-8cabf31ddc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:to="loc_us-gaap_CommonStockValue_3413ee5c-2b65-4863-a8b3-8cabf31ddc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_15edff75-2104-4304-b9fa-bf8f633fe1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_15edff75-2104-4304-b9fa-bf8f633fe1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87831307-3873-44ae-aa81-bf3ecbe5ea01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87831307-3873-44ae-aa81-bf3ecbe5ea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3c33919b-01c4-43d7-8cff-0d831b31eb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3c33919b-01c4-43d7-8cff-0d831b31eb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a57518a2-5554-4670-ba17-a9596531055a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_608f4048-7790-439c-a84c-86ac84d375b7" xlink:to="loc_us-gaap_StockholdersEquity_a57518a2-5554-4670-ba17-a9596531055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8144cb90-beb7-4303-9b27-363671d6d211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce9cefe5-118a-412e-8318-21e62a42db0a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8144cb90-beb7-4303-9b27-363671d6d211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_90222263-2edc-432d-b47e-a896318b02a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_90222263-2edc-432d-b47e-a896318b02a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3b7262fd-7e73-4dc7-9242-c192614fd5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3b7262fd-7e73-4dc7-9242-c192614fd5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_99188bdc-df5e-4967-97a3-b4bc59511081" xlink:href="nktr-20200930.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_nktr_PreferredStockShareDesignated_99188bdc-df5e-4967-97a3-b4bc59511081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_756ee7ec-abc1-415c-8fe9-5e777501ed4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_756ee7ec-abc1-415c-8fe9-5e777501ed4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22fe1fb0-2d0e-44bb-ba6f-e066fda02268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22fe1fb0-2d0e-44bb-ba6f-e066fda02268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9be641a0-afbf-433b-a387-2c428f3bb002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9be641a0-afbf-433b-a387-2c428f3bb002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fbec97a0-0901-4d1d-9ac6-eea3479ec1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d4d2e16-8811-435b-91cc-7a550a37c566" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fbec97a0-0901-4d1d-9ac6-eea3479ec1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_05a38ac7-92cc-4704-903e-f406f3e9f32b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_05a38ac7-92cc-4704-903e-f406f3e9f32b" xlink:to="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:to="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73a3d128-0156-4516-a98b-447cd5f9cec3" xlink:to="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_56efe2d1-4093-45f8-a9bb-ff423dd50f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_us-gaap_ProductMember_56efe2d1-4093-45f8-a9bb-ff423dd50f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_827b957f-90bc-4946-9b3b-1bf438e6da8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_us-gaap_RoyaltyMember_827b957f-90bc-4946-9b3b-1bf438e6da8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_904d833e-01de-4af8-ab8f-0c8a1c205dc8" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_904d833e-01de-4af8-ab8f-0c8a1c205dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_46fba007-ffca-4e31-956e-346ec767824e" xlink:href="nktr-20200930.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14a12b32-e46c-46e1-a206-8dc1dc98832b" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_46fba007-ffca-4e31-956e-346ec767824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26597210-fa93-4a93-be5b-68fa97c2a032" xlink:to="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5393adab-442a-47b6-911b-e0cb26ad12e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_RevenuesAbstract_5393adab-442a-47b6-911b-e0cb26ad12e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe4395f4-260f-4473-a672-3eedd7753594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5393adab-442a-47b6-911b-e0cb26ad12e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe4395f4-260f-4473-a672-3eedd7753594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_aae30515-3b07-4db3-9c5e-3691d6bbf564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_aae30515-3b07-4db3-9c5e-3691d6bbf564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_efa5e7f6-1031-48e7-bb13-d1999fb9cde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_efa5e7f6-1031-48e7-bb13-d1999fb9cde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8b74cad4-c96f-4aff-b4d4-108f0ecfe4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8b74cad4-c96f-4aff-b4d4-108f0ecfe4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_d1ea82bb-a2b9-43d0-ba30-9422c0f81185" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_d1ea82bb-a2b9-43d0-ba30-9422c0f81185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_700dd7a0-3afe-486b-8783-d99083ee14bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8d8b9717-9cf3-4cab-81aa-0919b0e1e58c" xlink:to="loc_us-gaap_CostsAndExpenses_700dd7a0-3afe-486b-8783-d99083ee14bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_19dc6091-cfd5-40c8-bbb3-789d3fe1a0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_OperatingIncomeLoss_19dc6091-cfd5-40c8-bbb3-789d3fe1a0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_64f0bf97-c55b-42dc-b67d-ffc4b0f989e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_us-gaap_InterestExpense_64f0bf97-c55b-42dc-b67d-ffc4b0f989e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f1218247-9ac2-4d39-a428-089b404e7549" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f1218247-9ac2-4d39-a428-089b404e7549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f6ec5f8d-07a7-455c-8e8e-e078aa790a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f6ec5f8d-07a7-455c-8e8e-e078aa790a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_70857031-04a4-44b6-aa5f-75db94307b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_36511d2c-ef39-4021-9d07-f728496e0e91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_70857031-04a4-44b6-aa5f-75db94307b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_caee1c50-ab43-4b06-94dc-ebaf5de510f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_caee1c50-ab43-4b06-94dc-ebaf5de510f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b0cb273-085f-475c-bcd5-e567cbb78a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b0cb273-085f-475c-bcd5-e567cbb78a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_857c0096-8887-4b72-a7c6-f56f8dbc7bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_NetIncomeLoss_857c0096-8887-4b72-a7c6-f56f8dbc7bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_c5b84edb-a0b5-44d8-b5b3-b5c81cf24a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_c5b84edb-a0b5-44d8-b5b3-b5c81cf24a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0aa1841c-2d5d-4f75-b324-e9eeb51cfe24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01b239a4-431c-4378-91ab-17598261ae12" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0aa1841c-2d5d-4f75-b324-e9eeb51cfe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_23048d27-d735-4d5f-8024-3493b2165dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72cc45ea-3ebb-422c-9570-9c349882b210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_23048d27-d735-4d5f-8024-3493b2165dd9" xlink:to="loc_us-gaap_NetIncomeLoss_72cc45ea-3ebb-422c-9570-9c349882b210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_86123f09-8b43-4cbf-a193-745323ec34b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_23048d27-d735-4d5f-8024-3493b2165dd9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_86123f09-8b43-4cbf-a193-745323ec34b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e44703ab-6371-407c-900e-943a3fa6c43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_86123f09-8b43-4cbf-a193-745323ec34b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e44703ab-6371-407c-900e-943a3fa6c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bca4bd26-ad34-48a7-b57b-29c2570ab27d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_86123f09-8b43-4cbf-a193-745323ec34b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bca4bd26-ad34-48a7-b57b-29c2570ab27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0bc594-a2b0-42ca-8183-4353404f95a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_86123f09-8b43-4cbf-a193-745323ec34b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0bc594-a2b0-42ca-8183-4353404f95a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c851794c-5594-4626-b60a-e74b6351e19a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_23048d27-d735-4d5f-8024-3493b2165dd9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c851794c-5594-4626-b60a-e74b6351e19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_808fce00-7da7-4f3d-aa82-9cf6b8772288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_808fce00-7da7-4f3d-aa82-9cf6b8772288" xlink:to="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4ff2adb-dac7-4a98-ac4d-8e03647653bf" xlink:to="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a7ce15e-d698-4b25-b554-3066d8daaf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_CommonStockMember_9a7ce15e-d698-4b25-b554-3066d8daaf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6cc35fac-dc09-4c35-ab24-bcd8cafffe11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6cc35fac-dc09-4c35-ab24-bcd8cafffe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_977213f5-32a0-4e05-b5df-c1c9257d46ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_977213f5-32a0-4e05-b5df-c1c9257d46ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c1248dcb-93af-4d23-aa1f-b24315195528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7772d216-438f-412e-8c5d-1cefb8e8c499" xlink:to="loc_us-gaap_RetainedEarningsMember_c1248dcb-93af-4d23-aa1f-b24315195528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9e7de3ca-eb19-4108-874b-c611c842959c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3409bac5-3044-460c-a1a2-ee88ba9fc689" xlink:to="loc_us-gaap_StatementLineItems_9e7de3ca-eb19-4108-874b-c611c842959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e7de3ca-eb19-4108-874b-c611c842959c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_fdd6503c-85ba-469b-8d7b-e4645f8672be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_SharesOutstanding_fdd6503c-85ba-469b-8d7b-e4645f8672be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ad8eff4-20e6-480b-a83a-beef1449ae4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockholdersEquity_9ad8eff4-20e6-480b-a83a-beef1449ae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_808f0045-dcca-44c3-a44c-c8ee96d27296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_808f0045-dcca-44c3-a44c-c8ee96d27296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_901d75f4-6b8a-491c-a35f-d875784e99c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_901d75f4-6b8a-491c-a35f-d875784e99c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237eeda8-fea6-4638-89c9-f7b5c6c5d6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237eeda8-fea6-4638-89c9-f7b5c6c5d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_68bc7648-e7af-4f28-9a31-997fa2218295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_68bc7648-e7af-4f28-9a31-997fa2218295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c1e80e57-971f-42fd-a3e9-b3881fdc68db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_SharesOutstanding_c1e80e57-971f-42fd-a3e9-b3881fdc68db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e955b3a4-5c92-4949-a8b6-ad9296fe56e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_123b4475-8cfa-4e6a-b2e3-b1923c4d8187" xlink:to="loc_us-gaap_StockholdersEquity_e955b3a4-5c92-4949-a8b6-ad9296fe56e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae480a22-c82e-4f19-b1fb-ba502d3e3227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae480a22-c82e-4f19-b1fb-ba502d3e3227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f73e1102-420e-4ed2-8f34-a6485b55724a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae480a22-c82e-4f19-b1fb-ba502d3e3227" xlink:to="loc_us-gaap_ProfitLoss_f73e1102-420e-4ed2-8f34-a6485b55724a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae480a22-c82e-4f19-b1fb-ba502d3e3227" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_f4f45210-008d-4b92-ad3e-22133bf9a00d" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_f4f45210-008d-4b92-ad3e-22133bf9a00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_d0b4200c-6fa7-4333-b892-00915aa34fca" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_d0b4200c-6fa7-4333-b892-00915aa34fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a5e9d6e6-d7c3-415f-abc5-1d573c79ef75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a5e9d6e6-d7c3-415f-abc5-1d573c79ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fc4c80a2-0cdc-4fa6-be26-c40c73faa963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_us-gaap_DepreciationAndAmortization_fc4c80a2-0cdc-4fa6-be26-c40c73faa963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_8bf0a99d-b514-45a0-a24a-38b75e517cc1" xlink:href="nktr-20200930.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_8bf0a99d-b514-45a0-a24a-38b75e517cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_69ce485a-f340-4c80-8b51-d703684f6203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_69ce485a-f340-4c80-8b51-d703684f6203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7f102ac-bcfd-487a-8a66-6b1320d183fd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dad6a8cb-cbbe-4937-9b66-a13d7661a77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dad6a8cb-cbbe-4937-9b66-a13d7661a77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_40effc89-d74f-4c33-98dc-5f0cb913c486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_40effc89-d74f-4c33-98dc-5f0cb913c486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_3d1f7051-9b5a-4b71-9472-c5458f1a6879" xlink:href="nktr-20200930.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_3d1f7051-9b5a-4b71-9472-c5458f1a6879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_67151d2b-2d63-4899-ae3f-48c468e49e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_67151d2b-2d63-4899-ae3f-48c468e49e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3f310e4f-d55f-46f5-b50a-b5968cdee0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3f310e4f-d55f-46f5-b50a-b5968cdee0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ec420b2f-4da3-4cee-94f6-df7c6d5fdcce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ec420b2f-4da3-4cee-94f6-df7c6d5fdcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_69e7ee30-be55-40cf-b5ba-e9f7d052bf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_69e7ee30-be55-40cf-b5ba-e9f7d052bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_892b9eac-a2fd-4b42-a1b9-4c80030fe30b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_845b0602-ae30-4a9c-b825-4aa3eff243b5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_892b9eac-a2fd-4b42-a1b9-4c80030fe30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_771e4c04-7fa2-419f-803c-8df277d59ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae480a22-c82e-4f19-b1fb-ba502d3e3227" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_771e4c04-7fa2-419f-803c-8df277d59ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58b1c448-1e37-4c94-820f-4b5c69c0cee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58b1c448-1e37-4c94-820f-4b5c69c0cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9316ac62-f945-4476-a0a5-fb80d9284c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9316ac62-f945-4476-a0a5-fb80d9284c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f85c916e-0bc3-41b8-943d-d20915dad7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f85c916e-0bc3-41b8-943d-d20915dad7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c4debcf6-d110-4f16-873c-97e793e3c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c4debcf6-d110-4f16-873c-97e793e3c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3efc02ff-5564-498e-b128-86e216ac27bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_923f731b-9abb-4af5-a193-56da9d3b8499" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3efc02ff-5564-498e-b128-86e216ac27bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8fcbf8f-ceae-426d-b007-fffd4617bff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8fcbf8f-ceae-426d-b007-fffd4617bff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_04d1b794-3682-41b8-b554-767225f28313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8fcbf8f-ceae-426d-b007-fffd4617bff6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_04d1b794-3682-41b8-b554-767225f28313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_3c1036ff-fa65-41aa-b0a5-f697f7693661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8fcbf8f-ceae-426d-b007-fffd4617bff6" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_3c1036ff-fa65-41aa-b0a5-f697f7693661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d504557-4902-4184-9bec-b68a46296aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8fcbf8f-ceae-426d-b007-fffd4617bff6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d504557-4902-4184-9bec-b68a46296aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d745174a-8473-42c4-9217-3ad36d795355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d745174a-8473-42c4-9217-3ad36d795355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_09f43544-1735-43f8-a3cc-7c96e29d8243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_09f43544-1735-43f8-a3cc-7c96e29d8243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df671b97-0246-4887-bdf2-f99c7ed64f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df671b97-0246-4887-bdf2-f99c7ed64f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f56917f4-c2b5-4696-ae0a-b64b53f8fa05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f56917f4-c2b5-4696-ae0a-b64b53f8fa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_16f6b316-0cbe-433f-bbcb-4612861743bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fff77cd6-3453-4035-affd-3653f1d25a39" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_16f6b316-0cbe-433f-bbcb-4612861743bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_69b9e433-8ebe-41ef-bf84-6d140c0b23f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_16f6b316-0cbe-433f-bbcb-4612861743bb" xlink:to="loc_us-gaap_InterestPaidNet_69b9e433-8ebe-41ef-bf84-6d140c0b23f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2b942cc6-10c4-42d7-963a-b80ca108106a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_16f6b316-0cbe-433f-bbcb-4612861743bb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2b942cc6-10c4-42d7-963a-b80ca108106a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0001dcb1-f761-4161-8ecc-603e7e328572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_59016210-d0a1-4f75-9075-a0b40017f92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0001dcb1-f761-4161-8ecc-603e7e328572" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_59016210-d0a1-4f75-9075-a0b40017f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_770e0da2-a7b0-422c-9727-e8acdf6a66df" xlink:href="nktr-20200930.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_nktr_OrganizationPolicyTextBlock_770e0da2-a7b0-422c-9727-e8acdf6a66df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_47035626-3641-43b3-a295-73a9d7e2d523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_47035626-3641-43b3-a295-73a9d7e2d523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ea7006fd-d116-4541-9a90-9c9d899690e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_UseOfEstimates_ea7006fd-d116-4541-9a90-9c9d899690e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_50245493-6033-4290-ba8e-a289da945cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_50245493-6033-4290-ba8e-a289da945cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0d2a8b83-b863-4813-828e-84fb44965134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0d2a8b83-b863-4813-828e-84fb44965134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a2ae022c-c23e-4a8f-9a43-e8fc9254d409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a2ae022c-c23e-4a8f-9a43-e8fc9254d409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_00eba7ba-e305-4377-89ea-e855edd9ad3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_00eba7ba-e305-4377-89ea-e855edd9ad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1fbe0b44-7f66-41e0-a0b5-41c9a70bbd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1fbe0b44-7f66-41e0-a0b5-41c9a70bbd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ca7139f8-a7f1-4fc7-8813-b9336c2d5476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ca7139f8-a7f1-4fc7-8813-b9336c2d5476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b07da8c7-c213-4a64-be3b-a32e690f18c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b07da8c7-c213-4a64-be3b-a32e690f18c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f1f003c-953c-4d45-a8ce-7dbe87787fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f1f003c-953c-4d45-a8ce-7dbe87787fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_e4492148-ee58-41db-8236-937f1426986b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_e4492148-ee58-41db-8236-937f1426986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_bc0c7584-becf-4010-b2d2-ca2cd16856e4" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d920c2e8-677d-401c-8461-d40dae7585b7" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_bc0c7584-becf-4010-b2d2-ca2cd16856e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d54412e2-c489-48a8-9333-40f2c20e8ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:href="nktr-20200930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d54412e2-c489-48a8-9333-40f2c20e8ca9" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c58cfae-9c97-40a6-a9d9-cf99bbcf918c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember_458dacfb-4355-4b65-bc68-5d6f4da78925" xlink:href="nktr-20200930.xsd#nktr_CollaborationPartnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:to="loc_nktr_CollaborationPartnerMember_458dacfb-4355-4b65-bc68-5d6f4da78925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_11114828-361e-428b-a674-a7656f076afa" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f512243-5996-41fd-9289-e2f2303f7b58" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_11114828-361e-428b-a674-a7656f076afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bade456b-13de-4954-8cbd-ac3da1812a55" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2801fadd-7862-4418-9a5c-9f0713a9c805" xlink:to="loc_srt_ProductsAndServicesDomain_bade456b-13de-4954-8cbd-ac3da1812a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_350dd45f-27f2-43c0-aae9-eb80e0509a76" xlink:href="nktr-20200930.xsd#nktr_NKTR181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bade456b-13de-4954-8cbd-ac3da1812a55" xlink:to="loc_nktr_NKTR181Member_350dd45f-27f2-43c0-aae9-eb80e0509a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b03436b-d726-4ddc-8039-5d3a49277e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cc02a53b-2a82-4667-b9fd-36f379917515" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b03436b-d726-4ddc-8039-5d3a49277e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_74ea4b42-3829-44e9-8fa3-373fdfc2ad98" xlink:href="nktr-20200930.xsd#nktr_A775PercentSeniorSecuredNotesDueOctober2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b03436b-d726-4ddc-8039-5d3a49277e67" xlink:to="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_74ea4b42-3829-44e9-8fa3-373fdfc2ad98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_34f719ac-f20b-4d42-a3e1-f6b97338baa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ce88c85e-cf42-4647-9010-76305592498e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_34f719ac-f20b-4d42-a3e1-f6b97338baa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_59ab0187-7581-46c0-9dca-8705aa9ecb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_34f719ac-f20b-4d42-a3e1-f6b97338baa8" xlink:to="loc_us-gaap_SeniorNotesMember_59ab0187-7581-46c0-9dca-8705aa9ecb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:href="nktr-20200930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_ba85da11-2abf-4413-8413-515b95aa9b70" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_162878b7-08b0-4f54-96d4-ef436e86bb2d" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_162878b7-08b0-4f54-96d4-ef436e86bb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0e9c84ce-10f2-4656-92c0-4711a005bdb9" xlink:href="nktr-20200930.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0e9c84ce-10f2-4656-92c0-4711a005bdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4381e763-3ded-44dd-ac7d-b02eccbe3f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4381e763-3ded-44dd-ac7d-b02eccbe3f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_5e513356-37d9-4ba7-a69b-60d7fb4cc72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_5e513356-37d9-4ba7-a69b-60d7fb4cc72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_932da772-1bc8-4dd3-b8c1-cc9e60e97473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_NumberOfOperatingSegments_932da772-1bc8-4dd3-b8c1-cc9e60e97473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_41d39940-883d-4839-b88c-0a596d7cd282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_41d39940-883d-4839-b88c-0a596d7cd282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_db30beae-27bb-456f-a58f-a1ee9d0e53c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_db30beae-27bb-456f-a58f-a1ee9d0e53c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed65b145-ecd8-414d-80a3-46178df0e71c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed65b145-ecd8-414d-80a3-46178df0e71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_4a6772b5-69a9-4bc5-b82d-53c33be28094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_4a6772b5-69a9-4bc5-b82d-53c33be28094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidCapitalized_387c38ef-dd32-45fc-a843-dafb5b957a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidCapitalized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_InterestPaidCapitalized_387c38ef-dd32-45fc-a843-dafb5b957a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_24275f37-77bd-4cd2-a738-62258dd5f180" xlink:href="nktr-20200930.xsd#nktr_WriteOffOfPrepayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_nktr_WriteOffOfPrepayment_24275f37-77bd-4cd2-a738-62258dd5f180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7c321e81-9d5f-4f9e-975c-b403c122c22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b80c3380-7cdc-4e7f-946d-90aa58d56a04" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7c321e81-9d5f-4f9e-975c-b403c122c22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b49b094d-2201-4b2c-acf6-25d1e1988505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_37230638-eb5d-4e38-a3d8-48cfe95f80d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b49b094d-2201-4b2c-acf6-25d1e1988505" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_37230638-eb5d-4e38-a3d8-48cfe95f80d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c012b765-a5df-4db0-ade4-432b85ef68f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b1b9edbf-1434-4c4b-86e7-07757e97d114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c012b765-a5df-4db0-ade4-432b85ef68f7" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b1b9edbf-1434-4c4b-86e7-07757e97d114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9d90cf1a-74d6-4385-addc-f389cb3c053a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c012b765-a5df-4db0-ade4-432b85ef68f7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9d90cf1a-74d6-4385-addc-f389cb3c053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ada9ba24-bc96-4483-94de-548681d772ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3726928b-5ecb-4cc9-93a0-928f712b9c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ada9ba24-bc96-4483-94de-548681d772ab" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3726928b-5ecb-4cc9-93a0-928f712b9c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1550ef01-6c81-4aa6-9ac4-9951b30a5686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3726928b-5ecb-4cc9-93a0-928f712b9c57" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1550ef01-6c81-4aa6-9ac4-9951b30a5686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_321c3c68-1fc4-4363-9d53-06f7853e0e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3726928b-5ecb-4cc9-93a0-928f712b9c57" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_321c3c68-1fc4-4363-9d53-06f7853e0e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f36f1f7c-41fc-44aa-8dae-15e728313b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3726928b-5ecb-4cc9-93a0-928f712b9c57" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f36f1f7c-41fc-44aa-8dae-15e728313b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_9a27703f-9f2a-4412-b2c0-ed9ac789eb74" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3726928b-5ecb-4cc9-93a0-928f712b9c57" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_9a27703f-9f2a-4412-b2c0-ed9ac789eb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6edaf03a-4877-434c-b35f-f5edc34146dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:href="nktr-20200930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6edaf03a-4877-434c-b35f-f5edc34146dd" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:to="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1ce41c90-8068-47a2-876b-b685917c2cd2" xlink:to="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c00072e-7d23-44ef-8459-93f7666238a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:to="loc_srt_MinimumMember_1c00072e-7d23-44ef-8459-93f7666238a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a3808d8-d4a1-40ac-97ed-e17dd92f70e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_808ff811-b9d0-4668-8bc9-be2cf2fab5c8" xlink:to="loc_srt_MaximumMember_2a3808d8-d4a1-40ac-97ed-e17dd92f70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:href="nktr-20200930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2b6b899f-c3d0-4bce-9f7c-d81407cad479" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_48e46721-4a09-4048-9fa3-812d9144a68a" xlink:href="nktr-20200930.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_48e46721-4a09-4048-9fa3-812d9144a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_a637a87f-86e2-44b5-a180-bd7078d5f1e5" xlink:href="nktr-20200930.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_a637a87f-86e2-44b5-a180-bd7078d5f1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_91145e4c-68cd-45e5-a6ff-1c3089852532" xlink:href="nktr-20200930.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_91145e4c-68cd-45e5-a6ff-1c3089852532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_23b85131-0f8f-4f78-9f1f-720902b6912e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_23b85131-0f8f-4f78-9f1f-720902b6912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_f0925f24-ff65-4cb0-9a2c-cf2fd98b6517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_87c20976-8389-4232-8123-061ff9be7781" xlink:to="loc_us-gaap_InterestReceivableCurrent_f0925f24-ff65-4cb0-9a2c-cf2fd98b6517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9ff71767-1889-41f7-95bf-64ad8b5909cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9ff71767-1889-41f7-95bf-64ad8b5909cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:to="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_b4354c68-1b9d-424c-953d-cbd9f941fa68" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1032a545-ba9d-4e8b-bc9f-51f4e3dfa805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1032a545-ba9d-4e8b-bc9f-51f4e3dfa805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_dd143272-e0c7-40b0-8dd1-27007139a4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_CommercialPaperMember_dd143272-e0c7-40b0-8dd1-27007139a4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6faba11a-0618-4ae9-85d6-d91f50f018f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6faba11a-0618-4ae9-85d6-d91f50f018f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a0377067-8ea2-4b0a-9810-de6bc253127c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a0377067-8ea2-4b0a-9810-de6bc253127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7bebb58e-93fb-4c73-ba92-25751f29d92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b140243a-627a-4a1e-ba08-a09f5c1298d3" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7bebb58e-93fb-4c73-ba92-25751f29d92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2f87f1a-1fc0-4d7e-80d5-421eea612ff7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46bf5632-cd90-45d8-82c2-c0271335f08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46bf5632-cd90-45d8-82c2-c0271335f08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1df6fe2f-601e-484d-a44b-c38ef011d07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8132031f-91c1-4ad1-b44e-6d08c6cc9324" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1df6fe2f-601e-484d-a44b-c38ef011d07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aaa23be-27dc-4bcd-a329-74e63b30e76a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c4426d38-7111-4829-a431-3284990ae7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c4426d38-7111-4829-a431-3284990ae7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69628023-4795-46af-9bc8-8c8b4236f334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69628023-4795-46af-9bc8-8c8b4236f334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb694bec-55e7-4b44-8d82-30dc611fd14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb694bec-55e7-4b44-8d82-30dc611fd14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_128ec0c7-29f8-4af6-b98b-1300170a2d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_128ec0c7-29f8-4af6-b98b-1300170a2d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_283b32cb-e53d-4980-95c0-04cfe91ec02c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_283b32cb-e53d-4980-95c0-04cfe91ec02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_3f01db4e-cb9c-47c2-8edf-c38ab2e8b25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_us-gaap_Cash_3f01db4e-cb9c-47c2-8edf-c38ab2e8b25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c294d29d-8d55-4c79-8ecc-74037b49aae4" xlink:href="nktr-20200930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e959de9-c7a1-4417-8f43-29772f109f52" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c294d29d-8d55-4c79-8ecc-74037b49aae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20200930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d3b67db7-45e0-4a2b-ad90-ee37eeab6850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e57a1897-d3c0-4ea6-b274-29fc5a9fa5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d3b67db7-45e0-4a2b-ad90-ee37eeab6850" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e57a1897-d3c0-4ea6-b274-29fc5a9fa5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e23d9e7e-a01a-4b6d-a141-66cdbdf828d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_58ec18e3-6375-453d-8f39-30aa4023e4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e23d9e7e-a01a-4b6d-a141-66cdbdf828d0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_58ec18e3-6375-453d-8f39-30aa4023e4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20200930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5316def1-5636-4e02-9044-f5d9736891c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_54f939f9-6b46-4071-a46a-ae40844be3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5316def1-5636-4e02-9044-f5d9736891c8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_54f939f9-6b46-4071-a46a-ae40844be3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_61a9a6fb-9922-430f-8dc3-d3f7c9c5b03b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5316def1-5636-4e02-9044-f5d9736891c8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_61a9a6fb-9922-430f-8dc3-d3f7c9c5b03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_beb9036d-85d4-49f2-a76b-ce87d90dab40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5316def1-5636-4e02-9044-f5d9736891c8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_beb9036d-85d4-49f2-a76b-ce87d90dab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_679b24ca-c34d-41c1-b88d-96beef3ea389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5316def1-5636-4e02-9044-f5d9736891c8" xlink:to="loc_us-gaap_InventoryNet_679b24ca-c34d-41c1-b88d-96beef3ea389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20200930.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e6c7c16b-1b27-4439-8595-5d3540f3e25e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_5179cd54-5210-4b35-a3ec-42692a6a0ac4" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e6c7c16b-1b27-4439-8595-5d3540f3e25e" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_5179cd54-5210-4b35-a3ec-42692a6a0ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_92bdac97-066f-4437-9954-090352953407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_92bdac97-066f-4437-9954-090352953407" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b684d560-cc45-418f-a3b0-a3dab8bc71a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eac5ad5a-6037-4b66-9ca9-a378420c82c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b684d560-cc45-418f-a3b0-a3dab8bc71a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_62d810c4-a0ce-49e5-b0d2-5fff2b18de7c" xlink:href="nktr-20200930.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b684d560-cc45-418f-a3b0-a3dab8bc71a1" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_62d810c4-a0ce-49e5-b0d2-5fff2b18de7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:href="nktr-20200930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_eb81e139-5463-4418-8a64-f6251dcffe13" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_bf1d4d1f-211a-4d73-8537-a24f2912595d" xlink:href="nktr-20200930.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_bf1d4d1f-211a-4d73-8537-a24f2912595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_da4af112-4754-45c5-adfe-0eb67d375289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_da4af112-4754-45c5-adfe-0eb67d375289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0e77e0ae-8921-4e73-8e1d-47b96f487a2e" xlink:href="nktr-20200930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0e77e0ae-8921-4e73-8e1d-47b96f487a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_24b91229-499c-4dde-a80c-33411ac8dbd5" xlink:href="nktr-20200930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_24b91229-499c-4dde-a80c-33411ac8dbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a05ff71d-a910-4333-ad55-c351932df690" xlink:href="nktr-20200930.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a05ff71d-a910-4333-ad55-c351932df690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_f8aea713-e522-433b-bbf9-ba9db32b5d4f" xlink:href="nktr-20200930.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_140173d5-d288-49fc-a8cc-77287769e286" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_f8aea713-e522-433b-bbf9-ba9db32b5d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714c08b4-f546-463a-8598-8cdb1d938487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2e0d4e47-9890-401a-832f-ebecd1eb94c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714c08b4-f546-463a-8598-8cdb1d938487" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2e0d4e47-9890-401a-832f-ebecd1eb94c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#CommitmentsandContingenciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dbd9a873-cc1e-462f-a28e-cc2aea208a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dbd9a873-cc1e-462f-a28e-cc2aea208a9b" xlink:to="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_43333078-bd33-4a73-aaa2-e82279790c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_30db2396-5749-4bbe-b2b3-dc925c020262" xlink:to="loc_us-gaap_LossContingencyNatureDomain_43333078-bd33-4a73-aaa2-e82279790c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_b744b363-9145-40dc-bf33-2b9991dfe537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_43333078-bd33-4a73-aaa2-e82279790c59" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_b744b363-9145-40dc-bf33-2b9991dfe537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9937dedd-aefa-44d5-a9af-18d6d44a9e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d8ed2f5-5a2d-4e3d-91ca-77ffed8026d2" xlink:to="loc_us-gaap_LossContingenciesLineItems_9937dedd-aefa-44d5-a9af-18d6d44a9e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ab575dd-27db-4601-81e9-ad903af8b606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9937dedd-aefa-44d5-a9af-18d6d44a9e2d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ab575dd-27db-4601-81e9-ad903af8b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31059907-9265-45d2-a0a1-07bfe700207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_27da8723-bcdc-46c0-91df-9e43f8aee60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31059907-9265-45d2-a0a1-07bfe700207c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_27da8723-bcdc-46c0-91df-9e43f8aee60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_753706df-84ca-49f1-a6d1-0b6a1e6f2e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_197ee932-1040-46ec-a984-017ecf1e8175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_753706df-84ca-49f1-a6d1-0b6a1e6f2e23" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_197ee932-1040-46ec-a984-017ecf1e8175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c41f16a9-0c18-490e-8c50-6577612e6f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_753706df-84ca-49f1-a6d1-0b6a1e6f2e23" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c41f16a9-0c18-490e-8c50-6577612e6f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c08e55d8-6b58-46aa-9185-65257ca5f8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c08e55d8-6b58-46aa-9185-65257ca5f8ad" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:to="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_16f49c5c-cccd-4d34-b70f-5f54757815c2" xlink:to="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_d781cc32-d071-4068-8c64-c9153795eb1d" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_d781cc32-d071-4068-8c64-c9153795eb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_9ce6d24e-8355-4747-b482-d83157cfc9ca" xlink:href="nktr-20200930.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_EliLillyAndCompanyMember_9ce6d24e-8355-4747-b482-d83157cfc9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_ef06ba43-69fd-44ea-a2e4-d0a7a01a59a9" xlink:href="nktr-20200930.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_AmgenIncMember_ef06ba43-69fd-44ea-a2e4-d0a7a01a59a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_0d729e21-d76e-4896-9ac7-c499f2e96edf" xlink:href="nktr-20200930.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d186e2c-2c3e-44ef-a92c-e3255f4ba33f" xlink:to="loc_nktr_OtherPartnerMember_0d729e21-d76e-4896-9ac7-c499f2e96edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bbe5009a-b45f-4773-9f59-ef3648536b14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_f96eff60-e92e-4e3a-8db1-cdef379775f6" xlink:href="nktr-20200930.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:to="loc_nktr_Nektar214Member_f96eff60-e92e-4e3a-8db1-cdef379775f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_cd1eee45-e68f-4f11-81bd-9cbbb6c32f98" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:to="loc_nktr_Nektar358Member_cd1eee45-e68f-4f11-81bd-9cbbb6c32f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_5c26d24b-ec33-40db-9229-5eb306492536" xlink:href="nktr-20200930.xsd#nktr_NeulastaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bee95f77-747d-4e22-8e5b-4e03ed4d10b3" xlink:to="loc_nktr_NeulastaMember_5c26d24b-ec33-40db-9229-5eb306492536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_1c985ad5-8ab2-4ff1-8092-d57adb732fb5" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_941eb043-b817-4e34-9bad-8ab4f02cb2af" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_1c985ad5-8ab2-4ff1-8092-d57adb732fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_67e44127-815c-44ce-8eb6-18cbe83fa3be" xlink:href="nktr-20200930.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_1c985ad5-8ab2-4ff1-8092-d57adb732fb5" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_67e44127-815c-44ce-8eb6-18cbe83fa3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd0775dd-f05d-4156-ba0b-525ec8a292e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_c710d28b-f3e0-4af0-9524-14d9085fbbb4" xlink:href="nktr-20200930.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd0775dd-f05d-4156-ba0b-525ec8a292e7" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsAbstract_c710d28b-f3e0-4af0-9524-14d9085fbbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_c710d28b-f3e0-4af0-9524-14d9085fbbb4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8d02799b-9419-4577-846e-01f06b5732b7" xlink:to="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9cdb12cb-3bf3-457f-93c9-476a869fb233" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9cdb12cb-3bf3-457f-93c9-476a869fb233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_63ae07a7-b0ef-4bf0-8fee-fe87099e0beb" xlink:href="nktr-20200930.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_EliLillyAndCompanyMember_63ae07a7-b0ef-4bf0-8fee-fe87099e0beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_d6971edf-f069-4c49-b7b0-943e4d921085" xlink:href="nktr-20200930.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_EliLillyMember_d6971edf-f069-4c49-b7b0-943e4d921085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_10671831-cfdd-4fe1-ac94-fbb7969ad11d" xlink:href="nktr-20200930.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_10671831-cfdd-4fe1-ac94-fbb7969ad11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_b8c41ce1-dac4-4a67-a6e1-0740c2b54147" xlink:href="nktr-20200930.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_AmgenIncMember_b8c41ce1-dac4-4a67-a6e1-0740c2b54147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_011f4f6c-3751-42e1-9f5e-6d7961590994" xlink:href="nktr-20200930.xsd#nktr_AstraZenecaAbMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_AstraZenecaAbMember_011f4f6c-3751-42e1-9f5e-6d7961590994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_d40ee096-51eb-47a2-8a6e-5e40d745dbe2" xlink:href="nktr-20200930.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161e5cb1-6ef0-4183-ab65-c6a0fc7199c4" xlink:to="loc_nktr_OtherPartnerMember_d40ee096-51eb-47a2-8a6e-5e40d745dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0094b7e7-e16d-4d98-b9cb-68342f3d7f63" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_032a00f4-aa28-4c75-b761-697bf2855177" xlink:href="nktr-20200930.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_032a00f4-aa28-4c75-b761-697bf2855177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_6010dde2-9ff4-43e5-896d-3009201fcf11" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_Nektar358Member_6010dde2-9ff4-43e5-896d-3009201fcf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_656a4607-0a21-45f5-b78c-549a97fd19e0" xlink:href="nktr-20200930.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_656a4607-0a21-45f5-b78c-549a97fd19e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_eb35c7f7-0f33-4502-ab94-7b7f7a9bafac" xlink:href="nktr-20200930.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_DrugProductDevelopmentMember_eb35c7f7-0f33-4502-ab94-7b7f7a9bafac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember_0c90360f-4ef7-40a8-8753-7c06561d3037" xlink:href="nktr-20200930.xsd#nktr_HemophiliaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_HemophiliaMember_0c90360f-4ef7-40a8-8753-7c06561d3037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_b95f4a19-4d9d-4127-873b-5444326c73ca" xlink:href="nktr-20200930.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_b95f4a19-4d9d-4127-873b-5444326c73ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_660acb46-4c9a-42b4-ad61-0b65d4f3f531" xlink:href="nktr-20200930.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_660acb46-4c9a-42b4-ad61-0b65d4f3f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_3fa803fd-a1fb-4d6f-965c-a10ee889576b" xlink:href="nktr-20200930.xsd#nktr_NektarMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5779421-8b5e-4a20-b523-90cafeaedde7" xlink:to="loc_nktr_NektarMember_3fa803fd-a1fb-4d6f-965c-a10ee889576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_11873add-0592-4c54-a9f0-652c2073bd4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c18b0a8e-53bf-4416-ac28-e174b3bdfd88" xlink:to="loc_srt_SegmentGeographicalDomain_11873add-0592-4c54-a9f0-652c2073bd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_559fabb4-d544-47b5-94f1-3c987ffabaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_11873add-0592-4c54-a9f0-652c2073bd4c" xlink:to="loc_us-gaap_EuropeanUnionMember_559fabb4-d544-47b5-94f1-3c987ffabaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_33a82f69-ca49-473e-a4ff-14e8a231ea3f" xlink:to="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_926d73c8-6196-4c95-8067-6ef13dc7ecb4" xlink:href="nktr-20200930.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:to="loc_nktr_Nektar214Member_926d73c8-6196-4c95-8067-6ef13dc7ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_f60a57d0-d633-4d90-8a62-d51c711fca5d" xlink:href="nktr-20200930.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:to="loc_nktr_Nektar358Member_f60a57d0-d633-4d90-8a62-d51c711fca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358LicenseMember_d063d8ff-1d83-4951-a634-10e31a0ad483" xlink:href="nktr-20200930.xsd#nktr_Nektar358LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b56f2d27-fbbd-4807-a34c-93fea6f22f78" xlink:to="loc_nktr_Nektar358LicenseMember_d063d8ff-1d83-4951-a634-10e31a0ad483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_13223e61-fb00-4f37-ae9c-2773825b6e68" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c40a5e00-1db7-441b-9aae-bcd8d0d85520" xlink:to="loc_srt_ConsolidatedEntitiesDomain_13223e61-fb00-4f37-ae9c-2773825b6e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_978580b2-b05b-49e4-b6b5-91368d2611fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_13223e61-fb00-4f37-ae9c-2773825b6e68" xlink:to="loc_srt_ParentCompanyMember_978580b2-b05b-49e4-b6b5-91368d2611fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35eb21e0-f8bd-4b94-8277-949d832cee02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_407397f5-165f-4128-b65c-ccb6fada4654" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35eb21e0-f8bd-4b94-8277-949d832cee02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_d3c48f92-9d26-4e51-aba0-34a046dbdc16" xlink:href="nktr-20200930.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35eb21e0-f8bd-4b94-8277-949d832cee02" xlink:to="loc_nktr_OpdivoMember_d3c48f92-9d26-4e51-aba0-34a046dbdc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f4cf6229-200f-4e9b-8d5b-4a8cef9554b7" xlink:to="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d8ad691d-cffd-42c4-a1fe-3940628e1593" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:to="loc_srt_MaximumMember_d8ad691d-cffd-42c4-a1fe-3940628e1593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ada66bd4-a98e-4e70-a5b0-93afbd8d0cfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54764a79-3f0a-40d7-8e36-dd3a2e626753" xlink:to="loc_srt_MinimumMember_ada66bd4-a98e-4e70-a5b0-93afbd8d0cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63390e1d-e0e5-49ea-ac05-71d9ac487bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d75f90c-d8a1-437b-986a-9e761d5da417" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63390e1d-e0e5-49ea-ac05-71d9ac487bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_a88a12f2-605f-4cc6-be6f-6a9c74d3f392" xlink:href="nktr-20200930.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63390e1d-e0e5-49ea-ac05-71d9ac487bfb" xlink:to="loc_nktr_SharePurchaseAgreementMember_a88a12f2-605f-4cc6-be6f-6a9c74d3f392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_047cd6db-aef0-4856-8249-044c1e372450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b014275-669f-40b7-a159-9fd8f13dd45b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_047cd6db-aef0-4856-8249-044c1e372450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_700c735a-d5d4-4adc-bd2b-d93eae2ae92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_047cd6db-aef0-4856-8249-044c1e372450" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_700c735a-d5d4-4adc-bd2b-d93eae2ae92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a0c9f3cc-b76b-4c86-b2c9-5b3d57d32be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_b533e9e8-f410-4b14-8629-3e43bd69d9ed" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a0c9f3cc-b76b-4c86-b2c9-5b3d57d32be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_15760eb0-8378-4ebc-8fb6-023058d3a4ee" xlink:href="nktr-20200930.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a0c9f3cc-b76b-4c86-b2c9-5b3d57d32be5" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_15760eb0-8378-4ebc-8fb6-023058d3a4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:href="nktr-20200930.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_67bec678-d021-402f-9698-676e991ee91a" xlink:href="nktr-20200930.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_43ae04fb-3267-494d-ab28-5a2a54b1fd46" xlink:to="loc_nktr_MilestoneDomain_67bec678-d021-402f-9698-676e991ee91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_81c512a4-1a80-420e-aadd-56e7cfe251d0" xlink:href="nktr-20200930.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_67bec678-d021-402f-9698-676e991ee91a" xlink:to="loc_nktr_MilestoneOneMember_81c512a4-1a80-420e-aadd-56e7cfe251d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_860ff50c-3f3d-4ec9-9ddd-16c91b2832ed" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a18832-48af-4589-aa25-22fab8448f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a18832-48af-4589-aa25-22fab8448f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_20bab456-a12c-4924-be98-841a9eabf650" xlink:href="nktr-20200930.xsd#nktr_SalesMilestoneRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_SalesMilestoneRevenue_20bab456-a12c-4924-be98-841a9eabf650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_c7249560-9a30-4304-9d3b-4da138cb54f6" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_c7249560-9a30-4304-9d3b-4da138cb54f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_b1a7cada-3186-4e03-9812-65c30b01e879" xlink:href="nktr-20200930.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_b1a7cada-3186-4e03-9812-65c30b01e879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_bd70a028-8d77-4b0c-8c71-337e483af0e3" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_bd70a028-8d77-4b0c-8c71-337e483af0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_5047594a-ed8c-43c1-9da0-3988aca2a716" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_5047594a-ed8c-43c1-9da0-3988aca2a716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_de0b48c0-89e8-496e-b2ac-a9061e3ca655" xlink:href="nktr-20200930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_de0b48c0-89e8-496e-b2ac-a9061e3ca655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_2f24e60f-8455-4eaf-ade4-c429bcb7dd5b" xlink:href="nktr-20200930.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_2f24e60f-8455-4eaf-ade4-c429bcb7dd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_2ab19643-402b-4a83-8d17-46e9f88d1b6a" xlink:href="nktr-20200930.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_2ab19643-402b-4a83-8d17-46e9f88d1b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_241855fd-482e-4b3c-a9da-1cf314716f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_SharesIssued_241855fd-482e-4b3c-a9da-1cf314716f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_c1f97cad-1c89-4929-8de9-9d755d33c4f2" xlink:href="nktr-20200930.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_c1f97cad-1c89-4929-8de9-9d755d33c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_ab6a8a28-6e87-49e9-8776-f57125985ef3" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PotentialDevelopmentMilestones_ab6a8a28-6e87-49e9-8776-f57125985ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_a81ac6f5-450c-46be-9ba2-3681bfa48d49" xlink:href="nktr-20200930.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_a81ac6f5-450c-46be-9ba2-3681bfa48d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_b576604f-8fe3-42ea-84ab-4f31f5003610" xlink:href="nktr-20200930.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_EstimatedFairValueOfShares_b576604f-8fe3-42ea-84ab-4f31f5003610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_e488f36c-74d9-40b1-a5b2-829de02799ff" xlink:href="nktr-20200930.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_e488f36c-74d9-40b1-a5b2-829de02799ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_2fb8e821-814d-4b38-ae63-9bec5ba41cc1" xlink:href="nktr-20200930.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_2fb8e821-814d-4b38-ae63-9bec5ba41cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_808d9d28-8596-43b3-a9dc-b13da8b09461" xlink:href="nktr-20200930.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_ReimbursementOfExpenses_808d9d28-8596-43b3-a9dc-b13da8b09461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_80b3445a-a720-448c-a70c-ef9d501841f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_80b3445a-a720-448c-a70c-ef9d501841f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_a9786d97-db64-4bb0-87b5-d547b7d3665d" xlink:href="nktr-20200930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_a9786d97-db64-4bb0-87b5-d547b7d3665d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_d60562a8-42e5-4b6b-bcf9-a1017c8dfb49" xlink:href="nktr-20200930.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_d60562a8-42e5-4b6b-bcf9-a1017c8dfb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_6c2c7afa-00f7-4288-9e40-f17af50ce78f" xlink:href="nktr-20200930.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_6c2c7afa-00f7-4288-9e40-f17af50ce78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_5880b26a-3f5d-454f-975a-ea02db33a080" xlink:href="nktr-20200930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_5880b26a-3f5d-454f-975a-ea02db33a080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_517a5d11-1086-40dd-99c5-5e8997117c1c" xlink:href="nktr-20200930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_517a5d11-1086-40dd-99c5-5e8997117c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_577dc3c4-9b38-4947-83b8-e6db29b5575c" xlink:href="nktr-20200930.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_577dc3c4-9b38-4947-83b8-e6db29b5575c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248b78c9-1a72-45bc-b3f2-e29549c58670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248b78c9-1a72-45bc-b3f2-e29549c58670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_5cd11141-0c76-45c5-9a29-358afefe3e43" xlink:href="nktr-20200930.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_5cd11141-0c76-45c5-9a29-358afefe3e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9a3d507f-7816-4e76-9d08-e68a9b453d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9a3d507f-7816-4e76-9d08-e68a9b453d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_abcde825-b6a3-4ccc-9047-a96497655929" xlink:href="nktr-20200930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_abcde825-b6a3-4ccc-9047-a96497655929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_517dff16-b37f-4f9b-a960-58d53d21b61c" xlink:href="nktr-20200930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_97a155e9-9970-4d05-9faa-349fb92b4bcb" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_517dff16-b37f-4f9b-a960-58d53d21b61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0465defc-6e90-4145-8e80-8aa0c6c498c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerLiabilityRollForward_9ed4af25-468a-4ccb-8703-09e1ee12a827" xlink:href="nktr-20200930.xsd#nktr_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0465defc-6e90-4145-8e80-8aa0c6c498c7" xlink:to="loc_nktr_ContractWithCustomerLiabilityRollForward_9ed4af25-468a-4ccb-8703-09e1ee12a827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_acefcb7e-2064-4a75-9479-2f24f657810b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ContractWithCustomerLiabilityRollForward_9ed4af25-468a-4ccb-8703-09e1ee12a827" xlink:to="loc_us-gaap_ContractWithCustomerLiability_acefcb7e-2064-4a75-9479-2f24f657810b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_aab209f6-4d77-4ca5-b9e8-de747ab78799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ContractWithCustomerLiabilityRollForward_9ed4af25-468a-4ccb-8703-09e1ee12a827" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_aab209f6-4d77-4ca5-b9e8-de747ab78799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_985dadb5-574e-4014-9710-db443c04d793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ContractWithCustomerLiabilityRollForward_9ed4af25-468a-4ccb-8703-09e1ee12a827" xlink:to="loc_us-gaap_ContractWithCustomerLiability_985dadb5-574e-4014-9710-db443c04d793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a975d992-1bc1-4cbe-8efa-af7fb1048ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fa9268b8-0f22-4dae-ad10-9e676439cf29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a975d992-1bc1-4cbe-8efa-af7fb1048ae2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fa9268b8-0f22-4dae-ad10-9e676439cf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6f86b59-6cc4-4a52-8de5-0b986983e024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_43bdb474-b289-455d-8418-fd0301efb983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6f86b59-6cc4-4a52-8de5-0b986983e024" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_43bdb474-b289-455d-8418-fd0301efb983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_8e3aa4b5-a6fd-42cc-a502-f0505dc83c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6f86b59-6cc4-4a52-8de5-0b986983e024" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_8e3aa4b5-a6fd-42cc-a502-f0505dc83c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a0dc1eb-6fb3-4b00-aee1-a4cfe0c1bf32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a0dc1eb-6fb3-4b00-aee1-a4cfe0c1bf32" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_768d66c5-e6ce-4bc5-9671-993b5927f88f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_585489bc-220a-4271-930e-7def6047acda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_us-gaap_CostOfSalesMember_585489bc-220a-4271-930e-7def6047acda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51422ee1-5af5-4fa0-9e2a-92911deeb69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51422ee1-5af5-4fa0-9e2a-92911deeb69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72eb03f8-404d-44fe-ad8a-db6e0b7b9292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72eb03f8-404d-44fe-ad8a-db6e0b7b9292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember_3b76e02f-da36-442f-8340-457aece8f352" xlink:href="nktr-20200930.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54749c43-594f-4e99-98c8-45ca653e6218" xlink:to="loc_nktr_ImpairmentAndOtherMember_3b76e02f-da36-442f-8340-457aece8f352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c07a1e7-33ee-4fd7-bf9c-77032fba2037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31e533b4-fa18-4097-85ea-9289632a5bb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c07a1e7-33ee-4fd7-bf9c-77032fba2037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5723d67b-bd1b-49b0-9c5e-42d9ac59eeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c07a1e7-33ee-4fd7-bf9c-77032fba2037" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5723d67b-bd1b-49b0-9c5e-42d9ac59eeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#StockBasedCompensationActivityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9f9fd6e-2931-4d28-b0a4-b82ed858625b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9f9fd6e-2931-4d28-b0a4-b82ed858625b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:to="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ce1f5bfc-d5e2-4618-b485-3437418e73bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0b8724fc-c6a9-4536-949a-4df9b85c9bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0b8724fc-c6a9-4536-949a-4df9b85c9bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_baeb662c-5367-4639-abae-5458dcdcc55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_baeb662c-5367-4639-abae-5458dcdcc55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3cc69760-cc88-4686-b17a-0da109ab97bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cc166ee-9fe4-4b3f-a098-740997c3811a" xlink:to="loc_us-gaap_EmployeeStockMember_3cc69760-cc88-4686-b17a-0da109ab97bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:to="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea09d224-38eb-430c-af72-7dc85d8c83de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8e87d9f8-8799-4f77-8484-fb35d1136e96" xlink:to="loc_us-gaap_PlanNameDomain_ea09d224-38eb-430c-af72-7dc85d8c83de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Restated2017PerformanceIncentivePlanMember_954161ab-7756-4317-aa82-0406469b2b27" xlink:href="nktr-20200930.xsd#nktr_Restated2017PerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ea09d224-38eb-430c-af72-7dc85d8c83de" xlink:to="loc_nktr_Restated2017PerformanceIncentivePlanMember_954161ab-7756-4317-aa82-0406469b2b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0d38de6-791a-478c-9315-2724db37784d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d45f84fa-9333-4e45-9e1c-03f17636836f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d45f84fa-9333-4e45-9e1c-03f17636836f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44897d38-961c-4939-806f-eb8bd3c78c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44897d38-961c-4939-806f-eb8bd3c78c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1125878e-80bf-40ca-b31b-8d8a4a7d4427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1125878e-80bf-40ca-b31b-8d8a4a7d4427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37cebe2f-fe6c-4a3e-826b-446b0b164c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37cebe2f-fe6c-4a3e-826b-446b0b164c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1bb90943-3f16-40d3-924f-5b59eecab5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1bb90943-3f16-40d3-924f-5b59eecab5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommonStockAdditionalSharesAuthorized_6616c3e2-4460-4b81-b92d-91fede7d7c19" xlink:href="nktr-20200930.xsd#nktr_CommonStockAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_593f8e34-cde8-4e1a-a240-230589e2ab96" xlink:to="loc_nktr_CommonStockAdditionalSharesAuthorized_6616c3e2-4460-4b81-b92d-91fede7d7c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20200930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9a7c609f-a848-4420-8037-8158411f8c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_215bb193-1e84-4376-af59-0e7ff1c8c2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a7c609f-a848-4420-8037-8158411f8c9d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_215bb193-1e84-4376-af59-0e7ff1c8c2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="nktr-20200930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d804132f-b0ee-452d-9fd3-30545a28395c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e67f6646-152d-4b47-91d7-518d2ff4b25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d804132f-b0ee-452d-9fd3-30545a28395c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e67f6646-152d-4b47-91d7-518d2ff4b25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20200930.xsd#NetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0b5e5511-f53e-435b-8946-587f3e0c336b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_994baed5-6777-4114-9ed2-b74eb6d35acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b5e5511-f53e-435b-8946-587f3e0c336b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_994baed5-6777-4114-9ed2-b74eb6d35acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>nktr-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20200930.xsd" xlink:type="simple"/>
    <context id="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic767cc0152094283b2c82057c082b070_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="i6de4d4cf296147b9b48d391257b6a758_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0cb27177fc6d4020b6959a80b73dd02f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f71a0b03c924b7ebf4cd6dbf957f7c8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75044dd0147640e5b1fac0562a87587c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6969bdf41a51409b8a3d5bf7778889bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2800d81e37fd467db7a4aca36a05d4bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia126490b6ef14bb4a093175bf42e2418_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i303a516554ef450b8448d3c781d28e80_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id10840689944434c895b2dfca85a5616_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c2f1f1d59f94c80a40b88d73a9a2be8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idb124e879ded4a61bfe1de6ec906bff3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0fb8ea2d87eb4ce4ab0dd27a38c19513_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i20f858bd314a45b9ae191c88d38cd186_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95068a05c9ad44ddb61821a3b2c8a545_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2590b46764604c54a3d32865b6ec27bc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53db0c02ed7c4e17a3693e7d65bc6cae_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i313a392f3bd047bdb605af3500053b1f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i78caf101002144188da0d0d44a27eaf1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i157373b14ace4588bdde4627501185ae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieaaf5f4ff58e4da6bca583978f3daf4a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib3ff659e615b460f9c093c4a103a776e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i858dd57c9a6f47d1bd0a261f843802fe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a84d3c13ef34b45b2f416e11bddf2ca_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia970b1a5f74e4c1fba7646c288d7230c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i87caf582c5b348409d849ad28e65fb60_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia6d1a58961d641009b5e86d347a0058d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iddea23a1ec4b41868773cb20d92277fc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7d4417f3eae14daa9f325143c6d2f354_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia7284e4ebcf84dd3adb2a1222f43f4a2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i11f2ffe64a6e4e6e97acf57b6dc4a3b8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1d0b165e31da484a832227b4de929b21_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i45990bd690b44a3a8403017280dfa90a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9ad0245d6766404ea4787ad9559bfd8e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic244ee9628594318be13017bcb360127_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i96a7699705cf4129838e5f75907bd07c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i32375c3beebb4e78b2f7c912d4700f16_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibf8a195c14f447e9a410d1fb69eca97b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9cdb5931a79a4157adfde1e280185bb4_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="icee27510abcb4480a16999d9a511ef67_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i07c206fe665047a39807c0608f01de69_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9cb0cdd57490423f8151ff5d9f8d3808_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if0b87bba6556485180623116c2eec80e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6e77eaab1bd5407c90009309bd132727_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie64a09a837b3492bab38342b31ec23d3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6be993ee27de4d5482714a9a8d0bbdba_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie847c6b6f4ac493aa3ce259242b96632_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia2d60f5bc3164799b0998de07ea9cd3c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id09986fe227e4792bf9ce78a90cd56a1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2f4942ff30d942a493ecdc359f515bc5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i95d5c14945d649cdbf34148f277c6321_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0027733ae46c426cb1305e97f7951913_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb4997e742034bfcb18329b32d6494b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia250ad305dd745fb96c8da18a5a40df4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2da35b042264ec58ed356a8af423513_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6a69e560a4145479538f76aa786d0de_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i42af22d15904460ca50e4626fa04aa1f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id8d3221693d14493a695856c97fd42d6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4113b9c3da104478b5f0000b7c68a664_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i556ea3ab98f84204a42ed81a9ee36489_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icdc06d2c657945d9a36b5af38466ad66_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia6cf1302dfa64b698b6c252166b100f4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1445fc508f7c4c48b2ed3508a75cb01b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i777f5bdef8e24ef0b10ba35773ffbeb7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id1c030ee76e84c0692871baedf495fd8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i762ce4970a5f44b595a60613ff383dd0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i401f9b86bf1042419786acedec068f35_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie8582351bb534ee8ad9404fecfdcdf22_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id85af4c6dbd84c249ab3d00291d566bd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i00153f8c513746068c52bffc86e33bdc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idf9e807e7b494401938118258ef486c7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iabe10e55d58b42c3a4ccd2c01211cfb3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib024f3e4564e41a4a8e24660abc87c66_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1fb35818bd5746499ac50bdf2cf1d6cc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39788d0d7cfb42eda37e02c0b7b04e7b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87d271708d2b4cad96036ef906972a1a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66fc796f6db24fe1a7fdadd7ca120a84_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c5d1fecab1a49a6b1af85520f20a093_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ida1d2d4811144e91aa10ee049f266ae8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic88bf65501e44247a07c0e4d791274ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i70f70ef47de44a5c9d729e3baf53387e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:A775PercentSeniorSecuredNotesDueOctober2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="i343224da827f4bbeac5b7f4ae124d5ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd7c1bf4db6948b1bb6785b82b5b0daa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie5f9ecd4583d46a880165db35da02267_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0fc1a07c27b84916915a50371664cedf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86d011c835d542eb8b915f244d635460_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:A775PercentSeniorSecuredNotesDueOctober2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-05</instant>
        </period>
    </context>
    <context id="i4092cae66ba8439e93d82fcef25ef788_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2ec4527be1534df98cec180cba27efc6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i47d77652e9b74bc68a1e5f8c43837e06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88d27ec3cd0a45d79c70cd319b7561fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieddedc2d43614f2087b4f389cf2e70c7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1705ff08143644c9aeb769a8d112dba7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99e7e0b20231423f97aeee88223671b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b4109b2d9da47bf8b79061158ea7bed_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie8ad5f6efc6b4bf5a108654c05274301_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3e408faa719445eb3434a16e7c18e9f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i55c58c72e60443e98000bbf5d2344984_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic88c859d81c749cea39bca6e05b73950_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i681a6443e0ce4fa6947d2139b2f64812_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdc9da2b38604cb796fa39f895a0a59d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i77ce117291d34d628c9bc23c2c80ca8d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03d1299e9f894636b79988ee324b7611_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic439350a60194b1db29410760ac99acc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0c4343e72de4e6dbb67b27ed682ae85_D20120223-20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-23</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="iafb87b6b488548d1888654100aa59ffb_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="i04a6efe880524704ab1efed03af7179b_D20120223-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-02-23</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5f32928a5bb24c13afe5414f859db8ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8dbe95429a94b1c9fd1c219421ebb89_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id64de59193e145bbaa8bdb17a62c36da_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff6d1e8753ba4393b9f44eb4e488b692_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3db9156ad10469f95b14481d96f4a7f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic68cb20163e74653bd4f64db0c6311c7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4343dbd440dc46b69ff260a863af163c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7162a81a95b64baeb3fac89305ceb96e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id53b17ca10224ac0ac514957ad57da99_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50c27af66b7349d5aea18d07614a95df_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibad28b26555d4a329b5591d767c77570_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18551d4bf36b467d8fdc3c19c639a8b6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i86ea63c983d8410db8d44a3393069d40_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6ed2104c72e46488602d090a349d252_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8c1a1a466fb4bc0bc106d1025995c65_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie76e0a45148544e2a7c2e165f1d8e4ab_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibee96693c04e4f7db443a9718ecae73f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib5211c0643104c9bae3e1bc6a61751c3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i01e0829dcbda4d3cb7e7f5488eaa3b04_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac03f04314684a77ac56ecd63ce7fd06_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="idea06231b1c44280b52f314d797baf6f_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i3ebd9a821b2a46cfb77bd1fed0e162c0_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i6c5e9092d71c49cc890b7c52af5e1209_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i839037e7f6a34cd693275417607356c0_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i99091a9d1fe04ff8974bd1aaf88b38b4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ab76208d9ee4ff2988ff083957e0c4b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ia70be8a1e2a64792b0121d05ff80c80d_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i1580321c09614031b9d42400c15746cf_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i62d453fedad74b76a89c1def968cf6c9_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="ib62bb08ae1ed42499bf0502605a0aabd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a47c82fe5384724ac972e8f0118a042_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i55e78d80f65f41df99be245f4785d48d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ca0ee0445d2406481c1a68226274962_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i345310330b5c404386610c6ffb7eb919_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i91f01add1280492bb87f2040bd86e237_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i399485e14223466ab18e166f27bb67af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e9a8b5809804afe80662a5640dc611a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide0ac9a686224749809a811eb1aee975_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i972a45764b0e465282335687170894e5_I20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="i845230a255e24070ad64f4430f5f672e_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ifa275d5aaa564026bf559d0b72b3f69f_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i1a6b27f69ae44774a99f76b9be930ea9_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i82c5b100e5d54cb1b29df1fb69b79fcf_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i1fd4979f3b7b4006aa4dc73336bb0e51_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i825ba9383adc4f57b11ab95a166bb2c3_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i8ac727c6b64f4df7857a4b3e2d0ea358_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i1f4bc86daabe478d9199134b3ced767a_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="icd4450164353469089e6a5715b63820c_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i5825f573d218444c8a02aa2a76c1e143_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i01a3e8af9af343f3af75c19ca2ff410e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf21631db7ee40ac9b0a17f839fb1811_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="ic45d9817ecdf46ae9c87ba4e76263729_D20101001-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i2981e0957f0f4a1695bcd34c346c09c3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c367beebd6f4d79ba026bb215d28964_D20090901-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i5cfa614f55b340eca7394aa4a2d91432_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i26da6534944946e088095dadd2086834_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i007147b59fd8496894c45965e29e7c2e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i11cfe9f36c27416a8410b5c100442563_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie0d135950a41412bbe0141268927497b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f2917a58fe349269bb836b1b174986d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia646a70ced924165adc2d5633324fb08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68c2ed5b2588478a815cd96dd3fa4d70_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i94ed0979123649adb4dc059466490ec4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb4f7a1f2a934d41827c699b4ead106e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i421586bc96a448849e0605a587727f4c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98ee132789b94f38b825c9ceecbd65a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb8af90d2ea34d3e9c87ef4323285570_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac31e6a7286d4bbfa722ce15fd4b5f5d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id69fe287ef8140e69c41a0fc1cf62e80_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f16026628714f2a9d7e1c922ae55c2f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i30945d826eaa4db1aee3efa6d35c52bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8d1bab0b44b74b74ab8679821ad533a9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3e080a50510b45d7985955e0bc237be8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea6b1642d5d74c94b8fc02f648ad3e3a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie8ebfaa0c2694404bb2fe78ec756a33b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6bd21aca8ffb4b5b93b574af7f8c16bc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i39cc4e2705b448d299937048e267e868_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if19b4a9eac04440dae63a1c159632e2a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib03e08fc98c644e6be4bef8a349474ac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1d349f8e26343058e7e9dd3492bdb7e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia6c6d347086b42f780f70922a18208d4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib2129dcc350a4c9fb39c6f59f2f20fe8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8432c50c56094a11aa02e5f29d960026_D20200617-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:Restated2017PerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i3bf8410935d84e55bd4f0436c35fcb2c_D20200617-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nktr:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF8yLTEtMS0xLTA_a2ed7d8f-0651-4c0c-b148-e58e173717c6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF80LTEtMS0xLTA_a9f04263-6efc-493f-9184-d9f04d0e62cf">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF81LTEtMS0xLTA_7b3073df-6280-42da-8db3-4bf1bdb0a3dc">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF84LTEtMS0xLTA_3533ea13-28e3-4b93-90d5-de3540f0cdff">0000906709</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80L2ZyYWc6MmZlNGUyNmJiOGEzNGQzMDhkMGRkN2RhNzZmM2Q2ZmYvdGFibGU6YmQxOGJiZjE4OWEyNDRiMDgwYjBhZDZkZmUyOTVmNWQvdGFibGVyYW5nZTpiZDE4YmJmMTg5YTI0NGIwODBiMGFkNmRmZTI5NWY1ZF85LTEtMS0xLTA_55dc0fd8-5a16-4d59-a530-5b4f492ebeba">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i343224da827f4bbeac5b7f4ae124d5ec_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a">us-gaap:AccountingStandardsUpdate201911Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i2ec4527be1534df98cec180cba27efc6_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_6487ad2f-0a2c-49f7-a09d-7a3056d0d81a">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i47d77652e9b74bc68a1e5f8c43837e06_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_fdc76534-bf62-4bbf-b64b-4b7ddc523e0b">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <dei:DocumentType
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY2_a6e30f12-548e-4e18-b137-7dd92d803843">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6NjEzMjUyYzEzMGVmNDkwMThlYjM5ODZkMTdjYzk4MzgvdGFibGVyYW5nZTo2MTMyNTJjMTMwZWY0OTAxOGViMzk4NmQxN2NjOTgzOF8wLTAtMS0xLTA_e8d017e7-4e40-47fb-8ee8-d232f362de11">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yNjg_64552413-21a1-42ba-86c1-af68524c9ce3">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTVhNjJiZjA1NDMwNDg4NGE5YWU1ZmFiOTExY2I2MmQvdGFibGVyYW5nZTplNWE2MmJmMDU0MzA0ODg0YTlhZTVmYWI5MTFjYjYyZF8wLTAtMS0xLTA_34afd9c1-6db6-48e1-99b8-522a71743093">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY3_f533f20f-463a-4fd4-bcf1-8a446b3368af">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcw_7d15d19b-3334-49e6-9442-a22e260ab60c">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6MjhjMDAxZGIzMjRjNDI2NTlhODQwZTljZWE5MDNiZWUvdGFibGVyYW5nZToyOGMwMDFkYjMyNGM0MjY1OWE4NDBlOWNlYTkwM2JlZV8wLTAtMS0xLTA_947e0c3e-4aed-44be-a013-e5ac2f15a529">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6MjhjMDAxZGIzMjRjNDI2NTlhODQwZTljZWE5MDNiZWUvdGFibGVyYW5nZToyOGMwMDFkYjMyNGM0MjY1OWE4NDBlOWNlYTkwM2JlZV8wLTItMS0xLTA_8ebc2414-c201-413c-a9e2-4daad125fe44">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcx_6a38625e-921c-485c-8889-8fef68b3dabe">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY4_121ad538-e5bc-4e24-b0be-fffa0fc6e82d">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcy_2c3c53cc-1175-4e1e-b327-2aa1406fd20a">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjcz_ab595b50-3e07-4e5d-9039-bf90c89e3437">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY5_6c0ff24a-09c8-4c45-9ce9-f11fd49005f9">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjYy_e5be27fd-96b6-409f-a2a6-b059aea638eb">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTlmOTE1YzMxOGIzNDRhZmE3OWY5ODJkZTlkMmRhYWIvdGFibGVyYW5nZTplOWY5MTVjMzE4YjM0NGFmYTc5Zjk4MmRlOWQyZGFhYl8yLTAtMS0xLTA_09d5a2bd-8e52-4382-9f80-4a30f68ff600">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTlmOTE1YzMxOGIzNDRhZmE3OWY5ODJkZTlkMmRhYWIvdGFibGVyYW5nZTplOWY5MTVjMzE4YjM0NGFmYTc5Zjk4MmRlOWQyZGFhYl8yLTEtMS0xLTA_09d1b7c3-8914-46e6-aa63-72bdb1c96ec5">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZTlmOTE1YzMxOGIzNDRhZmE3OWY5ODJkZTlkMmRhYWIvdGFibGVyYW5nZTplOWY5MTVjMzE4YjM0NGFmYTc5Zjk4MmRlOWQyZGFhYl8yLTItMS0xLTA_cb47f7b2-d6d5-48f1-9238-22e1f9c8a6b8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjYz_0bd5878f-e21e-4ff0-96e6-18e801d907d0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY0_70df4be4-b9cf-4380-b018-19a53e764da5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZjEyMjVmODZjNjk5NDliMWI5ZTViM2Y5NmQ1ODhkNGMvdGFibGVyYW5nZTpmMTIyNWY4NmM2OTk0OWIxYjllNWIzZjk2ZDU4OGQ0Y18wLTAtMS0xLTA_6272aefc-60aa-4e61-8614-6d16cefe5f9c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZjEyMjVmODZjNjk5NDliMWI5ZTViM2Y5NmQ1ODhkNGMvdGFibGVyYW5nZTpmMTIyNWY4NmM2OTk0OWIxYjllNWIzZjk2ZDU4OGQ0Y18yLTYtMS0xLTA_4c99a3e0-c93a-4ea5-8326-9a8c160e7b4e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGFibGU6ZjEyMjVmODZjNjk5NDliMWI5ZTViM2Y5NmQ1ODhkNGMvdGFibGVyYW5nZTpmMTIyNWY4NmM2OTk0OWIxYjllNWIzZjk2ZDU4OGQ0Y180LTItMS0xLTA_788a5f5e-b984-420c-9a67-89d9c10bd5c1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjY1_94576380-f1aa-4fbe-bd49-395d257fc5de">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic767cc0152094283b2c82057c082b070_I20201030"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xL2ZyYWc6ZTE2NzZlMzNlNzI5NGJkMjhjN2M4YWFmZjUxYzczNjUvdGV4dHJlZ2lvbjplMTY3NmUzM2U3Mjk0YmQyOGM3YzhhYWZmNTFjNzM2NV8yMjU0_0481dfdb-6941-4d2a-87b2-7fca22db16cc"
      unitRef="shares">179398666</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMy0xLTEtMS0w_98c4442c-5e78-43d1-9f70-192d5e55ea96"
      unitRef="usd">55843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMy0zLTEtMS0w_a5805052-b512-440e-bb11-9fd3cd7c410e"
      unitRef="usd">96363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNC0xLTEtMS0w_14ddbf41-27a4-43f4-bcfe-6b4cfdcb6180"
      unitRef="usd">900163000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNC0zLTEtMS0w_f283befe-7cbd-4488-aad5-1c74c48f741b"
      unitRef="usd">1228499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNS0xLTEtMS0w_3702c036-19bf-45a3-8c84-483237258926"
      unitRef="usd">42925000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNS0zLTEtMS0w_da69ef57-0773-4417-80d5-f9fac1bbbfc3"
      unitRef="usd">36802000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNi0xLTEtMS0w_b82b6f4b-9cf7-4fd8-bd72-a51b2512d725"
      unitRef="usd">12892000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNi0zLTEtMS0w_6c1a5389-fff7-467a-ad33-cf172c330647"
      unitRef="usd">12665000</us-gaap:InventoryNet>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNy0xLTEtMS0w_8323aef0-7613-4aea-ae5a-acc25808192e"
      unitRef="usd">10483000</nktr:AdvancePaymentsToContractManufacturers>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNy0zLTEtMS0w_754c8d24-3362-470b-bb16-12b0d238b6c5"
      unitRef="usd">31834000</nktr:AdvancePaymentsToContractManufacturers>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOC0xLTEtMS0w_bd269cf5-b1a5-43c0-a6d5-c02023ebdffd"
      unitRef="usd">21550000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOC0zLTEtMS0w_1935c4ad-2c9a-4c6d-b6a3-db41f1251c8f"
      unitRef="usd">15387000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOS0xLTEtMS0w_65d9fe9e-b145-45f5-8b78-59293134c6e2"
      unitRef="usd">1043856000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfOS0zLTEtMS0w_4750be0d-af92-4643-bfde-17b27ecbebff"
      unitRef="usd">1421550000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTAtMS0xLTEtMA_cf3c4944-77ed-4fd7-acc7-0838fd9fb39b"
      unitRef="usd">197715000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTAtMy0xLTEtMA_512deccb-7c82-4e68-9ead-4c2fe4c9c56d"
      unitRef="usd">279119000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTEtMS0xLTEtMA_6e69c711-3002-471b-80be-88b391d12da4"
      unitRef="usd">60189000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTEtMy0xLTEtMA_9c0f8480-21f8-42e6-bcc6-4ebac9961fba"
      unitRef="usd">65665000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTItMS0xLTEtMA_3e4a282e-96b7-46db-b93c-d77ba98690e5"
      unitRef="usd">128985000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTItMy0xLTEtMA_9e2629b3-a7fa-4fc1-bd22-ac5fbd67db16"
      unitRef="usd">134177000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTMtMS0xLTEtMA_946298f3-8307-4709-b43e-6d2eb7c1c921"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTMtMy0xLTEtMA_9e463bca-8e5a-44e5-853d-4d91f350bc2d"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTQtMS0xLTEtMA_7af48295-cb40-48cc-b57e-19218d3ff872"
      unitRef="usd">1420000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTQtMy0xLTEtMA_aff38a12-8b68-4897-a26f-4543872fb216"
      unitRef="usd">344000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTUtMS0xLTEtMA_cbf9904e-ab89-4f50-99c8-6f9b5ae2e5f5"
      unitRef="usd">1508666000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTUtMy0xLTEtMA_75e4d996-35e3-4103-bd3d-e38fb48f1f9d"
      unitRef="usd">1977356000</us-gaap:Assets>
    <us-gaap:SeniorNotesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTgtMS0xLTEtMA_ba72e06b-9135-4d7e-8e01-888345f665d2"
      unitRef="usd">0</us-gaap:SeniorNotesCurrent>
    <us-gaap:SeniorNotesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTgtMy0xLTEtMA_5a80e086-fe6f-422b-a594-7c7072287d80"
      unitRef="usd">252891000</us-gaap:SeniorNotesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTktMS0xLTEtMA_3d5a1c56-81fd-4f61-9fe3-9818a3ca440e"
      unitRef="usd">15484000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMTktMy0xLTEtMA_eb295b34-c4ed-4571-9f07-ae5b33bcbc9b"
      unitRef="usd">19234000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjAtMS0xLTEtMA_efeceac6-5185-4895-8f40-a451a7bdca95"
      unitRef="usd">29504000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjAtMy0xLTEtMA_18d34be3-aff3-4bf2-a284-dd52470b96ce"
      unitRef="usd">11467000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjEtMS0xLTEtMA_256dfd74-cd25-49fb-8632-b12745b304a0"
      unitRef="usd">48886000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjEtMy0xLTEtMA_2058ae8e-0b27-4b3f-b235-aa1f7beef294"
      unitRef="usd">32626000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjItMS0xLTEtMA_594870b6-db8a-47ef-8a8a-669356333d9c"
      unitRef="usd">7141000</nktr:AccruedContractManufacturingExpenseCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjItMy0xLTEtMA_90c697fd-b254-4d49-9720-0b0d0a216a75"
      unitRef="usd">7304000</nktr:AccruedContractManufacturingExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjMtMS0xLTEtMA_a956b065-c8b8-4244-878d-0a658c95d3e9"
      unitRef="usd">9630000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjMtMy0xLTEtMA_80540f86-fd17-4f4b-8c90-7c6637e3b039"
      unitRef="usd">12338000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjQtMS0xLTEtMA_25c0b929-31b9-40de-ae1b-2f64d8426a5e"
      unitRef="usd">15348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjQtMy0xLTEtMA_b60c0a6a-587f-4793-8f5f-6d3dfb6e75e1"
      unitRef="usd">12516000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjUtMS0xLTEtMA_6701c8c0-b886-40eb-90a1-1889d38f4a3d"
      unitRef="usd">507000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjUtMy0xLTEtMA_b6430e25-7960-4cb8-a7e5-577eddabccb5"
      unitRef="usd">5517000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjYtMS0xLTEtMA_fc748132-6bf6-4eed-bd6a-ccb7079aa904"
      unitRef="usd">126500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjYtMy0xLTEtMA_f5820b06-34db-43ab-9263-6fcdc18c1213"
      unitRef="usd">353893000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjctMS0xLTEtMA_19dead38-a481-44e2-b2ff-4e588faf0bb7"
      unitRef="usd">139022000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjctMy0xLTEtMA_c6d2f914-44b6-4308-9e55-2d5654e79400"
      unitRef="usd">142730000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjgtMS0xLTEtMA_3ab538d6-3fd0-43eb-9dc5-86cc1582c423"
      unitRef="usd">66378000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjgtMy0xLTEtMA_dfe96a04-19c5-4158-adcc-180aabbb707a"
      unitRef="usd">72020000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjktMS0xLTEtMA_9159bf9d-26b4-46c0-a351-4130949c5909"
      unitRef="usd">2494000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMjktMy0xLTEtMA_e5394489-1fad-45cc-9900-243e09223e06"
      unitRef="usd">2554000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzAtMS0xLTEtMA_ab33d887-e1c0-411f-87f4-adecf86aa856"
      unitRef="usd">3291000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzAtMy0xLTEtMA_307ac47a-58df-4b21-9feb-d8ae9f392df8"
      unitRef="usd">768000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzEtMS0xLTEtMA_14810238-744f-495d-9d36-e61d63eedb17"
      unitRef="usd">337685000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzEtMy0xLTEtMA_1e97aac0-95c3-4078-ae65-810421fa6810"
      unitRef="usd">571965000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzItMS0xLTEtMA_dab13ea7-17cf-4cff-8bde-bd88b85f31a8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzItMy0xLTEtMA_86ad250e-f63a-415d-bd3e-9935debb16cc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzIx_54734187-3aa3-447d-bb5e-056ad2f9df36"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzIx_cf1b9864-ec3d-464f-afa7-54abd8b98f37"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzM1_282bec2f-7bc3-472d-9dc4-bb2c9887d967"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzM1_312fe389-a1d7-4aca-a106-eb06a835650a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <nktr:PreferredStockShareDesignated
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_4b8fe738-78b8-4ae5-86f1-8e431e7eee0d"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_69b9af42-9a5e-42d2-9a8f-298024ae7fa2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_cb62c63e-41f5-4515-a047-5a8e69a0650f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM4Nzc1NDViYzI5ZDRkM2JiZDYyODM5OWZlNzBmYjZlXzU3_d91b7e05-b8df-4737-8c2a-83ea2847666e"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockValue
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMS0xLTEtMA_e928c38f-82d9-42d3-8397-343f47119579"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzQtMy0xLTEtMA_67aeddc3-e0d6-4367-8ce1-d208b21c7a21"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzE4_7a47cb85-661d-442b-bc0f-7c1ca013960b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzE4_9254e6f2-762e-4ed8-b9a3-cac61a1b3421"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzMy_05c9c975-b2f6-422d-8a1c-e5a0ff29ced9"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzMy_7fe8c8e5-d16d-49cb-848e-241d36e81088"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzU0_c843524d-4fc2-449b-8bbf-6c577dbf6018"
      unitRef="shares">179394000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlNDYzY2M3NGViNjQ2NDdhOTU2NDU5MTNjNDc3MjY4XzY4_7a64c088-a5ad-47b3-b179-2f3a52371373"
      unitRef="shares">176505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMS0xLTEtMA_9433fdf6-dcf4-4180-ae61-80cb09279697"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzUtMy0xLTEtMA_4d9f7848-163e-4e9a-8327-fe45104cada8"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzYtMS0xLTEtMA_30894dad-d982-46b8-b8d9-2bd1cbef915c"
      unitRef="usd">3363998000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzYtMy0xLTEtMA_da1baddc-9ec3-447a-9ac0-e192cd6d33d4"
      unitRef="usd">3271097000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzctMS0xLTEtMA_112eae8c-e074-4705-a9a7-7838ed08f2b7"
      unitRef="usd">-1080000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzctMy0xLTEtMA_f3fdaa93-b805-4ed3-b4e0-923d31fc4de7"
      unitRef="usd">-1005000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzgtMS0xLTEtMA_688ceec4-0a01-4cfa-8f5f-9fddfb828da7"
      unitRef="usd">-2191955000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzgtMy0xLTEtMA_d48dc79d-d649-4248-89c3-a84884b11474"
      unitRef="usd">-1864718000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzktMS0xLTEtMA_81b90f67-88ef-4b02-b728-902251b8f7dd"
      unitRef="usd">1170981000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfMzktMy0xLTEtMA_b38461bf-65ed-46e4-845a-d577a8b3376d"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNDAtMS0xLTEtMA_0bf21ca9-a2e4-47c4-aa0f-6efc5d832c94"
      unitRef="usd">1508666000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8xOS9mcmFnOmVjYmExMDM2NzcyNDQ0YWQ5ZTUwODBjMGZmODYzZDdjL3RhYmxlOmQ2OTVjMDA3ZWRlMDRkYTJhYzQxZTViZmY5NTUzMTI3L3RhYmxlcmFuZ2U6ZDY5NWMwMDdlZGUwNGRhMmFjNDFlNWJmZjk1NTMxMjdfNDAtMy0xLTEtMA_06c4565b-38ff-4d04-b033-e5ec54390b11"
      unitRef="usd">1977356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f71a0b03c924b7ebf4cd6dbf957f7c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy0xLTEtMS0w_ae405de1-8036-4639-b4b4-d0e659f8bf47"
      unitRef="usd">5691000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75044dd0147640e5b1fac0562a87587c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy0zLTEtMS0w_cb649b9d-2429-409d-a106-2887fcda0033"
      unitRef="usd">5558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6969bdf41a51409b8a3d5bf7778889bb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy01LTEtMS0w_9f87cc00-44d8-47fb-9028-6c7a961bbed8"
      unitRef="usd">14620000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2800d81e37fd467db7a4aca36a05d4bb_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMy03LTEtMS0w_2272a060-3448-4ca7-bcd3-6450ae779104"
      unitRef="usd">14302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia126490b6ef14bb4a093175bf42e2418_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC0xLTEtMS0w_979b0a41-ec01-4f12-9d23-8e4a415e9c03"
      unitRef="usd">12289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i303a516554ef450b8448d3c781d28e80_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC0zLTEtMS0w_4f6ab030-a41a-4143-a875-2d6575f1f93d"
      unitRef="usd">10275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id10840689944434c895b2dfca85a5616_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC01LTEtMS0w_ba9b13a7-ce42-490c-9821-a243e40af695"
      unitRef="usd">31411000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c2f1f1d59f94c80a40b88d73a9a2be8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNC03LTEtMS0w_16cc8b98-cee1-45b0-88e1-a95edbfeee9b"
      unitRef="usd">29008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb124e879ded4a61bfe1de6ec906bff3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS0xLTEtMS0w_84c82ff0-5c6b-4872-9a8e-63e5f3f3482e"
      unitRef="usd">10422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fb8ea2d87eb4ce4ab0dd27a38c19513_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS0zLTEtMS0w_cb134ae7-8ea5-4ef0-bf75-20219795e53f"
      unitRef="usd">10264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20f858bd314a45b9ae191c88d38cd186_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS01LTEtMS0w_19269715-bec5-4b60-ae24-d22b0d1d3069"
      unitRef="usd">28001000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95068a05c9ad44ddb61821a3b2c8a545_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNS03LTEtMS0w_cd0d33f3-059f-42e1-bacb-abb724f366ee"
      unitRef="usd">27585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2590b46764604c54a3d32865b6ec27bc_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi0xLTEtMS0w_242792c6-f93e-465c-bc76-661e34184fcd"
      unitRef="usd">1631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53db0c02ed7c4e17a3693e7d65bc6cae_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi0zLTEtMS0w_6f264b7c-d5eb-43e6-9f44-b49575620a98"
      unitRef="usd">3121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i313a392f3bd047bdb605af3500053b1f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi01LTEtMS0w_b762701a-7625-4571-97de-184fa60270d4"
      unitRef="usd">55421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78caf101002144188da0d0d44a27eaf1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNi03LTEtMS0w_a57f3a82-fcde-430c-8ef6-47d254400b61"
      unitRef="usd">9860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy0xLTEtMS0w_aba71af2-2078-49a5-a6de-7eddbf8f5154"
      unitRef="usd">30033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy0zLTEtMS0w_3ee5b5aa-8fc0-4f8c-8412-fd4b8705d6bf"
      unitRef="usd">29218000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy01LTEtMS0w_04d2662f-e136-4588-a602-abd53c74c96a"
      unitRef="usd">129453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfNy03LTEtMS0w_63689299-a580-4acc-96c8-c23ebdc39a6c"
      unitRef="usd">80755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS0xLTEtMS0w_b230b063-bf54-4434-8fcd-0e4ac4b0fe5c"
      unitRef="usd">5570000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS0zLTEtMS0w_cced3e21-0f05-4079-98e9-8ece8e5aaef0"
      unitRef="usd">4927000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS01LTEtMS0w_e7f440fc-d0cf-4bcc-b92e-f1830b6f758a"
      unitRef="usd">15154000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfOS03LTEtMS0w_cbdab8d1-d4f3-42dd-9a94-600e43dc7732"
      unitRef="usd">15385000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtMS0xLTEtMA_9bb4cac6-e6f4-4e4e-bc3a-350ac4201d8f"
      unitRef="usd">100531000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtMy0xLTEtMA_015f10c1-6bea-433e-9c56-0cbb8ba7ad03"
      unitRef="usd">99048000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtNS0xLTEtMA_976597ba-1929-4aa4-a688-54d6c3b93242"
      unitRef="usd">305954000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTAtNy0xLTEtMA_09b5c83f-3f3b-4c35-ac83-c1f01873ea13"
      unitRef="usd">324197000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtMS0xLTEtMA_8e84dec0-fc72-4989-ae6a-d3e6ea035403"
      unitRef="usd">26982000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtMy0xLTEtMA_51b2ef6d-ff1b-4fe2-98cc-e5e8bcb455d3"
      unitRef="usd">23983000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtNS0xLTEtMA_df74a5e9-f0c9-44c4-94b5-1209e7c6a869"
      unitRef="usd">77546000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTEtNy0xLTEtMA_2e9d3f17-0408-4f36-b7a3-b93e8db165fd"
      unitRef="usd">71570000</us-gaap:GeneralAndAdministrativeExpense>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItMS0xLTEtMA_f8756397-019a-41fb-976d-7eaffce41541"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItMy0xLTEtMA_852b56fe-07f8-4ba4-a574-74ba82f0005d"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItNS0xLTEtMA_dc8438cf-e272-471e-9fd0-8ff0db6674c8"
      unitRef="usd">45189000</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTItNy0xLTEtMA_22726e16-f0b9-449c-88cc-2624babe9a1c"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <us-gaap:CostsAndExpenses
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtMS0xLTEtMA_0d87e205-0b4a-4329-9d5f-88d7fd56b73b"
      unitRef="usd">133083000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtMy0xLTEtMA_b0c897d0-5309-4ac2-a9d4-f6f098eaabb5"
      unitRef="usd">127958000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtNS0xLTEtMA_78ea1a78-bf9f-4c42-8407-786ef3a054ea"
      unitRef="usd">443843000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTMtNy0xLTEtMA_f653809d-369a-4ad8-8dfd-868c993683de"
      unitRef="usd">411152000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtMS0xLTEtMA_971c9945-21f9-45f8-948e-9843804f4e97"
      unitRef="usd">-103050000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtMy0xLTEtMA_ec481c72-1de6-4682-8160-c72df789781c"
      unitRef="usd">-98740000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtNS0xLTEtMA_1d136f67-8126-4a88-836e-074ccfe8646d"
      unitRef="usd">-314390000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTQtNy0xLTEtMA_ffbcadb0-0fdf-4859-9048-a7eaf3f9fb1e"
      unitRef="usd">-330397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtMS0xLTEtMA_968d57f4-9fe9-49b0-aa8c-97cb17bd6c68"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtMy0xLTEtMA_cf04ad68-a981-4787-8aa6-8bb41288d0e8"
      unitRef="usd">5425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtNS0xLTEtMA_e75b6bca-f7da-4d99-80d8-1e235859be28"
      unitRef="usd">6851000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTYtNy0xLTEtMA_fbc1108b-5220-405e-b7a3-e6676b393ba4"
      unitRef="usd">15882000</us-gaap:InterestExpense>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctMS0xLTEtMA_5bc2d863-4d85-406d-ba98-dff3b3f9dad7"
      unitRef="usd">8425000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctMy0xLTEtMA_a1c275e1-5376-4445-a81a-aec831c1d737"
      unitRef="usd">5813000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctNS0xLTEtMA_0a73f47b-78ec-4e9b-8080-f7d40d972f32"
      unitRef="usd">22084000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTctNy0xLTEtMA_464bee43-daa0-4128-838f-d91d6279ea86"
      unitRef="usd">17853000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtMS0xLTEtMA_fcb92f0b-3e24-47ff-b652-d4ae9aa54864"
      unitRef="usd">2910000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtMy0xLTEtMA_1224a64b-7b18-4627-8838-f319bc6616d6"
      unitRef="usd">11492000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtNS0xLTEtMA_9d2366d8-e8d0-4d24-bea4-7524f5ffa5d8"
      unitRef="usd">16453000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTgtNy0xLTEtMA_1f82b11b-a191-4002-a0a3-2a3101410811"
      unitRef="usd">35964000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktMS0xLTEtMA_d79116a1-ffaa-4f73-b38c-8587a23c8a98"
      unitRef="usd">-5515000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktMy0xLTEtMA_324e14f9-28a5-4074-9dab-5050a021e48f"
      unitRef="usd">254000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktNS0xLTEtMA_ef439b62-e698-4239-a82a-9b40a37b9dca"
      unitRef="usd">-12482000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMTktNy0xLTEtMA_8fd8a77c-f29e-4b08-9d6a-0e4f0f8c3a52"
      unitRef="usd">2229000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtMS0xLTEtMA_1b08d3c8-355d-4b5a-84b7-0caab5b61c74"
      unitRef="usd">-108565000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtMy0xLTEtMA_cd997429-22c6-40f9-bcf7-4323db7dc807"
      unitRef="usd">-98486000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtNS0xLTEtMA_d0585313-e839-4a32-9021-654f7631ccec"
      unitRef="usd">-326872000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjAtNy0xLTEtMA_6ceeddc0-a2ab-4a05-adde-bedbe3d94ab6"
      unitRef="usd">-328168000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtMS0xLTEtMA_83c8bf13-7623-4021-a817-afa184d91528"
      unitRef="usd">21000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtMy0xLTEtMA_f6e533ca-c6c5-495e-ab11-9e2faff63989"
      unitRef="usd">99000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtNS0xLTEtMA_119f5ea5-fc1e-426d-8479-425b0bb2712d"
      unitRef="usd">365000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtNS0xLTEtMA_77fe5b5b-d9f7-4c72-835a-c0aec7d3c4f8"
      unitRef="usd">365000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjEtNy0xLTEtMA_c0b314c7-c74d-4b53-b5f5-a6f6780f8255"
      unitRef="usd">335000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItMS0xLTEtMA_c2545cfd-e6ea-4281-95b8-169231d665df"
      unitRef="usd">-108586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItMy0xLTEtMA_a6e98004-fccc-4614-a3d3-503664b37524"
      unitRef="usd">-98585000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItNS0xLTEtMA_7bd574c7-5376-4dd0-8310-9a4b00c480b1"
      unitRef="usd">-327237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjItNy0xLTEtMA_34d836f0-3a66-4522-ad4b-6183bb4c7a9f"
      unitRef="usd">-328503000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtMS0xLTEtMA_aaa555e7-a148-4306-9c1b-5f2a08c42d5c"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtMy0xLTEtMA_896180d0-2281-42f8-b2da-7ca8e37dfdc7"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtNS0xLTEtMA_207658fd-e83e-4526-8b1a-cfb8b67c2b81"
      unitRef="usdPerShare">-1.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjQtNy0xLTEtMA_d8c2f586-68be-4576-9162-22260557804e"
      unitRef="usdPerShare">-1.88</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtMS0xLTEtMA_591fa54a-1e0d-4fd9-9ad0-7f300193a64b"
      unitRef="shares">179090000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtMy0xLTEtMA_37e5196c-691a-45ce-b172-625bb79fb8c7"
      unitRef="shares">175402000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtNS0xLTEtMA_16273641-1a7a-4208-9f3c-b11e469dd845"
      unitRef="shares">178203000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yMi9mcmFnOjgxYjY3MDhjMzVmOTQyMjBhNDViODgwZTBhMTE5YjdiL3RhYmxlOjBjMjRjYzY3MDYxMDQ1N2NiYTc3YWE2Y2NiMWY2NWZiL3RhYmxlcmFuZ2U6MGMyNGNjNjcwNjEwNDU3Y2JhNzdhYTZjY2IxZjY1ZmJfMjUtNy0xLTEtMA_14ce3cae-94ce-4ca7-9175-17417fce8936"
      unitRef="shares">174609000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi0xLTEtMS0w_2a6e2b39-52ac-435e-b9d2-2cee0d4b8716"
      unitRef="usd">-108586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi0zLTEtMS0w_78a7a77b-938e-477d-82a9-1899c1040d63"
      unitRef="usd">-98585000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi01LTEtMS0w_66af4f95-1bb0-4fb4-90a4-09b635eafa39"
      unitRef="usd">-327237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfMi03LTEtMS0w_e63cd70e-4b98-4df1-8787-b3b87b0443f2"
      unitRef="usd">-328503000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC0xLTEtMS0w_fca12fff-2e76-41b0-afd6-89edde3c5725"
      unitRef="usd">-2144000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC0zLTEtMS0w_3ee5f51c-9c85-4c2b-a228-00ee23ea621d"
      unitRef="usd">-261000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC01LTEtMS0w_b6ff2516-8d5f-4085-803e-701a8e7011c2"
      unitRef="usd">423000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNC03LTEtMS0w_8e6dff85-e664-4d83-8f51-27189bb40b4b"
      unitRef="usd">6621000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS0xLTEtMS0w_e58361ce-b40a-4940-a524-ef4271ba398a"
      unitRef="usd">349000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS0zLTEtMS0w_7f16ea2c-9879-4ec9-9833-696ff40f4a49"
      unitRef="usd">-360000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS01LTEtMS0w_1ee7252e-f2b3-4757-ac8d-db6de1372f0a"
      unitRef="usd">-498000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNS03LTEtMS0w_400c4a89-0964-46bc-a47b-a0706da1a094"
      unitRef="usd">-217000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi0xLTEtMS0w_517890c4-056a-40ac-b573-3af668bc364f"
      unitRef="usd">-1795000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi0zLTEtMS0w_aa7cbaf8-af90-4c8c-b5d5-9661b9bc5704"
      unitRef="usd">-621000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi01LTEtMS0w_2796bd6e-943d-40f9-8390-55d4c1357841"
      unitRef="usd">-75000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNi03LTEtMS0w_e35ac300-21b8-49cd-808e-9a9abbf0894e"
      unitRef="usd">6404000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy0xLTEtMS0w_2e68f70b-e8b3-4c5d-a4a6-10b6116d1709"
      unitRef="usd">-110381000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy0zLTEtMS0w_cc1b2556-2cfa-4db8-b157-5831d079b87a"
      unitRef="usd">-99206000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy01LTEtMS0w_1d22485b-fa20-4049-a0c2-021a5f22cde9"
      unitRef="usd">-327312000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yNS9mcmFnOjU1Y2ZjODZkNjk1NDQ0N2Q4YmRjYTRmZWQ5NGRiZDdjL3RhYmxlOjk5YzA3NzI4NzExMjRmYWY4NDM3ZWVlYWMyMTFiMDZiL3RhYmxlcmFuZ2U6OTljMDc3Mjg3MTEyNGZhZjg0MzdlZWVhYzIxMWIwNmJfNy03LTEtMS0w_17df0dfc-46a8-4918-a24d-f1cda1ee7663"
      unitRef="usd">-322099000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS0xLTEtMS0w_910c720c-12ba-4c3f-b929-a87ccde72649"
      unitRef="shares">173530000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS0zLTEtMS0w_5a392380-5190-487c-acdf-f2717f99d5da"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieaaf5f4ff58e4da6bca583978f3daf4a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS01LTEtMS0w_2eb3c160-4ba9-4190-87af-3170adb857df"
      unitRef="usd">3147925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3ff659e615b460f9c093c4a103a776e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS03LTEtMS0w_80826eaf-d381-4982-9c7c-ecb95e44cf6d"
      unitRef="usd">-6316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i858dd57c9a6f47d1bd0a261f843802fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS05LTEtMS0w_23fe19c8-231f-445d-87db-9836196847ad"
      unitRef="usd">-1424051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a84d3c13ef34b45b2f416e11bddf2ca_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMS0xMS0xLTEtMA_044bd8d0-9fcf-41e0-9ec2-ee84aee4fefd"
      unitRef="usd">1717575000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia970b1a5f74e4c1fba7646c288d7230c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMi0xLTEtMS0w_27daf50e-94b8-480d-a7e4-eb7bede61219"
      unitRef="shares">698000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i87caf582c5b348409d849ad28e65fb60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMi01LTEtMS0w_b0d09c2b-40fe-48fa-96b2-cfb142e46d5c"
      unitRef="usd">5463000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMi0xMS0xLTEtMA_d4b0673b-9e4d-4417-ba9d-ed61d7acbe08"
      unitRef="usd">5463000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i87caf582c5b348409d849ad28e65fb60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMy01LTEtMS0w_9485e113-a465-4683-9e3d-083b4fa0b623"
      unitRef="usd">25385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMy0xMS0xLTEtMA_7456a566-afc5-407b-87f9-dd6a955ed3b5"
      unitRef="usd">25385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia6d1a58961d641009b5e86d347a0058d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNC03LTEtMS0w_64953914-8ba6-4150-a764-bc1053fcdf4c"
      unitRef="usd">4720000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iddea23a1ec4b41868773cb20d92277fc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNC05LTEtMS0w_29821733-93d9-484e-8f08-bc8ef0f70119"
      unitRef="usd">-119632000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia65784fb60854ef6ba36076bd463b7a9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNC0xMS0xLTEtMA_fd387ed3-2f21-401a-af9a-54bbdb981a8d"
      unitRef="usd">-114912000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i7d4417f3eae14daa9f325143c6d2f354_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS0xLTEtMS0w_76287e37-2268-490c-be16-2f8ce28d6449"
      unitRef="shares">174228000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7d4417f3eae14daa9f325143c6d2f354_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS0zLTEtMS0w_9fc46d1b-28f1-42b0-97c4-8e640bbcf5eb"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7284e4ebcf84dd3adb2a1222f43f4a2_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS01LTEtMS0w_98b74297-2dda-447f-8f11-1a38556dbb27"
      unitRef="usd">3178773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11f2ffe64a6e4e6e97acf57b6dc4a3b8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS03LTEtMS0w_f276cb6b-15a3-49cb-a125-e7e8c7390275"
      unitRef="usd">-1596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d0b165e31da484a832227b4de929b21_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS05LTEtMS0w_c26df1f7-e440-4111-9bdb-742ca2ef8a6d"
      unitRef="usd">-1543683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45990bd690b44a3a8403017280dfa90a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNS0xMS0xLTEtMA_ac56db3b-08fd-49b7-bffe-deca09db3af4"
      unitRef="usd">1633511000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9ad0245d6766404ea4787ad9559bfd8e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNi0xLTEtMS0w_a906bcd7-c70c-41d4-bafa-19334ad858b5"
      unitRef="shares">738000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic244ee9628594318be13017bcb360127_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNi01LTEtMS0w_81018759-0ad3-462f-bc7c-710904ffc5bc"
      unitRef="usd">7103000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNi0xMS0xLTEtMA_02ac8876-2c61-4cc6-810b-873ceb8edc94"
      unitRef="usd">7103000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic244ee9628594318be13017bcb360127_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNy01LTEtMS0w_8c4fe7ed-2c9c-47d3-8771-6b5b66cc8c27"
      unitRef="usd">24522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfNy0xMS0xLTEtMA_e8dfa859-edc7-4a73-9c52-f0a850b4ca76"
      unitRef="usd">24522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i96a7699705cf4129838e5f75907bd07c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOC03LTEtMS0w_aa482c29-786b-4e52-9357-0fa25dcffdce"
      unitRef="usd">2305000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i32375c3beebb4e78b2f7c912d4700f16_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOC05LTEtMS0w_f781b7a3-b72c-46c4-a668-77b47400d8d9"
      unitRef="usd">-110286000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i605c4008d4f0460dbfe97c12a5231cfb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOC0xMS0xLTEtMA_a1858091-c73b-463a-9add-93e1f7d93d4d"
      unitRef="usd">-107981000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ibf8a195c14f447e9a410d1fb69eca97b_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS0xLTEtMS0w_c9eb2447-f7d0-4fb7-aef0-0832f235f390"
      unitRef="shares">174966000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibf8a195c14f447e9a410d1fb69eca97b_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS0zLTEtMS0w_12b657f1-4a53-4fe1-a725-5956bc34dd36"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cdb5931a79a4157adfde1e280185bb4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS01LTEtMS0w_83473aae-3591-408d-9742-a4372e697be1"
      unitRef="usd">3210398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icee27510abcb4480a16999d9a511ef67_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS03LTEtMS0w_5370b9ba-52d4-4831-a2e0-cd4ad26a576f"
      unitRef="usd">709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07c206fe665047a39807c0608f01de69_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS05LTEtMS0w_928610db-f7bf-4593-b82a-667513883415"
      unitRef="usd">-1653969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cb0cdd57490423f8151ff5d9f8d3808_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfOS0xMS0xLTEtMA_fdb26d54-817c-481f-a6bb-8c6530460d48"
      unitRef="usd">1557155000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if0b87bba6556485180623116c2eec80e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTAtMS0xLTEtMjI_12a05acd-61cf-46b7-8a89-61a7b5e6091d"
      unitRef="shares">820000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e77eaab1bd5407c90009309bd132727_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTAtNS0xLTEtMjI_076b9357-0746-4725-ae3d-640f564b073b"
      unitRef="usd">5882000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTAtMTEtMS0xLTIy_1cb0fd22-0711-4b19-b08c-f0f084106d0e"
      unitRef="usd">5882000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e77eaab1bd5407c90009309bd132727_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTEtNS0xLTEtMjI_b5aa6650-cfd5-44b3-b0f7-9cb8bef67658"
      unitRef="usd">24880000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTEtMTEtMS0xLTIy_3a19a50b-c9be-45e4-a216-306956245322"
      unitRef="usd">24880000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie64a09a837b3492bab38342b31ec23d3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItNy0xLTEtMjI_bca08951-f371-4b22-80c9-533556f890b6"
      unitRef="usd">-621000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6be993ee27de4d5482714a9a8d0bbdba_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItOS0xLTEtMjI_dfffa52d-d702-46fd-ba88-f247be2377da"
      unitRef="usd">-98585000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMTEtMS0xLTIy_365bcfb9-0802-45b9-9308-c5a95142b979"
      unitRef="usd">-99206000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ie847c6b6f4ac493aa3ce259242b96632_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMS0xLTEtMjI_d0ec3607-fc1c-4033-bc79-f1fd22d33ba1"
      unitRef="shares">175786000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie847c6b6f4ac493aa3ce259242b96632_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMy0xLTEtMjI_830d47a7-3470-4897-97ce-a1cf979f82be"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2d60f5bc3164799b0998de07ea9cd3c_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtNS0xLTEtMjI_e97cf6e3-02d0-4e57-8219-638fd8112db9"
      unitRef="usd">3241160000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id09986fe227e4792bf9ce78a90cd56a1_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtNy0xLTEtMjI_b4724369-7547-4373-a0e7-3aafc206bbf9"
      unitRef="usd">88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f4942ff30d942a493ecdc359f515bc5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtOS0xLTEtMjI_07692460-f6cf-4da3-ba05-2e4e0f94cfda"
      unitRef="usd">-1752554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95d5c14945d649cdbf34148f277c6321_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMTEtMS0xLTIy_7a1d0d0d-1827-4e0f-b66a-d5944201ee2e"
      unitRef="usd">1488711000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0027733ae46c426cb1305e97f7951913_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMS0xLTEtMA_169f902e-8785-4982-b28d-20f10ab3d818"
      unitRef="shares">176505000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0027733ae46c426cb1305e97f7951913_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMy0xLTEtMA_d67e2e97-4b65-4627-86e0-d11c1ed7dcc1"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb4997e742034bfcb18329b32d6494b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItNS0xLTEtMA_384c0b0b-ad9a-4626-b0ae-c7fa128fcd45"
      unitRef="usd">3271097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia250ad305dd745fb96c8da18a5a40df4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItNy0xLTEtMA_54d96b46-c9c3-4038-b82a-372715913b3d"
      unitRef="usd">-1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2da35b042264ec58ed356a8af423513_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItOS0xLTEtMA_7725916c-3bfb-44da-8d02-00ae7676b110"
      unitRef="usd">-1864718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTItMTEtMS0xLTA_6c3b4868-51fe-4f57-97b7-6b5b29fd1577"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if6a69e560a4145479538f76aa786d0de_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMS0xLTEtMA_459f48c2-e19c-48f8-9841-664e92ed5774"
      unitRef="shares">1358000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i42af22d15904460ca50e4626fa04aa1f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtNS0xLTEtMA_b02b1e7c-7606-47d8-afc4-550322d14072"
      unitRef="usd">11347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTMtMTEtMS0xLTA_704b99cb-fc48-4515-b933-20163babed96"
      unitRef="usd">11347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i42af22d15904460ca50e4626fa04aa1f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTQtNS0xLTEtMA_ea14a99a-7111-49df-a4be-a87e60db203f"
      unitRef="usd">24211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTQtMTEtMS0xLTA_258b3c25-beae-4808-aaeb-24d4ce6f3c81"
      unitRef="usd">24211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id8d3221693d14493a695856c97fd42d6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTUtNy0xLTEtMA_664b13a4-1a42-4e12-ab15-6b0c2c655245"
      unitRef="usd">-5872000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4113b9c3da104478b5f0000b7c68a664_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTUtOS0xLTEtMA_772384e3-6e6c-4fbc-b24d-a7ee70de6cf7"
      unitRef="usd">-138651000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2c5b32c8abed415d928d7849c24ba9d8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTUtMTEtMS0xLTA_ad4fd8ec-2eae-4505-8dcc-fbd4009bb664"
      unitRef="usd">-144523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i556ea3ab98f84204a42ed81a9ee36489_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtMS0xLTEtMA_3cebd1c5-f14f-46a6-aa14-22f09871b9da"
      unitRef="shares">177863000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i556ea3ab98f84204a42ed81a9ee36489_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtMy0xLTEtMA_365b801b-5cda-4494-8e5a-008ba2343b20"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icdc06d2c657945d9a36b5af38466ad66_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtNS0xLTEtMA_48fcd045-e9c5-431f-a7c0-d4faa3033ea5"
      unitRef="usd">3306655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6cf1302dfa64b698b6c252166b100f4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtNy0xLTEtMA_1a136a48-992f-44b2-906a-f6019a78e4de"
      unitRef="usd">-6877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1445fc508f7c4c48b2ed3508a75cb01b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtOS0xLTEtMA_79208f3f-97a6-4893-aaaf-9a5851198550"
      unitRef="usd">-2003369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i777f5bdef8e24ef0b10ba35773ffbeb7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTYtMTEtMS0xLTA_4f5c29a3-16fc-4032-a4fb-6ea017951110"
      unitRef="usd">1296426000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id1c030ee76e84c0692871baedf495fd8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctMS0xLTEtMA_39e9e7bb-3854-4ab7-aa6e-fc5a531538cc"
      unitRef="shares">947000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id1c030ee76e84c0692871baedf495fd8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctMy0xLTEtMA_bbeb13ff-bfa0-45fe-b63c-c5265ee76d31"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i762ce4970a5f44b595a60613ff383dd0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctNS0xLTEtMA_54763042-5e6d-41bd-af60-c58b2363d67d"
      unitRef="usd">7825000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTctMTEtMS0xLTA_ea2d93f3-fd55-4f7c-b0af-5361520541e5"
      unitRef="usd">7826000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i762ce4970a5f44b595a60613ff383dd0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTgtNS0xLTEtMA_2a38ff5d-76af-4814-bdba-0fe9655d01fc"
      unitRef="usd">24396000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTgtMTEtMS0xLTA_597c3b34-4720-4c06-b53a-a276ea7b15dc"
      unitRef="usd">24396000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i401f9b86bf1042419786acedec068f35_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTktNy0xLTEtMA_608c5447-855c-4c68-af6e-53507825db8b"
      unitRef="usd">7592000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie8582351bb534ee8ad9404fecfdcdf22_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTktOS0xLTEtMA_8cc4b32a-b906-47f1-90b2-ef89113b7bea"
      unitRef="usd">-80000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i453fd7ca169a41f98fd06f08582aea04_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMTktMTEtMS0xLTA_11b6dc07-b8ed-4f6e-87cc-9cd9dc0fbbb0"
      unitRef="usd">-72408000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id85af4c6dbd84c249ab3d00291d566bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtMS0xLTEtMA_af4bf50a-275f-47a5-a216-83a08d86c21f"
      unitRef="shares">178810000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id85af4c6dbd84c249ab3d00291d566bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtMy0xLTEtMA_3bb88ee9-6027-4df0-b93d-be6a5baf487b"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00153f8c513746068c52bffc86e33bdc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtNS0xLTEtMA_b3096514-0a2d-40eb-a8d3-e135d0a69f9c"
      unitRef="usd">3338876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf9e807e7b494401938118258ef486c7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtNy0xLTEtMA_4595dc55-73e9-46ae-bbe4-f6a9c8ebed1a"
      unitRef="usd">715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabe10e55d58b42c3a4ccd2c01211cfb3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtOS0xLTEtMA_a8f75c95-ea75-4bf3-9ff6-488836e86962"
      unitRef="usd">-2083369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib024f3e4564e41a4a8e24660abc87c66_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjAtMTEtMS0xLTA_c069a568-8916-437c-bdfe-385c66ac2131"
      unitRef="usd">1256240000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1fb35818bd5746499ac50bdf2cf1d6cc_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjUtMS0xLTEtNDY_a6d81d21-73ae-44a5-b712-097e5e2e603d"
      unitRef="shares">584000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i39788d0d7cfb42eda37e02c0b7b04e7b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjUtNS0xLTEtNDY_d6657ec3-dc21-4f5d-88a4-0e3240ebedf5"
      unitRef="usd">1455000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjUtMTEtMS0xLTQ2_e51589f7-98a3-4c0f-9d8d-22f82fc45a21"
      unitRef="usd">1455000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i39788d0d7cfb42eda37e02c0b7b04e7b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjYtNS0xLTEtNDY_face02a0-4d4e-41c3-847e-e82e0b7d312c"
      unitRef="usd">23667000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjYtMTEtMS0xLTQ2_5decf3b1-4e5b-4d25-9e01-d459f4b28ef0"
      unitRef="usd">23667000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i87d271708d2b4cad96036ef906972a1a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjctNy0xLTEtNDY_6abde88f-e0df-4046-9785-fa9c3127d8d3"
      unitRef="usd">-1795000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i66fc796f6db24fe1a7fdadd7ca120a84_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjctOS0xLTEtNDY_6a21f8bc-c121-499a-9ee4-e1c8df6437ea"
      unitRef="usd">-108586000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjctMTEtMS0xLTQ2_0a046b67-7702-453e-8585-7e40e24e9b0b"
      unitRef="usd">-110381000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i4c5d1fecab1a49a6b1af85520f20a093_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtMS0xLTEtNDY_072b7c53-ddbd-4cb9-8792-69bf4847b0e5"
      unitRef="shares">179394000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c5d1fecab1a49a6b1af85520f20a093_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtMy0xLTEtNDY_911e197f-ae80-4916-9127-0536b3b8d40d"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida1d2d4811144e91aa10ee049f266ae8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtNS0xLTEtNDY_772738b5-3269-4366-97e6-a6ece081b2f2"
      unitRef="usd">3363998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic88bf65501e44247a07c0e4d791274ca_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtNy0xLTEtNDY_80ae1d6e-ada1-43a0-8419-2eaa5dfc3bf2"
      unitRef="usd">-1080000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70f70ef47de44a5c9d729e3baf53387e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtOS0xLTEtNDY_ccbbb623-7534-462a-b753-5876aa994f24"
      unitRef="usd">-2191955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8yOC9mcmFnOmU5ZmFmYjIxYTQ4ODQzMTJhYzliNjUwNmYzZmU2MDMxL3RhYmxlOmRkZjJmZDgzN2FiMjRkOTU5MGI0NTg5ZjdkM2FmNzYyL3RhYmxlcmFuZ2U6ZGRmMmZkODM3YWIyNGQ5NTkwYjQ1ODlmN2QzYWY3NjJfMjgtMTEtMS0xLTQ2_55b9c317-4986-4f97-b1d7-f51fcc8e4460"
      unitRef="usd">1170981000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMy0xLTEtMS0w_ee781f22-a57a-4af6-9f13-36b509ed9735"
      unitRef="usd">-327237000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMy0zLTEtMS0w_261788de-568f-4f70-85ef-2db49b23d463"
      unitRef="usd">-328503000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNS0xLTEtMS0w_d3964a41-77c2-4530-bc93-ea8949b047b0"
      unitRef="usd">28001000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNS0zLTEtMS0w_fbf4678c-565d-43aa-a408-abd8ff5adf4d"
      unitRef="usd">27585000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNi0xLTEtMS0w_30b062c5-f88f-44b5-a473-ce89e74b7aad"
      unitRef="usd">22084000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNi0zLTEtMS0w_7d606c43-c116-4eaf-a2ef-d5e07de79536"
      unitRef="usd">17853000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNy0xLTEtMS0w_f91166c9-204a-485d-a181-b6c738e6ea6b"
      unitRef="usd">72274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNy0zLTEtMS0w_56b76578-da1e-4607-9fe7-cbfc14cf6d8e"
      unitRef="usd">74787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOC0xLTEtMS0w_9b96a17b-748a-40ed-bb21-2c5b2c40a904"
      unitRef="usd">10937000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOC0zLTEtMS0w_a279e180-5658-4e6e-bb3c-6891b69a049d"
      unitRef="usd">9582000</us-gaap:DepreciationAndAmortization>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOS0xLTEtMS0w_c70785ce-a382-406f-9a0e-df1926f6c570"
      unitRef="usd">20351000</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfOS0zLTEtMS0w_7bcd4212-f43f-4d3a-985e-5680e7ff2fa0"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTAtMS0xLTEtMA_4795ebe6-1c40-4829-8687-d4b1bfd60e12"
      unitRef="usd">-1150000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTAtMy0xLTEtMA_6320bb94-f5fc-4e4b-82e5-e11b7abfbd2c"
      unitRef="usd">9147000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTItMS0xLTEtMA_01e5f7c3-05f3-4318-ac94-ff84536f5e3a"
      unitRef="usd">6123000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTItMy0xLTEtMA_000c0cfd-7cb9-4bd6-8edb-e49c968a3cb7"
      unitRef="usd">-2008000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTMtMS0xLTEtMA_73f8d7f5-1379-47d2-859c-3c174f69c1a2"
      unitRef="usd">227000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTMtMy0xLTEtMA_5944b1fe-3794-4a91-aa84-ecfed9bbbda6"
      unitRef="usd">2339000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTQtMS0xLTEtMA_75d9a771-6a9d-40af-90e6-494fcc0e1570"
      unitRef="usd">-4316000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTQtMy0xLTEtMA_e5101397-7d7d-4985-aa9e-19f721e115c7"
      unitRef="usd">-11550000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTUtMS0xLTEtMA_c0a17a20-5f3a-4017-8532-3d58733bbab3"
      unitRef="usd">5588000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTUtMy0xLTEtMA_fe70fc46-b05b-4e9c-a929-97146c748d23"
      unitRef="usd">-18127000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTYtMS0xLTEtMA_9ae9d33d-589f-458b-850f-d6d4d5d78ae0"
      unitRef="usd">-3337000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTYtMy0xLTEtMA_0d054560-bb66-456c-8ae6-2bbdceffecf5"
      unitRef="usd">16109000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTctMS0xLTEtMA_f7ceef5a-7679-4f39-bb06-f7cc50894d76"
      unitRef="usd">20478000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTctMy0xLTEtMA_a4fb1961-33bf-4988-9998-1b8538f57d2c"
      unitRef="usd">13164000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTgtMS0xLTEtMA_ec86b90b-2e49-4dc0-a07b-82ede8b44faa"
      unitRef="usd">9340000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTgtMy0xLTEtMA_774f7b40-10b2-41ec-88ff-def19feeab45"
      unitRef="usd">10401000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTktMS0xLTEtMA_0b0ff5c5-16b9-42f7-b49a-04b8e224f1b7"
      unitRef="usd">-5070000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMTktMy0xLTEtMA_dfee6daf-7a23-4d08-8ce7-9c3d541c8dbf"
      unitRef="usd">-9465000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjAtMS0xLTEtMA_35b30601-1e26-48f4-a638-66ebbaaf7a45"
      unitRef="usd">-214653000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjAtMy0xLTEtMA_387381c5-7acb-4f18-b844-74e22ef487df"
      unitRef="usd">-203458000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjItMS0xLTEtMA_0068f15d-5af0-4f84-b6d5-fa6b35c79f49"
      unitRef="usd">791445000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjItMy0xLTEtMA_143d8f3d-e97f-44ef-a3f5-4286f1038053"
      unitRef="usd">1028883000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjMtMS0xLTEtMA_34ef3ad8-4ce0-4ced-81fb-4ea9f33e8cd8"
      unitRef="usd">1158722000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjMtMy0xLTEtMA_d4acdc9e-3f76-485f-a751-758ba51b4a50"
      unitRef="usd">1122902000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjUtMS0xLTEtMA_22ef80c0-111e-4b6e-a823-fc398c018b2e"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjUtMy0xLTEtMA_0e16a046-4dd7-4071-b89c-f8cc5a0bae7e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjYtMS0xLTEtMA_d1df9ae7-95e0-4935-8858-1437977c9df6"
      unitRef="usd">5504000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjYtMy0xLTEtMA_e6168e05-ef99-45b9-8023-57c1a84d5524"
      unitRef="usd">22614000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjgtMS0xLTEtMA_60a29960-f6b2-4748-8e11-83e34b95e426"
      unitRef="usd">403473000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMjgtMy0xLTEtMA_b947f967-64b9-4e75-ad8c-1805ddf7b5c6"
      unitRef="usd">71405000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzEtMS0xLTEtMA_6ce5a5a3-f23e-4a50-a5db-0053711d7c23"
      unitRef="usd">20651000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzEtMy0xLTEtMA_f0db6702-3f68-4db7-a732-531ffc56728f"
      unitRef="usd">18449000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzItMS0xLTEtMA_924b08c2-bd36-4ef3-98fa-0019a3dca9d7"
      unitRef="usd">250000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzItMy0xLTEtMA_12281fb8-5891-446d-8ba1-35167e2d9fa3"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzMtMS0xLTEtMA_a892f93d-3198-4f00-8489-03d3a7f99355"
      unitRef="usd">-229349000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzMtMy0xLTEtMA_ea836089-47df-4d93-93a3-875ec9d5f209"
      unitRef="usd">18449000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzQtMS0xLTEtMA_1f565fb2-f5b9-4d6e-a3bb-6e1cadbafe0c"
      unitRef="usd">9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzQtMy0xLTEtMA_4e871667-6c94-4b8d-81a4-b457e6c422c5"
      unitRef="usd">-77000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzUtMS0xLTEtMA_5cf32839-bdbe-45e9-9f17-0910ce3f7203"
      unitRef="usd">-40520000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzUtMy0xLTEtMA_fd27b6bf-1122-4202-a72f-2c351584c2ee"
      unitRef="usd">-113681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzYtMS0xLTEtMA_bfb10b91-69c3-4a77-8e76-585eacba9cdd"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a84d3c13ef34b45b2f416e11bddf2ca_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzYtMy0xLTEtMA_e7b9da87-6ed9-487e-b571-eb39f3522ae6"
      unitRef="usd">194905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzctMS0xLTEtMA_cd85154e-f00d-4117-bf99-e82187481d55"
      unitRef="usd">55843000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i95d5c14945d649cdbf34148f277c6321_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzctMy0xLTEtMA_9a591969-6892-4668-b137-af4dfe013700"
      unitRef="usd">81224000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzktMS0xLTEtMA_a36b75d4-7e06-49fb-a4a8-80a8542b30bb"
      unitRef="usd">9742000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfMzktMy0xLTEtMA_9871eb6c-5692-4ae0-8b10-9bd59543467c"
      unitRef="usd">14299000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNDAtMS0xLTEtMA_baae3893-c94e-414f-90da-5f45d39f40cc"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zMS9mcmFnOjA2OTU0OTMwMTExOTQyMDhhNDIyNzZiYWQ0NzY1NTc2L3RhYmxlOjI5YzcxNWM2N2RjYjQ4NGNhZjI1OWE1MDQzM2JkNTEzL3RhYmxlcmFuZ2U6MjljNzE1YzY3ZGNiNDg0Y2FmMjU5YTUwNDMzYmQ1MTNfNDAtMy0xLTEtMA_a7a74c22-8cf0-4402-a13b-f51d407fbe6e"
      unitRef="usd">56025000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTM_93490f1f-2310-4fe4-9782-82eba7a1c990">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At September&#160;30, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8&#160;million, as described further below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a"&gt;ASU 2019-12&lt;/span&gt; - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss). The tax effect in continuing operations was a tax benefit of $1.3&#160;million for the nine months ended September&#160;30, 2019, and was a tax expense of $0.2&#160;million for the three months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of September&#160;30, 2020, our accounts receivable includes $13.0&#160;million under customer contracts from our collaboration partners and $29.9 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2020 and 2019. We have not recorded a reserve for credit losses at September&#160;30, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would have been due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program in the three months ended September&#160;30, 2020. As of September 30, 2020, we have substantially completed our wind-down and do not expect additional costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Aid, Relief and Economic Security (CARES) Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. We do not expect that the CARES Act will have a material effect on our results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDk_25851213-abcc-413c-b11d-9f31860af7d1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTAyOA_e52a015d-1386-40bb-a3a7-2458b904b3c1"
      unitRef="usd">1200000000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:RepaymentsOfLongTermDebtIncludingInterest
      contextRef="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTE3NA_0b6ac86d-7289-48a2-aa33-2a59b9372cd3"
      unitRef="usd">254800000</nktr:RepaymentsOfLongTermDebtIncludingInterest>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTU_2fe49aac-8c79-4ece-bc02-99bf26cb7c68">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTc_68c56063-6b6a-4bbb-8589-329805d4a5f0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MTE_661659d8-56d3-48ff-afe8-666a25a86a22">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a"&gt;ASU 2019-12&lt;/span&gt; - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss). The tax effect in continuing operations was a tax benefit of $1.3&#160;million for the nine months ended September&#160;30, 2019, and was a tax expense of $0.2&#160;million for the three months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNjYwNg_dd3d500f-9ff2-4a8c-ba69-698988daba0c"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfOTg5NTYwNDY3NzUwOA_7fc262e5-66ce-4493-99c4-40ea98207215"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MTI_cf17f4ec-d367-4528-80dd-47d780efa4e9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNjk5Mw_147b6def-a077-41b5-b356-0e8622cad47e"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNzMzNQ_c66b9801-6fc4-44a9-ac58-8683bdd4a5d3"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDU_d4b5de26-710c-4bf8-9fdb-2a14754b16dc">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of September&#160;30, 2020, our accounts receivable includes $13.0&#160;million under customer contracts from our collaboration partners and $29.9 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2020 and 2019. We have not recorded a reserve for credit losses at September&#160;30, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idd7c1bf4db6948b1bb6785b82b5b0daa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNzkzMg_bc806379-1e59-4b5f-a787-49d9ad1369c4"
      unitRef="usd">13000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5f9ecd4583d46a880165db35da02267_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNzk5Ng_b7c8c80e-4979-43f2-b2fe-34013b497044"
      unitRef="usd">29900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0fc1a07c27b84916915a50371664cedf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfODQ1OA_e1747581-16dd-42f7-b6f8-e8860a7e1a54"
      unitRef="usd">12800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i86d011c835d542eb8b915f244d635460_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfODQ4OQ_e300c589-e777-4994-9276-590f4fc70e4e"
      unitRef="usd">24000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTA1MDI_076ec937-e06f-4dab-869a-cc67d13d8a73"
      unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTA1Mzg_d8acafd5-a994-4ac2-a952-b1e0d857f077"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9f1ff99600d4f57b18ffdda1b1dc625_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTA3MzE_e4d434d1-46b8-443b-a321-fcd01a9cc446"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTExMjA_34c33653-67dd-47e9-bfcc-192c75377a2b"
      unitRef="usd">250000000.0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:InterestPaidCapitalized
      contextRef="ia43c6afa8095449b8c83ea792f271487_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMTExNDc_120fefa9-fbc6-4ea6-954d-a84a4d30f6d1"
      unitRef="usd">4800000</us-gaap:InterestPaidCapitalized>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDY_51cbbce0-1ac1-4abd-b62a-39fa7aeebedb">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MTQ_95a40d64-6371-4ae8-bc5e-7f0797270d2f">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDQ_ab42048a-c988-47e4-9bde-0ddeabcc3dc9">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program in the three months ended September&#160;30, 2020. As of September 30, 2020, we have substantially completed our wind-down and do not expect additional costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nktr:WriteOffOfPrepayment
      contextRef="i4092cae66ba8439e93d82fcef25ef788_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjM1OTg_7f9c4147-0b70-4a30-8fe0-4ed46efc607b"
      unitRef="usd">19700000</nktr:WriteOffOfPrepayment>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i4092cae66ba8439e93d82fcef25ef788_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjM3MDA_c45d373f-6f03-4295-b957-48cc64ef8077"
      unitRef="usd">25500000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY3OTk_04d75785-43cd-476c-8e57-b3670f5fba5c">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfMjY4MDc_462abec8-2a01-4dd4-8eec-1203a410b733">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjIwMQ_9372ce71-87d4-4087-83a8-cf59064b18e8">Cash and Investments in Marketable Securities&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of September&#160;30, 2020 and December&#160;31, 2019, all of our long-term investments had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_6487ad2f-0a2c-49f7-a09d-7a3056d0d81a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_fdc76534-bf62-4bbf-b64b-4b7ddc523e0b"&gt;one&lt;/span&gt;&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020, we sold no available-for-sale securities. During the nine months ended September&#160;30, 2020, we sold available-for-sale securities totaling $41.7&#160;million. Gross realized gains and losses on those sales were not significant. During the three and nine months ended September 30, 2019, we did not sell any of our available-for-sale securities. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report our accrued interest receivable, which totaled $5.4&#160;million and $6.5&#160;million at September&#160;30, 2020 and December 31, 2019, respectively, in other current assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&#160;&#x2014;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&#160;&#x2014;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&#160;&#x2014;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2019, our gross unrealized gains and losses totaled $2.1&#160;million and $0.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjIwNQ_cd7d5f3e-a6da-4d18-8ad1-8fdf87ea6265">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMi0xLTEtMS0w_bd57c4ba-ae61-4060-b3fa-c7b5c7b1784f"
      unitRef="usd">55843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMi0zLTEtMS0w_3d4dccc0-0182-4e5a-93e0-c3edcb314550"
      unitRef="usd">96363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMy0xLTEtMS0w_87dbcce3-fe13-443f-b5fb-036de6e3c39a"
      unitRef="usd">900163000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfMy0zLTEtMS0w_68a892b3-0f2d-45f0-9b74-6968ddb7211c"
      unitRef="usd">1228499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNC0xLTEtMS0w_3f5dc393-536a-4224-a0bf-7846162f7db5"
      unitRef="usd">197715000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNC0zLTEtMS0w_6e0cf04c-6db2-448c-a6e8-4793cf5208c3"
      unitRef="usd">279119000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNS0xLTEtMS0w_52ebb527-9710-4798-b2e5-0b21fca4fd01"
      unitRef="usd">1153721000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOmJlYWI3MDEwMTc1OTQ5MjM5YjJhMWY1MGM2OWExNmQyL3RhYmxlcmFuZ2U6YmVhYjcwMTAxNzU5NDkyMzliMmExZjUwYzY5YTE2ZDJfNS0zLTEtMS0w_ce5549ae-43ac-4da5-a779-6cd8c2861fde"
      unitRef="usd">1603981000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:DebtInvestmentMaximumMaturityPeriod
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNDAw_3b7b5d34-db5b-4b0b-b023-dc7040974dfb">P2Y</nktr:DebtInvestmentMaximumMaturityPeriod>
    <nktr:DebtInvestmentMaturityTerm
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNDU1_0f9e4f58-034e-42e9-a619-bd3a64a01ebe">P1Y</nktr:DebtInvestmentMaturityTerm>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i88d27ec3cd0a45d79c70cd319b7561fe_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQ3_1940f999-ec57-4b95-be73-a5ac198ebe70">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="ieddedc2d43614f2087b4f389cf2e70c7_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQ3_84f15026-7032-4641-87dc-f153680d4d58">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjc0ODc3OTA3MTc1MQ_dbd00752-2f4a-4d43-9411-37455fe94245"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNjQw_41e26e15-fb8e-442c-aa4d-26d6685de5ea"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNzcz_84eae040-23bd-4f78-b9e0-bb227d752ecd"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNzcz_fa8bf450-6523-4697-b476-8811dc3c882b"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:InterestReceivableCurrent
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfOTU3_6f22432c-982d-46e1-982c-d230cefa90d3"
      unitRef="usd">5400000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfOTY0_12ba013b-e718-4926-a527-e59495879494"
      unitRef="usd">6500000</us-gaap:InterestReceivableCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjIwNw_d2799a72-ae29-48fa-8910-9548cba7612a">&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi0zLTEtMS0w_2f239360-3a26-483c-a49c-74eb87cf221f"
      unitRef="usd">831575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi01LTEtMS0w_c95a8264-23c0-4c93-8d26-0ca6d617ab10"
      unitRef="usd">2341000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi03LTEtMS0w_a2e832e9-66a3-46f5-a678-4c5f7aa6627c"
      unitRef="usd">201000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1705ff08143644c9aeb769a8d112dba7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi05LTEtMS0w_06a31b7d-3293-4ecd-9e7b-dfd345096832"
      unitRef="usd">833715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99e7e0b20231423f97aeee88223671b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMi0xMS0xLTEtMA_5fe5ace8-d812-4157-8a02-cbbfef811b21"
      unitRef="usd">1132182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy0zLTEtMS0w_1f029280-1dc6-4c91-8482-6b1af908bcb3"
      unitRef="usd">245796000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy01LTEtMS0w_87ecc527-7ffc-4a42-85f7-1116f42b9973"
      unitRef="usd">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy03LTEtMS0w_166d6dc2-fafe-4ae4-9abc-ef50786ed5a3"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b4109b2d9da47bf8b79061158ea7bed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy05LTEtMS0w_e2b4e6b5-02a4-48b5-94d3-a5457e0bad06"
      unitRef="usd">245913000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8ad5f6efc6b4bf5a108654c05274301_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfMy0xMS0xLTEtMA_eed648af-e81e-4b58-bb22-5eb568145e3a"
      unitRef="usd">375473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC0zLTEtMS0w_1b536970-21b9-4d38-92d2-45addf7efb96"
      unitRef="usd">9998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC01LTEtMS0w_fd29e5f6-7240-452c-9b7e-449249e15189"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC03LTEtMS0w_18bce600-7c86-4f74-aacc-f0c3c13ef816"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3e408faa719445eb3434a16e7c18e9f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC05LTEtMS0w_326af3ba-ecfc-4952-9932-ef869ebd0ec5"
      unitRef="usd">9999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55c58c72e60443e98000bbf5d2344984_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNC0xMS0xLTEtMA_3d685abc-e9e2-4498-a99a-131b7e609b69"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS0zLTEtMS0w_35bc103e-d818-4b75-9b3e-070dbac448b0"
      unitRef="usd">1087369000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS01LTEtMS0w_35717a70-512e-452c-bb67-e7240c2cbc11"
      unitRef="usd">2473000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS03LTEtMS0w_28011306-de08-4be0-ad74-56d47e78a63f"
      unitRef="usd">215000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic88c859d81c749cea39bca6e05b73950_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS05LTEtMS0w_416b6ada-0af6-40a7-8bbc-c5daa7f3eea7"
      unitRef="usd">1089627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i681a6443e0ce4fa6947d2139b2f64812_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNS0xMS0xLTEtMA_8f223e43-58c3-4813-a9c4-2791474a1748"
      unitRef="usd">1507655000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icdc9da2b38604cb796fa39f895a0a59d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNi05LTEtMS0w_b3dbc435-f9db-4c59-b4c3-c33ebe6ea9e3"
      unitRef="usd">48931000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i77ce117291d34d628c9bc23c2c80ca8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNi0xMS0xLTEtMA_0af1bc99-f984-40f0-9e83-07fa6b051cc0"
      unitRef="usd">83546000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i03d1299e9f894636b79988ee324b7611_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNy05LTEtMS0w_f89424a2-4357-4861-9d8e-02ff1082fae5"
      unitRef="usd">8795000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic439350a60194b1db29410760ac99acc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfNy0xMS0xLTEtMA_ead809f3-8f5f-4374-a533-0f9a471fa986"
      unitRef="usd">6951000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOC05LTEtMS0w_7b70fb21-a6a5-4ebe-a15f-ea2d48a7767c"
      unitRef="usd">6368000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOC0xMS0xLTEtMA_3b2b81a1-aff4-415f-ac6a-b1cdce5071df"
      unitRef="usd">5829000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOS05LTEtMS0w_c2e8fee6-1d98-4c2b-84f7-705d9080cb5d"
      unitRef="usd">1153721000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RhYmxlOjkzZDgxYzc1MDVmMjQzNzdiYzY2ZWQzNGE1OWI2YWVkL3RhYmxlcmFuZ2U6OTNkODFjNzUwNWYyNDM3N2JjNjZlZDM0YTU5YjZhZWRfOS0xMS0xLTEtMA_915ff078-abf7-447d-a202-f196be38fa6f"
      unitRef="usd">1603981000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjE3OA_65d2d368-0e08-4d22-a229-35c9d0c9c064"
      unitRef="usd">2100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfMjE4NQ_59976113-5189-430d-bd75-3f9d59f7336a"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RleHRyZWdpb246ZWZlYWYxNWY2YmQ1NDMxYmI0YmViNTgyN2ZjYzkwZGZfODQ4_8f96cbc4-c4d3-4ae1-a0f2-d89c1d0bd276">Inventory&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RleHRyZWdpb246ZWZlYWYxNWY2YmQ1NDMxYmI0YmViNTgyN2ZjYzkwZGZfODUw_687eb20a-4de2-4c0f-8221-3e748ca8f35a">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMS0xLTEtMS0w_a6cc89e8-956a-4ce4-892b-274102bc15f9"
      unitRef="usd">1387000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMS0zLTEtMS0w_585c706a-a003-4263-9950-6e9b9eadbc19"
      unitRef="usd">1673000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMi0xLTEtMS0w_8c52c7e6-5237-4cd0-a2fe-1f50822a16f7"
      unitRef="usd">11188000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMi0zLTEtMS0w_1602ec9c-d5f5-48d9-960a-fe409f2a4ac6"
      unitRef="usd">8267000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMy0xLTEtMS0w_4d234618-a0c3-444d-8296-331ec1b06625"
      unitRef="usd">317000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfMy0zLTEtMS0w_80d697a8-0dbc-46e5-8d0b-9f5920893729"
      unitRef="usd">2725000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfNC0xLTEtMS0w_e0abbee6-d20a-4b00-80d0-0631e1b03c3c"
      unitRef="usd">12892000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RhYmxlOjdmODQwMzZiNjVjZjQ1ZGI4ZWUxNmE1YTFkMzMyODBmL3RhYmxlcmFuZ2U6N2Y4NDAzNmI2NWNmNDVkYjhlZTE2YTVhMWQzMzI4MGZfNC0zLTEtMS0w_807dcda2-c9bd-4b4f-b7c4-0af026475c66"
      unitRef="usd">12665000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80OS9mcmFnOmVmZWFmMTVmNmJkNTQzMWJiNGJlYjU4MjdmY2M5MGRmL3RleHRyZWdpb246ZWZlYWYxNWY2YmQ1NDMxYmI0YmViNTgyN2ZjYzkwZGZfODQ0_f327b88d-0654-4f34-97aa-60a4645befb7">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMzg2NA_5be8147d-e472-4fbc-b0fb-6b3ebe7e96f4">Liability Related to Sale of Future Royalties&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately $4.4 million in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the effective interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products are remitted directly to RPI. During the nine months ended September&#160;30, 2020 and 2019, we recognized $28.0 million and $27.6 million, respectively, in non-cash royalty revenue from net sales of CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and we recorded $22.1 million and $17.9 million, respectively, of related non-cash interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. From inception through 2017, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately 17%. We have periodically adjusted our imputed interest rate over the years since inception as actual and forecasted sales of CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have increased and such increases have been sustained. During the three months ended September&#160;30, 2020, primarily as a result of increases in the forecasted sales of CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, our estimate of the effective annual interest rate over the life of the agreement increased to 20.2%, which results in a prospective interest rate of 48%. Since the proceeds from this agreement are fixed, any future changes in royalty revenue results in an equal corresponding change in imputed interest expense, which would result in changes in the prospective interest rate we use to amortize the liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations (often with time limitations) that are customary for a transaction of this nature. For example, we provided representations and warranties concerning intellectual property matters in the Purchase and Sale Agreement; however, the time limitation we have to indemnify &lt;/span&gt;&lt;/div&gt;RPI with respect to any breach of these intellectual property-based representations and warranties has passed. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="id0c4343e72de4e6dbb67b27ed682ae85_D20120223-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfNjk4_9779ebbf-b387-4df4-b0ef-75dd4fde3576"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="iafb87b6b488548d1888654100aa59ffb_I20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfNzc4_7f728b05-1744-416f-a72e-3b286c489196"
      unitRef="usd">4400000</us-gaap:DeferredFinanceCostsGross>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="id0c4343e72de4e6dbb67b27ed682ae85_D20120223-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTE4MA_cc6888cf-5dac-45c9-851e-c6758bae2f62"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTQ5MA_14da0501-5904-4bd5-a566-e368386a5e2e"
      unitRef="usd">28000000.0</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTQ5Nw_2bfbc8de-cf65-4b0d-9a07-cd90f03d5d33"
      unitRef="usd">27600000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTU5OQ_e2d390cc-67dc-49e5-b90a-57f5e916ec8e"
      unitRef="usd">22100000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMTYwNg_971bc270-197f-4b4d-91c1-c66109d07aa2"
      unitRef="usd">17900000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMzg2Mg_fa528f52-c5ad-4568-aa26-7ea9d3776728">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.</nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i04a6efe880524704ab1efed03af7179b_D20120223-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMjE0MQ_7050a022-54b7-40f7-a10c-7378163cdf9b"
      unitRef="number">0.17</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMjc0ODc3OTA3MzY3Mg_1f1d251a-b2d3-4985-8be1-20b7af0d923a"
      unitRef="number">0.202</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81Mi9mcmFnOjZmMjUzNDA3ZDVjNDQ1YzU4MzE5NDRiN2FhYTIwZTZmL3RleHRyZWdpb246NmYyNTM0MDdkNWM0NDVjNTgzMTk0NGI3YWFhMjBlNmZfMjc0ODc3OTA3MzY3OQ_8a040d33-4aee-4460-ad70-3ae5ccfd961d"
      unitRef="number">0.48</nktr:ProspectiveInterestRatePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81NS9mcmFnOjVhNTg3MTM3MzMzNjQwOGJhOWFhNzhkMTM3Zjg4ZWJmL3RleHRyZWdpb246NWE1ODcxMzczMzM2NDA4YmE5YWE3OGQxMzdmODhlYmZfNTM2OA_32992d95-8342-49dc-beb3-e1c64b9f2948">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019. Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On July 13, 2020, the U.S. District Court in California Court granted Nektar&#x2019;s motion to dismiss all claims in this securities class action filing, stating (among other things) that the amended complaint failed &#x201c;to adequately allege that any of the statements &#x2026; identified by Plaintiffs were false or misleading.&#x201d;  Following the motion to dismiss, on August 10, 2020, the class action plaintiffs filed a second consolidated class action complaint, and the matter remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either September 30, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 4. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, &lt;/span&gt;&lt;/div&gt;we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Condensed Consolidated Balance Sheets at either September&#160;30, 2020 or December&#160;31, 2019.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i5f32928a5bb24c13afe5414f859db8ad_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81NS9mcmFnOjVhNTg3MTM3MzMzNjQwOGJhOWFhNzhkMTM3Zjg4ZWJmL3RleHRyZWdpb246NWE1ODcxMzczMzM2NDA4YmE5YWE3OGQxMzdmODhlYmZfNTI2Nw_3be15b95-2e75-4819-9afe-bcdaed76e823"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic8dbe95429a94b1c9fd1c219421ebb89_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF81NS9mcmFnOjVhNTg3MTM3MzMzNjQwOGJhOWFhNzhkMTM3Zjg4ZWJmL3RleHRyZWdpb246NWE1ODcxMzczMzM2NDA4YmE5YWE3OGQxMzdmODhlYmZfNTI2Nw_da9c5787-c9c7-4087-b7c8-f65f539b4f93"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk3OTg_b37356ab-84c2-4124-9824-a0f550cb9e40">License and Collaboration Agreements&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Drug or Drug Candidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020, we recognized $22.7&#160;million and $109.4&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as $50.0&#160;million in BMS Collaboration milestones received in the nine months ended September 30, 2020, as further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7 billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our collaboration agreements in the three and nine months ended September&#160;30, 2020, except as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (nivolumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, BMS paid us a non-refundable upfront cash payment of $1.0 billion. We are eligible to receive additional cash payments up to a total of approximately $1.455 billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones, and up to a total of $350.0 million upon the achievement of certain sales milestones. In April 2018, BMS also purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2018, we aggregated the total consideration of $1.85 billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2 million in stockholders&#x2019; equity. We allocated the remaining $1,059.8 million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $1.8 billion to be variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020, we updated the transaction price by $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial. During the three months ended June 30, 2020, we updated the transaction price by $25.0&#160;million for the milestone for the first patient, first visit in the registrational adjuvant melanoma trial because we concluded that a reversal of the milestone was not probable. Since we had already completed our sole performance obligation of delivery of the licenses, we recognized $50.0&#160;million in license, collaboration and other revenue during the nine months ended September&#160;30, 2020. We continue to exclude the other milestones from the transaction price as of September&#160;30, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#x2019; costs as research and development expense. During the three and nine months ended September&#160;30, 2020, we recorded $29.2&#160;million and $93.8&#160;million, respectively, as a reduction of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses. During the three and nine months ended September&#160;30, 2019, we recorded $28.3&#160;million and $81.4&#160;million, respectively, as a reduction of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses.&#160;As of September&#160;30, 2020, we have recorded an unbilled receivable of $29.9 million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;): NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0 million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and are responsible for certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#x2019;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we are entitled to significant development milestones under this arrangement, through September&#160;30, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $150.0 million received in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0 million upfront payment as $125.9 million to the license, $17.6 million to our portion of the Phase 1 clinical development and $6.5 million to the drug product development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the $125.9 million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of September&#160;30, 2020, we have completed our performance obligations and we have no deferred revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Baxalta Inc. / Takeda Pharmaceutical Company Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Hemophilia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This Hemophilia A program includes ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $10.0 million development milestone, which we received in March 2018. During 2018, we earned an additional $10.0 million milestone for annual sales of ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/ ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $12.0 million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of September&#160;30, 2020, our deferred revenue from this arrangement is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.: Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#x2019;s right to require production of PEGylation materials at any time. As of September&#160;30, 2020, we have deferred revenue of approximately $0.4 million related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In September 2014 and December 2014, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; /MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was approved in the US and EU, respectively. As of September&#160;30, 2020, we have received a total of $385.0 million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving 60% and Nektar receiving 40%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of September&#160;30, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma and Pfizer, Inc., under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of September&#160;30, 2020, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk4MDA_5608f3dd-3f70-4d76-8592-4e3fbc59edc2">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Drug or Drug Candidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="id64de59193e145bbaa8bdb17a62c36da_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi00LTEtMS0w_f8a9f18e-d782-4abd-8557-d36f5c49995e"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iff6d1e8753ba4393b9f44eb4e488b692_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi02LTEtMS0w_eea64df0-8103-4b7c-8428-104af12fa62a"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="if3db9156ad10469f95b14481d96f4a7f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi04LTEtMS0w_aa1b82f4-65d2-4012-9b25-d5b6516f8a73"
      unitRef="usd">50000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ic68cb20163e74653bd4f64db0c6311c7_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMi0xMC0xLTEtMA_f0ae12b0-d1a3-4c2d-9bf6-1ad62935aa09"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4343dbd440dc46b69ff260a863af163c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy00LTEtMS0w_56f56f29-1898-4db5-9684-a63ac98f5e01"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i7162a81a95b64baeb3fac89305ceb96e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy02LTEtMS0w_9359e51d-38b6-4755-9091-af3cbcd5fda8"
      unitRef="usd">1500000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="id53b17ca10224ac0ac514957ad57da99_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy04LTEtMS0w_4ae0984d-24bb-4b54-8ce7-1106a166f04d"
      unitRef="usd">1259000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i50c27af66b7349d5aea18d07614a95df_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfMy0xMC0xLTEtMA_b3e5abc6-ca75-4958-9d78-30a2d7cd90ea"
      unitRef="usd">5200000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ibad28b26555d4a329b5591d767c77570_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC00LTEtMS0w_b668cc60-2696-4d50-a313-8c44305fbe48"
      unitRef="usd">1250000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i18551d4bf36b467d8fdc3c19c639a8b6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC02LTEtMS0w_8d718821-aaa5-4051-8fff-0d4886d66639"
      unitRef="usd">1250000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i86ea63c983d8410db8d44a3393069d40_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC04LTEtMS0w_200c1cd9-49f3-4b20-a6f2-7e41d676d3b4"
      unitRef="usd">3750000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ie6ed2104c72e46488602d090a349d252_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNC0xMC0xLTEtMA_48fd90d7-ba5e-4e15-ac49-b9e0962567b6"
      unitRef="usd">3750000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ib8c1a1a466fb4bc0bc106d1025995c65_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS00LTEtMS0w_d74878d2-7fb6-4cad-bad1-8a8b90d7d3d0"
      unitRef="usd">381000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ie76e0a45148544e2a7c2e165f1d8e4ab_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS02LTEtMS0w_5ef20af9-8fce-42a3-bec3-c7a68f34873d"
      unitRef="usd">371000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ibee96693c04e4f7db443a9718ecae73f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS04LTEtMS0w_154d3d2f-fbe0-472c-a078-070430e1b1f7"
      unitRef="usd">412000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ib5211c0643104c9bae3e1bc6a61751c3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNS0xMC0xLTEtMA_4ec58440-8d6e-4a04-8a54-2616916f9fd9"
      unitRef="usd">910000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi00LTEtMS0w_55e330c9-aec7-477c-b28f-7afd978abbe1"
      unitRef="usd">1631000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi02LTEtMS0w_dc3a9fb7-658f-4021-9919-dfe0c952f0e7"
      unitRef="usd">3121000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi04LTEtMS0w_2967b3a9-a4a7-4347-aef6-80451a4aeaf4"
      unitRef="usd">55421000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOjY0Y2UxOGIwYmY2NjQ3YWI4MGZmZTFhNzFhYzg5Y2Y1L3RhYmxlcmFuZ2U6NjRjZTE4YjBiZjY2NDdhYjgwZmZlMWE3MWFjODljZjVfNi0xMC0xLTEtMA_588c4fcd-a182-4cba-ac44-bfeea7f641bb"
      unitRef="usd">9860000</nktr:LicenseCollaborationOtherRevenue>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTE2Mg_b58daba4-6aaf-474d-9331-2f6c0ec128e1"
      unitRef="usd">22700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTE2OQ_aeb3604b-8a0f-4423-a5c8-f0688ab5c2e3"
      unitRef="usd">109400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <nktr:SalesMilestoneRevenue
      contextRef="i01e0829dcbda4d3cb7e7f5488eaa3b04_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTM2Mg_48ca4222-5734-47e1-a72e-9fff4189677d"
      unitRef="usd">50000000.0</nktr:SalesMilestoneRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk3OTY_df88aeee-4907-4778-9b8b-77a9005b9ec6">&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0cb27177fc6d4020b6959a80b73dd02f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOmExYmE0NGY3ZmI4ZDRmMDNhYzI4ODNkOWRkNjgzOGMxL3RhYmxlcmFuZ2U6YTFiYTQ0ZjdmYjhkNGYwM2FjMjg4M2Q5ZGQ2ODM4YzFfMS0xLTEtMS0w_25f2cae1-97e4-4714-b0a2-111fdc785842"
      unitRef="usd">8071000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOmExYmE0NGY3ZmI4ZDRmMDNhYzI4ODNkOWRkNjgzOGMxL3RhYmxlcmFuZ2U6YTFiYTQ0ZjdmYjhkNGYwM2FjMjg4M2Q5ZGQ2ODM4YzFfMi0xLTEtMS0w_6ed26947-4ff8-4b4d-8862-6be26800f89f"
      unitRef="usd">5070000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RhYmxlOmExYmE0NGY3ZmI4ZDRmMDNhYzI4ODNkOWRkNjgzOGMxL3RhYmxlcmFuZ2U6YTFiYTQ0ZjdmYjhkNGYwM2FjMjg4M2Q5ZGQ2ODM4YzFfMy0xLTEtMS0w_d997fa55-3069-414a-bfcb-418ef1f77595"
      unitRef="usd">3001000</us-gaap:ContractWithCustomerLiability>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i6de4d4cf296147b9b48d391257b6a758_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTkxNw_79d346cb-b26f-4cad-9c81-5bea4ca41cbc"
      unitRef="usd">1700000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="iac03f04314684a77ac56ecd63ce7fd06_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzIxOQ_ed712079-f7d4-4087-b3b2-1dcd34daf558"
      unitRef="number">0.65</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="idea06231b1c44280b52f314d797baf6f_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzIzOA_07e6b456-8d9e-4722-8c1c-16365dee9b96"
      unitRef="number">0.35</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i3ebd9a821b2a46cfb77bd1fed0e162c0_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzU5NA_39083b35-e7e8-4772-bf94-c17150d963af"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i6c5e9092d71c49cc890b7c52af5e1209_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzYxNw_e8364641-03dd-4e46-9c5d-ea72a35a51c4"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="idea06231b1c44280b52f314d797baf6f_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzgxMg_a22d9cdc-5a49-4dda-a5ed-d1f41e7c5543"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="iac03f04314684a77ac56ecd63ce7fd06_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzgzNQ_ae7cd0fc-b807-4c8b-899a-15fa0b7f21b0"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i839037e7f6a34cd693275417607356c0_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMzk3Ng_83a1059f-2ebf-40cd-9a96-9240bb80e88c"
      unitRef="usd">1000000000.0</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
      contextRef="i99091a9d1fe04ff8974bd1aaf88b38b4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDA2Mw_f5b45bbf-39c8-49c0-a1c8-c2b7089a262d"
      unitRef="usd">1455000000</nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones>
    <nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
      contextRef="i6ab76208d9ee4ff2988ff083957e0c4b_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDM3OQ_80036199-b66d-4f1e-9bde-990509b4f7b8"
      unitRef="usd">350000000.0</nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones>
    <us-gaap:SharesIssued
      contextRef="ia70be8a1e2a64792b0121d05ff80c80d_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDQ2Ng_2330bbd2-9bcd-4cc6-8a63-bec2b2643534"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="i1580321c09614031b9d42400c15746cf_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNDU4MA_1e4f9b1a-6637-4b0b-9d56-4cf4e1fde2f6"
      unitRef="usd">850000000.0</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i62d453fedad74b76a89c1def968cf6c9_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMjc0ODc3OTA5NDA4MQ_4a552cf8-b63a-4f87-a8e8-1a54d7bcfd82"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i62d453fedad74b76a89c1def968cf6c9_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNTAxNg_703dae9b-6307-4aaa-9997-586acc9bcf29"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:AggregateConsiderationReceivedFromAgreements
      contextRef="ib62bb08ae1ed42499bf0502605a0aabd_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjM0NA_4b59a3e3-6b83-46d1-8323-af5cc4781f80"
      unitRef="usd">1850000000</nktr:AggregateConsiderationReceivedFromAgreements>
    <nktr:EstimatedFairValueOfShares
      contextRef="i3a47c82fe5384724ac972e8f0118a042_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjY5NQ_eabc6629-58a7-4015-ba08-f03b5794497d"
      unitRef="usd">790200000</nktr:EstimatedFairValueOfShares>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="ib62bb08ae1ed42499bf0502605a0aabd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjc1MA_18aa37f9-d2ea-42ed-b3b3-87134170c403"
      unitRef="usd">1059800000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:PotentialDevelopmentRegulatoryAndSalesMilestones
      contextRef="i3a47c82fe5384724ac972e8f0118a042_I20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNjk0MA_110d1d82-ff9d-4ada-8c7b-22121f3e664d"
      unitRef="usd">1800000000</nktr:PotentialDevelopmentRegulatoryAndSalesMilestones>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i55e78d80f65f41df99be245f4785d48d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNzA1Ng_5b513ded-9312-4970-8625-efbe5a763b0d"
      unitRef="usd">25000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i4ca0ee0445d2406481c1a68226274962_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNzI1NA_05edc301-14e0-4b60-8ab7-60561786350c"
      unitRef="usd">25000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i345310330b5c404386610c6ffb7eb919_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfNzY0OA_1e1f7946-a336-435b-8bdd-6564652922fa"
      unitRef="usd">50000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:ReimbursementOfExpenses
      contextRef="i91f01add1280492bb87f2040bd86e237_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfODkzNw_36c5dbf1-b22a-4966-a9b7-e75c6902ba15"
      unitRef="usd">29200000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i399485e14223466ab18e166f27bb67af_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfODk0NA_f6473b10-91bc-4af4-9428-5bca27169468"
      unitRef="usd">93800000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i3e9a8b5809804afe80662a5640dc611a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTEzNA_f62236f5-9e21-4e6b-be86-336272ab9657"
      unitRef="usd">28300000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="ide0ac9a686224749809a811eb1aee975_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTE0MQ_dc333bd7-91f0-473e-a98e-ba5a694276e3"
      unitRef="usd">81400000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5f9ecd4583d46a880165db35da02267_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTMzMA_b7c8c80e-4979-43f2-b2fe-34013b497044"
      unitRef="usd">29900000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTc0NQ_d20ea313-b9e9-481f-92be-345f828a454a"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i972a45764b0e465282335687170894e5_I20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfOTc5Mw_162c70c2-f9b5-4611-852e-5f06d62ac03c"
      unitRef="usd">250000000.0</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i845230a255e24070ad64f4430f5f672e_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAwODk_bd681273-b43b-4cd7-a21e-771cf2076bd3"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="ifa275d5aaa564026bf559d0b72b3f69f_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAxMjY_593cb609-e174-419c-a1f2-e1b659d0d3c0"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i1a6b27f69ae44774a99f76b9be930ea9_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAyNzY_317629e3-2582-46cb-860b-5a4889d45b42"
      unitRef="number">0</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i82c5b100e5d54cb1b29df1fb69b79fcf_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTAyODI_310aa385-17a9-4f36-93e5-9f91c2adaf31"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="i1fd4979f3b7b4006aa4dc73336bb0e51_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTA3MTA_a2cb92b2-33d5-4e7c-b900-5a11a4312b00"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="i1fd4979f3b7b4006aa4dc73336bb0e51_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTA5NDU_dfbd8351-4a63-4d32-a3b2-24555d4b7e4d"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI2NTQ_b978815e-203a-4771-b51f-5981fa00ef87"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="ib8566ff5611c4425975f7d16263adc16_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI3ODE_919a8925-93d3-44c2-95c1-5b9203ed9cb8"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i825ba9383adc4f57b11ab95a166bb2c3_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI4MDM_1320c68b-b99a-448f-8dec-bb136ffa8b89"
      unitRef="usd">125900000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i8ac727c6b64f4df7857a4b3e2d0ea358_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI4MjI_cd7b59d0-5768-4d86-b1ea-6ccaaf8329ef"
      unitRef="usd">17600000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i1f4bc86daabe478d9199134b3ced767a_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI4ODA_8a95c27b-23ee-443d-b6ac-ddd67a21a660"
      unitRef="usd">6500000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd4450164353469089e6a5715b63820c_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTI5MzQ_ff930a6f-6490-4c4d-ac67-5b871b0f4e6f"
      unitRef="usd">125900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5825f573d218444c8a02aa2a76c1e143_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTQ4NDE_13391f79-efb7-4267-954c-3de640f1ca44"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01a3e8af9af343f3af75c19ca2ff410e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTQ5Mzc_a9c90f11-28ad-4bf8-a417-76ff7c8e9930"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:PaymentsReceivedUnderRightsToSublicenseAgreement
      contextRef="icf21631db7ee40ac9b0a17f839fb1811_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTU1NDY_8a25c572-0fa5-460a-8e2d-c1c1beb5b9cb"
      unitRef="usd">12000000.0</nktr:PaymentsReceivedUnderRightsToSublicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="ic45d9817ecdf46ae9c87ba4e76263729_D20101001-20101231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTYzNjc_62c23179-e31f-4b8f-8ddc-5f4f9afb2cc9"
      unitRef="usd">50000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2981e0957f0f4a1695bcd34c346c09c3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTcwMjY_e2bff106-b375-420f-a4cc-ee94873d56f5"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiability>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i0c367beebd6f4d79ba026bb215d28964_D20090901-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTc3NjQ_03d568e4-f29a-4351-b38d-d2dc98324c68"
      unitRef="usd">385000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
      contextRef="i5cfa614f55b340eca7394aa4a2d91432_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTg1MzU_c7d3ad09-8013-4274-baec-049da7f2fda0"
      unitRef="number">0.60</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
      contextRef="i26da6534944946e088095dadd2086834_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTg1NTk_bcc6fa66-9232-4104-94b4-76b5631e0b92"
      unitRef="number">0.40</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i007147b59fd8496894c45965e29e7c2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTg1ODA_a7cfe093-30ec-437d-8e80-5702665577bd"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i11cfe9f36c27416a8410b5c100442563_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTkxNjE_73173e96-7ba0-460a-b101-05699b79b3a7"
      unitRef="usd">40000000.0</nktr:PotentialDevelopmentMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i11cfe9f36c27416a8410b5c100442563_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82MS9mcmFnOjE2MDA2ZDBhNDViMDQ0OWJiZmU2ZGFjMmIyNDhjYTQ0L3RleHRyZWdpb246MTYwMDZkMGE0NWIwNDQ5YmJmZTZkYWMyYjI0OGNhNDRfMTk3NDU_e941c5f8-1934-49ab-b9dd-2aaff4021304"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAxNQ_5f04e5f7-6099-44b9-8655-d3ee77490d5a">Stock-Based Compensation&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we accounted for as a liability award. Upon issuance of the award in the three months ended June 30, 2020, we reclassified the award into equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 17, 2020, the Stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 10,000,000 shares, and an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by 1,000,000 shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAxMg_b69c84dd-d50e-4448-8272-118266eb4f47">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0d135950a41412bbe0141268927497b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi0xLTEtMS0w_107472e7-2a65-49fc-a620-f763f99ac897"
      unitRef="usd">744000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f2917a58fe349269bb836b1b174986d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi0zLTEtMS0w_2e619715-a958-4f76-92c8-77037b5dda73"
      unitRef="usd">1119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia646a70ced924165adc2d5633324fb08_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi01LTEtMS0w_e16627bf-71ac-406c-aed2-f8fe4b542a4b"
      unitRef="usd">2168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68c2ed5b2588478a815cd96dd3fa4d70_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMi03LTEtMS0w_4f4a24fd-f608-4cbf-a8cc-8a75f389517b"
      unitRef="usd">3208000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94ed0979123649adb4dc059466490ec4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy0xLTEtMS0w_73576421-4dc1-45d5-b986-a4466f37c7e1"
      unitRef="usd">14212000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb4f7a1f2a934d41827c699b4ead106e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy0zLTEtMS0w_95f8b4f4-57f2-456f-9784-70e3fbebbf90"
      unitRef="usd">15680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i421586bc96a448849e0605a587727f4c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy01LTEtMS0w_1046901b-9c5a-4068-ba9b-d1c6c0cc04af"
      unitRef="usd">43826000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98ee132789b94f38b825c9ceecbd65a6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfMy03LTEtMS0w_497fbf81-3e37-4d12-9734-77f1969cd5aa"
      unitRef="usd">47549000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb8af90d2ea34d3e9c87ef4323285570_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC0xLTEtMS0w_1569e770-a2d4-413e-abb4-57a029db6512"
      unitRef="usd">8711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac31e6a7286d4bbfa722ce15fd4b5f5d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC0zLTEtMS0w_6f704ce8-9149-4166-8c0a-32ba36dad55c"
      unitRef="usd">8081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id69fe287ef8140e69c41a0fc1cf62e80_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC01LTEtMS0w_cf54cb8c-ece0-41f8-8b84-273f3ccb46be"
      unitRef="usd">25255000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f16026628714f2a9d7e1c922ae55c2f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNC03LTEtMS0w_aa3f69b6-be36-4c7f-80aa-b2bcd9d085ab"
      unitRef="usd">24030000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i30945d826eaa4db1aee3efa6d35c52bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS0xLTEtMS0w_5812d6b8-01b8-452f-b6de-da7556fd1b9f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d1bab0b44b74b74ab8679821ad533a9_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS0zLTEtMS0w_fade4827-5186-47df-b49c-68c2ffc0b2a4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e080a50510b45d7985955e0bc237be8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS01LTEtMS0w_e1034031-832e-48f3-888b-f8ae182d9a05"
      unitRef="usd">1025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea6b1642d5d74c94b8fc02f648ad3e3a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNS03LTEtMS0w_1547d22e-d9d4-404d-b33c-75e159517e58"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi0xLTEtMS0w_a2c7a980-cbfa-4287-aaf1-a263672a571b"
      unitRef="usd">23667000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi0zLTEtMS0w_b1c95a65-2e1a-4268-8aa1-f529d494652c"
      unitRef="usd">24880000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi01LTEtMS0w_eb3ed979-5a75-4689-8bff-21684aec65ed"
      unitRef="usd">72274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOmYzMWU0MjhhM2I3ODRkZTBhN2VkODkwZDVmMjAxYjQ3L3RhYmxlcmFuZ2U6ZjMxZTQyOGEzYjc4NGRlMGE3ZWQ4OTBkNWYyMDFiNDdfNi03LTEtMS0w_7fabea2b-41a7-46cf-b4cd-a3813c509f7b"
      unitRef="usd">74787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAxNA_8ed515b5-5afb-48ac-ad88-0b47370588fc">&lt;div style="margin-top:8pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie8ebfaa0c2694404bb2fe78ec756a33b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi0xLTEtMS0w_8a9b1037-62b8-448e-bf8c-d7a67a2fc7a7"
      unitRef="shares">233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6bd21aca8ffb4b5b93b574af7f8c16bc_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi0zLTEtMS0w_c354a88f-98c2-4a35-844c-7d8278a0b2ec"
      unitRef="shares">131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i39cc4e2705b448d299937048e267e868_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi01LTEtMS0w_50e60ddf-7ccf-419a-855f-7f055b6fd024"
      unitRef="shares">282000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if19b4a9eac04440dae63a1c159632e2a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMi03LTEtMS0w_5f79e228-7d4a-48df-934b-0a49d5a455d1"
      unitRef="shares">246000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie8ebfaa0c2694404bb2fe78ec756a33b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy0xLTEtMS0w_55d1fd81-4587-4283-b5c7-9a7dc37566bf"
      unitRef="usdPerShare">11.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bd21aca8ffb4b5b93b574af7f8c16bc_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy0zLTEtMS0w_b8d901e6-7d65-4751-9f05-19b881d09760"
      unitRef="usdPerShare">13.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i39cc4e2705b448d299937048e267e868_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy01LTEtMS0w_b0a0be77-2932-47a0-a77d-ecb58a4660af"
      unitRef="usdPerShare">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if19b4a9eac04440dae63a1c159632e2a_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfMy03LTEtMS0w_642b6f36-5d9f-49f2-8df5-fe5e29e6aa40"
      unitRef="usdPerShare">15.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib03e08fc98c644e6be4bef8a349474ac_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC0xLTEtMS0w_fdc985a1-3d46-47fc-975f-0321f6aa59f7"
      unitRef="shares">693000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id1d349f8e26343058e7e9dd3492bdb7e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC0zLTEtMS0w_010eb307-8628-476c-9286-3c31986a375a"
      unitRef="shares">316000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia6c6d347086b42f780f70922a18208d4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC01LTEtMS0w_d8c62307-f7da-404a-a67b-d75ef923e3f6"
      unitRef="shares">1213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib2129dcc350a4c9fb39c6f59f2f20fe8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNC03LTEtMS0w_84575bcd-a870-4062-ab50-232110cbf974"
      unitRef="shares">712000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib03e08fc98c644e6be4bef8a349474ac_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS0xLTEtMS0w_5bdff9b5-ae21-410c-aa30-38fc171d0914"
      unitRef="usdPerShare">21.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id1d349f8e26343058e7e9dd3492bdb7e_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS0zLTEtMS0w_56e75a82-45ed-4e02-ac46-d680c38c7609"
      unitRef="usdPerShare">28.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia6c6d347086b42f780f70922a18208d4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS01LTEtMS0w_6eeb7d23-3ad5-4216-a727-b5c23ef7f068"
      unitRef="usdPerShare">21.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2129dcc350a4c9fb39c6f59f2f20fe8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNS03LTEtMS0w_9ae2f07f-d987-4364-b48c-8cda5e0adcc4"
      unitRef="usdPerShare">31.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi0xLTEtMS0w_6f22e8fe-7e87-4439-bb78-24a7316114c0"
      unitRef="shares">584000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi0zLTEtMS0w_597dcec1-dff9-4f9c-b2cc-c39370442ca3"
      unitRef="shares">820000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi01LTEtMS0w_c05076ed-6453-46e2-b0b1-813457352d67"
      unitRef="shares">2889000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RhYmxlOjM5N2Q3Y2Y1MjM4NDQ4NmI4YWNmMDhiMDZiNjk0NTkzL3RhYmxlcmFuZ2U6Mzk3ZDdjZjUyMzg0NDg2YjhhY2YwOGIwNmI2OTQ1OTNfNi03LTEtMS0w_ed78eb10-b160-47d2-b207-d869f9c072ce"
      unitRef="shares">2256000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <nktr:CommonStockAdditionalSharesAuthorized
      contextRef="i8432c50c56094a11aa02e5f29d960026_D20200617-20200617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfODAx_b16c54bd-3f7a-455f-9248-ed0a5d036641"
      unitRef="shares">10000000</nktr:CommonStockAdditionalSharesAuthorized>
    <nktr:CommonStockAdditionalSharesAuthorized
      contextRef="i3bf8410935d84e55bd4f0436c35fcb2c_D20200617-20200617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF82Ny9mcmFnOjU4OGNjYzhmOTQyYjQ1ZGRiN2EwOWI1N2IwZmNkNjNkL3RleHRyZWdpb246NTg4Y2NjOGY5NDJiNDVkZGI3YTA5YjU3YjBmY2Q2M2RfMTAwMw_5ba392c8-cba0-4398-a8f2-b1ae9b12aec2"
      unitRef="shares">1000000</nktr:CommonStockAdditionalSharesAuthorized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RleHRyZWdpb246NDAxNjg2ZWEzYmJmNDQyMWExMDNmMGRhMDY3ZmY4OTNfOTQ0_8c650b10-5be7-4516-a039-0f9a1c55e53a">Net Loss Per Share&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three and nine months ended September&#160;30, 2020 and 2019, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RleHRyZWdpb246NDAxNjg2ZWEzYmJmNDQyMWExMDNmMGRhMDY3ZmY4OTNfOTQ3_79cc949f-4587-48c4-a8ea-6e150941750f">During the three and nine months ended September&#160;30, 2020 and 2019, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i157373b14ace4588bdde4627501185ae_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi0xLTEtMS0w_24c72de7-1dc6-4fd8-97d0-cebf8a11ed2e"
      unitRef="shares">16575000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi0zLTEtMS0w_d0304230-901f-4550-a12b-6bcb0b080ff0"
      unitRef="shares">17163000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi01LTEtMS0w_564ece33-dbfb-42ee-9de0-cfe479c46f35"
      unitRef="shares">17499000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i926a3ba597b6417eab9c6f14e70cfe6e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF83MC9mcmFnOjQwMTY4NmVhM2JiZjQ0MjFhMTAzZjBkYTA2N2ZmODkzL3RhYmxlOjIxYmVlM2JmYTIxYjRkYTM4ZDFiYzlhZjM5MTVlMzUzL3RhYmxlcmFuZ2U6MjFiZWUzYmZhMjFiNGRhMzhkMWJjOWFmMzkxNWUzNTNfMi03LTEtMS0w_a670ff1b-94f7-4eec-b9b6-6f12984f1922"
      unitRef="shares">18012000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525322984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,398,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525170504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,843<span></span>
</td>
<td class="nump">$ 96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">900,163<span></span>
</td>
<td class="nump">1,228,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">42,925<span></span>
</td>
<td class="nump">36,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">12,892<span></span>
</td>
<td class="nump">12,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AdvancePaymentsToContractManufacturers', window );">Advance payments to contract manufacturers</a></td>
<td class="nump">10,483<span></span>
</td>
<td class="nump">31,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">21,550<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,043,856<span></span>
</td>
<td class="nump">1,421,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">197,715<span></span>
</td>
<td class="nump">279,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,189<span></span>
</td>
<td class="nump">65,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">128,985<span></span>
</td>
<td class="nump">134,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,508,666<span></span>
</td>
<td class="nump">1,977,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Senior secured notes, net and interest payable (see Note 1)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">252,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,484<span></span>
</td>
<td class="nump">19,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">29,504<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">48,886<span></span>
</td>
<td class="nump">32,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedContractManufacturingExpenseCurrent', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">7,141<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">9,630<span></span>
</td>
<td class="nump">12,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">15,348<span></span>
</td>
<td class="nump">12,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">5,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">126,500<span></span>
</td>
<td class="nump">353,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">139,022<span></span>
</td>
<td class="nump">142,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">66,378<span></span>
</td>
<td class="nump">72,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">337,685<span></span>
</td>
<td class="nump">571,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2020 or December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 179,394 shares and 176,505 shares outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,363,998<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,191,955)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,170,981<span></span>
</td>
<td class="nump">1,405,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,508,666<span></span>
</td>
<td class="nump">$ 1,977,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedContractManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedContractManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AdvancePaymentsToContractManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance payments to contract manufacturers, net of amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AdvancePaymentsToContractManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697605483400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">179,394,000<span></span>
</td>
<td class="nump">176,505,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525919640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 30,033<span></span>
</td>
<td class="nump">$ 29,218<span></span>
</td>
<td class="nump">$ 129,453<span></span>
</td>
<td class="nump">$ 80,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,570<span></span>
</td>
<td class="nump">4,927<span></span>
</td>
<td class="nump">15,154<span></span>
</td>
<td class="nump">15,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">100,531<span></span>
</td>
<td class="nump">99,048<span></span>
</td>
<td class="nump">305,954<span></span>
</td>
<td class="nump">324,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">23,983<span></span>
</td>
<td class="nump">77,546<span></span>
</td>
<td class="nump">71,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">133,083<span></span>
</td>
<td class="nump">127,958<span></span>
</td>
<td class="nump">443,843<span></span>
</td>
<td class="nump">411,152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(103,050)<span></span>
</td>
<td class="num">(98,740)<span></span>
</td>
<td class="num">(314,390)<span></span>
</td>
<td class="num">(330,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,425)<span></span>
</td>
<td class="num">(6,851)<span></span>
</td>
<td class="num">(15,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="num">(8,425)<span></span>
</td>
<td class="num">(5,813)<span></span>
</td>
<td class="num">(22,084)<span></span>
</td>
<td class="num">(17,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">16,453<span></span>
</td>
<td class="nump">35,964<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="num">(5,515)<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="num">(12,482)<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(108,565)<span></span>
</td>
<td class="num">(98,486)<span></span>
</td>
<td class="num">(326,872)<span></span>
</td>
<td class="num">(328,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (108,586)<span></span>
</td>
<td class="num">$ (98,585)<span></span>
</td>
<td class="num">$ (327,237)<span></span>
</td>
<td class="num">$ (328,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (1.88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)</a></td>
<td class="nump">179,090<span></span>
</td>
<td class="nump">175,402<span></span>
</td>
<td class="nump">178,203<span></span>
</td>
<td class="nump">174,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="nump">$ 5,558<span></span>
</td>
<td class="nump">$ 14,620<span></span>
</td>
<td class="nump">$ 14,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">12,289<span></span>
</td>
<td class="nump">10,275<span></span>
</td>
<td class="nump">31,411<span></span>
</td>
<td class="nump">29,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10,422<span></span>
</td>
<td class="nump">10,264<span></span>
</td>
<td class="nump">28,001<span></span>
</td>
<td class="nump">27,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 3,121<span></span>
</td>
<td class="nump">$ 55,421<span></span>
</td>
<td class="nump">$ 9,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Equipment And Other Costs For Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697526037672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (108,586)<span></span>
</td>
<td class="num">$ (98,585)<span></span>
</td>
<td class="num">$ (327,237)<span></span>
</td>
<td class="num">$ (328,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(2,144)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">6,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="nump">349<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(498)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,795)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (110,381)<span></span>
</td>
<td class="num">$ (99,206)<span></span>
</td>
<td class="num">$ (327,312)<span></span>
</td>
<td class="num">$ (322,099)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697601726376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,717,575<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,147,925<span></span>
</td>
<td class="num">$ (6,316)<span></span>
</td>
<td class="num">$ (1,424,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(114,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
<td class="num">(119,632)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">1,633,511<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,178,773<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
<td class="num">(1,543,683)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,717,575<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,147,925<span></span>
</td>
<td class="num">(6,316)<span></span>
</td>
<td class="num">(1,424,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (322,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">1,488,711<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,241,160<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="num">(1,752,554)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">1,633,511<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,178,773<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
<td class="num">(1,543,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">7,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(107,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
<td class="num">(110,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 1,557,155<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,210,398<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="num">(1,653,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 5,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(99,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(621)<span></span>
</td>
<td class="num">(98,585)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">1,488,711<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,241,160<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="num">(1,752,554)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">1,405,391<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(144,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,872)<span></span>
</td>
<td class="num">(138,651)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">1,296,426<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,306,655<span></span>
</td>
<td class="num">(6,877)<span></span>
</td>
<td class="num">(2,003,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,405,391<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">2,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (327,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">1,170,981<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,363,998<span></span>
</td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(2,191,955)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">1,296,426<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,306,655<span></span>
</td>
<td class="num">(6,877)<span></span>
</td>
<td class="num">(2,003,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">7,826<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(72,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,592<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 1,256,240<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,338,876<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="num">(2,083,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(110,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,795)<span></span>
</td>
<td class="num">(108,586)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 1,170,981<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 3,363,998<span></span>
</td>
<td class="num">$ (1,080)<span></span>
</td>
<td class="num">$ (2,191,955)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525173736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (327,237,000)<span></span>
</td>
<td class="num">$ (328,503,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(28,001,000)<span></span>
</td>
<td class="num">(27,585,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">22,084,000<span></span>
</td>
<td class="nump">17,853,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">72,274,000<span></span>
</td>
<td class="nump">74,787,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">10,937,000<span></span>
</td>
<td class="nump">9,582,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram', window );">Impairment of advance payments to contract manufacturers and equipment for terminated program</a></td>
<td class="nump">20,351,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Accretion of premiums (discounts), net and other non-cash transactions</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="num">(9,147,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6,123,000)<span></span>
</td>
<td class="nump">2,008,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(227,000)<span></span>
</td>
<td class="num">(2,339,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="nump">4,316,000<span></span>
</td>
<td class="nump">11,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(5,588,000)<span></span>
</td>
<td class="nump">18,127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,337,000)<span></span>
</td>
<td class="nump">16,109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">20,478,000<span></span>
</td>
<td class="nump">13,164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">9,340,000<span></span>
</td>
<td class="nump">10,401,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(5,070,000)<span></span>
</td>
<td class="num">(9,465,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(214,653,000)<span></span>
</td>
<td class="num">(203,458,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(791,445,000)<span></span>
</td>
<td class="num">(1,028,883,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">1,158,722,000<span></span>
</td>
<td class="nump">1,122,902,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">41,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(5,504,000)<span></span>
</td>
<td class="num">(22,614,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">403,473,000<span></span>
</td>
<td class="nump">71,405,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">20,651,000<span></span>
</td>
<td class="nump">18,449,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(229,349,000)<span></span>
</td>
<td class="nump">18,449,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="num">(77,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(40,520,000)<span></span>
</td>
<td class="num">(113,681,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">96,363,000<span></span>
</td>
<td class="nump">194,905,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">55,843,000<span></span>
</td>
<td class="nump">81,224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">9,742,000<span></span>
</td>
<td class="nump">14,299,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 2,133,000<span></span>
</td>
<td class="nump">$ 56,025,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Equipment From Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentFromTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697519685784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At September&#160;30, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8&#160;million, as described further below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a">ASU 2019-12</span> - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss). The tax effect in continuing operations was a tax benefit of $1.3&#160;million for the nine months ended September&#160;30, 2019, and was a tax expense of $0.2&#160;million for the three months ended September&#160;30, 2019.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of September&#160;30, 2020, our accounts receivable includes $13.0&#160;million under customer contracts from our collaboration partners and $29.9 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2020 and 2019. We have not recorded a reserve for credit losses at September&#160;30, 2020 or December 31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would have been due and payable.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and other Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program in the three months ended September&#160;30, 2020. As of September 30, 2020, we have substantially completed our wind-down and do not expect additional costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security (CARES) Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. We do not expect that the CARES Act will have a material effect on our results of operations or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521037160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,843&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,363&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,715&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,721&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of September&#160;30, 2020 and December&#160;31, 2019, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_6487ad2f-0a2c-49f7-a09d-7a3056d0d81a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF80My9mcmFnOjJhZGUxMWU3YjUzZDQ3MDhhZTY2Y2NiNDIzMDVlMDUyL3RleHRyZWdpb246MmFkZTExZTdiNTNkNDcwOGFlNjZjY2I0MjMwNWUwNTJfNTQw_fdc76534-bf62-4bbf-b64b-4b7ddc523e0b">one</span></span> and two years.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, we sold no available-for-sale securities. During the nine months ended September&#160;30, 2020, we sold available-for-sale securities totaling $41.7&#160;million. Gross realized gains and losses on those sales were not significant. During the three and nine months ended September 30, 2019, we did not sell any of our available-for-sale securities. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $5.4&#160;million and $6.5&#160;million at September&#160;30, 2020 and December 31, 2019, respectively, in other current assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507,655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2019, our gross unrealized gains and losses totaled $2.1&#160;million and $0.3&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697519610552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,892&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521037160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">Liability Related to Sale of Future Royalties<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately $4.4 million in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the effective interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. During the nine months ended September&#160;30, 2020 and 2019, we recognized $28.0 million and $27.6 million, respectively, in non-cash royalty revenue from net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we recorded $22.1 million and $17.9 million, respectively, of related non-cash interest expense.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. From inception through 2017, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately 17%. We have periodically adjusted our imputed interest rate over the years since inception as actual and forecasted sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have increased and such increases have been sustained. During the three months ended September&#160;30, 2020, primarily as a result of increases in the forecasted sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our estimate of the effective annual interest rate over the life of the agreement increased to 20.2%, which results in a prospective interest rate of 48%. Since the proceeds from this agreement are fixed, any future changes in royalty revenue results in an equal corresponding change in imputed interest expense, which would result in changes in the prospective interest rate we use to amortize the liability.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations (often with time limitations) that are customary for a transaction of this nature. For example, we provided representations and warranties concerning intellectual property matters in the Purchase and Sale Agreement; however, the time limitation we have to indemnify </span></div>RPI with respect to any breach of these intellectual property-based representations and warranties has passed. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697519699832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019. Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On July 13, 2020, the U.S. District Court in California Court granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, stating (among other things) that the amended complaint failed &#8220;to adequately allege that any of the statements &#8230; identified by Plaintiffs were false or misleading.&#8221;  Following the motion to dismiss, on August 10, 2020, the class action plaintiffs filed a second consolidated class action complaint, and the matter remains pending.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either September 30, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 4. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, </span></div>we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Condensed Consolidated Balance Sheets at either September&#160;30, 2020 or December&#160;31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697520964568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:31.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug or Drug Candidate</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen, Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, we recognized $22.7&#160;million and $109.4&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as $50.0&#160;million in BMS Collaboration milestones received in the nine months ended September 30, 2020, as further described below.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"/><td style="width:84.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of previously unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7 billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three and nine months ended September&#160;30, 2020, except as described below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, BMS paid us a non-refundable upfront cash payment of $1.0 billion. We are eligible to receive additional cash payments up to a total of approximately $1.455 billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones, and up to a total of $350.0 million upon the achievement of certain sales milestones. In April 2018, BMS also purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we aggregated the total consideration of $1.85 billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2 million in stockholders&#8217; equity. We allocated the remaining $1,059.8 million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $1.8 billion to be variable consideration. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, we updated the transaction price by $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial. During the three months ended June 30, 2020, we updated the transaction price by $25.0&#160;million for the milestone for the first patient, first visit in the registrational adjuvant melanoma trial because we concluded that a reversal of the milestone was not probable. Since we had already completed our sole performance obligation of delivery of the licenses, we recognized $50.0&#160;million in license, collaboration and other revenue during the nine months ended September&#160;30, 2020. We continue to exclude the other milestones from the transaction price as of September&#160;30, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the three and nine months ended September&#160;30, 2020, we recorded $29.2&#160;million and $93.8&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. During the three and nine months ended September&#160;30, 2019, we recorded $28.3&#160;million and $81.4&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.&#160;As of September&#160;30, 2020, we have recorded an unbilled receivable of $29.9 million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0 million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and are responsible for certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through September&#160;30, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $150.0 million received in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0 million upfront payment as $125.9 million to the license, $17.6 million to our portion of the Phase 1 clinical development and $6.5 million to the drug product development.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the $125.9 million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of September&#160;30, 2020, we have completed our performance obligations and we have no deferred revenue related to this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Inc. / Takeda Pharmaceutical Company Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Hemophilia</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Hemophilia A program includes ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $10.0 million development milestone, which we received in March 2018. During 2018, we earned an additional $10.0 million milestone for annual sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $12.0 million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of September&#160;30, 2020, our deferred revenue from this arrangement is not significant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.: Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. As of September&#160;30, 2020, we have deferred revenue of approximately $0.4 million related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2014 and December 2014, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> /MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the US and EU, respectively. As of September&#160;30, 2020, we have received a total of $385.0 million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving 60% and Nektar receiving 40%. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of September&#160;30, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma and Pfizer, Inc., under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of September&#160;30, 2020, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521728088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we accounted for as a liability award. Upon issuance of the award in the three months ended June 30, 2020, we reclassified the award into equity.</span></div><div style="margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2020, the Stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 10,000,000 shares, and an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by 1,000,000 shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521043208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three and nine months ended September&#160;30, 2020 and 2019, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697520983848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a">ASU 2019-12</span> - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss). The tax effect in continuing operations was a tax benefit of $1.3&#160;million for the nine months ended September&#160;30, 2019, and was a tax expense of $0.2&#160;million for the three months ended September&#160;30, 2019.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of September&#160;30, 2020, our accounts receivable includes $13.0&#160;million under customer contracts from our collaboration partners and $29.9 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2020 and 2019. We have not recorded a reserve for credit losses at September&#160;30, 2020 or December 31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and other Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program in the three months ended September&#160;30, 2020. As of September 30, 2020, we have substantially completed our wind-down and do not expect additional costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697607140872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,843&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,363&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,715&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,721&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507,655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697519721272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,892&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521191096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:31.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug or Drug Candidate</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen, Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Deferred Revenue Balance from Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"/><td style="width:84.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of previously unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697519611112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Compensation, Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525197768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">During the three and nine months ended September&#160;30, 2020 and 2019, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525592904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,153,721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,603,981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201911Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax benefit elimination in continuing operations and tax provision in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_A775PercentSeniorSecuredNotesDueOctober2020Member', window );">7.75% Senior Secured Notes Due October 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RepaymentsOfLongTermDebtIncludingInterest', window );">Repayments of long term debt, including interest</a></td>
<td class="nump">$ 254,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior notes</a></td>
<td class="nump">250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidCapitalized', window );">Cash paid for interest</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_WriteOffOfPrepayment', window );">Write off of prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitment, remaining minimum amount committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember', window );">Collaboration Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RepaymentsOfLongTermDebtIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Debt, Including Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RepaymentsOfLongTermDebtIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_WriteOffOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Prepayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_WriteOffOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest capitalized, classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_A775PercentSeniorSecuredNotesDueOctober2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_A775PercentSeniorSecuredNotesDueOctober2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NKTR181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NKTR181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521952744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,843<span></span>
</td>
<td class="nump">$ 96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">900,163<span></span>
</td>
<td class="nump">1,228,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">197,715<span></span>
</td>
<td class="nump">279,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 1,153,721<span></span>
</td>
<td class="nump">$ 1,603,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697524840504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityTerm', window );">Weighted average maturity term for debt securities investment (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Available-for-sale securities, sold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521789720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 6,368<span></span>
</td>
<td class="nump">5,829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">1,153,721<span></span>
</td>
<td class="nump">1,603,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,087,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">1,089,627<span></span>
</td>
<td class="nump">1,507,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">831,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">833,715<span></span>
</td>
<td class="nump">1,132,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Corporate commercial paper | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">245,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">245,913<span></span>
</td>
<td class="nump">375,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. government agencies | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">9,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value Hierarchy Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">48,931<span></span>
</td>
<td class="nump">83,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 8,795<span></span>
</td>
<td class="nump">$ 6,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697517021368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,387<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">8,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 12,892<span></span>
</td>
<td class="nump">$ 12,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697524824312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">70 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2012</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,001<span></span>
</td>
<td class="nump">$ 27,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,425)<span></span>
</td>
<td class="num">$ (5,813)<span></span>
</td>
<td class="num">$ (22,084)<span></span>
</td>
<td class="num">$ (17,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Purchase and Sale Agreement with RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annual interest rate over life of royalty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProspectiveInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prospective interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProspectiveInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521008680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525859976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 3,121<span></span>
</td>
<td class="nump">$ 55,421<span></span>
</td>
<td class="nump">$ 9,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | Neulasta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697506862360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">76 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Aug. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized in period related to performance in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,802,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,033,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,453,000<span></span>
</td>
<td class="nump">$ 80,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesMilestoneRevenue', window );">Sales milestone, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones', window );">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones', window );">Eligible additional cash payments receivable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember', window );">Nektar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments', window );">Percentage of upfront payment, market access milestones, royalties and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Bempegaldesleukin | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,800,000<span></span>
</td>
<td class="nump">$ 81,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AggregateConsiderationReceivedFromAgreements', window );">Total consideration received under agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedFairValueOfShares', window );">Estimated fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RemainingAmountAllocatedToTransactionPrice', window );">Remaining amount allocated to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones', window );">Potential future development, regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Phase 1 Clinical Development | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Drug Product Development | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyMember', window );">Eli Lilly | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement', window );">Received under right to sublicense agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia | Annual Sales Level Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB | MOVANTIK and MOVENTIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB | AstraZeneca-Kirin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner', window );">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AggregateConsiderationReceivedFromAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration received from agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AggregateConsiderationReceivedFromAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible additional cash payments receivable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments received under rights to sublicense agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentsReceivedUnderRightsToSublicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development regulatory and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RemainingAmountAllocatedToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount allocated to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RemainingAmountAllocatedToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SalesMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar358LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar358LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525112152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Beginning balance</a></td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of previously unearned revenue</a></td>
<td class="num">(5,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Ending balance</a></td>
<td class="nump">$ 3,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697521944184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 23,667<span></span>
</td>
<td class="nump">$ 24,880<span></span>
</td>
<td class="nump">$ 72,274<span></span>
</td>
<td class="nump">$ 74,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">14,212<span></span>
</td>
<td class="nump">15,680<span></span>
</td>
<td class="nump">43,826<span></span>
</td>
<td class="nump">47,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">8,081<span></span>
</td>
<td class="nump">25,255<span></span>
</td>
<td class="nump">24,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697525883544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 17, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584,000<span></span>
</td>
<td class="nump">820,000<span></span>
</td>
<td class="nump">2,889,000<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_Restated2017PerformanceIncentivePlanMember', window );">Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CommonStockAdditionalSharesAuthorized', window );">Common stock, additional shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="nump">282,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.64<span></span>
</td>
<td class="nump">$ 13.43<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 15.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,000<span></span>
</td>
<td class="nump">316,000<span></span>
</td>
<td class="nump">1,213,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, RSUs (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.56<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="nump">$ 21.04<span></span>
</td>
<td class="nump">$ 31.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CommonStockAdditionalSharesAuthorized', window );">Common stock, additional shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CommonStockAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CommonStockAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_Restated2017PerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_Restated2017PerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140697620808072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">16,575<span></span>
</td>
<td class="nump">17,163<span></span>
</td>
<td class="nump">17,499<span></span>
</td>
<td class="nump">18,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M8*[);&,O.U%BF^Z-K812(DP//<Y<+O4#<'\MA#J=Z!?DVZO#_P!02P,$%
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MR*300J,UWVO>/$(TO)ZI&J-[7AX?.D]*CZ_0)N@< T&3<[=,@&5AP)JE)MJ
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MU@'7%U*:-\.>BO4E:/P/4$L#!!0    ( &&E95$;KUXISP8  %,=   8
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULI5G;;MLX$/T5PMB'%DAB7D1=@B1
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M-DK[\X?#-YPC4L1";S?%C-C.@1WUBK]0KTZS]54O7J_1G4?=P!2)09NP1=Q
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M ?Q_IT$(^R]^@>&>\^I?4$L#!!0    ( &&E95%\H7\DN"$  /EI   8
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MB7L+%]0B\]>LD">C117BZGAI7/:&6R*V;%H(+K)H<!AA%7,.SVDFCK5FWCD
MGZB952;YY'.=[Y%&TU*#[;<^!H=^$WYW[:E(8A)1J]XKEQ)8P8K /D$*VR.
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M8SJ 'S6!- WY6QN:?>54!+&"_2M[#F_]8&!@WIT_\J1QT:G=U(A%-V?J[)]
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MBP?H>]P_[W_!!.&O/7WWWU!+ P04    " !AI651GD^4$-L&   W$0  &
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MWVF+<&R[QK']>M-/VD4!T:)D^-D\"I>HM%(8<2'[P6BD'L-9H>X%VR+W727
M:Y8JY4\HU1P&44B4&T&@M^2VEAN9\]J%#_-!!KZ,GLH ](4L.I,8M-#<#V7Y
M0J)^A;=<H]4@/@K4YT):/WB+#C[T&I$36B8+U-;C]A.^$@BN".G0&=& $SK'
M>6Y:48RZ&^T#-@$4 "YE7G;IA,BS-)P/R?11/UN$Z7'C)'4]TI#PU A_XU![
M8E&F@=Q@HAL#S*!-*YRO!T&\ULAH31'B"2'+PM/F%5>\SL'>--U[9J"P0+A2
M4Z+^/X[JJ%P\).JO(N01AU]6 .$;[)HJUC7=A_K0=C_XMGNP_:[KP9&AT>.U
M-@B-^ O-([JF72,MEL4@U!5@I,L43W&0S(EBGP/4"_\F\>3M"3B)@V@5CVSE
MNJJ$R27XO.$-PHE9/$^#9;9@41*QY]'\A=_(HH0ERS28+Q/V\UK)K6\HST$?
MPIN0;358JZY\Y;:BSBF=,<N"+%NQB'W[S2J.XM=^G1U6EP\;?EPF CQ;+3'
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MYVJ9TND(U>G(WM/H?[,I/FMQ14O;H#A%LN 4SY.Q6),@[<E"6&F(2W'3V+1
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M-1$_F#S'<?WM1XD,82*(CSX+(D^?7.MT@ER:%86:0G<E:R/EI(MGCB;B5^J
M@)X5#*X8Z52Z0M36I$29XX0=S)/%9(:.5Y;<O#%]Q!Z4)N+< 4OK6<P7R@58
M F^53IO@@JRA^T&AB1/"/%A,%KUFI05*7#L9IT1JG >DD5H2Y2$K8[WZ3XQ#
MA4( 6^FAYEP*<T_1,=P,ZC.D.:?HRK.% +=+7YAFU3-8R+)DP9ZT[BEKN4Q[
M,NX2BDT\0A]!9TW*\0  "54.LZHS8?3*,/Y[V6"6I0(XR(J#:-\^V/**--GP
MJ(W4#1P,J4_1]I5N**"?IJ8!J5H0AV?9,4OWA),=-8S-V!"L/.( D.H9TN8
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M5SNV*5".(9XL>2#"8 '3AF#BFJRO>=MPC]O4YI*ZME(OR] L,W5OWOYC:[/
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M-9@&!@(C@UYI7ERX G8+EHXT#$"9A6$[4 4[@+" &=#@-W>X)B*Z@%$Z>+H
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M\01?P 4#]BR_@'T#J7"RK (%O=\53C"U",*!K7VM:G10Q0VB4R#XMZ[ +V;
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M$JZII$WP[G@ OT0,(="P$U5GW' ,XC\/$/_Y4>S]R1$I;R'P:-"+3J'WAXU
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M[;0^L9H=JVS)3!:L@8@*C=9RZ >;Y1)<C!369K5.N9LN!QR2$F;$K, HVL#
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M;0?[OUKW[B[/2-3(D;BD"AKS^0EZG/ ^V>IJ-+U4BU!UFHOVJ#F:F>!;C1-
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M+:^<TG/Y/^K:]?:%:7DI)@$VKQ%Z*X('//(QGOH!CSG (P<\I5,4#W@(<"V
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M#.@R^@&)%,YFJ5-Z-(NC_=HJG24S4N/U^NMWX_0T@HBE)"3.(IB3T/]]X&=
MI"DV2U([9K,P'->A91&Q&4EMO2_MV+"!JJ0 OPVDAN<B[1M!N219#)DM%<F4
MJD;;)WU1FL'!+=:B*MU=K0EQZ,QXH4UOI]^!\_$6_&X^_DM\$JJL*72#6W(-
M9W-2I!KOYW%A9._NQ(TT=,.Z:46_-*BL 7W?2FF>%C; ]).T^@=02P,$%
M  @ 8:5E40#-V72V @  "P8  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&ULC53?;]HP$/Y73GEJ)=:$ &U!@ 1MI^VA$RKM]C#MP2078M4_,MLI[7^_
MLQ-2IK6L#Y"S???=]YU]-]UI\VA+1 ?/4B@[BTKGJDD<VZQ$R>R9KE#12:&-
M9(Z69AO;RB#+0Y 4<9HDY[%D7$7S:=A;F?E4UTYPA2L#MI:2F9<E"KV;1?UH
MOW''MZ7S&_%\6K$MKM$]5"M#J[A#R;E$9;E68+"818O^9#GT_L'A.\>=/;#!
M*]EH_>@77_-9E'A"*#!S'H'1YPFO4 @/1#1^MYA1E](''MI[],]!.VG9,(M7
M6OS@N2MGT64$.1:L%NY.[[Y@JV?D\3(M;/B'7>N;1)#5UFG9!A,#R57S9<]M
M'3X2D+8!:>#=) HLKYEC\ZG1.S#>F]"\$:2&:"+'E;^4M3-TRBG.S6^845QM
M+:S0P+ID!N'DGFT$VM-I["B!=XNS%FS9@*7O@(WA5BM76KA1.>9_Q\=$K&.7
M[MDMTZ. :ZS.8)#T($W2Y C>H%,["'B#CZO]N=A89^AQ_#J"/^SPAP%_^!Y?
MZIF\%@BZ@(5R/.>B]J\.UIC5ACN.5)OG3-14'BB,EG"E954[%EXH!?U+\*U;
M.$K"M_'$5BS#641]:M$\832_IO1J"ZY$^AE$8"H'2H4@FRM#?V7$LW(H-Y1\
M7_7@F";]<0\J[9!$,2%>H%-F7Y5EFGK5.H(A);O0#YA_8D]HJ+WI5%(JL%Z4
MA9K2&?'B.=&HL(ZR>)O>>_8(NO+UL"'UW?J!# N%%C1 +)QP10IT;>G0GD[@
M/J@Y(N+;1T1Z@0?6ZC]*^^>]T<4(^A>]_OG ?X;C,?0O>TD_A;>>47S0H!+-
M-HPA7[!:N:97N]UNTBV:!G]U;\;D+3-;3K416%!H<G8QBL THZ=9.%V%=M]H
M1\,CF"5-:S3>@<X+3>+:A4_0S?_Y'U!+ P04    " !AI651YPL[IA,%  #G
M$P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6S%6&UOVS80_BN$L0$=
MD,8B;?FE< PD<;L4;1,C;M</13_0TMDF*HD:2=GIL!^_HZ1(=B0S+C @7Q))
MYCWW'.^Y.TJ3G50_] ; D(<X2O1%9V-,^J;;U<$&8J[/90H)_K*2*N8&;]6Z
MJU,%/,R-XJC+/&_0C;E(.M-)_FRNIA.9F4@D,%=$9W',U<\KB.3NHD,[CP_N
MQ7IC[(/N=)+R-2S ?$GG"N^Z%4HH8DBTD E1L+KH7-(W-\RW!OF*OP3L]-XU
ML:$LI?QA;]Z'%QW/,H(( F,A./[;PC5$D45"'G^7H)W*IS7<OWY$?Y<'C\$L
MN89K&7T5H=E<=$8=$L**9Y&YE[L;* /*"08RTOE?LBO7>AT29-K(N#1&!K%(
MBO_\H=R(/0-&CQBPTH"=:M K#7I/#49'#/JE0?]4#WYIX#\QZ ^.& Q*@\&I
M'H:EP?!4@U%I,,JS6Z0CS^6,&SZ=*+DCRJY&-'N1"R*WQA2*Q&IW813^*M#.
M3._4FB?B'UX(*0G)HA QD2NR$.M$K$3 $T,N@T!FB1')FLQE) (!FKR:@>$B
M^F/2-<C$XG6#TNM5X94=\7J9JG-">V>$><S[LIB15[^UH5R[41:0GI.>9U'H
M^#C*[&24BHN&-=:G:0%[^[]0>N=&F4& */0YE#_=*)^X>D1Q;?*-&^4N,.?$
M\W,N?BM*%R57Z8Y5NF,Y;.\4W5WNZ>[N>=U]^XA@Y+V!6']W4.E55'HYE?X1
M*M=<;W+IBV0+VMC$:[S&*E,_4.#+"(B&(%/"H/,V?17P@QS>SHKME%*_-V34
M\[Q)=[N?]Y:E Z\W'ATL/8BB7T71=T:QMU$+@]%P%6KR)0VY ?+M[8.QX\:&
M\E%H\[U-DF[X3+]><YZ^J=U47@HG5JJ4?H)X"<J1%+\*QW?Z^\P?R!(26 E#
M(!+8^0JI8%X":?UG-E(<X2I_KO,$&C1*E=P*72Z59@,*#6*<ZQN[ UO QW@/
MY%4DM6YM.GXC1W@0:*3R;7/9:]H[7'@0^:"*?.",_#:S6VC[[S+3^)O6I&Q'
MFOQ+CG>F60'K[VNKG<FP8C(\15(:SR@!B*VMA#:_P\9&]-F8^4WQ-Q?V!B./
M'=VQ4<5SY.1Y#RG_66P0[IJ&1$A%$FG:JW74V*:<:TN&1PV^1XB.*Z)C)]'A
M^=#_G2P*@@O;4R DMY8HF65 L-5*FWK;KS'5Y;K;9B 'SJE7CWKOI7LNW3MW
MT%](6B31F0$5X[ES:<YLD499:!F(!!]C6VX]9-!FJ?K]D:,(:3V?*'/RFR$/
M=*Z-RBS+,[+B 1 >VYUIG:*LA<M371URJ0<4=4^H4@FZ5$PN[;-J9PBVP+;"
MO'D&-5>C*Y?UZ*'NX?!+!7A5@KDK\)!)/36H>VSDLSSE(B3X6N?63K-_NY53
M]V_Z3 /_\/F>O"9T1%V;6S=A.GSQJJT[+76WVJ]X"@),\LHF&H=JF??6PVFS
M?=+QT+7#=1NE[CXZSU2PP1=6.]EC88KZ5&!?U6WX>%@0<1:7Q5HN,A"VLARW
ME*WO8,GJ=LL\MQ9E%/&E+ XH9,Z529Q'(U;W3D9?6A)L[R#O;I0GGA)*E(/C
M2:]M[+YK6\E<I<GJ1LK<+>_JTX(<IN5RK0":$C[$KQLAZ[]X8NI>R-R]\-3$
MM)QWQ^/6Q+2L[+?V[>[>!PG["0Q?1=<X2TD$*S3U</!TB"J^*A4W1J;Y-XJE
M-$;&^>4&> C*+L#?5Q*G27EC/WM4W_:F_P%02P,$%     @ 8:5E40U]'%F[
M @  $@<  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE55=;]HP%/TK
M5K2'5FJ;+Q*@ J06UJW2)E6EW1ZF/9AP(58=F]H.=/]^UTX(E*]U+XD_[CD^
MY]J^[JVD>M$Y@"%O!1>Z[^7&+*Y]7V<Y%%1?R04(G)E)55"#737W]4(!G3I0
MP?TH"%*_H$QX@YX;>U"#GBP-9P(>%-%E45#UYQ:X7/6]T%L//+)Y;NR /^@M
MZ!S&8)X7#PI[?L,R904(S:0@"F9][R:\'J8VW@7\8+#26VUBG4RD?+&=^VG?
M"ZP@X) 9RT#QMX0A<&Z)4,9KS>DU2UK@=GO-?N>\HY<)U3"4_">;FKSO=3PR
MA1DMN7F4JZ]0^TDL7R:Y=E^RJF,#CV2E-K*HP:B@8*+ZT[<Z#UN L'4$$-6
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M90-P?B:E67=L76R>P<%?4$L#!!0    ( &&E95'I6(O-:P,  !@-   9
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MA0?]#%4%)UT\V&4YAI<++99V;)P*C4.H?5S@IPM((X#O9T+HIX514'\,#7X
M4$L#!!0    ( &&E95&C@W+.[P0  $@7   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;,U8RV[;.!3]%<+HH@6:2"2M5^$82!RT#9#,!''360QF0<NT
M3402/21M-\5\_)"R(CJ6Q,1!%M[8>MS'N9<\1R0'&RX>Y()2!7[E62'/>@NE
MEE\\3Z8+FA-YRI>TT&]F7.1$Z5LQ]^124#(MG?+,0[X?>CEA16\X*)_=BN&
MKU3&"GHK@%SE.1&/%S3CF[,>[#T]N&/SA3(/O.%@2>9T3-7]\E;H.Z^.,F4Y
M+23C!1!T=M8[AU]&.#0.I<5/1C=RYQJ84B:</YB;J^E9SS>(:$9394(0_;>F
M(YIE)I+&\6\5M%?G-(Z[UT_1OY;%ZV(F1-(1S_YB4[4XZ\4],*4SLLK4'=]\
MIU5!@8F7\DR6OV!3V?H]D*ZDXGGEK!'DK-C^DU]5(W8<8+_# 54.Z+4.N'+
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M3T6C&>6PE$@U547DXS4P<9@%4?#T847WI;8?POFT)GM8@_Y2+Z49A=[+EE;
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M4$L! A0#%     @ 8:5E40=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !AI651Z7U( .X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !AI651F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( &&E95&NY?-:/P4  &H5   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !AI651 %B\0CX'  "K'0  &               @(&"#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 8:5E47*CB#S+ @  $ D  !@
M             ("!]A0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( &&E95$;KUXISP8  %,=   8              " @?<7  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !AI651'K^X<G(#   8
M"P  &               @('\'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 8:5E495?RW.]"   B34  !@              ("!I"(
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &&E95&-]A_Y
M/ <  /,<   8              " @9<K  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !AI651?*%_)+@A  #Y:0  &
M@($),P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 8:5E
M49Y/E!#;!@  -Q$  !@              ("!]U0  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( &&E95$C;<=9: (  " %   9
M      " @0A<  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 8:5E4:U3O#@9!P  9A(  !D              ("!IUX  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !AI651;LR9X= )   3&0
M&0              @('W90  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( &&E95'5<8CK1QD  "92   9              " @?YO  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 8:5E43@YQQ/1
M!   80L  !D              ("!?(D  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !AI651.\5RE7P#  "K"   &0
M@(&$C@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &&E
M95&HUHVYOR    AK   9              " @3>2  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 8:5E4:?&>:/\ P  E0D  !D
M         ("!+;,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !AI651>=SZ"FX"   ?!0  &0              @(%@MP  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &&E95%_?P]"R0,   4)
M   9              " @06Z  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 8:5E4?X_7DKZ P  , D  !D              ("!!;X
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !AI651 ,W9
M=+8"   +!@  &0              @($VP@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( &&E95'G"SNF$P4  .<3   9
M  " @2/%  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M8:5E40U]'%F[ @  $@<  !D              ("!;<H  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !AI651Z5B+S6L#   8#0  &0
M            @(%?S0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( &&E95&C@W+.[P0  $@7   9              " @0'1  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 8:5E47%RZ'5D @
M*@8  !D              ("!)]8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !AI651]"*0]DP#   C"P  &0              @('"
MV   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &&E95$P
MD(X;&0(  ,($   9              " @47<  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 8:5E4;C>-/V* P  /0X  !D
M     ("!E=X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M" !AI651EE4WA)T+   N2P  &0              @(%6X@  >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &&E95&9/I-,D (  .D%   9
M              " @2KN  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!
M A0#%     @ 8:5E41.\B-:[ P  "0\  !D              ("!\?   'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !AI651T" '0>0#
M  "0#P  &0              @('C]   >&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;%!+ 0(4 Q0    ( &&E95%8 0$?=P(  *<&   9              "
M@?[X  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 8:5E
M40GT/8$T @  W0D   T              ( !K/L  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !AI651EXJ[',     3 @  "P              @ $+_@
M7W)E;',O+G)E;'-02P$"% ,4    " !AI651^SEJCC8#  !1%P  #P
M        @ 'T_@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8:5E48S?
M7ZUN 0  W10  !H              ( !5P(! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 8:5E40970G>/ 0  <!4  !,
M     ( !_0,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "H *@!="P
&O04!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>201</ContextCount>
  <ElementCount>281</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/InventoryTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Liability Related to Sale of Future Royalties (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail</Role>
      <ShortName>Liability Related to Sale of Future Royalties (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesDetail</Role>
      <ShortName>Commitments and Contingencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CommitmentsandContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail</Role>
      <ShortName>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Stock-Based Compensation - Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nktr-20200930.htm">nktr-20200930.htm</File>
    <File>nktr-20200930.xsd</File>
    <File>nktr-20200930_cal.xml</File>
    <File>nktr-20200930_def.xml</File>
    <File>nktr-20200930_lab.xml</File>
    <File>nktr-20200930_pre.xml</File>
    <File>nktr2020-09x30xexx311.htm</File>
    <File>nktr2020-09x30xexx312.htm</File>
    <File>nktr2020-09x30xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 201,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 362,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://www.nektar.com/20200930": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 48,
   "keyStandard": 233,
   "memberCustom": 30,
   "memberStandard": 25,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Liability Related to Sale of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties",
     "shortName": "Liability Related to Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Net Loss Per Share",
     "role": "http://www.nektar.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - License and Collaboration Agreements (Tables)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:AdvancePaymentsToContractManufacturers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.nektar.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i4f14aba4530a48d794a8a42ec8a4e466_D20190701-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i0cb27177fc6d4020b6959a80b73dd02f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i0cb27177fc6d4020b6959a80b73dd02f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory (Details)",
     "role": "http://www.nektar.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Liability Related to Sale of Future Royalties (Detail)",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail",
     "shortName": "Liability Related to Sale of Future Royalties (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "3",
      "lang": "en-US",
      "name": "nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "ic8dbe95429a94b1c9fd1c219421ebb89_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Commitments and Contingencies (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
     "shortName": "Commitments and Contingencies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "ic8dbe95429a94b1c9fd1c219421ebb89_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i6de4d4cf296147b9b48d391257b6a758_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "License and Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i0cb27177fc6d4020b6959a80b73dd02f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail",
     "shortName": "License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "ie0d135950a41412bbe0141268927497b_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Stock-Based Compensation - Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
     "shortName": "Stock-Based Compensation - Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i8432c50c56094a11aa02e5f29d960026_D20200617-20200617",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nktr:CommonStockAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Net Loss Per Share (Detail)",
     "role": "http://www.nektar.com/role/NetLossPerShareDetail",
     "shortName": "Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "i157373b14ace4588bdde4627501185ae_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "ibb3bc1da93a7468b8ce9fa44f16fd7d9_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "ia970b1a5f74e4c1fba7646c288d7230c_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200930.htm",
      "contextRef": "if1cd28c80d78486b9b531cea54dd92e4_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_A775PercentSeniorSecuredNotesDueOctober2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "7.75 percent senior secured notes due October 2020",
        "label": "7.75 Percent Senior Secured Notes Due October 2020 [Member]",
        "terseLabel": "7.75% Senior Secured Notes Due October 2020"
       }
      }
     },
     "localname": "A775PercentSeniorSecuredNotesDueOctober2020Member",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedContractManufacturingExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued contract manufacturing expense current.",
        "label": "Accrued Contract Manufacturing Expense Current",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingExpenseCurrent",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AdvancePaymentsToContractManufacturers": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of advance payments to contract manufacturers, net of amortization.",
        "label": "Advance Payments To Contract Manufacturers",
        "terseLabel": "Advance payments to contract manufacturers"
       }
      }
     },
     "localname": "AdvancePaymentsToContractManufacturers",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AggregateConsiderationReceivedFromAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate consideration received from agreements.",
        "label": "Aggregate Consideration Received From Agreements",
        "terseLabel": "Total consideration received under agreements"
       }
      }
     },
     "localname": "AggregateConsiderationReceivedFromAgreements",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen, Inc."
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation.",
        "label": "Amount Of Transaction Price Allocated To Performance Obligation",
        "terseLabel": "Amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "AmountOfTransactionPriceAllocatedToPerformanceObligation",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AnnualSalesLevelMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual sales level milestone.",
        "label": "Annual Sales Level Milestone [Member]",
        "terseLabel": "Annual Sales Level Milestone"
       }
      }
     },
     "localname": "AnnualSalesLevelMilestoneMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AstraZenecaAbMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca Ab [Member]",
        "terseLabel": "AstraZeneca AB"
       }
      }
     },
     "localname": "AstraZenecaAbMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AstraZenecaAgreementWithKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca agreement with Kirin.",
        "label": "Astra Zeneca Agreement With Kirin [Member]",
        "terseLabel": "AstraZeneca-Kirin"
       }
      }
     },
     "localname": "AstraZenecaAgreementWithKirinMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BaxaltaIncorporatedOrTakedaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Baxalta Incorporated or takeda PLC.",
        "label": "Baxalta Incorporated Or Takeda P L C [Member]",
        "terseLabel": "Baxalta Incorporated/Takeda"
       }
      }
     },
     "localname": "BaxaltaIncorporatedOrTakedaPLCMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborationPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration partner.",
        "label": "Collaboration Partner [Member]",
        "terseLabel": "Collaboration Partner"
       }
      }
     },
     "localname": "CollaborationPartnerMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.",
        "label": "Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones",
        "terseLabel": "Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CommonStockAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Additional Shares Authorized",
        "label": "Common Stock, Additional Shares Authorized",
        "terseLabel": "Common stock, additional shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalSharesAuthorized",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Liability",
        "label": "Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_DebtInvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt investment maturity date description.",
        "label": "Debt Investment Maturity Term",
        "terseLabel": "Weighted average maturity term for debt securities investment (or less)"
       }
      }
     },
     "localname": "DebtInvestmentMaturityTerm",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DebtInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt investment maximum maturity period.",
        "label": "Debt Investment Maximum Maturity Period",
        "terseLabel": "Maximum maturity term for debt securities investment"
       }
      }
     },
     "localname": "DebtInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DrugProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Drug product development.",
        "label": "Drug Product Development [Member]",
        "terseLabel": "Drug Product Development"
       }
      }
     },
     "localname": "DrugProductDevelopmentMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible additional cash payments receivable upon achievement of certain sales milestones.",
        "label": "Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Eligible additional cash payments receivable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated annual interest rate over life of royalty liability.",
        "label": "Estimated Annual Interest Rate Over Life Of Royalty Liability",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_EstimatedFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated fair value of shares.",
        "label": "Estimated Fair Value Of Shares",
        "terseLabel": "Estimated fair value of shares"
       }
      }
     },
     "localname": "EstimatedFairValueOfShares",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_HemophiliaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hemophilia.",
        "label": "Hemophilia [Member]",
        "terseLabel": "Hemophilia"
       }
      }
     },
     "localname": "HemophiliaMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment And Other",
        "label": "Impairment And Other [Member]",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentAndOtherMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment Of Equipment And Other Costs For Terminated Program",
        "label": "Impairment Of Equipment And Other Costs For Terminated Program",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfEquipmentFromTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment Of Equipment From Terminated Program",
        "label": "Impairment Of Equipment From Terminated Program",
        "terseLabel": "Impairment of advance payments to contract manufacturers and equipment for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentFromTerminatedProgram",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties Policy [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liability related to the sale of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]",
        "terseLabel": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MOVANTIKAndMOVENTIGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MOVANTIK and MOVENTIG.",
        "label": "M O V A N T I K And M O V E N T I G [Member]",
        "terseLabel": "MOVANTIK and MOVENTIG"
       }
      }
     },
     "localname": "MOVANTIKAndMOVENTIGMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NKTR181Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NKTR - 181 [Member]",
        "label": "NKTR - 181 [Member]",
        "terseLabel": "NKTR - 181"
       }
      }
     },
     "localname": "NKTR181Member",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Bempegaldesleukin"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358LicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar 358 license.",
        "label": "Nektar 358 License [Member]",
        "terseLabel": "NKTR-358 License"
       }
      }
     },
     "localname": "Nektar358LicenseMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "NKTR-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar [Member]",
        "label": "Nektar [Member]",
        "terseLabel": "Nektar"
       }
      }
     },
     "localname": "NektarMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "negatedTerseLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "terseLabel": "Non-cash interest expense on liability related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to sale of future royalties",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PaymentsReceivedUnderRightsToSublicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments received under rights to sublicense agreement.",
        "label": "Payments Received Under Rights To Sublicense Agreement",
        "terseLabel": "Received under right to sublicense agreement"
       }
      }
     },
     "localname": "PaymentsReceivedUnderRightsToSublicenseAgreement",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments",
        "terseLabel": "Percentage of upfront payment, market access milestones, royalties and sales milestones"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner",
        "terseLabel": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PhaseOneClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 1 clinical development.",
        "label": "Phase One Clinical Development [Member]",
        "terseLabel": "Phase 1 Clinical Development"
       }
      }
     },
     "localname": "PhaseOneClinicalDevelopmentMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development regulatory and sales milestones.",
        "label": "Potential Development Regulatory And Sales Milestones",
        "terseLabel": "Potential future development, regulatory and sales milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentRegulatoryAndSalesMilestones",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Global commercialization profits and losses sharing percentage"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_ProspectiveInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prospective interest rate percentage.",
        "label": "Prospective Interest Rate Percentage",
        "terseLabel": "Prospective interest rate"
       }
      }
     },
     "localname": "ProspectiveInterestRatePercentage",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and sale agreement.",
        "label": "Purchase And Sale Agreement [Member]",
        "terseLabel": "Purchase and Sale Agreement with RPI"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreementMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RemainingAmountAllocatedToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amount allocated to transaction price.",
        "label": "Remaining Amount Allocated To Transaction Price",
        "terseLabel": "Remaining amount allocated to transaction price"
       }
      }
     },
     "localname": "RemainingAmountAllocatedToTransactionPrice",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RepaymentsOfLongTermDebtIncludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Long Term Debt, Including Interest",
        "label": "Repayments Of Long Term Debt, Including Interest",
        "terseLabel": "Repayments of long term debt, including interest"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtIncludingInterest",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_Restated2017PerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restated 2017 Performance Incentive Plan",
        "label": "Restated 2017 Performance Incentive Plan [Member]",
        "terseLabel": "Performance Incentive Plan"
       }
      }
     },
     "localname": "Restated2017PerformanceIncentivePlanMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SalesMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Milestone Revenue",
        "label": "Sales Milestone Revenue",
        "terseLabel": "Sales milestone, revenue"
       }
      }
     },
     "localname": "SalesMilestoneRevenue",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_WriteOffOfPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Write Off Of Prepayment",
        "label": "Write Off Of Prepayment",
        "terseLabel": "Write off of prepayment"
       }
      }
     },
     "localname": "WriteOffOfPrepayment",
     "nsuri": "http://www.nektar.com/20200930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r284",
      "r285",
      "r290",
      "r291",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r284",
      "r285",
      "r290",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r48",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r360",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r360",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r153",
      "r216",
      "r219",
      "r327",
      "r359",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r153",
      "r216",
      "r219",
      "r327",
      "r359",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r223",
      "r232",
      "r233",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r360",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r223",
      "r232",
      "r233",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r360",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r216",
      "r220",
      "r362",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r216",
      "r220",
      "r362",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r272",
      "r273",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r20",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r53",
      "r55",
      "r56",
      "r349",
      "r371",
      "r375"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r56",
      "r57",
      "r100",
      "r101",
      "r102",
      "r289",
      "r366",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r234",
      "r236",
      "r259",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r236",
      "r247",
      "r258"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r136",
      "r145",
      "r151",
      "r167",
      "r284",
      "r290",
      "r300",
      "r330",
      "r347"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r47",
      "r96",
      "r167",
      "r284",
      "r290",
      "r300"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r163",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r160",
      "r164",
      "r174",
      "r335"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r162",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r162",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r238",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r33",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r33",
      "r91"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r91",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r301"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r278",
      "r279",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r187",
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 179,394 shares and 176,505 shares outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r70",
      "r340",
      "r356"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r124",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Deferred Revenue Balance from Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r203",
      "r204",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, Ending balance",
        "periodStartLabel": "Deferred revenue, Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r203",
      "r204",
      "r217"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r203",
      "r204",
      "r217"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Recognition of previously unearned revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized in period related to performance in prior periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r216",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [
      "r216",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r224",
      "r231",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73",
      "r327"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r331",
      "r332",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r310",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior secured notes, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r89",
      "r181"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r111",
      "r113",
      "r121",
      "r171",
      "r201",
      "r202",
      "r254",
      "r255",
      "r256",
      "r272",
      "r273",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r296",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r224",
      "r225",
      "r230",
      "r231",
      "r296",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r224",
      "r225",
      "r230",
      "r231",
      "r296",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r179",
      "r180",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r136",
      "r144",
      "r147",
      "r150",
      "r152",
      "r328",
      "r337",
      "r342",
      "r357"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r112",
      "r113",
      "r135",
      "r267",
      "r274",
      "r276",
      "r358"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r94",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r195",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r134",
      "r309",
      "r311",
      "r341"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidCapitalized": {
     "auth_ref": [
      "r80",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.",
        "label": "Interest Paid, Capitalized, Investing Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r83",
      "r86",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r177"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r44"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r45",
      "r94",
      "r120",
      "r175",
      "r176",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r177"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r177"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r96",
      "r146",
      "r167",
      "r285",
      "r290",
      "r291",
      "r300"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r96",
      "r167",
      "r300",
      "r334",
      "r351"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r96",
      "r167",
      "r285",
      "r290",
      "r291",
      "r300"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r40",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r58",
      "r61",
      "r68",
      "r90",
      "r96",
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r114",
      "r136",
      "r144",
      "r147",
      "r150",
      "r152",
      "r167",
      "r300",
      "r338",
      "r354"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r144",
      "r147",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r99",
      "r130",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r37"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r50",
      "r51",
      "r53"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r62",
      "r65",
      "r69",
      "r201",
      "r302",
      "r307",
      "r308",
      "r339",
      "r355"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r54",
      "r69",
      "r267",
      "r275",
      "r277",
      "r302",
      "r305",
      "r308",
      "r339",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax benefit elimination in continuing operations and tax provision in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Accretion of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r77",
      "r79",
      "r161"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r238",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2020 or December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r81",
      "r249"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r77",
      "r78",
      "r161"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r77",
      "r78",
      "r161"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments",
        "verboseLabel": "Available-for-sale securities, sold"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r58",
      "r61",
      "r84",
      "r96",
      "r103",
      "r112",
      "r113",
      "r136",
      "r144",
      "r147",
      "r150",
      "r152",
      "r167",
      "r283",
      "r287",
      "r288",
      "r292",
      "r293",
      "r300",
      "r342"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r182",
      "r352"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r17",
      "r333",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitment, remaining minimum amount committed"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedTerseLabel": "Repayment of senior notes",
        "terseLabel": "Repayments of senior notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r262",
      "r406"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r94",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r202",
      "r257",
      "r350",
      "r370",
      "r375"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r111",
      "r113",
      "r171",
      "r254",
      "r255",
      "r256",
      "r272",
      "r273",
      "r366",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r132",
      "r133",
      "r143",
      "r148",
      "r149",
      "r153",
      "r154",
      "r156",
      "r215",
      "r216",
      "r327"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, excluding assessed tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "verboseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r236",
      "r246",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r236",
      "r246",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r240",
      "r242",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Share-based Compensation, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.",
        "label": "Senior Notes, Current",
        "terseLabel": "Senior secured notes, net and interest payable (see Note 1)"
       }
      }
     },
     "localname": "SeniorNotesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, RSUs (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r100",
      "r101",
      "r102",
      "r104",
      "r111",
      "r113",
      "r121",
      "r171",
      "r201",
      "r202",
      "r254",
      "r255",
      "r256",
      "r272",
      "r273",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r121",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r201",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r202",
      "r237",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r96",
      "r159",
      "r167",
      "r300"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r224",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121548805&loc=d3e10037-110241"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e13051-110250"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r409": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r411": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r412": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0000906709-20-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-20-000017-xbrl.zip
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M=QOA=0(X&R+YYZO^CW^^ZA=MV_[R]9\^_UKI="\;X:\5GW?.&N9RO=5N!:A
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M]<NS<%M6^K4H7S^)9#^FCR0ZH[<^)PAEE!#FC2(R,FN#<=S")Q,P_,K#W?,
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M'R,THS@.5T0E>OKOO,B?'33-A/A@D9:_/DY\Q-A6RA+AC>"4:0;_+P)2"GR
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M?CKDNYO_?('K7ZK-/2!QV]],$DWW5.L?3ZM76^SP%.KS[FWSL.[XT>D7!L_
M]0^71^_>GAPVU.7H\!_2GAMB?:8")QFC0/)T5"ACAJ(H5(P"H?X\.)#_<M^$
MU<K_+@?W<>7,%)6OIM'[F5'!I3J\C#H,S/U^:>V7NO (7=@:U05LI:.9TIAE
M3 21&8A^,IDV#\-.B^ X>(=_U_<F+_ O[7 72!GNYI:3!_\VK3ST&UL#_SZW
M<P8GK2\W@^O.,AFE)9D7GF=,19QI0E5&2,!1.V6$5: O&_N;&Q\J[QIM:QH0
MSS0@HJE43?$E='\\VO[@D&DIT'DK#;NN<U8&X(_8_^2!IR8H\F5&8KOETTAQ
MJ-C+BCL)[DNE"?T!]#*48_$IQ!N9T/@;_KT_>_[$="HQ;T"$:!H-N".MB4F!
MXW]Z>0H;(5JT87 #%#R('/N/8IK&[_MK&P9!Y$CL.=2!%%BFRVEM0\7#58@;
MTJUG17"AC"(PJ93+!SN5WZ \T+1*IP>4N'/23O,KAVL'NB>F>[<5Y^9V55,]
M^P\/&O+[:L6T?.4W,M):"TH+-]G3)#/P4'D_/)FJ,B@L+13JE#4I:VHZW8I&
M%6\N.VNW5AZ\]*#'FUY10%7Z*Y62!^Z:;J\SEQ;E6>G$J\_(>JZDBED@.&0L
M1I3IY$NQ"@IAKY'T0"D/0^?!3.(C=?(3='.2RLXCTX/W*^/%$]\Z5DLP*J*U
M=N5Z,=8BV:^DR*##S;S;!=4O[7_1;B7NT;BL!. AEY7M1$F,*T>.-DW7]%?;
MW+%L-V6,)LCV>G G0SS9K;UPW&OT9^#L9_7*;ZE?Y1^$DK7!#=V3O)P,?I8F
M@[^TA>O7]]IFA<[OD[5((YV:^G1@H'X]BX0^2^0CLX%E5KN8@ER46815AK7A
M-$C!O.%+B_3K6"0P J;2, 4P'N,<6*0B[?=9*FF16,B]OU9 +K)[+W2:8,K@
M+<70]X,R-Z$3+E<3Z8+B@*2D\:+CRG'1/N^>#"^O 0<+9=U\B'FK7'Y9#JBG
M82H"S7R@AN5E_,?PMA_>\'#]AC<FXC6X^8&Z#N_,6WV+BXG-R)!*CO+'M>D/
MFNDUQ<5/#9KA-3"GXU][0M:0>($E+3]?[/>ND34AY?@K^_-=^_W*<DI?8+$0
MY8\;Y!SO;@\3&O685AZF9"6EA4JF^KA=7-XWTR]1O^+-X(:Y9"N#C,SI%K"/
MC\W=S:/3VND77MMLY-5/V_RH_C&ODD->:Z:ZGGR!]]W-R#2K]>W+VJ=#!G4E
MN_4O:/?3]L7A::-1^[1]=73ZA1QM'K#==Q_0(;Z]F$<024R(+A/(F(P%@3,E
M,,N$Q\*%&'C4;N7USOU^96IK>\:A"N/=^^1Z>ZXYZH&Q&H.-&^'H4\&!A,Q1
M?[R 1+ _[AOQ'=;E$;L-_[!WQ#1N72 G5KN/HR_%=JYZ8*P"L=^/??I&[#H
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MY!P&AAP@7QV:[,%/YWFC<?>W<'$&*';N_ES"?/?'&V"^N73=Z]\4-,1U^#L
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M6VX""3RFD18(PM2J$"^^\&66,BI+8[8T9I-?V[,T9D\U9C?L47+P.%J+C/)
M,X81S:RG/@M41? ^$4?MDS'34J[2EU_%-Y?YIAD\VG1G>^/O[9WM^O;6?F6C
MMEG9K^^^^?>_=G<VM_;VRT/5Y1^5K0\'V_7#YY]V.0(F!<1\NY<.CA[+^:>/
MC<Y?II:_3)0R/ "UD1N;-\I%"<\Y!76,I]:^6!ECLA&E?1KL;#33;&4_M/)V
M4>FD52?!5UKM;NB4D^[+>?AY,E6ADTZZORR/??^M$T*E!C=5\._/21 L&I6[
MKXD+0]C&$WU>A:+M3>?D+E?K2V"2J>5B[)_B;<>C0:@UD@0D;*8QY1GS,F0J
M()PII2CC40CNR<KKTM63/V8H\S<FS[^T00MJ@R80-"X-T?,-T<BZ2P G("6R
M&-*@ R$V,URS3#J))"%*^G1,(.%I6_UG3TJ8[R&(&=P6\_H\L0'Q6\YKG'Z"
M?@#)^SXB2Q/U,R;JRZVE$9X;[+C(%(YITP>1SF .--,**T.=24<SESOL,35+
M&_<N9SG.'[=8*N]XE/>&7P1+-+>498ZE'5NX3,J+9-I"WU)JG77]'5M6R7+7
M[5FD%T4OI!YHGH56QR10EHLPITXQMIIGC?9E"'NA8;K![]RD?9<&ZR<,UNFM
M+:9"#"X8)S*.%4_SL7BF(D.981P;:;TSFD- I%<YFJ4I6<L)D_/'-I9Z/'8]
MOB$>:7(SLQ FI F6&;.19(8HEGG/23K\0PN7H@:\RL0OOA1SEHD'7$JUKG2+
M'/X-%XF&A.618],^<JP/SYL!.O4$SM8 FZ7I^AG3=6NW*<*%CUY"S/3_L_>N
M37$=R=;P7^G@.?'&3$2GIRY9-WN""(TES]&<$;(E/#[2%T763;3,1:<;;$N_
M_LUJ0#1"DH%NP6ZHF G<HJ'9>V>M59E9F2NS8A<DU C>:@51*H<<-@DDL;&)
M?NS]JBIZ>L)C@##^ZA/'.HQ7#^,S#T0)XZGX H+-R!Z(KA"5-D DJXN\?E7
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M$N9>Z#(;?QB=^O9@VHM#AN&)G!/W/>6Q=YW%KL-B/YT_EDDB!A5 RQ@ 12Y
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MO\I!+6BDP$29YG[4@'#9VT[F^6MZ.VDB')/]4?DC-?70@WJ6'NK'X[>NNO&
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M(EL9-%5K?4S:8MW8E&,7OF:3RKJ>JMQ;)KB=E$6'^_7@?I: ('(I4O5 -0C
MY!O<LX%@K>1@-!DGV%7YU,%)!_N]!?OM)"TZV*\']K,4A'+!QFR;'K+.O+?7
M %XS[(W)F*0V;$VYL>GZQG['L;Z&A10=_-<#_T(#DS:4M!"@9/2 (67PPC,7
M4* 8J_"A3:&S8Q07*YFO5R31>YB6%6(^!X:K:2&=EZ,_D17]A.KX_>Q 7?'3
M&3;=#SZC\PG.[WQ_';Y_MZBJ5*RO3D0HOITW)9.!D"Q($:V4-DLGPL:FE&*L
M_3+1W6JA=,O'59U..YT.-2W6Z?3FZ?0L49:2C,H8"RI5 LSL0T?>+,%X+;-P
M(7I'&YLAC)581J.NLVEGT\ZF0U*'ZFRZ,C9=*(;*2J$WD=>4$H " Y!("H22
M9*I2*9<3K2@M+TYY[73:Z;33Z: *TCJ=WCR=GN5VI<M5Y)H +;7<KO1 "C.T
M#9-:X:EMTJ):J;$(%UM'UHU.^TS$Z\Y$O(_##.U*AAGZC<T^S/ 6KN76AAE^
MO65ZS\8+/M]^^OW__/?3?S]\].SY__?_O)+NN]&CGWY^O/UB\/=WR3&#EQO=
M=RLW<%<'#RK[C9:??_O:$^?X377=$7A?_),ZK/QBPS=!7N]3O_P>^M4/2>S7
MNDYK0#*X5C_5DZ_UDJ,GERWM6(6 Z%J,!>-@>N]@?SX_^?D.1Q*?%_#L3^_B
MT_N1IO-']Q_:/2K]R5UEW=';R2''G)/CM??HCU1F,W:\Y__BQSKJC_2JC_1!
M2D=[1[LMJ)\_Q7DQY/S5^2*PQR=-:__^8M-:?\)__H0?ECI)D\/^#*\R</B
M87^\WQP>I%]W#G8Y$)B=A'7'7/!_1Y/#=_=N5N4_:)?V4QG1X>AA22=CAN5X
MI(3TO;7TS^K.9W/GY:/CB1AU3#)3T.30^NA3"940J[0UNQQ>/6X/5RHMKUUQ
M?NPT/3TZG!URB,]/<S!'$$^_/SF"V/O9O-S[8>_%F\=_O-C^"9\^_.G]D^U_
M[;QXOSO9>O/S[UM[+]Z_W/N9_]Z3/SX<0>P]^_7EFW_MO7SX^OV6^F'RY,VS
M7Y]N_VR>_'/^-\W+-_G7)^J'/?Y;[SX^@GCYSV=[3_9>_LK7I5_\\OC=UC]_
M,EO;O_[^8GY_NWM;ZJ?W+WYYP??UK_ID4;DJ2)&<$@FDB@28=(485 #R+J5<
MG+)-R48Z/3;ZHIK-$ O,^PB@KW@H>Y=& %WAR/7ZG/81<2WLOL<[;F>NJS'7
M666?(1V4]@*,;"VPS%= *5>HRDE70\@F4V.N3EJ=M.XE:16B:BK6:GS!3#8F
M,EX'YZO.5)%6X8AU/EN2SQ:Z?$O4B9D),%( ;*3F'570T@G*T1N7Z\:F'DMT
MXZ N-OMV6NNTMK:T=I7ZMZAKM284*TU$*VI((NB$) 5[9\Z6S_/:U<O>.L$M
M2W +<N_"*UN8T;+V$C!X!2&QUU92#*8@IFISZV36<IE.C,YKG=>&<]=7X35O
M?,[&I4"VHLLR9D'*RNJ1HQQ5.Z\-BM?,F>.F:Y$A>6#+5$ TF1VW')LBM)7!
M>G24F_0:*AP+<U\4F3JWW75NNP*U"?*8.;K1I6J,:**J*&V1S'&YJM1#T2$P
MVA\?#@8>O!*(,?LL(-3$G"8+ORI)02D>J12LI<XYS4DW-I]0GAIB,+K2P3UJ
MX)1T?$0VFLQF1R6/YH79HS*'Q5Q-M^S/CN?WO-WE/](G]WSA/)."$[&U-SHL
MF&2-Y"S:I+S/3FF1/FZWTI<Z!'@\-\S#HRD_NQ_Y-@[RL<7F7_]!LY*_7S!3
MI[*K4-FB+JYRF:H133NOR6=YD8%<02C1Q9*+E4H&#CH_(=_?)_,,&\7SZA7U
M73?3L,UTE0#8)<:J5\E$C1Y%R!X#9>6+-35:<0FFO9J[>)&$YP60G8-7P<$+
MHUU%%J'-:$91"W-P)0@V*D@U2E0%;39I8].,T2X]W+7#N[-P-U,WTYJ:Z0J;
M)=FF^]RV16^P5!M)6^%LS,RBT5'HF^4Z;9:+N9>,45BG(X2"&1"E@T@A0\E6
M9D<I%N&'MUVNJ%I\3;(K#1!LE6-=A[-EOTS)^!K2U?5VE17.XKX%1?ENIFZF
M6]_\;S)2/ILP.-L^>,!/M5T<[?Y(D_QX_Z2C<.X$Q(^=@&<MX3R;');G9?K;
M))5CK^%920>O]^>?,G<@NJMP%5=A48TOH#=%2@V$U@!:K]EET!F$UQ$KB6B5
MWMA49JS]JDYH.AMTTNYFZF9:-S,--+#N>^NP]M;%,-RAL62L!:J)=U?A(GA7
M ^1L*1A3LHYF@+OKO:IR^'[%@X'7-W/8$[S=3-U,W4SWRDQ7\NJR)..#E=DB
M_W:(IGB;-3H2POB\2J]N';2RU\$AV_I^H7O(8C Z2 0?R0)*(Z 5XD%,4AA=
M4ZZ8-C9Q[-32,A4=QP/NDLFYD-(D2\*(TEOOG$Y1B1R4<JY>IASS;JK?KPFB
M%_IF0I.?TAJ"S@'08P%?A6=$^U)%=4+*^:2[,+9Z!<-$.IR'".<59%LZG&\1
MSHL9DYJU=R5K4%5)0"$)J 8"@S'F&+PDWYI&)([#*J8##:AJ8=!)D@6-NR<T
M33NG G>A"]Q=JR'$Y5:34W6A(C$3A:J5D:B3S:IJ@_-FMB4+KKK W3*TM"AP
MYZQB4M(.E+)MQHY($(NTS%$^%>4Y&CP6N,.Q4DLW@:Q3@VY'^Y][)]>'>F].
M72V@SW3?0DUHLXR@?&4O0T4!P24$7RR*&%,U)=XWW;>.Y4M$&DYQB(F%5XC'
MG#7EJ$@JI2KJBJ16L6UWF"\)\X7B)A\=JL#[=LX$B*X"XUV").V-L3E&Y>9R
M:,Z/G5NZ$KJC?0W0?I7$@I15U<I[ ED&O2W!$6\-+MJ<D'3TGX=[5].Y>=R?
MY?FK<C9%&T$:TNROIPC,T@:**SXY'81RIBE/F'!?5,(ZW"\#]RRBM*9HF0D]
MDM>\L[N(N005HI(=[D."^]DA0%(V5UD=%$0!*'F'#S%'X+T_D2K5DYT+S1C4
M8^LO;O,=\G<*\E= /)H01,R6OR#OZ.11:"'9R1>Y4A#4_?D! 'WQ>(!2<]MU
M!.%KYIT].HCLH;4!LB0"OT,5&]2MUF,C+^KD#=&COU?5EEU3:E5'"(&R4&BR
M==:BP$+HO*,<C FQ9E].3CWQ]-33:M$UI6Z5RA8UI7AWL3%E!\F)Q#Y+1HA4
M"630&BE[XUMEN--=4VK=4-SK/M?"3%?P$I-"+"58Y4U +7TLLGF),45MA53N
M$DS;93(&P\%GZ6$OA?3.!!"4-:!5%6(3DW=2L#5K328FYN"Q%$,2R>CP[BS<
MS=3---#-T@J3^$-\QBK0BAQK"2Y)149IF6KLF^4Z;9;G]+P5)>^=!96L!$S)
M N^@K:-5IQ)]R2G@\+;+KBG5-:6ZH$(W4S?3'8N4N^[%D%R%14TIG[ 65S([
M"B$!.@ZNO7,2;#31VI1\:F57"L=&76SAZ&PP;#;HI-W-U,UTQP/KOK<.:V]=
M#,.+SY78OP(.N!T@.0TA&055\'=%Q$3.#G!WO5=5#EU3JB=XNYFZF;J9[J69
MKN#5!<O;=0B.G;N*4@6O?3'5F2!<S,*E57IU7;)B-0[9TT5-*2+T*JD SML(
M6-@3"]HX$)64R:G6G J[8V,MEE;X[#@></.(5MJ9I&,I,6)Q/JKJ4I JHQ.B
M2GL)('<1FEM$]%D[275>1D<:HE,)T"8$LM:#<Q$=+Y3L\UQ32HR57Z9_K,-Y
MP'!>0;:EP_D6X7RN:41ZXT60D-I$++2:(/#JY7VZR.IRT!E;?YAPX^ OMHQT
M3:FOKRGUKZ/],M*B2THMT0\2JR<93))8$5T)A%)D6:,-)5%P\:27;:EZJRXI
MM0PK+4I*I5"B8CL!$Y  K-$!E2K:W!U5E395!W$L*17L12=CB&ULO6WUQI(&
MUX=Z[TU=+:#/)*6DBM:XIB9%1C.@BP1RRH )QL:DFUJ0[9)2'<L7$H I1Q.T
M)-=@;!SEFHLLR@OV6F/$56S;'>9+PGRAMDFCTT0%M E-G]9S&.%0 :%VJE@F
MWR*;I)228JQ#%X/L:#]?(%F*<D8*BBDB>D'2AA!R("-EJ=;UG?NF('V6P3?:
MB1@B@5$9 ;WFG5L5 2DC967).%LW-IT('<SW ,Q721(*EY2PM5AK!#IBON?O
M""M\%3+S9O!Y-'?!J)M'_%F&/RAO.6**''S'"LCN%T2O"*QE;M:>]W@YUX>S
M1G/X?1'W73#J3D'^2MYZ%"EGXS (5+IZ:62M)H?JL_;"=V]] $ _/T\B*IL-
M@I<N\>8N*Y"-$7QB<,]/=M#/M>&,&TNSJB&<73"J"T8-[H"@BNA=C&2-L>B-
M],(J+:5-JI3DQ:E@E#L]T@Q=,.J6APEO/SC\0&5O'K^2BH2AE,'*Q&Z+C0X\
M^<#_)!=-L2+(O+'I^_"ZM0-RK^M<"S-=I7ZD.%>(HHSL?'!4&/C*F%!#S%(K
M]Z$3]DMDVV4PAD/#6PLTW$;+'9=X.K2 [9"'BF961E%Y9XW"Z;BQ:<;>+]U_
MTQ'>B;B;J9MI3<UT%27N*I$B(0?EA#Z[@.0)%0<FA 6M[?OE6NV73XY3K;QG
M/G[W2J8H:E:*-TPI :,,$(5/4$45'J6P693A;9A=.*H+1W75A&ZF;J8[%BYW
M<8M!.0N/S@77T1"UXW1(-1M C)I]A>H@I.ACJY"QQL_5+;Q?.LW9":'S=C=3
M-].:FFF@T77?7@>VO9Z+Q37)0$9$2"$60%,02$D+6MA@K.(5HM0 ]]=[5?+0
MU:-ZGK>;J9NIF^E>FNDJ%>AM-KD(Y+6+&H.*%+77J**6)2F=]24<NP^EZ%V+
MXNMX8(\/FX+GAP1'(N&#D5"U:X<A2H$7*8#1VAA;?1#1;FQ:-1 AB@[9E2O+
MQ!*";GU@N6 VZ)7CX(PQG$6,.=)5(-N596X!S4\7TI69%RP9E2$[H0!MS1#)
M>Z@*72Q*.Y=I8S/XL?$7:\L[H.\$H%>07.F ODU GT^06!-3C0&$;X@V_(H-
MYB$9XEV;7:O@ B,ZC)48B/C;/=.*>E[>'I:]6*9=,&JY?I#BT24;;45*&#21
M3D69H-H:MU:KDUZVI2JMNF#44MSTY%S_1Q8E:2L<U"03H-"ZS:L-4&6KKLI:
M1Y)-8L:,W2>$*8?8R;:B@YZO"/+!,>%_?1T+7L%R@V*V3Z1$KDUKO0]WU>2U
MD/?P6F1TY$"C$X ^. @N%2"9*KM4U:M8[IL^5N>MSEL?>(M4MJ)R\*&E11="
M%"'X7(0K%%+6:17N6*>T92EML5:M*4)76S0(U30\BW'@E0Q@M:_92ZER#',M
M,)1CYK#.;)W9[B6SY<9DMA:E7&%F4[&&5)RG(%(VEF3WR&Z.OA9/HM IU#:
M,^@ M=- HK"#1E2;KE5D.VUL^GNE8=AYZZ[SUE4R^ZIB0%4KAR[\7^)HLJ2<
MM G52';4S.>)J^N[W0*Y/3W?I,\AOQ50;=-*R6V<"PD#JF 1-6"J[6!.CIU1
M8V/PGDB\=7J[Z_1V%2T[DYN$?$"3+389ZJI1HJ_*N62U^H);UDGM!G-HBX>3
MCF06_#^07K'+QDP&T5J"; (B6ZL4U9)H8_1^[.3%$J(A>FXGQY>G5W&ZFLV<
MN%9=K7")SUBX6\VWE ^.XFXY?[O+?'R_Q'Z)]_D2E^WD6,7]?L)]285WQNG-
M;.7^HYW<?:X+9.]@_^]Q^K<3#<S/ECGTIW?QZ?U(T_FCF[>,]2=WE75WW*(W
MFAROO4=_I#*;C0[J_%_\6$?]D5[UD3Y(Z6CO:)<.2YX_Q:>'.^5X>9YO]7I\
MTNKU[R^V>O4G_.=/^&&IDS0Y[,_P"L]P^X!A?[S?+(1M\Z8A]]TQ%\Q#N',/
M=46-F8/.)"P4'SXLZ:3V4"Y1>WC1=;IOM8="*.>TIM+&*RN;HM3"E."J"T8&
MJ8]S#U)IV6L/;Z\N^DQ&7]I0@U %O/,&,'@%4?D,2E0I*.KL99/1=W9L5C;G
M?A@9U3_9#;XBQ@?'@Y?/J%[MYM>4V#XQ#^C:K-;3IJOFKG<?N"M;5Q1; 3!:
MYBZK''A;!&0IDRS9Y93D*BH/.VUUVAK.75]EG'#$$%QQJ(3&6)FVO%8A:M7.
MA?!T!.ERSEAGM*6;R,^\,>TQB2@B4 [4&,U"%%0@N4I2^9HRFGGAH9-C$3JQ
M=6*[0\1VE0(>4D909B<L9X>FQF"3SR0]&4*1ZQ>8K1?PW*9.QH-7!G.P$2VD
MD'3K=?/'(QJU8U(S[$MSS-E.NL4GPLTK=^%V9NO,-H"[O@JS995)FRA0*8LE
M&5^R-I8\553:?"G4[,QVFYHA#UXYIYB_; (=:P3$3."S4"#8@W/6V2BE:,SF
M+8Z=O%A]W=FML]LZLMM5\F@I\B[O7$TVHU BVF ">1&=S@R5V@/2(7#:667B
M@U<VZ8C>>C"R%L!J6G=O=&"CB2K4+(US\\)$8<8Z+%V8>"/,=K\&P'SU,;MW
M4&C[TV-V+=E0C!6$$@VZ8+2OSA(Y;[/(\S&[2@@YEX/B%WI9%NL3>&]&@>7!
M*S2AHD\*B@QMF'CU$#Q*L.R"!U4RDQPVEM-F54US ^H=N>,@[T,/UL),5]'E
M4U258M<C"$0K$AE16JZ\DD B66^ B/M(P:^@O/#@510JRN(2."O:!-[L@6I"
M,$;H9G$43C$/,Q'CJO1D.L([$7<S=3.MFYFNTNV>3-0J>8HEHS0Y*)^=QY 4
M1@K9]_URK?;+Q?2,$QA#2!%XE_2 1AJ(0>NF1VQU; 8/=H ;YKV:^K/2$;R?
M>!!K0EA]2$DW4S?3'0^7^XS 03D+/RT&UX7:.)) X*24@"%7((P%R+MB18Y*
MZ#J?$*B6%YCH?-!INYNIFVE-S330X+KOK@/;71=#<65\U$EQ %ZH 'KA@:A$
M4)@Q%5MU\G* V^N]*H8XK\K0!N_>LXJ'GMSM9NIFZF:Z5V:Z4OF]SUHI:8/.
M$MN4&1N,-S8%5S.J;"_ASO69?[?GDOV\V&ID+4:I"4$2*L B%5"4!FP4225K
MC&K=E&;LG5I>)KC#>8AP1BEU#$EGD@+1^6AJN[KHDO7$ZZ/#>>!P/M]?HST6
M#;;8!%AC@LC!%9 KQ8G,WZRM%%W[L37+#-GN@!XPH%>0;NF ODU +Z9,*&/-
MOB10\Y2)$09\3@EJS+Q20HS,T(QHQ+%1>AB(OF>R>$]HFG9.-/&4Z)IXUVH<
M,<86TA2#KQZ5P#9#/'M)H11MT8?6];9LV577Q%N*EUXL=H/H5&*6R4"56 $M
M62"2"$I5$;R3,<Q'C#@W]O8B+0VQX^T63GWN!]XO.BC7!WOO8UTUI,]2 =J:
MZ(6,8%(F0 P(OA@"(7PDI5%')>Z;5%Q'\Y^C.>4D;&[)(M?&Z032-AJJ'(=:
M2]G:56S='>C+ GVAR F;2)I  R7P!HY:5B"7!'"D0:394(7F"FI:V+$U]TK1
M]M[B_4K"8C95J87*E2Q&&WRT21DEK8W\8<?"8JM**W3D+X_\LRU>DM26T$,(
MBKUVC J"L 35"AG(^8*Y;&S:L7<7=_F[*;W3 7\)P$M$4Y,1OKJ$"7U437!+
M>'(F1?88.^ '!?C%\X"@V&JZ0G <H7-HI3E,)_XG&6^D#-X8]NG5F(TWUC9T
MT-]MT%\!\\ZY:F(NU1>%I0K>VB-IXYRN-9;HNE<_!*@OGA1@-4EQ] 72UM14
M0Q40U@BVD)!-A/]$6T\%.T9EU\*MOU>5EUV&:E6G"5DFH44ISI:F%FZ#:BEI
M*KEB,/7#"2B>GH#:BV-^N];4S7)9.G>Z$$HH+D;0WB @1<=NBRW 3B@9+8WV
M*6ULAD'U:_<ZAA5[(#<%XJZ[L$(,G^4:(GN)DIU%B)4$< !9(%J=(!EE3;-J
MUFWR3$?PW46PLRH5#$Z0J8C1!$-6V+8HM&]BMI= <!=5&0ZX%XX0##HV%BHP
MQ69 &3-0M8+![:/25F?K\L:F&WNU]/%!!WCOV.AFZF9:4S-=I1#?Z)I=(FD#
MH:S!URQL%=YX184$]NURK;;+Q=Q<(96#KAIJ-@:PNM2&EE4PVDJCA$%9S/%^
MN71>;GB%O&N2?>L29%U]HYNIF^D>!,M=)&50OL+KQ=!:D?:UF@S.LH. 7B+$
M' E$+<$:DX6L::Z1HL.JSO Z'W3:[F;J9EHW,PTTMNZ[Z\!VU\5(W 27=-0(
MZ)2 =JX(T6@"4LX6<E&:/,3M]5X5PIR7()O,F\E'?VE29!?J$>]X]K G>;N9
MNIFZF>Z5F:[BUG$T'**WL4J!"F5PWE(J[)@)ZZLVJW3KNL+)JCRR7\\ID F?
M#*(#;TQBA\RV>6:V@-%&.*],CCZVHQ$3+BJ0=20/&\E7:3(J+1;31D9VQ[$4
M3SF@P%I2S2E7I2X!Y:Y:=)N87F@[\BEAU(H@AOF,PBHAB*B@5!^:VIR+A38V
MO1CS\AN&9E''\\IE!9?/N'0\WR:>%[,F4D:;DW 0?<F ;7_V+B4(*0?^?HTQ
M"MZDU1C%Q>G/783LZXN0_>MHOXRTZ!IDRW0->4.5'= <L\>D,%#460@59#;6
MQGS2\KA4V577(%N&E=X\6.P28F/%:@2!<J:RET$&2$D+7I/PV=ND9&V"17[L
MY44W8XCMCBLZ]OF*&!\<!_[7U['@%2PW*&+[E%K[=5FM=VNOFKL6Q-9B]+Z4
M %8H!YBK:$-I,\1BR40VF'>1N>NB,]5IJ]/6?: M(20'D#X9J1U:8?F5BK4F
M;XO6,:=5.&.=T99EM(6ZM:A%L$8B"%(<(HH2@7S64*0V69 --:2YJIQF?\RM
MA_Q$)[9.;"OWQVHH7KCB(@9$(8/V4GIE?.%-WR;7_;&;8Z\S?PQ-,#D9 TZS
M4X:6"L18$*JED'R))4O:V'3R7JEA=MZZZ[QU)=G/6*0HQF3C(ZJD"5/**@FI
MI$PUZL\35U<!O 5R6SB.(U^=2<% (6< 8]40:FUZ@-YK6[P-5LU5 /U]4@'L
M[';7V>T*Y!:%PJH+&HL%)2$UV4-K!<7D7?H@8M[#S=M-H"T<239%*#+6@P^2
MJ4RWENI<2Y,,8WM14G*N+S16QHX5KD?^_UY5>7>YPU4=7$KVOHR7/F;CT&((
ME(Q@,*A49;8IG91:N--2B]#E#F^;RW[^<)"Y]?#%*[+9RZPD1Y]MR!N2@>BD
M A%<,445*W3>V#0>>P7DF@&YEYROA9FNX"GJX+S/(CN.>=O<*M*N" Z#HXL"
MBXN7(-NNTC,<&MY:H.%LK7$E:<CL/0*V)GSO"4$4K=J!1LG5-)<2EQ^*TQ'>
MB;B;J9MI3<UTE>$QQFFGHT1*!8WG("47M,H9(:4W5/I^N5;[Y5D*YB?UJAAI
M?*@.@B?=FNDKA.QSFP+K54UH2,GA;9A=UJ[+VG5%EVZF;J8[%BYWX9U!.0LO
MS@77E?T_H=HHB(P%4'*8[=$5*%X57@U92]6$=_38VE6-F.Z$T'F[FZF;:=W,
M--#HNF^O ]M>S\7BAJU6>24 %A-YDU4&0F&S9S2A8E2^5#' _?5>E3QT8;N>
MY^UFZF;J9KJ79KI*M;UW63GIA,\J8J(<K-"VU"!L<(HD7<*QZ_(YM^><I0_-
M12WW82GFXGV%(G(%%&@A.&]XE86DI7+99]W.25RX>$[2Y;#N!)ZMK<D%6VV.
M"FN1Y&KF.VX"64J0QX[G@>/YZ?-%/"M9?4R09"L4"H$XUBH(12:?JT7MFKZ=
M%'YL_,5.YX[H.X'H%:1>.J)O$]'GTB>">%>.UH%S0@$:7< ;WJ)=05$4EA!%
M$V218JS]Q:'57>+NZTO</2]O#\M>+--5ZMP=W]RWFDV0#X[B;CENYKG'*GB8
M3):U)(J2,)#E_U1OC!*5_10FL9-.N*7*M+H*WE+4]?I<\XAP*KID-.0<,V"*
M ;P+"FR(%3VZ*-IL4>G"6(>E&TA6B)[U:/]=/4$,CF.OVQR\W*-94\[\A-#Q
MM0FS]P>OFA87<BY!RB*#JT#%"X[1I(4@E0-AM(TZ^HPBKUYAKS-B9\1[SXB9
M9%89O902.7*21%*4(C!492W#<14N9"?+9<ERL3C/.>6TCP:TL@%0VY:@+A;(
MEE2$EU%5-1?OLWH<0N?,SIF=,U><3DS>QVJ-$;(@*G0D7!(%LVM>"R;Z/&EV
M>:W;8,\%5],+*C+; L0['[,G"? H ZA"9')-.C;VE&/AEYEVTTFSDV8GS?.D
MZ41UHE1TN335E!2R4Z'H2-5H[5WII#DHTEP\0TTIQFB5!F?:-&;;IH7Q2S#>
M6:(0L"ILHH0RR''X1/]H)\Y.G)TXKQFA6^;+C*FJ8"6Z&"+ZK-G1-"Y:<J9'
MZ(.@R_/U_2:V8C$'&+P%K,%!E-E!-;*FY'G_LZ(YF=*)<?C$$?7ZA>CS\^V_
M'1+_.?YOGORV^7?^<GK)>S1]/=D__MOB/%NEPDM]>H+"S;_'Z=\V/]SW=3_F
M!L&L&IBW=\J(4NO8I_UW_"1'^P>'_.DTY6_OCR9\9:^GM#MZ2]/#T4$='>Z4
M66'$TU&>',Y;_?=SV3]N^M^?VX7:M^MDG_;3A']Q=LC?F/?R?'/AV5SJP9U<
M+:IOG.$[>GLPFW?R?#LMNW0X^:U\]_LD'^Z<4M/"+YZL)7'V*Q3Y"H\./_\K
M0S&*._\T%K^VJYV3FK-).N*0KUJ%QENOM57>"H[AT5GA7S59TI-?VIF>WL%;
M>ET@3@O]"E3Y!K^EW=_I_V?OW9O:1K8]T*^BRCGWUDR5FU%++:F5.3=5#)#9
M[#- $LA))?^D^@E.C,V6[1#RZ>]:W7K9V( 3'@9TZNP,8$MJ=:_';[TOQB_^
MF"56H-1JWW'3Y_=KZ:Y8>V>[XCD&E,"H<+5>+UTG3_P6K$FLS5J"DP(UWW]=
M?SX9,!_*'&2K+52:P"/_\X=XM>CL'Y1&LX4TNK_SOT>;[X*C?^V\VWRS\_YH
M=^MP*0^ORYJW#O:W=_8/=[8#^.GPX)_=[<TC^.7P"/ZSM[-_=!@<O ZV-@__
M%;S^Y^##^K_/;[M#D,BC*=Q#MTJ[UG:Y[RN]4:_U(:1K<)V2+C5'ND1-.Z30
M:!D'36#M W$V-B^K'_[4_?'90%R\[ _="MQ%\S@$T$ C6S="+U_+3+OR_N7'
M&^ZC.33E/\OBC93SI1^'&W3I9U?=EM(-FL0_==NK/TM"=C>+36YTVVNR&:]-
M2,XO?76!'>MIY7ZL-GX=[SFRVH>_!*?PM9-Q8$!;Z=D\QQF\_JM;U/(\+ /N
M"[#[>N_?E7F@*[[P,]LXFJ]"73=-95X3M]'BE]X2XY/ #D;GX\ 6H]-@=&80
M*8)YA5;R-S!'S/CE3<AIV6;<&IW]=&'&G2SR.:2:[YM)@*7XO](%X8DZ3Q^1
M$W25Z)&E2D=<\5!GG/%4YC*)J3(B85KGD:EJ\NBM5O"\*4:V/_D'"&U=_*$_
M]@Y+?^B7S>C@Z'UX<+1WOG>T\_W@Z.W%WO;)R?[V[L7^CT_]CQ_>XC5T_TA%
MM3_TRV[R\8?ZOO]A+]J/WGWY^.4MV_][_^33EUUZ\&&'[J%/-?KWU_VCG1_S
M_M"]+X,O^S]VZ,<?'^-/?^_W][>/PX_1Z].]+^^3CT?OS_=AO1]/W]*]HWU;
MSTX^#,\_&Y-Q:J.(B"03A F;DMS2F,2I3,+<Z#R+DQ>OXBCK1?'E9B<K1XX>
M402H$T;K]&ZK"*,\2D4L19)G,F4T,T+F*K64F2Q4UJ2NG)#FI3""'SIA]*#"
MZ$<MC**48HM+0Y*46\)L%A*>&$LB+5DNHUBS-$9AQ'M)&*^','I:4'\Q[[6Z
ME06345 8X#;5'YA@6.(\_"O^K- FF&*HI#^\?8-@73#_7<)ZKV?H1I2L.4WL
MCX;$'7<QNA"#R050Q3<SG)K !:V  H DQL*[_NUT,BU,^4V@@F?6,/N><?2U
M&FOX=5*\A/-#"_Z=/[UW_O#>^;,[&AW"R1W8U^[<WE7'UNFU%?1:51+@])J.
M\Y0)1DF6*5<1'Q*I\I@8P7-0;"%6EKYX!6H-3G8]U%K7770-06G'V6O"V0UB
MM=*R-.,*$&NB,5]=$,%"3H34W-I$:,LT<';62_@MY%VN$6!]?$ %$WT*,YX$
MYCMVTP5D,@P&?2'[@[Z#+W<#6QYO Y\U1BV[Y5'N^).<$VZ=6/LIL=9O 98X
ME&$:J818;+7'F$Q K&4Q48;G)F,R$P+%&LZY[P:I/F'&OF_0TC'VG3!V@U<R
MG8:I8L#)%$>]&V&)B(PE.C%AIDV6)W&*'6YZ/+GL8'LB<\8> 6CI1HVM(P2I
MIS<,!B.%@FGQ(,12>'5":A4AU8Y)VAR$4ZIR."DF".-@60G**9&IRF(.:D>D
M\L6K+.I%V6UUX>I\)FO(T_>!/CJ>ODN>;H!'DLHL33).M*"&L#3,2&Y-1I2T
MBC)E4\T-\#3K9?S)SE1Y!,!CVYP5P"".Y@,QU($X'<'J?OP\^G@6=M)]HH_V
M$6T.]6;K@#KQM()X.MAJ08Y<YJF@F209XP Y0J.)E!&<EDIDI%@H\I!A&_)>
MOB +JG-X/!E&OD_(T3'RK3%R@S-$E.6&\A #,IPP.#)@Y%B1E.=4IKD(6:Y?
MO,I["8_6B(^?FW]C]_1,] O,*,) B]#?7&?R,W%1)QDA5^*Y!/"LJ84?IH4I
MQ@Z2X 3$,W<ML%HP,<5I?^AB-V?%Z+@0IYV3Y,'C-,WY'MB=ZKA>%Z/3H_JT
MWOC#ZB3=*I*NG52BLC#CB3)$Q#P"R)): N+-$&TI:#&;JB3#I)*P%R>WU<*B
M\Y*L(5/?,F3Y88J1%N.3CI_OA9];H1FI-(MH1"R++6$Z%B3GB<N%#DUF;61%
M6,\G7".&?FXNDDVE"N.8$J +(/C3_O1T'/RF^V,%;SD9_]YSN="(5$:3$U,$
MPRH#!0#-<.S/JTLF6:]2L@,\J?W14+D@-,Z"ZCR^/U',<;19SU/9V_S,LCPQ
MTJ2$*A82QJ.<\)1G1#-)I=5I:*AKYDJ3R\U<.Y_*>C/TNJ6^=HQ\ZXQ\43-R
M&D>AE#DC-K&*,,,DX9%)B*%49D):J2.%3A7*?J5$=/W\*6N-0[9.Q/ 8;C=;
M:C4>FXEWDU2YK3]==G53"^PA[_$,P:<#F5B$9_K?L./2,T.2ZU9-52D>4#:%
M$6.S;?Q_=X?56;VKCZK302OIH-TVF RI26RF8A(F-B8LIIP(A2K)<I;$J4U,
M+%Z\2GLT^I7*X Y'KJ]A^"!E_1U;WP5;-] 2J$O!\6F2X;1-)G5*N-&2&):K
M/.4B5C+#WO5A^,NCDM8/7SX:V+$[_&:&DU%Q\<QB:_<,-JX3/=4Q="40J\J<
MO3:4R&++=6830N,,9$ZF(\*37)%8T8S9-%=41%C=]+3Z'76L^B .J8Z+;Y6+
M&^20Y(Q):@T!)F:$B9P2(3@C!HY0YU)*+5)$#G&<KP<?/S=?Q4'ME1H@X8]=
M7.R9>2O6->[EH_J71%-]9/_@[^_P10[L^['9=&[%?0._S7[EG\;)V,FRE639
MVQE$DNA<9!DEJ<@U8:&P) ]-2EC.K%*AH2Z7A_5BFJZ1%=1Y.!ZSAZ,3 6L@
M AHX8Q(XUCC/2*8SC9.I$H SN2$TMUE$#:6)REZ\HK27K%6T_+EY0EQ\N0RS
M=<Z0-8V\N$.JI9277)UL6DDVO6_#$Q4*FHDH)(F-L3J*9H0G<41BG? LCJ44
M,G[Q*NDE_+*3MG.9K"U#KRLRZ1C[;AF[ 1T6SL\JEA(9)I(PDRLB\B@G>499
MJC+&=02,37F/+G"&=BG']Y[U<28NNI2/]?&B7!\D?N,/K)-1*\FHCVWPD0N3
MZSC6).&Y)2SA$L!':(E.-=,)'+,PX8M7<2_^I?D4G5OD28./CI4?CI5;R1XZ
M3%B2AD3*- 563A4![DU))*560,=&V03@1MJCX>683>?CN,\*IVG7>>Y1N#IV
M3L\&HPM3M<KLG+$_*ZA4&W/8#*5'(DB68H:(C7,066%*X.\J"7G.=):ZVFJ6
M_7):6N?V6%_>?ECDT?'V[?%V T($LY+F*25Q+"T&6CC)\YP3*GD2<YMDKIB)
MQCV:KE-WR>?F\R@#+244*7OV=V73:PI#W&F5N+&34S\KIX[;&,0H/,50$C@\
MP"!:A42$F:N\U(9+QJP06'09LW6*!W?.CR<%03J^OB6^;O!'EC&;2182&LJ(
M,&H4X=Q:HHVEN35PP"QQK2;9@F%@G1/DOEATVUA3%  ]RL&&S\P!\@AC+EME
MR\ /_<G)UG0,>V>*2F9==!)K)8GU=:;T5H;6)BHA-,4:O<AF1+)<D)!);J*(
M68HU>DDOS"XCD2[]XTFP^)KD?W0L?JLLWH 2#< CU<*23$0Q&!LA)UR9C.0J
MU@FCBFMIT=A@Z=,:8[C6$&3_)B.U?\4C(D>%-@69C,Y>XCF,1X.^#O"]GKHX
M>Q#$ L>),\[>%*-O?6WT7Q?OX5A;"?>;]9EVDFP52?9EINE<G,@X3.'@J(E2
MPKAE1*0Q)VEJI!3"9@+-JXBR7KI@Q-G*"2,W8Z%'Y$UYMC+A02!.)Q/N3B8T
MZ";F6<PI&#"94)* O<*)Y(R1C('Y8BSCF;88SHU[+/F5#/9[D0E/J[==MKBW
M':(>.QB=CP-;C$X!^WPSXSG@\TM-[:X_HH=N=[?B"I];>/#-M% G6%6.79@]
M>;C9$<\L0+BN-5EORE$>1Z--]9]IOS";WT1_@/F3KT<%3O,]-&I:.#[>-G+2
M*;>5E-ML8[PPY98FFB3"AJ#<.",RU0G06RKC1&6Y9?F+5UE.>XS]BO'>!0G7
MF+?O,TK8\?8=\W8#7"F+-;>Q)B;/+&',6")BFQ 6<3C=,.9A@O59O3#B/<[7
MI/'E<XL4[HE)2>ZW@44>;SQA7:%(,0+:UF,<5],<U9O"5./&-H=Z2PP&XP.[
M7)!U0FPE(3;3;B\&L14+S0E3)L1_-.'48KFIR&T<&ZXT]V,@>"^+?GDL7Q='
M7%^^OU>8TO']0_!]*Z;(A-(J-R2V&7KB$P O64))EG @ 2J92$+']U'4R\-U
MXOMK$(SNC\\&X@(7:ZX6%??US>?F_4$F?>:>GT> MO"4KA*NG76XLH"=:<N#
ML0L>JI!02@UA,C5$\"@F5L4Y5R'E,@()P6@O"[L4\2?,WW<\ ;1C[?MB[5:E
MO*&I"!G )JTSPL*,$LES12Q7*A&A%"8SMS8,M//]W$X8ZJS !*W)12\ @#:<
MS XK?V;.H$<3F'I3'MH;/#(P">OQQIWX6DE\S?3LT53;7&#^:((NGSQ.".<)
M)Y3%69YE*M<V=0T#P\LEMEW&^)-@Z@>-2'5,?6M,W>I0G-*4FS AQN8Y88G,
M"0_!W$@R105G.DDBAF-3>BE=$ZY^KGZ<M89,=5;[69GT&,B+A0E>=Y+9_D@3
M6=<432U)7]VM3K-+7_U)P3O3"2 -193G:4ALBA7#&>.$&TH)CTW,)$ L%@&:
M8IB^FEW. ?@Y8_#&#/2(O$#/6"C<)QKKA,+="84&C<F<939/,Y(R+,HU64*$
MYHI0'B9:VTPF"H1"1GLLO)SUMZ8RX3FFMMO^4 S5?:2V/XKL]I]-<'^R6/[Q
MN$++\( GZ_&)*.#>_?$8VW?!6YK"^4(G%S-M19VGM O=K@68;\=W=N'<0"R9
M WOH#O(]'N N_&$(,LIL#K7[\U\"-/M6ZSC1W])I]96T^H^=&:BO3"(2$1,;
MQ89@A@P1B98D#),XHU1G"@<R1&$O3=:I.5 7TGW$>+WC^X?B^]8@EE#+- LC
M$MN4$Z9E1D061P2DO;4J2;.(6S>(A;&N,_K#<?"[*GD4P[UC,^R/BF XFORD
MK_)Y!(+N$\+4YS,& >:.ITM$65DPS507YA&3(5<1D3I."6;RDYQ; 8"$YB+6
M2N0Z T"2A+UP09)9%\M=6Q9>O_RRCGEOAWE;Y8-1A)4V'$<G4<)8J@F7@I(X
MH6EF(IU;$=]:%EG7W.O7PZ"_E9V^?E_H%NP"HH^_V]?KZER[*,A/2KB9VD+!
M\\CFL28QS<%NLF%(X(AS$L8Z%IG-\SC!;E\1MDF_;#C=7F>?+BJZ-I)A3;TL
MG3RX.WG0RE$3/$Y#$  LTY8PG8.Y$HN8\"PQ*M>)C<+\EOTH753T%IAV!X?_
M.:\*,!1\, S,=W4BAL<F*,0$T^N''BUA3KW[ 8-)WX!-?K'/PC.6?K< BV9%
MG#_$ [M3'MT[.+F#(4H]_-].<V#OS'A2]-7$:/Q@<ZAG_]#Z9B<+5Y*%;]O8
MB-HD3:R,B,547::Q/#"6DJ2&*J&EL"94+U[]LAA<E9$>D5OGJ0F'AVJ'VHF)
MM1,3#61BAF<TQ40RE3/"),?V+((1R9+,I(I%D0(3*ON5X=KW)2*>B]](EP,1
ML"?\[:*B)VH3KKVWZ)>DWQO8E)&^/"U##:9X4&TYZV5O)RY7$I<S31<29>.(
MXT!@+0UAB<E);FE&PIR&RL0VB\(8D_%[2?0K\;#.X?0DA<N#-)GOA,MZ"Y=6
M&I".@#"D)91&$6&@7XC((DLB%2<TX4Q%QKQX16G<2_GE_+_UDR[/P76UM0R
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MY;2;EZ-<[I +ZCC,4?75+!%[F5M?+>K/=J?HY<6HOGJ@/5,6SF\X7E1?^^C
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M!UZ\T#2TTW/PW57A#%SEQ&_.<3&:PNKT^/>7U^'ATAW@[9[RP96C /N<$V>
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MM"?.?9?O5;K@6Q"2$B!;#+B- VYC@@LPA13\"R(S+7%;5N*V3E+>$UW^4#\
M,1AA0A:2*)::,)MQ(G,3$BFC*-,@-(W2*SFX\R@5L11)G@'FIYD1,E<I$ #B
M/6O2>9#>'?8]'K857%J6A"0%(PS@89X1R;*4<$ZI!KN*\T@N5(27_H#NS\'
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MUK)N.BN**^YD"6+.E&55,"JJ0FM>%B)HJX/Q(.V2K!-?/R'E1\FZ:]HL]T$
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MS1"7E%)H'&BJ?EH??H+;>=*?EN?-IN;\,8A@8^>47] :>&8GW?JV#Z?C[!P
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M>+41Z-IW,A7H4V]8+=K;#/55P9SDH\L-OJY\I7L(TY>[6E,0/'<]S, K^>3
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M&/QZ)_'"/GQ-D.+>[>7N_^Z_+BJN?L#VT9MMWU)M>:^U!JL8 &7/6.D=$Q:
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M>L:K&+SQ /^E,$H[XD/40KDHG*[3ADFI;R<EEJ4-K_%+W/G@RKVGKMK;W^*
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M=,.)&$^$-P\F8H*Y08-CZ4K] )7B3UL^C/W0<T4@IO.Y/_1'_FS@CR9#,9\
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M'$T"AT"^830UIS7:5,Y8N?*CN^AZ?$B&UR?I@%P,RAB5A2]R(.\$H!,C=%8
M'6)[AX<'ICP1\Z*9<E[I&#T[4*F:L@#EE:"-ZX3DO[ ^(2<&EH=G),WG1$57
M[2*,XA)_>XM]5+JN-LW0VE '%69<TMY6P.V 71'':_XX3Q0-8,M%!#+/>8WS
M0^-XR\[5D% <-;H$[*UQN9<IXA4W"O^BIJ^DP#]H-4_[>@=K$3&!78!3%\UA
MQ;F(8IJ3"$K=WKVV@^5_2]"0]%DS5%6_W7.NFL=X< 2(L*WFK"(E)+MGG[&?
MI4>OTM/H9'<4Y>+/EU /_A]^*@?I"P1)$+9A+WDP)D/VOV642>U8R*](*_(J
M2M&S9],R#IT%D"69>_"">1;</AD42,&;^^O=MYZIQL*>6'OZ8+;_"Y\R?)VE
M2XPIE 51Z+MYJZ",@AK\9S(+@MD0&[M0B]%I, 1+2HKN6+HC<-?<R:@_;RHH
M,*^&\T$X'@[%=.AC&^H^8&X\ T4W&LUF;E-!O:JDY>WXXBJ"A6WF48[\ C)I
M0Z#6Q3EY!#&).%NR*]&J^BZ3SX*51O;DV.;(V,MT[64C9'^L"['O=FCF*Z'=
M3J)M)]$^L<VVDVBWNWOM)-IV$NV] K =&MI.HFV)ZG  ]\"3:!_"Q?[M<B=@
M)R&UXZ+N/_5V[UR 6[KL)TO 7G$HV0$W]=Q5=L#IUW\O_Q7#\\M_?X1_?WX/
MS[T9_O'J=?3O/^/%'Y_?C-Y\A+__^?MF=L#GU]$?GW['/2[PWV_1P_]S\>7-
MI[]_?O?I]?+-GU^^OH6_OVW.IO6&P<0+Y:3KAL&X.YR'T^YL$O:[@?3G4^&Z
M,O3 ;W?'G=%D="SCH]KQ<L>7Y-O*BT.6%U5&<-@?](?>H-^=]5T,%8[Z7>%Z
M?G?L!W[?[T_[\SGV@)YTW'$[SKJ5%P^?3MS*BP>0%];LVO%0!G(PZ(;^W.^"
M3I#=62C!OIC+X606#,?SP8CDQ7!V5QG&K;QX;/+B6^8FM_+B >1%E:TLQA,P
M(5R_.QO.)]VAE$$7U,.X"^CV9E,P-&<>YG--._T[Z\OX;<;9FESFC=2RRU+.
MKIGD\-/_^=GWNR\>%0L.X84?5VE.*84_9#(62.SJMD_QI_66NJ?L5Z\('X!4
M%KM?V8B5/5"$R',;>7W6_UXCHV]@,OH6616?/9-=/Y/B2U?,X80_B/A"K//O
MOJ\C#K!F0[T)L)U@F<_O#2Q,/B#^4L[4^8$OP.$IV),XF+TXBPR%___L@9_O
M?OI(]]Z4 YQ@4##_O^_%3]MPOSLE4[-Z%^.</TR\!I]U\3</E+9Y6L@ERS:O
MQ__=_-\W(A'<R8.R.R<_YLZK* _*/$?]BND+)XF(UWE$:5JOHT0D021BRNHB
MKM9IV67<S.2Z4>[5^,$RKSXNI$K1H 2]"@@H7D648 )'AJU-NG&:?N%4#Y/"
M5BQ$X43)>1J?2R>+\B^<^E$F 4AX>)D3Y]Z5F0,ZIP3X90IB 25'A=%\+C,'
M3 W8.P6FYV Q8)9(+O569.A@#47/>0U+I)GZ)K\?B!(>3#/::Q;Y(&0Q3RLO
M@X5:6\).<I7D)SL./$'Y7TE:.'&TC##EA2I&ZA^D3!5 ?2[9WA*Y<R'CF+)9
MU"Y"F0?P17[X-Y$5SNEIQZE(SSVAO&&O_^-[ (O>?(]^Y_ZX22-[RM;QX69+
MOP.M?A[)BSWI__YV22O^$!6@48,]]OVA ,:59U$ $B!3"$>&!J+]N<SA\?S8
M6%H52 %G9V(EP38/L-&*(Y#[I,B"19<S:/TH78$5OA0!/03LJ?)7F<>0'])S
M3#:EC$IY+N-TA<R4I.=D SD)['<IPRA *"$C""P^0>@M8#L@!I:RX =@[43*
MD&6!WH:]+N58KJ*5Q./@"K@V2!:9%]&9X&H.)\S*,\/-( G@:P4+(BQ:";!B
M)>M@+4L:+9=82 9'H&H8_-!YE,$243)G'(-<^B2=6*HD-\P 767I*HLDP&Y-
M;U!]&0C"A5Q&>0&_7('MAZX1R@P-'76('*PWVC/N$;<24L(O? 70@,*E_FL'
M !X#2NF[(CS'K<,'TWB]E"3./I=4N%/(8)$ V9Q5'\\[*L$4!1E_F*683#AA
M>"%K0%6P7*:QQ-3JS,%;0$K[(RS#:<\ 2U^2]"(!7 4+D43YDI#(?@+!22<R
MXG>6XHMT\+/1'!";% I-C @@ K^,8LH)I$HG.AMG"V8U!-O0;D*'!*[CP[-P
M$+5/%,@19SS[\#E@*N+;-6Z)/NG$*=@CH$J6=JHTMS[?:0CLP]J;19(/Q]NG
MB4.TG7;3)&#">'[:??>B@P!#BI!? <T%@=\)X'WBO1J39>E9)I;$,KY<KN29
M #CEL2Q!NSO/5YD\C](R!V4,%J7,,B8NP,C;?WQ\W_7<X0O,FG<H/=)7AJAS
M$14+YV>P (HT[KY9H]#X\-\R\GTL,R.1\OSG-Q]>V)HTQ=I(!R&ZD@36VBXO
MTNR+(Q%W@@ZSN5/:P]('TZS: :\)_(RD2+\QJ:\DVV*R6Y#B=E*Z /%6$C?"
M!T[*LS(G%L)(B29$Z;Q^=:*;Z .8?T:_IEB MPQ"CZ7N6G$F[VT[J+<=X-T*
M2##51'FG!#9&S_=J%V/3TT46Z [H[:;C#K*5/2%@ILGPQWO9]YZ,04"F5&FM
M%4C(P!$J8B@3^B,U'$,E%' ",+P(BDJ@70M6P!+.G<!^B!KDUQ5EZE^FM?"9
M)%>5&I68/,O2"X<T!.XJ ?'AS.&H:UA$"SAXDZM!0\6VK _\+!7A#9AWO[J/
M0Y)F6/ MDA(9<J9+OB]878.X<"@80IR($BCADEB"P]M42737>6Z*9?$O+W0%
M^,N:?#HYRR3Q?L_A.IS7TL_HN^X /^Q.>1W\ZHXW7_2PW!;K8NM5YOBWVJX%
MOD%"LUS1!([-[;RR4$JENUQGJPI'6)!; E;I4D4(6\5AS_D E$H:&?RHCK-J
M;)6W$EZQCTXKINY;3($)$Y2@59,"-*PO$9E*S;'* 1LFQ5]FX)*0B<.F;X$.
M,IE7\RC+BRY945ND5L?^>T"5"P4A$2!P%H&TZSB_O>K^ZH*Q=-&!_R%RJ2S0
MNB@L,U2H,6E/95QO_SH<!Y]!S1Z C(QP)\[S]R]?@JVP+/,@EB!LSD6.3H,?
MBQ")W9CK9"5^+L^16JMC6):"<'ZC(G?W>\\)T5/',IE8F# ,B5&*6>1%&9)!
MJ$&ZA9Y7<9FW!'P+ MXB#V3$AM=7.%(2^122 2GS)U:]X<^:;!TB'* +HO2,
M>@M@O&:%%8R YWE9E"#Z&-V#K3P @HY\ME@9>_5GNFHM*N@$QU,4F:H(S,5<
M%FNB$/1]M+5@'P7LA4URP7=;:KDQM9 F,_*.U-R%6/><DSA/B<ES2VUA>6UZ
M8?K!7J&0.[H3##J&E1L1,Y+7^WL-*[D$DPO<\7(IB%:%DZ1)-U]BM2\)M;A,
MSI3 <IZ__?#RUY<O+)G$='ELMM='VX!QP/.FJ*B("ZDY P0]7C C($'6+]*0
M_<V]D$-Q#S"_,XHT<.6M;<CBZGE5R2T%&#[X]-K$XS6E.^E% O[D(EJA'2BQ
M4XHNN$:7#J\H34S(E&*C5(#O<-&V_"K0]2,CC7>RU;;F+;6^VOV37H<H9SSI
MC?Y"\E7Q\<"#7S#*&!<@D.%;)<;<N11V S$=9P$"XQSM"%PR0K+)5UC.BHX=
MXG)0_\:6)\;P!/4(@$_V:!E4(C'2;8OBF[OC6$R'8%U@@)%#*R#S-0.FRZ7,
M\$HM^I-9BLXG0T9#A]!&SA2@#A'$Z.M4+I+JOH"<>283,@C8DEP":[-!<"ZU
M;\YQ9_XT[&F3ZX$LK/L@JM=/2C)[5_C",]<;]?H.P"FF.-%'=JI D%-K  Q-
M6B_ 3_)K #Z@#$GF7,!K<+X@/4MTR'=>PJ_,?EAB71%>T.ZE6BU:^N#B@6-7
MV3*"LFFJF(.U)04V?-67M)>,>DNA<<U!"XR9 0R$'\51L4;Q'>5;_\2K*)B3
M#P.".R*XX?;2!'X7;;.D$$A5S[804T<DOH^!QK ,.&1)QAO;8JF-,FR4 ._.
MHR*WKBOQE&Q85@0%EAY?;C^"^,C'RY4LA_)C^AY)-\ !X%8BY9<K_.F9VQN.
M1H[/A$O\J%1?!W4DMEI)U6V'!<%8E F0"QP(E&V:T!TN42G06_5+HFWUN5#9
M3)F<@SX6Y&<&@-:((VSF)2"5M8[-/4.>XBB.8BQ#R8Q3%;Q33J=S'H$HM!6\
MY1I<[F2RA6:$!U)]L,"K!;(]= 1*-TY0+BD*JTM.AS]_RQ-NN,B-0\GZF4K@
M+$^U4=38@R67(DK(GK.P^&QL"S>RV$6>IT )* [)U"%I0KRKQ*RBD*T>$_Y_
MY%(Z$O 04!MW9>!S_=[[T.LXO_Q.Z_Q=(%<]YS, >&,9%+JK#<B$P@;9L]HV
M ?Y7$MO^P-Z'?EZ UZ)N4<L80WX+R5XOG /^G5PA\LB77-L (4'*#6+J]VG+
ME>#V,*PJR"?.JER3U.2:T+?G)CLET-DINYV1IY?4YNU.:FOSTQYG?MH!:?!W
M99%'H;'RZK>FM9L=O ;@:]0W'SK5)4!"8E#= %!4GWXP+2Z=T^Z[W<8C7FR>
M\VW_[2Y3Z>J39-7U;E3)[C89-JG_&;,O8!6\R4\=;&OJQU&^V!9X0UG[1?(\
M()#FK%*7*$/QR/9VE;>?5\JJVB0E1BQT,UZ'&A:)C#H=!0AA^-(2!&NT0HK3
M5^JY+!!0F"-"D,#V8*#OT10SH8,:*G?$#0B/E:E\9? !U2]XGS[N4I5J@_;H
MPC<$-3?+V4I+\A(AJM $F]L=(K':-9EHB7VSV;BTW,CM0()2365Q#3O5 U8
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M,5%W N@O<>3\&E'2 HH.G>5,OWK!F.RJ4YCS$6M4,>5$,4=<BQF[H[X5Y@0
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M)"S]>Z+#M92LQY&: ,V6C,+-$H1CPLED2!S#QH7A5N'R,^PK+H1SF@0]Y[G
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M),IS52$/$ZC$7W2W6O_JA/P>9P,L4[HMQ@7,@V!GG5'PV>0U)M61*EKEV2&
M%, EY0)3").[AL(K(EZK!EW\"I@X*VRJ0\+<TFU6_@PASW2O\V4BYQ%':5"E
M9.<Z.JZ/7 .-: "F4_&1>L_^$CNC50*?8%IWN .O;A9HH'5T?N5IP@:=2E^K
MA!#F^$>)OB%CDR,@.B8)IV->\UA^C=3<+"5H0YYX5>6R5W57EV>HOD[3L&J-
M=&(-.DO-T!W.M<4Z+<RW=?ZJTPV>4YJ-L>+U-&BKM:3+K[S0,Z5"!^U3K_\C
MUO.9=>!++Y75@K>ZFE(^&N_H#0:D(S+==8%_R'EV52HS9T3\C3,B?L&NZ"!A
MUCWZGOLC3QXS7S13R$HU;0S7TOL'2.HJ9/X5Y[3[LNJYK4H2C;%](7WB.BSV
MN+CHS4/1 UNI5Y=A@.4V\<(D7HS:Q(L#V,L32;S@A/ YMQ0VZ5)A&I2<;&=5
M$=I"%$4(25"EOANV8ZU 7<DHV/,)21XC&Y3$.UV:$1AYL_I >_;/M3A[@4*F
M&H_+6IM+6\@(;L;[V1#6LLZ(*91%X.+W)&X2_V.WVU=]*G=(P:-3JI\:">&J
M1DCE;%:->TP-+N8IYSPM6E+LBR;"8/$$J#V%M'_(M?.JBO&PS_.1^\_!4[]&
M_U7Q'FK7K'H-O9<Y?!)L\(Y&R$45OC0NEW8T=(<BW'*ILD=TBHC9*T:T,*LO
M(\/,"ONISF_%A8S/50_K2^+L3T_+C%LM<P![^:9:9GI A7>WDQ][EAD>C 2V
MI)RN>[YO48>A1R 5XW)P4]YJZ"IM(6S<%SUS>Y[=,RT0^4)%S&JUY%PI2N28
M2]BH:B;_+G%.5ED4.^Z@-AF+!Q;3)1&6>ZW40!$1!!DWEU-#U/048IE@)5J2
M<F0)20H[NGFC86]:#87^(*7S%AN0NSHDC:X2S@[ ^0 )C;<@K^6UJ8DEST[9
M-7A)5UU\1-B%82DN'^9YJ+STOJKH?6<2+@^W$G=7C4RF6A&_Q>O'-WQ5]PM=
M>%9^LZ9?>M#KN[/#/>8N7'';O^<4)TM+6!UM+2Q\6148ED*K +1N_N*JDRGC
M@P^G>%&;)5APU:5+J%4N?]#_^#&D-+_U#U%"&Z.7F@F/ #"EP&>SWM ;H0XO
M,OB_4"^OU'N/U/OW1;CYM^&LUQ\.=_ZYWW-W_NVR95VWYTX'-UKV\K^-/.^)
M;[;?&XYW__D -[L?=7U/E,O4"UR #/7_OAM\5YFW(0;_?N@[+G&17L\\.MMX
MU%M]Q8=_W+#C-Q*'B3WO6NY,&_;&AI#I5[)TMP@UHJ5YWFN 9O/1HP#-J9J(
M\3VUJWC^2O*/+^A'TBSG8,C4-,O3 ])O1@TY-X37;1FO>E0I,S*Z0$/RU#(-
M@:."*D)K#Z+:Z\!/#'!WS8UW!>-[_>05/(0C1\ZH2+:K\! $4L[GE^$VEO/-
M"A>-V<LB-??J'O]F3Z]JQ#/J&G[GF?<F]KYS7;!\8X@0Q3]KDOO=G=\^=X:?
M/*B#CSKCF=N8'W37(,"_7A,4E_'U56S8E TM*3\54AZ-ID^;E)\ M1X10;J#
MP<W(\8 HSJSA7<\.VDI]AX<B[T$0]! G_<MUW,7-@\_I_QV?J?M>3X[E,/!V
M8W<O(M\"@2,A<M?K>-/9-2E].\+O510U/GDC473$6.IWO,FHQ=)A8\GK]-UA
MBZ0#1U+_03!TA&K]6"-8;VF*4[ZH)L.K:UYK"BI&MZ@?HQKUJL>!W<(&.%Y#
M%[3+T'L8:[=U1ZYE XROJUY:+'UK+-TTS-2BJ/7K#\P .%:__M<HP,S#3G-J
MK1D9\Z0=_LYX<-U+G=9)^<9(&G1<KT72@2/IN=L9SOHO6@0=+(*&TV^-G2/4
M\L?JYG_$6H3+5?F>5[LJ>7L Z [3$G.W]>[;Z_\[ ]!A\]"@W^G?]$;V[H!T
MX!D$+;NT[*)<Z%G'<V^73].R2\LN3X5=INYU[VX?&Z\\\I#BP^1R'8BS\3V5
M+EY1HGM)"X[]AM56%98_;C9KN:>*R]%X>L.*R_'L9M6&5Y3:32?C>ZD+O-F;
MCVFSPQN6R#[09J=MQ>7N$J4K:M:?<"UA6W#9%ERV!9?'!KBVX/(QQ[';@LNV
M2DW?S0\[XVOGISZR,K66EA\-+0_Z-TRU>BRT_ 3(]8@H<G#3&XL#HKA''D=M
M4S,?>6IF6W*)<J@S=-OLO@/'DC?K]/O751@MEKXUECK#_G4OWUHD?>OK[[;B
M\G&'L-J*R^N*K2DHEQNVUFJ]D6^&I4EG-+UAYDZ+I6^%I:$[;E%TV"AJW?I'
M[M:W%9>7T,1HU!FVU7R'CJ599SI^F-8P+9+VU_6CSFC\B%CI=KK@\/#SOV?%
MC_BOI^D&WW=%XNY[T:=PTW@GH#EL]G&]66<XNH\RQ#WA<^#WZ2UW/&7NF/8[
MD]%]%%*US-$RQ[$SQW#:&<_NHR+W.)CCD0?0KNV9/JH(VFT+#+^U'_"N- $O
M)\H=X)[H7(9J>CL.DZT'R<XRR7-0.TZ)LXC5\/,+Z? \^$#"Z\[*3A/7RW>J
M>[0.1=MB#L0Y<REY:/B%C'$F.VS"C/>E!WD9.+S,BQ3'P5>Q.AZV?H9/KL2:
M=M9S/N%E7I">)0 '<[B+A4QPGT4&T,*Q];#)980S7\_2-,R=%,?'9N>PIUR/
MA:V??26R(I$9K/]Q(1VQ!!*FP;/E"H %_\1C: B$"CJXBCXF;GH7-!T1QVF@
MKQ_5!/D(!ZW[0.4\E[7CY"7.F:_#![8--%#.15"4&;Y! "M7JW@-ZRR74:'0
M!<@%,,F,YM(;\(0,=U@RAFUG&G,$#OCW>13*VN<TB&A*L,#A\&5<='!$;\8D
MX$LG![Z,YL"C\/RYR"+>OD-S2P'^T9(.-F=8K0B&="&K$<CH);JD71*LZ'G"
M).%W*;Y(>L;'\;]F1C(\97V#1@4;/)FC$80TJN57G&[/</>16OY;1AG_."_C
M>004B9]9R8SF_":!M''2<_X*8..#E?"WK!!1@A2.IP7@2)$%/ ?9!F*-"A"O
M%L ^E^$9/13EM<W0@>$S>341^I*I](<Z<%C7CWS8K!\Y^%G<M=H7P&\0ER&*
M.AF"'$D =\!7\^@KH&N5 6GM9DN+[2^B8G&)J&$*S@CQBM<H+2'*ELZJ!-(2
M0 YD\N0LL8M%"K^I2ZJ*X?)%I&:F W'Y F4?6$@XOCME$@[EDKX(_Z=HCQ]7
MX[4OV20LF*2% W^BZG8U:SPM><KX&OA@/V(](,U8Q_<%"C@0S'F4%\B>. :<
M!JAC_2Y/3G=DO7ZW/C@=!2T(9( :,_0U7G9G)/-85#64J]X'"*N8X(S(HN^Q
M0(M3V#G.CD_40B>($D 7D(6D*>MA2J@# HYPPKJ>- \FF0P8][C^RW?_.GW5
M=6> =MCH,@J =N&+$1P(]D(BTM[7\8DFG>W[?EM(]."%$YL\9'PU\YI(,"C5
M= 4GLTQ@81!E3B(UE:&*!F-"9D$D8J-)>\[[YK>NS161JEH.;\P?.S&E #0<
M 017:4YVQ ^4Y05@^E$W**#F!=9;RK/L5Z\('Z1D6>Q^9:,D]X&(P)LT OG6
M_RZRJA+V3'9] /J7KIC#9G\0\858Y]]]7R=SH'$;@,VS[SSA?'YO)V1F"\$J
M9,+]@8QL? KV) YF+\XBD_/_]]W_1)-QX$[$P)_/Q]YP-!U/!X.Q-QWW)\-@
M.!GWI_^9?/?31]*7P%\OX8.H;/_O>_'3-C3N%$$/16R@39P0>!YX53.Q,?)K
MDH.-8X3.&@V1+8+D<K&T16>!J8PZR]C]^(DK%5:Z8V_7WI#EH*!)AH=J"-TC
MU'\F+[:A".&_)B_V@\J+?<UYL>^WY\4>O+)\#5I*.&&4!V6>*^<2T;DK-;CC
MK&(D;_ :V>FT7O7!J[MP_O=_II[7_Q$7>+D-AD@PYH^GJ"+0;?T%#+HDESUZ
MV_WQZ$C&9%*]W,BD>D?1F>.TI?9-$-,^8*[<LUJP0D>%=%"C4\6O+@]?52$D
MD*7P]P2$&JYI7,7]XDGX1V7S[8Q#@.4>G4?(P.PIQO@WW'R\+P1""10<DMA'
MX0BG5D)6!(L(GN$0U?S*V!TNAS!B<4S1+Z$A*;^"R\6*HQXV*6IA."6/MY]4
MAWLX\$@V&JX8)2#4$J":W5'.: ZOK&_HO+J]T8-1\2N..U X# R2AAW]AL T
M<-D*)YUJQ02?>:.>BN+#SF*$"6!X;ZK07D"#",A-C;(<:1V(+BDZZL?S""QM
M;3ID\@SPS6N#1EZ6>1!+@.BYR-&[\6,18F0UP% <?"9#M<W!5GS[YS<?&M+H
M1".SYUP.DK^7P)K:+]D*$><VP*C8W[CLUX6%"#^7YQ@D7()*3H!$^/A U'&>
M[@N$D[A88&R&7/\H9-^?$775KH#3HAC@%*\=;Z+AI+:Z<V\7Q-$D*$..+ B"
M308VF*:*"C87@@-)8(CY9!D+LL5JN&G$GO?&1.5JAA4A?)OXC3:4MR@*CNE6
M M(.]1"X+)E_]1DY**,.:@>6 6<*4YN1(OM8M%M1P5>C:'/73G&1VH)]/_H[
MMBB@%4%%:*N*L+P,0)L8-R',RK.:O@'R/<O$DK4=!V6O\"AH4?\S83T%Z"<E
MM0#$:X\H_\(+U6X8>D!KTCD%:F-2<T]Z_(_W\+SS&G1[FG%XL&[H$C)YR3Q/
MP>M!VYZ,"^4+@:W[U4D$G7/KIBOU>'Q>SLLT)Y+^*]WY?4ACCG;K6.]?LQ2P
M^H8V[SPGADE+V$$(EH#\&@!SXTV0ZKB7O[CJ^%4?V$/L^^JZ-^MY>FG#3[?G
MCD?'TIWTJ#9[='U?)VW?UZV"J,]Z!0W0MO%KV_BU;?QZ.%!M&[^VC5_;QJ^7
MV,V<*P>0"=ONKT^Y8^:H,YJTS5];4GX$I#SLS+S)TR;E)T"M1T20X^'#C&AJ
M:USV+WY]TD.TGD*7&!T1/J.(\"I+YU'Q)#O"M,/=#QY%XT&+H@-'T?.1V__6
M\]U;].R/GJG[K;%SA+K\6(-7=5W.=[-/LY7K$[5:6Z=F+TOO89K\/C[R./8U
MVDG);<;,8]ALFS'SF#)FVDG);<+,8T^8.;:DC]MER]Q)JLRQ@:S-DWG,H88V
M3Z9-+JCYU*...QH^[NR"ZX1%;D?7!XG?P4W'[AP+?MOLD6.2.,^]P37N,MK,
MD6^.GF^-G(>/KW[KI)&'OV/B?!'G^28G/O:+U-%@V-YS'RYZW$Y_.F@1=+ (
M&@UG;2K/@:/H89*MCE"-'VL0I\T7T>KB&KK\L1BKK1NS7\)<2QG'G.)Q9VDB
M37W@#1^-7Z<LYA>.=748+$1RAMV05MAKCEJI+W%. O7#P4[^."" NXR>49_A
MFA)Q%C2]0;6AZFUJUV.<'D(-RN39&GO TZ "W?9>VDWO5VF\7E*C*G%&<(-'
M\4]I9KJ'K[)(%B);<SNE %Z.0AQS@+,H\)%B$65A%ULFK:V.1-CEZ(+&3UQ(
M@"] 7.@M1<'&*)&JUVOT)W<SXH;0:8+-\?%+9BT>A8)=F?("FZ.+V)%!FJ38
M2M:7B00'GWIUT3=E;*9(I D<ERX>N;\@?G:)39L$]Q/*FZ,![!UL=F6*T^2L
M"XLM=S=[Y!DL>B+!$EO2KC!Q"H 6<)M;T\C4C&LYCX "%FF,O14#F@E";?QQ
M75@8:%=6AQ-MC^VJ[?&T[;%] 'OYECVV53;B0U#;MNDB 5XQ8Z?^#5&!0K(Q
M=<3J\%IKFF@/;*B%+%E:D;*BGG3U#H(T[0$^YZ]5W\:O],(Y\.Y2UH;LX-4W
MBA,I0-ZLX/1I>'2]_[;Y@=RA4BOW&TP!22X?\J$$;@.-689F!VDQPK30G0.Y
M1:1I1"QJ$VB47LB=&'L5T@P0W0!R[?AE!O"58>-31%WZ6$I9<]?<"ZLM):P)
M@EOUZ*TF5DG=2!#^KC<((%--$['G)-#A*5 6V'_ZU<8X$QQ6H3[K8&MW;"*:
MLQ$158TW]>*LK)&8^74DV>JP^/LK#TL=2JF!ZJ4#-.A,-0U,)ZEZR2*(KD<&
MB'/N8KSG%ZD%H>0^JI+-!OAWP])D/CXZ7MN<;U/C.IO&<#17#$^4V/F_(B\6
M,KGJ24TCCQ@_W-::!!O(*^Q&72,">WX2-;LL<S!.:.X ;"HHLTR2\+MB>[YE
M\T>):1G;[*.ZF[&!?X,L\G$2B@\.Q?'UUGQO=]]^91G>JL_]4334G/1<;WRC
M\H!);SJ^6;;Y%1GWP\G@/I+8![,GOME^;S*XE_* ^]KL?LL^T?* MJ%F6Q_P
MZ.L#MF0&'C94VX::;:' (1<*/,25POM=4VHDV\GWERO_.)-S'TVM0+_?&5V[
ME<\C2R9OB?EQ$/-LUND/IT^;EI\ N1X11;J=X;1MK'G@>45/M07-HVZY,NEY
MD_Z-8JK3WFBP^\^WZ6(RNEF,[JK(W_2);[;?F]RP1\[#;-;SVIAJVW*E#:FV
M(=6C@6H;4FU#JFU(M0VIME&HJP\^Z(\ZL\?>?Z4EYB="S-ZPX\[:446/G5Z/
MB"2?N]..-[Q&0X$VH/JM,31^>H6:1UE*=Y4)B_G/>907F.$=P1E@!YA3',!*
MB 78;AFN*:,][U"N=":"8DN^._PUC#+,9*:?<(VT+/(HQ(QRWD*GRKSOZ-1[
M^%<<!;B1G'8XE_B/W+F0<8S_7<DL3Y-$QFK9YUR3@%_-10S;Q154V5S.!05Y
MD09?NEC)0G5Y>$I*<W_1<ZX$!B7LF[*' $@1J^M2H,F%%"'\.4X#+JK3<*-4
M[[FI.:0SB""*J3JFJY/I:?,]YY,N H1CS=-L:4"SL:&JPL:AZB1'5"CYG$:4
MUUT]74OG1]CBBCFGG=<R_:F.XN<W'Z@Z(<,**$[ZU^?/9+3TRRSGU'&3NZ[J
M(G*=>8Z9ZJK.8N<)U)*FR$-]C8HJ%EA00112K?V__S/UW,F/^CW^5H+(H)#.
M/M\ZNNJ$G?3(Q*[K9;@29*\"D LD,$6:IJSG.FM@O=#'M  RVPGM^N;V+TXQ
M%<K$ED "INYFSS5H;_"XX80"A8FU'Z0G7P++GXD8&#B6Y9<(^.'M/SZ^[WJC
M$9WD[3_@WV,/"R[.,K',#86%-SC2[0Y"TA?W3EA+Y_-<%E@#IP&%>X-]RFY5
M7KQ-\M*^Z8SNU*U*<>%<6&0"N.-GN2YHU_MUF.:VJ.8"9QO&YF&;+!1 J]T,
M1E,J#TS20E>?=)JU*[@:'#?*E3A!>@TS<4'0-&=Z^^H$0?%WV#L6<B/H28*I
M:GF4RVJ'6N J?%P CW?#]"+1=3)F2;7;CE,IE$LA70ED?(76.@7<1QF='587
M.6"/E5@*?\VV;$AF6'-94"$=PPI% BZ'8'B9HCQ".H1_D2-%CWXHX#]<D U?
M>0>:0RF@:U,K,X\F+ORL1M,6]L[D'&O/M1)9KF))(E_A[+<%+N%NIP02&%AL
MKXN:[#^&,HY GZ(5!:"<4VF\HEAB T#I"N477ACC7]$2(XN$C0R%6/7]G^E;
M_(-G?Z:QLMBRL#>JUJ5E?HVPIB_*-YZ<6$\"1:LJ0ZQN[VCFNF'!GJ6'J>2N
MJ)1KOH_&H^V!/E?*,Z\K\%QCRYADS[Q93TUK G464\$_K/QL-NA-:[_N$! D
M$KV,USWGU2V.B6+GFQZ3/_[,F_8&6\XZ=7O#R\[*?_N=K"X\+WP7.-*VHDYT
MCX0._?$,S,^,>AWX6(KJC"<])ICM2G-#02$G H?Y*!N,D?9N!>9+J@V:.S5.
MQKW1/E7RFWT7T'SJ#NCMII<&#,C%_ "]R?#'>]GWGD8587E@,S="O2[--W#0
M<WZ+22KF0-MO06$Y8VJZL5LNO\;R>5(4EH3&+PDC'P"Q:.7KAB!G(N/ZT3*[
MC*AN;<5>D:_S]'IKS.JP:'MK/(G>&H?BY%4EZ%>J.:[WKO2)Y<B1Q=)T.=B3
M^%MZ 6ME5/FL3%EJ9G!-QX%:/MA^ Y6;NS,TV<,H#\H\K\SXBVL=RCCQC"(Z
MV\X#68&HD,OR17B.HE:)3OL;0"";ZK3<3W5;428,<F&H14>LR%D 0U!43U=N
M@F7^?N\I%Y2B9%L5"X%E!391!IKCSW(I?#*\/[S\]66M9T5'FZE6P ;6(UN
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MY5O/K'D@:A/.8-Q'GJ2*.JJK.0%A$3ONP"KS .:6<BFYX&4KTPN<I9[IHA@
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MK&M\)I=)1+4)5"B8.">K+(H==\!GIG*]G36'4F0)%QU66]1;NY#.JLR"!>&
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M*\$!+65K'97=/LY<(ZO7)"94.5?)V6X$/[UT@N'N=(+]ZVRFWG=M#L+CSD'
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MB9"G,N2.\<5*/<@"J&[;,%73U%U-"Z2=?MEI!ZEEJU,@'M@J@VMP>.B1)7Y
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M(N2\J;?D=V%[YK;W][/S'YZ_?OX_Y\=!?I]!WO3SDHX9H ;TL,?@\C^.V,V
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M5+2-/XW@3@6-(K],/<J.=$6^Q?B\*?931V24BC?^!;8[_&%-4J,),'A]^?Z
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M89/PL(7X2Z<ZFYP<QC_1(2;_XF3I7M2+MGUE/5,/<B 'I26 S "'3[;EA,D
M:X0, AZ'C0.B/1=)9M)-_39G;%5&(?@**@OH=*I,6V'!V-Z.B[.2/MUH!XG]
MA-XK='KAU[,W]*=,GD#TBSF7QRU?F7Z 'K5OD#;(9D6I \;&C<D8\HU8,=R
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M^.N&T:I<MHQK8%TVMHW@_[PI]EJ6K8J-SCU#L+1E+Q0]R#[1J5X8*#S 2[P
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ML>2<D+K([-^+S_9?__'HR\]_1\C-__KOX!B8N\!E!YD16?^N(AV.)J&<7I:
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M(/800PZ9&XS)*,>>I7#AI_76?%)9D:+?744)[R/\(, /'AWA!Q_!L_PQF)S
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M+B)NE\R:1B>6N^!\%$'I7;1DPTEF,UX:>##S8/GD6K2\EU/2BHI(K H(2+N
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MG<L<G(;4S;6Y_>QOD:P#)=2@-NGF]-,00"$!'E]PE?%5-X*XK!R!++2T2NC
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M*T.E%UEVQ:E&-+84J^<.E;9,.AFEDA!19MYI4;IOI&>H#?49V! W/2QLOBE
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MQ<-G=QU5$=8S:O<FY"%B"UL%<36-87H_\,-2^F_59*_#G)K64&TPJ8?)&#M
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MC(8XQIP;7?PW[7!N+-@("1X:*8'J] $H7P)P[6J4&Y.TX[69\:+Q$/0SX!C
M3N&D;<4%+<:MP.<NA Z#D3?A]-5DFA3.G9Y'AG7[%:I/=N_3?:PD__/ERX4M
M2/7"H-^JZ-[#H5<G0C%M9Q):M]6J)7#K]P8:M^K[J6R!^DZJ7AKR577DK).$
M!%$J$0]3&"4$*Y[V IB&*(4A30)&:>J'V.H21V]O<R/IYL;Y5DA+R[0764,#
MU!5>(W/O 53.<ZP8(>'45.SM<%J+T$3W \//Z*6A-\J_JY;RXOE=MLI*96!6
M9\T?Q5H? 92B4(2U\(*8(28XE $)(8IC#'&D3#PFD,?B" DI0KM;Y&?[G!N!
MM)+6\2.V]\;/0VS&(8Z!&YE)-M)>@0U\E<!70(E<'UK70KN\$6Z,D-M;X.>[
MG?CFMS$.A[>]S5\=QCG;D+=;V75@/XNE3GM7[?E5+B[M1 9OKTF&*)1(, ]*
M$<40>9Q"3)($QHC%22!]PGRK()/+Q)D;4W7B1=4,VXG[;Q2J(T.NCL7]#[_8
M>N&8FO'?="/ULIMYH]R2=0.>2]:\4*))"=4->OM<ZZC5@31<>:1MXJ*/ZG-]
MDS^0;+5@?N+%-&3*-Y14V7N^(E@_H3#F%"'A$1I+JZQ!ISJ:'776VTZMH,I,
M40];TN I3 T)S@%2T^S-[8($?JOE=$E79Z!P2D2G^IJ68LYH?$ >YYZWHX6R
M6"\^*)-/;TN)!RJ*A0B0X)@GT..)]OL2 =-4N8&,)B)07B".L!$/'+0\MXG?
M"&<VU0]QZI_;%VD_\F1NY *_U9(YF+XGM>V9K^J=SEQ5?]N?IX>-3C(Q3^K2
MSL33#PPX;/LH?E^3HOFD$N3A*.:Q<FK"!"(>^9 BH69B(IE'6(+BP/Q4K=OR
MW*9>+9O%2<X.3 8G7T.5'WGFU6*=GWAG + XLQH*Q$2'4Z: V)U!'5.Z][!I
MYX7I3I6.R;ES?'3T@0$L<\U8\21XF\#O UD]2?7G4Y&M[IL@J]=/1:'&>Q'[
M., X(9 %L0>1+SV8AIQ S!+J8>:E(3:Z+&C9[]P8JI$<L#:OY4-7=LMX2-LQ
M,""X<9 =F?Y:4#?)0G?$;D,J02/X.-A:<.<X&$_$K&8?,&"U JY._^TAZ^5E
MB^:F8VU['7<X?<#K]BZ=:KW,EQG7^TEO5^LZ5K[>D\ ^90&* D@D5@0?AAP2
M2A7?$^(GR$<HP)&I?W>ZF[GQ>5=2T(IJ[OKUX'G>#W2#TLC<?!0@ASL\9D!<
MZB_V]#"9\WA>RZXG:?#TP+2,[36.]SI[\R9/<[L.2HK]*$ <QGXL(<(40X+2
M%$K/2V*:4$P3JZ00_=W-C0XVTH)EE<Q\V<A;70YKUD3PF!=ZC;;,R=@/N]F.
ML#LP1V:-+8Z5I)U\[U=GS3C[G(Q&J#C-R=C?X[0Y&8VT/\C):/;6T+.DNK+"
MNVRE"WY6!U=U)CZ6A-2+)(-I&D00\429&TP0A:^/TX"PE+/8[C#I1$]S(Y:[
M@JQ*9<[ID_?Z^ES1G+^O<U!=X\VE(I:U C\C2R"?UOK,OLB?R=+<(CF/O^G!
MDP-4)SEY*LLG+6$;Q. X#>%9'-P>.YWJ;.)SIS,Z'QX\G7MAP,;4IW8FO!'?
MQ3)_K+(!KOAG<?^TU(/V_"%;BG*=KX3B%,E\WU,DDM J(7T801+3$.HH9DXY
M1S$R2@U@V_'<*.;3/GL0SC--..HW?*M-=4NUV.@#'C8*66RLV(R/P:[52*B/
M3$%;P#MB R4WV H./HP-K\7&U4@P3[1SM87;Z&MVM74U +3>O2N;]J;;O!J@
MY<[NU9#WAZP+12ZSZ@[X>[7"B"H<2AFQGX3ZQM0'>"\6B9\B'X<!9-+W(1(Z
M3"$1$L81BSCW222%Q6IPKKNYK0&_+G.J)@C+'QZ4C)G.%55'>S[6FE3395GI
M4J7GUA[:XT8;&X8Z.Q FM.\2WK')O@%0TWLM+6C$!9_& ="&V%T".16=FWR1
MSDC<%*!^ZC[;RH2$;:K1+DT;OS7D-/G^OJAJU>N]RXQ7&PPZ>I6)[+OR#Y3\
MU^J!*J996>V!\'S)$R@0E8JG,8<$Z6PZ(HS]2,0"I>8Q+38]SXVRZ^0ZK"NX
M,FAJR<'32OT.D(WP-F>?-J-A<K(\$L9CGRVW8H,=N4$K.-"2@^O1$;8Y7QX)
MZ:E.F#>(G_BH-9-UOFEG9\P#8.L_9;9I<,)SY@%Z[IXT#VG _JSYL[[ TD2F
M>2(DF.I]WS )($JD!ZD?)E#]EH2)G_C8EZ:'RYUVY\;EE6CFI\==A,X?%P_4
M>V1^U=>1LW*=,;6(?1!$WUZI+RTY/2$^HONE1\+=)B<[ SZB1_?0]]@_#SN"
M>;\]N-2IPM<Y^_U;OE3OE_6U\<U=.XEXDJ $PT398&IF$@DI3CR8*BH,/!S$
M(C0*^[#M>&Y3]_W-]:N;]S=W-V^_@.N/;\"7N]O7__'OM^_?O/W\Y;__8QKX
MR3^#M__SZ\W=_[8[BS$>"+.CF3'@'9DA.B+7&1+KG!)CW&JT1<?E^8UQWY,>
MY]@BLG^Z8_W^Q%7\WF<K<;,6#^4")WXH4AI!%@H?(BIB2%)?P#0._4@FF)/
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M;KD_-&!<S"AI7+1'YBE=X:("NQ5?']K_I#50I/\SV&;+V&HQRG;4<!!=\MH
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M/#>[^"E;$>:V-%52*M^KTJ&IIR[J>!_6K:CVJ-ZR/!(8,#YFNW+CHC[R4M0
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MR@A&,9<D,=JZ-NEL;LM!+6[C\U<";SU_FXK99R VX'F'P(V]A]V#V:!RXV?
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MN<)5$O$%ICY/(R^$/DD]B A'D&+/@S%F/&0DE8(8Y>SLZ6-NYN9&1%!J&:_
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M9@M-)?#<N*JZC]!$Y;".-I;Q[6,/LQG?S6GP1N;-ZT\WKZ^.A\)U8ZK:FZY
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MR3EZ%J<Y+E&<Z.C&Y%MT=4IC"D_OD<S91J8[?S'59^>PQ?BEH?77#GW*MB3
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MLWY^ERU%W?H"A5Z<Q#*$'.O#((8"2(@G%);<QS1AW(N,RDH>:WQN1%#+![2
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MSZE(A'G4[5[C<Z.[5T)A>$^67)1+\?1[9IBVZ"AN!CO^%Z Q,O'4D@$EVK#
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M,<DRG.;"7B?I7V-NVHCIRP,UD:"ATJ6C4S^(%OK']= $/ITU@:"#RZB65_T
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M ?"XA\!!]WK3=\Y"A_[/\B:%#MEU8>CVW-Z"]OW:(P$.4#0#X]IW[( &,'"
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M7]IL.E0(G! )5<JT@B"4A 1G&8QE'N,X9XP29*,@G'G^W+[L=6?N?[*4S.=
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M27&6RQ-;X/R5USJ)SLZOTV+'!+C/_',GR7Y;6;H'+X*,E"(Q9Y 7J58>TKB
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MK7D405)HR9YEF<H4(0(CX2+*!]::FW0VI(**5O#?E[+4L/YX 17!('83OT,
MVTE43[ %%I('Q+28K B]:0$+D&1B@8E/$3:TW*12R8+OUX+&YI:Q=9"\E%HH
M?9#U?S^M34766N^<:16 :43B-%:0R01!%$D""6,IC!%GLDABPF+J.A1F8+WY
MN?Y:XBSK$.Q0M1,9UR,U5<5D31_XI:7T'V"Y!AUB?59/6F#BMY!R:,&):RHM
M>#\MK[2Y:9SH^/A<;IXD7?^^UGI,\S6,>)XG.14PS6@*48XSB.-(PD3%>8:5
M3(O8JC?HP!IS4S-:$D%%HYN<Z(/03CI<"4Q@F7",20#=88!]G\>_;YE)#_T
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MMM$BCF01"0:+.%,029%"'!41Q))0GA%.2.I44-:_S-SD4T5EZSRJZ'031V?
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MG5/]11XX=501IWTG+-7)V>YT:-53LW)3Q_LZ')GA 2VS]3^:?7_]NZ,;:A!
M3]MMDZ_9CJILL:@R-T&-AD>5]4UVT:MZ.RT'TZK";[([)VKSVU Q[OOY9;/>
M9U74 =*/?YLYG7*1DX@R1A.(J!D.'],4DA2G,.:<<:8$(47L\JD[N]+<ODK?
MS1I@O5G#0[Y)V_I7UB1KB;.6CCV/SB-M]P'Q@E]@6=^E<9_ST9!Y/BO060I?
MA,*GP#R_V*2R[2+/K\70Y1O&)#.LEI^7J]5+DY>=%U)FDL50,AY!,]4*XDQ#
M2+(LD32/E(CMFXH</WMNAK>F#E3DN<3<C]&RR4D8C4'H/(26_<L9ZQ=Q<,DW
M&(W'5#D&+2[>T@EZ.1Y.(3B^9<*T@5Y:CU,%^B\9(7KNR@>Z7OY'M9^F"OWY
M\9&6+W?JV_)AO51+3D\Z !\:]$J>DT)A*.*80,12#"G7LBK%4L58,,69?:+
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M%ECL'@$6(./9'@RO WXNKSKMV!]K%$Z& =G?.4ZLW)O6I'47EJ^2K^AV6Y6
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M/VCK>B$SP2E*$DBQ1!!EB80TIOI;SY(LSADFDEKUDCZ[PMPD24LDJ*DTQ=?
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MONG?U,40^S?1I JG)JTOS3-MQ$><0E8("0M,25J0B*#,:7:$%ZKF=N*[3-V
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M_MM_:7^C_S!C"?[;?_G?4$L#!!0    ( &&E95'JWN_>8UX  ($:!  5
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MT#Y!RNV@Y!7*Z:$V&[]\B[/+DL<N,TCP?ZF\:L@@A5-9$J[+^$]I!/':<"(
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M*7H^ T;/K.;&@?WBJY_.RI.J5]VBW,!\@'BYV+3\3O_?Y7(]JNYZY@5(::A
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M$*JSL4H !5LEWWX@G2/[OF/"M*9&OR/ _M;-XY;#+'1FV<32\0S_P#U);/)
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MWH6[A9&[.S<JN%=2(0M%5F!#>9F1B6)9@DC9]YM=>_CK@:>H:@E1IT-@_UW
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M:I<#%_U&5'TGI3V'J.Z0TIY#Y#@V)AXM4-'" S7>D$ A$QE01#8#D S64.>
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M1$EE4TPQJOVFE9T5?HY3U7.J:FA0[$Z# X#CHWUUGV".43NC*8G1VO)P4)/
MC"<T>4:=#\Z$*B \0$N_U9_!0>^YVAH X.ZET?@S%JS!2-"2\AR9R&P,L=)*
MDH,H_8F%!J=K(&V7B*$DXON,8,Y6RH  M=E>@)LI<2Z)L!"(%#26-WV<F!2M
M2C9:D:I,7Q]2T'"^.H_@X@S9]EV-+J=T241QRLQ.A^F;:>D--OX*A;6-!75*
M,LU\(,:H,E2-&>*]Y81*JJ5V@8>6O7O:KSD,?)RCUEE]&0_ J/RE,3YFB[?E
M(^5$MB D*:T3B00TRIY+2KB@RI9K0Z'.V?9\TGMVN@9Q(KXP %XSY-?1^.(G
M_,/EXF:ZKJ7^-)\M%J,D5;8R>Y2[$"@"J8@#%@D5F1DMM!6Z2HJZ B\#S\=T
M#,>N=D-'V+BX[?&_4)JT0[KZ"G/_"9H/W^!1^C X?22E=0;M%W$:A2*=<,12
MG0D$&Y*(:,QDE18 +\SGP'-+KVE;=8NIU[SEWO[?:KS\=C-=+.>KQD]HKD]^
M^.RG!P4W8HPK:RR@-$(FDD9/@F"!V&2]]"9)N1\ ]+S73F1PX%FT@6ZRFBCZ
M&^VNOS9+PD0(P#/)H-$L>8$BY!HC4:D##4S+6*>OZ6 DT._]];_)_NP6AT/8
MP*4(<+-8K""]6959Q&L^&V$M#DMUQ$)PU$E!1&EC+S% )H[+3%0HETVC#RK4
M\2I/I[75IJ@V<:SO35%9MWUG9Y'PNTVSDZNTGDWI)VONKE;+S[-YT\16:Z:C
M*#==I*9$!LM(<#P1QS(D,,E$UF[.3:OE6@&NVD"QG@!721O#;"[T"RQ_GBT6
MN)<:YLZYE;[_%1U<0/\N51W=-7_KYU.T(@^+[+0X,5%3EXFWTI;'9!3=5V&(
M9<I*QK*-KLHMZ&,$/?L^P][W;GMC<:9"8$X0!E82*8PF/BM'*)B<6;21>_82
MG ZDAU\GB'AR/Z$3Z0_3>#SA[>QNIT>^J0-3TH;&VA8E62J90"\ZT/)L2I43
M(J,O@H>05)Y;X>I<8:ME4;;UJ*OI<IS&DU4I;?X&$?VR,BYJ/?,5TGHF[-V7
MU?WDD^.; ;3)6DM-6)&.#-+@(9H,4<PFGK,,7-6Y'MTY*P.U8:=@\/CKDE[T
M/4SCM^>CG/^J[_ 7=>]%57RW=Q1U-"A0BC&2E4#4"16(=:AU94T60*,0NLX=
M\DJ6[YGX7X]^'SDG@X>DB#9E$@DK<R(@<1*,A*"34#Y6\3 [H7Z@]NT4I#UY
MK?3B6JUOTC8?E/^4YX;__(__!U!+ P04    " !AI651U'&Z*P$(  "^)
M&0   &YK='(R,#(P+3 Y>#,P>&5X>#,Q,2YH=&WM6FU/([<6_MY?X09U"U+>
M7Q8(+!(+5(O4PI:F0O?3E6=\)K&8&4]M3T+ZZ_O8GH1 8,EN;[LLNDB;G1F?
M8Q^?\_@YQYXY_/[T\F3TGX]G;&*SE'W\_?W/YR>LUFBUKGLGK=;IZ)1]&/WR
M,^LWVQTVTCPWTDJ5\[35.KNHL=K$VF+8:LUFL^:LUU1ZW!I=M5Q7_5:JE*&F
ML*)V=.B>X)>X./KN\/M&@YVJN,PHMRS6Q"T)5AJ9C]FU('/#&HU*ZD05<RW'
M$\NZ[6Z;72M](Z<\M%MI4SI:]'/8"O>'+3_(8:3$_.A0R"F3XEU-[G63W?T^
M<8J(]V,>1]%@MX^_75R*-M%_.S"R!?&@8^P\I7>U3.:-";GQA_UN<W=0V(.9
M%'8R[+3;/]2\Z-%AHG*+\33TPV7H9JTS2[>VP5,YSH=^2K6@NFB.5:KT<*OM
M_PY<2R/AF4SGPQ]',B/#+FC&KE3&\Q_K!F%H&-(R"8)&_DFP">;YVUDP>1?]
MI#*GQ10Z76?TV>U$1M*R7J?9N6_QZL2Y'F/N5A700K<KML=P-NFO9/S)V=7H
M_*?SD^/1^>7%;YN:_X\;VW_4V/,Z^Z!F7 MVW41_D<SK+"9M93)G=L+MFZW!
MWL$F<WB+X0HN!!9((Z4$XPT6,9&Y0#R&#??D*TVSTUS,X=\?_;Y;>KM-[X9S
M-N%38IJFDF:@%CN1AOU:<@W@IG-V1872EJF<_:1TQCKMQJ\L41IBQ I8H00C
MN%6PWZBPE$6DWVQUWK8/>NUZH"&5P/H;RS4;34CS@DHK8X-P[K^"<'9?7#C?
M<X-@(%S9G-WD:I:2&%,]1%6'6 H%$W*%;((1N,P9S^>LS*TN"3- ?O&I!G'C
M+,.=ECQE"8_Q2#.5@0VM"G)K CG%9 S7<R>2\1OR,%GV:?!,P!@,F?H\A3&<
M0"PU\A+$<JC#$D&:S28RGC!3NI\[_1EIJCIQ$\BD29' 7"Z<23O!!$U!L3=P
M!9^QFD)-L&B^ZH97@L#>MX- 8HG,$6,'EY68\AS2:-4KS3('QP!;*)YP':>E
M8QC 9B5^=4!..H8J$'4'6 ?D-+U#9 4&\V!D@%[XJJSN),H4 H"A E;\<,&>
MF)L)2U(U,PN,:AI+8U'26<;=P[J7@Y7U%:B9A3%KUKX2M/5?'-I&]V+S9FNO
MV]D],!6@J@+"\8-*$HG;;;/C W?.N"8/$81<1BGYI$: 991*,W$:3BP#/3J*
M=/="FCA5IH2>(TZMTH"50JN8!!X;M@UH" +60OS/;N,)S\?$CL%)5V4*B4Z/
M-SJ#;0I6= 8BW(5;Z8K%/&#4]<\<<:U -T#)V?+L0"$)5Z,E]T9+=G;JRQ2^
M"FN(N%+@RRNMO<Y#J/;>?C6H;O.=EX+5;K^YWW&.."6#70%BYO/:\X"JNY0;
M\])LKN)R7T0 1S52R*:JU.@ )#65QE,?I"CW_;CB^HXT5XE74\H]VJIT>H>5
M>D7*KE&"0&&+4:D4?F]JRLA((;F6;@(R)'V?"7+74VE<(O;KT_BL[8D2FU\8
MA%VI5RI0?<JX3+GC=TS+&W&7T*$1RH/5J@97$3E!4##T27PYY;XL'$<O"<>]
M_CJ.-Z:M-3AO3G@;HQHK82J% RLW*N>.V;D!T%UMZ1",'>8"3<"WY)%,I9V[
M+/_8L&YM>>!Y3(5E<4]TI8[Q">2VFE!1Z@*8-KXJB6.EA3? 5ZECRE%LI( V
M6MRN27@15. !OEA;LO <_CH '+\D  <B/IORM/1LY:)+28)"44X1%_-(P;<L
M*C9@WW#[> WH\0I%,*<)E6:D2ONT!9OD![Z4)E=&)\_O>UBTJ,_]$J3@"=CC
MX1;J!HSR"G G7A+N*N(,(5V'AMN"5S6<;WD4?Y]!ERZIJS@NM0/ 2@9]I-=,
M&8OG[J@2?9D8'?T1CG_8]A,J"9 ,(GL@71F.O1/YTP-WL)"72[MV@E43;I;E
MAJ- CWP2/C=X?U2\/6>IO*&T.DIX(%__VRYJ?ON;L<'KV8SY(TBQ6!SU.XYR
ME+D*T#NZ<A#[C,ICK89=6L=1QUJES3+9^P?H,LNDM42?2 B1<@?6:!<2]OE.
MM@%C\*]Q_([_736]6'OT1REAOE]G91[[TX:=_^^V_K$D?YRB/D.]* $VM\%U
M&^98$J!1)>KEKF=&_,9EWE"O^=SK*TU_XKDX&?HLP%4;E'#(\ BC<0%%0TM"
M>Q*<57T*%2 ,960]I'^#W&_*#/B E_QDJD3RZ!F:3^WL=63U%[@=.D;R3C1H
MHXZPDR<[ ,<?4%<(JX?<)_.I2J?D$F#.Q]4YNZ[XD;(B57-"ZVRB B/R>_@%
MWOXGU<&SJ2]2UJIL&()L_1ZJ$HB 0-(->#OEA:'AXN( W%VD?#Z4N?>95SJ8
M.L9'A5"]# 6XJC?"^_O-O4'/O12V&O_$HOOJ?7'3OR]N6;'>-A@T!V\[3S:W
MFU_:-NAUOTCS4\;V.\U!>W>C;EO>$<$9<*HI>/ZNUJLM%"K<#;O%+5NNQN!5
M!\6'G@X!_/=7J'_1?PK,^ZS&+H! ]T:0#<*[P"7N*F]\8J)MYBE\$]%OP2=O
MMOI8HOZ7?;B\/KXZ]:^Y+]^?7]QSRH8P^ SO;"!:+6K_ 4 !U[B3/+;PR<OT
M\MH'#][+#SX@<)^9G$PD)>SLEN+2;:_99:@\Z^PCML_293.?/$^K^FT]&"U/
M92M<^>0W+"L\^N SF$*%[X"&X41U2FL?QMR%PC-O^TZ%1XA':==5GOF6IOH-
M7_;X;XR._@)02P,$%     @ 8:5E43!"__H<"   S"0  !D   !N:W1R,C R
M,"TP.7@S,'AE>'@S,3(N:'1M[5IM;QLW$OY^OX*5<:D-Z/W%+[)CP+&=UD":
MI(YZP7TZ<)>S$N'=Y9;D2M;]^GM(KF394F(E;5K'N )UM,L9<CCS\)DAER<_
M7+P['_W[_26;V"QE[W][]>;JG-4:K=;'WGFK=3&Z8#^/?GG#^LUVAXTTSXVT
M4N4\;;4NW]98;6)M,6RU9K-9<]9K*CUNC:Y;KJM^*U7*4%-843L]<6_PE[@X
M_<?)#XT&NU!QF5%N6:R)6Q*L-#(?LX^"S UK-"JI<U7,M1Q/+.NVNVWV4>D;
M.>6AW4J;TNFBGY-6>#YI^4%.(B7FIR="3ID4+VMR7_0/>7RPWZ;>0;\C>D=Q
MOS?H190<'/+!8??H/QT8V8)XT#%VGM++6B;SQH3<^,-^MWDP*.SQ3 H[&7;:
M[7_6O.CI2:)RB_$T],//T,U:9Y9N;8.G<IP/_91J0771'*M4Z>%.V_]W[%H:
M"<]D.A_^.)(9&?:69NQ:93S_L6X0AH8A+9,@:.1_"3;!//\X"R8?H)]4YK28
M0J?KC+Z\G<A(6M;K-+OW+5Z=.-=CS-VJ EKH=L7V&,XF_3<9?WYY/;IZ?75^
M-KIZ]_;#FOG?VJC^1J.NZNPGF;)?FNP-CW093] -U5E,VLIDSNR$VQ<[@\/C
M;;R]CQ$++@360B.E!$,.%NZ7N8#KAPWWYIN[?_-,.\W%'/[ZT>^[I7?0]&ZX
M8A,^):9I*FD&%K$3:=BO)=? :#IGUU0H;9G*V6NE,]9I-WYEB=(0(U; "B48
MP:V"?:#"4A:1?K'3V6\?]]KUP#@J@?4WEFLV0EAY0:65L4$XCYY!.+M/+IRO
MN$$P$*YLSFYR-4M)C+&4?%1UB*50,"%72!P8@<N<\7S.RMSJDC #I!*?51 W
MSC(\:<E3EO 8KS13&8C/JB"W)I!33,9P/7<B&;\A#Y-EGP;O!(S!D*E/21C#
M"<12(P5!+(<Z+!&DV6PBXPDSI?MSIS\C354G;@*9-"ERE4M[,VDGF* I*/8&
MKN S5E.H"1;-5]WP3!#8^WX02"R1.6+LX+(24YY#&JUZI5GFX!A@"W42?L=I
MZ1@&L%F)7QV0DXZA"D3= =8!.4WO$%F!P3P8&: 7O@"K.XDRA0!@J( 5/URP
M)^9FPI)4S<P"HYK&TEA4;Y9Q][+NY6!E?05J9F',FK7/!&W])X>VT;W8O-@Y
M['8.CDT%J*J </R@DD3B<=?L^<!=,:[)0P0AEU%*/JD18!FETDR<AA/+0(^.
M(MVSD"9.E2FAYXA3JS1@I= J)H'7ANT"&H* M1#_R]MXPO,QL3-PTG690J+3
MXXW.8)>"%9V!"$_A4;JZ, \8=?TS1UPKT U0<K8\.E!(PM5HR;W1DKV]^C*%
MK\(:(JX4^/I*Z[#S$*J]_;\-JKM\[ZE@M=MO'G6<(R[(8 . F/F\]CB@ZB[E
MQKPTVZNXW!<1P%&-%+*I*C4Z $E-I?'4!RG*?3^NN+XCS57BU91RC[8JG=YA
MI5Z1LFN4(%#88E0JA=^&FC(R4DB.$AX3D"'I^TR0NYY*XQ*Q7Y_&9VU/E-CG
MPB!L0+U2@>I3QF7*';]C6MZ(NX0.C5 >K%8U^!61$P0%0Y_$UU/NT\)Q])1P
MW.NOXWAKVEJ#\_:$MS6JL1*F4CBP<J-R[IB=&P#=U98.P5R+!9J ;\DCF4H[
M=UE^T[!N;7G@>4R%97%/=*6.\0GDMII04>H"F#:^*HECI84WP%>I8\I1;*2
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M<_M.A4>(5VG751ZY65/]#?=\_(VCT_\!4$L#!!0    ( &&E95%*5:5G_P4
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M,C R,# Y,S N:'1M4$L! A0#%     @ 8:5E42"T8>6@#P  &I\  !$
M         ( !_3P" &YK='(M,C R,# Y,S N>'-D4$L! A0#%     @ 8:5E
M43Q[!=!8&@  B@<! !4              ( !S$P" &YK='(M,C R,# Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( &&E95'H6B.[ZSP   IL @ 5
M  "  5=G @!N:W1R+3(P,C P.3,P7V1E9BYX;6Q02P$"% ,4    " !AI651
MC(-UR(FN  !P!P< %0              @ %UI ( ;FMT<BTR,#(P,#DS,%]L
M86(N>&UL4$L! A0#%     @ 8:5E4>K>[]YC7@  @1H$ !4
M ( !,5,# &YK='(M,C R,# Y,S!?<')E+GAM;%!+ 0(4 Q0    ( &&E95'4
M<;HK 0@  +XD   9              "  <>Q P!N:W1R,C R,"TP.7@S,'AE
M>'@S,3$N:'1M4$L! A0#%     @ 8:5E43!"__H<"   S"0  !D
M     ( !_[D# &YK='(R,#(P+3 Y>#,P>&5X>#,Q,BYH=&U02P$"% ,4
M" !AI6512E6E9_\%   C%P  &0              @ %2P@, ;FMT<C(P,C M
F,#EX,S!X97AX,S(Q+FAT;5!+!08     "0 ) %\"  "(R ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
